{"pages":[{"Cefotaxime":{"RelatedTo":["Penicillin-binding proteins 1A/1B"],"Synonym":["Cefotaxime sodium","Cephotaxime"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00493","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00493","Definition":"Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis). Pharmacology: Cefotaxime is a third generation intravenous cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against Pseudomonas aeruginosa. Cefotaxime works by inhibiting bacterial cell wall biosynthesis. A positive feature of cefotaxime is that it display a resistance to penicillinases and is useful to treat infections that are resistant to penicillin derivatives. Mechanism of action: The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefotaxime shows high affinity for penicillin-binding proteins in the cell wall including PBP Ib and PBP III. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Cephalosporins"}},{"Cefotetan":{"Synonym":["Cefotetanum (inn-latin)","Cefotan"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01330","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01330","Definition":"A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. (PubChem) Pharmacology: Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. Mechanism of action: The bactericidal action of cefotetan results from inhibition of cell wall synthesis. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Cephalosporins"}},{"Cefotiam":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":["CTM","Cefotiam hydrochloride","Cefotiamum (INN-Latin)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00229","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00229","Definition":"One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms. (PubChem) Pharmacology: Cefotiam is a third generation beta-lactam cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against Pseudomonas aeruginosa. Cefotiam works by inhibiting bacterial cell wall biosynthesis. Mechanism of action: The bactericidal activity of cefotiam results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Cephalosporins"}},{"Cefpiramide":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":[", Cefpiramide Sodium","Cefpiramide (USAN:INN)","Cefpiramido (INN-Spanish)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00430","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00430","Definition":"Cefpiramide is a third-generation cephalosporin antibiotic. Pharmacology: Cefpiramide is a cephalosporin active against Pseudomonas aeruginosa. It has a broad spectrum of antibacterial activity. Cefpiramide works by inhibiting bacterial cell wall biosynthesis. The plasma half-lives of cefpiramide in rabbits, dogs, and rhesus monkeys were much longer than those of cefoperazone and cefazolin. Mechanism of action: The bactericidal activity of cefpiramide results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Cephalosporins"}},{"Cefpodoxime":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":["CPDX-PR","Cefpodoxime proxetil","Banan","Doxef","Orelox","Otreon","Podomexef"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01416","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01416","Definition":"Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Pharmacology: Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Mechanism of action: Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Antibacterial Agents. Cephalosporins"}},{"Cefprozil":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":["Cefprozil anhydrous","Cefprozilo (INN-Spanish)","Cefprozilum (INN-Latin)","Arzimol","Brisoral","Cronocef","Procef"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01150","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01150","Definition":"Cefprozil is a cephalosporin antibiotic. It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections. Pharmacology: Cefprozil, a semisynthetic, second-generation cephalosporin, is used to treat otitis media, soft-tissue infections, and respiratory tract infections. Mechanism of action: Cefprozil, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefprozil interferes with an autolysin inhibitor. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Cephalosporins"}},{"Ceftazidime":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":[", Ceftazidima (INN-Spanish)","Ceftazidime Sodium In Plastic Container","Ceftazidime pentahydrate","Ceftazidimum (INN-Latin)","Ceptaz","Fortaz","Fortaz In Plastic Container","Pentacef","Tazicef","Tazidime"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00438","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00438","Definition":"Semisynthetic, broad-spectrum antibacterial derived from cephaloridine and used especially for Pseudomonas and other gram-negative infections in debilitated patients. (PubChem) Pharmacology: Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis. A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins. Ceftazidime has activity against the gram-negative organisms Pseudomonas and Enterobacteriaceae. Its activity against Pseudomonas is a distinguishing feature of ceftazidime among the cephalosporins. Mechanism of action: The bactericidal activity of ceftazidime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Cephalosporins"}},{"Ceftibuten":{"RelatedTo":["Penicillin-binding proteins 1A/1B","Oligopeptide transporter"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01415","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01415","Definition":"Ceftibuten is a third-generation cephalosporin antibiotic. It is an orally-administered agent. Cefalexin is used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis. Pharmacology: Ceftibuten is a third-generation cephalosporin antibiotic. Mechanism of action: Ceftibuten exerts its bactericidal action by binding to essential target proteins of the bacterial cell wall. This binding leads to inhibition of cell-wall synthesis. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Cephalosporins"}},{"Ceftriaxone":{"RelatedTo":"Gamma-glutamyltranspeptidase","Synonym":["Cefatriaxone","Ceftriaxona (INN-Spanish)","Ceftriaxonum (INN-Latin)","Ceftriazone","Biotrakson"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:29007","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01212","Definition":"A broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. (PubChem) Pharmacology: Ceftriaxone is a cephalosporin/cephamycin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. Ceftriaxone has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Ceftriaxone results from the inhibition of cell wall synthesis and is mediated through Ceftriaxone binding to penicillin binding proteins (PBPs). Ceftriaxone is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. Mechanism of action: Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Cephalosporins"}},{"Cefuroxime":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":["Cefuroxim","Cefuroxime (USAN:BAN:INN)","Cefuroximo (INN-Spanish)","Cefuroximum (INN-Latin)","Ancef","Biofuroksym","Cedax","Cefizox","Cefobid","Cefotan","Ceftin","Cefurax","Cefuril","Cefzil","Cepazine","Cephuroxime","Duricef","Elobact","Kefurox","Kefzol","Kerurox","Mandol","Maxipime","Mefoxin","Monocid","Oraxim","Rocephin","Sharox","Velosef","Zinacef","Zinat"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3515","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01112","Definition":"Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus. (PubChem) Pharmacology: Cefuroxime is a -lactam type antibiotic. More specifically, it is a second-generation cephalosporin. Cephalosporins work the same way as penicillins: they interfere with the peptidoglycan synthesis of the bacterial wall by inhibiting the final transpeptidation needed for the cross-links. This effect is bactericidal. Cefuroxime is effective against the following organisms: Aerobic Gram-positive Microorganisms: Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes. Aerobic Gram-negative Microorganisms: Escherichia coli, Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis (including beta-lactamase-producing strains), Neisseria gonorrhoeae (including beta-lactamase-producing strains). Spirochetes: Borrelia burgdorferi. Mechanism of action: Cefuroxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefuroxime interferes with an autolysin inhibitor. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Cephalosporins"}},{"Celecoxib":{"RelatedTo":["Prostaglandin G/H synthase 2"],"Synonym":["Celocoxib","celecoxib","Celebra"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:41423","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00482","Definition":"Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form. Pharmacology: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Celecoxib is used to treat rheumatoid arthritis, osteoarthritis, and familial adenomatous polyposis (FAP). Because of its lack of platelet effects, celecoxib is not a substitute for aspirin for cardiovascular prophylaxis. It is not known if there are any effects of celecoxib on platelets that may contribute to the increased risk of serious cardiovascular thrombotic adverse events associated with the use of celecoxib. Inhibition of PGE2 synthesis may lead to sodium and water retention through increased reabsorption in the renal medullary thick ascending loop of Henle and perhaps other segments of the distal nephron. In the collecting ducts, PGE2 appears to inhibit water reabsorption by counteracting the action of antidiuretic hormone. Mechanism of action: The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis. Unlike most NSAIDs, which inhibit both types of cyclooxygenases (COX-1 and COX-2), celecoxib is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme. It binds with its polar sulfonamide side chain to a hydrophilic side pocket region close to the active COX-2 binding site. Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-Inflammatory Agents, Non-Steroidal. Cyclooxygenase Inhibitors"}},{"Cell":{"EditorialNote":"This class needs to be replaced by CL or GO.","CurationStatus":"graph position temporary","SuperCategory":"Anatomical entity","Comment":["We are restricting ourselves to cells that are in the nervous system or closely associated with nervous system cells","e.g.","muscle cells.  A more complete ontology of Cell Types is available through OBO.  Eventually"],"Id":"sao1813327414","Xref":["NEMO_9559000"],"Definition":"The basic structural and functional unit of all organisms. Includes the plasma membrane and any external encapsulating structures such as the cell wall and cell envelope (Gene Ontology)."}},{"Cell Adhesion Molecule":{"SuperCategory":"Molecule role","Id":"sao1048879260"}},{"Cell biology":{"Synonym":"Cytology","CurationStatus":"uncurated","SuperCategory":"Biology","Id":"nlx_inv_100617","Definition":"Branch of biology concerned with the study of cells and cellular processes.(formerly cytology, from the Greek kytos, \"container\") is an academic discipline that studies cells \u2013 their physiological properties, their structure, the organelles they contain, interactions with their environment, their life cycle, division and death. This is done both on a microscopic and molecular level. Cell biology research encompasses both the great diversity of single-celled organisms like bacteria and protozoa, as well as the many specialized cells in multicellular organisms like humans.Knowing the components of cells and how cells work is fundamental to all biological sciences. Appreciating the similarities and differences between cell types is particularly important to the fields of cell and molecular biology as well as to biomedical fields such as cancer research and developmental biology. These fundamental similarities and differences provide a unifying theme, sometimes allowing the principles learned from studying one cell type to be extrapolated and generalized to other cell types. Hence, research in cell biology is closely related to genetics, biochemistry, molecular biology and developmental biology. - definition adapted from Wikipedia"}},{"Cell Body Referent Polarity":{"SuperCategory":"Polarity","Id":"sao311075036","Definition":"no def needed"}},{"Cell Capacitance":{"Synonym":["Cell_capacitance","Cm","C","capacitance"],"CurationStatus":"uncurated","Comment":["NeuroElectro Term 1","Note:  RM and CM are typically assumed to be linear","steady state properties and thus not influenced by voltage-gated channels.  Thus"],"SuperCategory":"Cellular physiology characteristic","Id":"oen_0001024","Has role":["NeuroElectro Term","Passive membrane property"],"Definition":"Neuron capacitance, typically measured by dividing membrane time constant by membrane resistance"}},{"Cell Cell Contact Zone":{"Comment":["We still don't know if the synapse","in the sense that it is typically used","belongs here or whether large","multicontact synapses like the neuromuscular junction and the calycl synapse of Held"],"SuperCategory":"Site","Id":"sao1299635018","Definition":"Extended zone of intimate apposition between two cells containing one or more types of intercellular junctions, e.g., the intercalated disk of muscle"}},{"Cell Component Aggregate Object":{"SuperCategory":"Aggregate Object","Id":"sao991156472"}},{"Cell diameter":{"Synonym":["diameter"],"CurationStatus":"uncurated","Comment":"NeuroElectro Term 11","SuperCategory":"Cellular morphology characteristic","Id":"oen_0001017","Has role":["NeuroElectro Term"],"Definition":"Diameter of the cell soma"}},{"Cell group":{"EditorialNote":"Use the overlaps with relationship to relate cell groups to other regions of brain;  this CUMBO term has not yet been vetted with the INCF Task Force","CurationStatus":"graph position temporary","SuperCategory":"Regional part of brain","Id":"nlx_532","Has role":"CUMBO term","Definition":"A group of cells that may not be contained within macroscopic anatomical boundaries, e.g., A9 dopaminergic cell group;  massa intercalata of the amygdala"}},{"Cell Interior":{"SuperCategory":"Site","Id":"sao1579007712"}},{"Cell layer":{"Synonym":["layer"],"CurationStatus":"uncurated","SuperCategory":"Regional part of nervous system","Id":"nlx_149357","Has role":"CUMBO term","Definition":"Single layer of a laminar structure, identified by different density, arrangement or size of cells and processes arranged in flattened layers or lamina."}},{"Cell line":{"Created":"2007-10-05","EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","Synonym":"cellline,","CurationStatus":"uncurated","SuperCategory":"Ex vivo anatomical object","Id":"birnlex_11036","Definition":"Established cell cultures that have the potential to propagate indefinitely. Year introduced: 1972(1969). Adapted from MESH."}},{"Cell Morphological Quality":{"SuperCategory":"Morphological Quality","Id":"sao1278200674"}},{"Cell Process":{"SuperCategory":"Regional Part Of Cell","Id":"sao-1828894864"}},{"Cell Protrusion":{"SuperCategory":"Regional Part Of Cell","Id":"sao-82111036"}},{"Cell Regional Part Aggregate Object":{"SuperCategory":"Regional Part Of Cell","Id":"sao1970895398"}},{"Cell repository":{" limit":"1000","Created":["2007-10-18* Comment: [[Comment:  I've moved this to child of biomaterial supply resource from Tissue bank"],"Synonym":["Cell bank","Cells supplier"],"CurationStatus":"uncurated","SuperCategory":"Biomaterial supply resource"," format":"CSV","Id":"birnlex_2479_2","Definition":"A resource that provides cell lines or isolated cells as opposed to intact tissue samples."}},{"Cell role":{"CurationStatus":"uncurated","SuperCategory":"Role","Id":"nlx_subcell_090803"}},{"Cell sorting":{"EditorialNote":"Eagle i has \"Cell separation\" as the preferred label.  I chose \"Cell sorting\" because I thought it would be more likely used in search, although I have no objective basis for this decision.","Synonym":["Cell isolation","Cell purification","Cell segregation"],"CurationStatus":"uncurated","SuperCategory":"Material component separation","Id":"ERO_0000725","Definition":"A material component separation technique used to separate populations of two or more cells, such as by magnetic bead sorting (Eagle i Resource Ontology:  http://purl.obolibrary.org/obo/ERO_0000725)"}},{"Cell surface area":{"Synonym":["area"],"CurationStatus":"uncurated","Comment":"NeuroElectro Term 15","SuperCategory":"Cellular morphology characteristic","Id":"oen_0001013","Has role":["NeuroElectro Term"],"Definition":"Cross-sectional area of the cell"}},{"Cell viability assay":{"RelatedTo":"cell viability","CurationStatus":"uncurated","SuperCategory":"Assay","Id":"ERO_0001352","Definition":"A cellular assay used to determine cell viability in an experimental setting; the capability of developing, growing, and otherwise sustaining life (Eagle i Resource Ontology)."}},{"Cell-attached single-channel recording protocol":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Ion channel recording protocol","Id":"birnlex_2283","Has role":"\tElectrophysiology concept"}},{"Cell-detached inside-out single-channel recording protocol":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Cell-detached single-channel recording protocol","Id":"birnlex_2286","Has role":"\tElectrophysiology concept"}},{"Cell-detached outside-out single-channel recording protocol":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Cell-detached single-channel recording protocol","Id":"oen_0001316","Has role":"Electrophysiology concept"}},{"Cell-detached single-channel recording protocol":{"Created":"2007-10-09","Synonym":"excised patch","CurationStatus":"uncurated","SuperCategory":"Ion channel recording protocol","Id":"birnlex_2284","Has role":"Electrophysiology concept"}},{"Cell-specific marker":{"Synonym":"cell specific marker","CurationStatus":"uncurated","SuperCategory":"Molecule role","Id":"nlx_152216","Definition":"A biochemical marker that distinguishes a particular population of cells, e.g., GFAP as a marker of astrocytes"}},{"Cellular adhesivity":{"SuperCategory":"Adhesivity","Id":"PATO_0001531","Definition":"A cellular quality that exists by virtue of the capacity of the cell to adhere to other cells and molecules, through the emergent action of the molecular parts of the cell."}},{"Cellular component":{"CurationStatus":"uncurated","Comment":["Equivalent to \"constitutional part\" in the FMA--a primary partition of an anatomical structure into its compositionally distinct anatomical elements.  In the context of the whole","an element is any relatively simple component of which a larger","more complex anatomical structure is compounded; i.e.","teh partition is compositional rather than spatial (Mejino JLV et al."],"SuperCategory":"Subcellular entity","Id":"GO:0005575","Definition":"The part of a cell or its extracellular environment in which a gene product is located. A gene product may be located in one or more parts of a cell and its location may be as specific as a particular macromolecular complex, that is, a stable, persistent association of macromolecules that function together."}},{"Cellular Excitation":{"Synonym":"Excitation","CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001146","Definition":"The depolarization of a postsynaptic cell, increasing the likelihood that an action potential will be generated."}},{"Cellular Inclusion":{"Synonym":"Inclusion Body","CurationStatus":"uncurated","Comment":"The preferred label for Gene Ontology is inclusion body.  Need to swap this category out at some point.","SuperCategory":"Cellular component","Id":"GO:0016234","Definition":"A discrete intracellular part formed of aggregated molecules such as proteins or other biopolymers."}},{"Cellular membrane":{"Synonym":"membrane","CurationStatus":"uncurated","Comment":"Gene Ontology has membrane as the preferred name","SuperCategory":"Cellular component","Id":"GO:0016020","Definition":"Double layer of lipid molecules that encloses all cells, and, in eukaryotes, many organelles; may be a single or double lipid bilayer; also includes associated proteins."}},{"Cellular morphology characteristic":{"CurationStatus":"uncurated","SuperCategory":"Morphology","Id":"nlx_155517"}},{"Cellular motility":{"SuperCategory":"Cellular spatiotemporal quality","Id":"PATO_0001488","Definition":"A cellular spatiotemporal quality inhering in a bearer by virtue of its ability to move spontaneously."}},{"Cellular physiology characteristic":{"CurationStatus":"uncurated","SuperCategory":"Cellular quality","Id":"nlx_155521","Has role":"Electrophysiology concept"}},{"Cellular potency":{"SuperCategory":"Cellular quality","Id":"PATO_0001397"}},{"Cellular quality":{"SuperCategory":"Quality of a single physical entity","Id":"PATO_0001396","Definition":"A monadic quality of continuant that exists at the cellular level of organization."}},{"Cellular Space":{"SuperCategory":"Site","Id":"sao1289190043","Definition":"Anatomical space occurring within a cell, usually formed by intracellular membranes."}},{"Cellular spatiotemporal quality":{"SuperCategory":"Quality of a single process","Id":"PATO_0001529","Definition":"A spatiotemporal quality inhering to a cell."}},{"Cellular Subcomponent":{"CurationStatus":"uncurated","SuperCategory":"Cellular component","Id":"sao628508602"}},{"Cellularity":{"SuperCategory":"Organismal quality","Id":"PATO_0001992","Definition":"A quality inhering in a bearer by virtue of consisting of cells."}},{"Center of Circular Collimator":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1710","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149670","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Required if Collimator Shape (0018,1700) is CIRCULAR. Location of the center of the circular collimator with respect to pixels in the image given as row and column."}},{"Center of Rotation Offset":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1145","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149671","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Average center of rotation offset of Nuclear Medicine detector in mm."}},{"Centers for Disease Control and Prevention":{"Synonym":["Centers for disease control and prevention"],"Listedby":"Resource:OMICtools","CurationStatus":"uncurated","SuperCategory":"Government granting agency","Id":"nlx_inv_1005036","Is part of":"United States Department of Health and Human Services granting agency","DefiningCitation":"http://www.cdc.gov/about/business/funding.htm","Abbrev":["CDC"],"Definition":"Government granting agency that works 24/7 to protect America from health, safety and security threats, both foreign and in the U.S."}},{"Centers for Medicare and Medicaid Services":{"Synonym":["Centers for Medicare & Medicaid Services"],"CurationStatus":"uncurated","SuperCategory":"Government granting agency","Id":"nlx_157919","DefiningCitation":"http://cms.hhs.gov/","Abbrev":"CMS"}},{"Central amygdalar nucleus capsular part of ABA 2009":{"PartiallyOverlapsWith":"Central amygdalar nucleus  capsular part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152965","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Central amygdalar nucleus lateral part of ABA 2009":{"PartiallyOverlapsWith":"Central amygdalar nucleus  lateral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153378","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Central amygdalar nucleus medial part of ABA 2009":{"PartiallyOverlapsWith":"Central amygdalar nucleus  medial part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153413","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Central amygdalar nucleus of ABA 2009":{"PartiallyOverlapsWith":"Central amygdalar nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153252","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Central amygdaloid nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["central nucleus of amygdala"],"CurationStatus":"uncurated","Abbrev":["CeA"],"AfferentProjections":["Lateral amygdaloid nucleus","Auditory thalamus","Auditory cortex","Posterior thalamus"],"PMID":"11054694,2468696,2166757,8636464,1969868,2836477,12541307,632368,1281170,16739166,16739197,1262547,3047185,7130477,20963828,7107988,9336231","Created":"2007-08-28","NeuronamesID":"225","Umlscui":"C0175219","SuperCategory":"Regional part of brain","Id":"birnlex_2682","Is part of":"Amygdala","Definition":"The output region of the amygdala responsible for controlling responses (Phelps & LeDoux, 2005, PMID: 16242399).","DefinitionPMID":"16242399"}},{"Central cervical nucleus":{"CurationStatus":"uncurated","PartiallyOverlapsWith":["Central cervical nucleus of PHT00"],"NeuronamesID":"1648","EfferentProjections":"Cerebellum","SuperCategory":"Regional part of spinal cord","Id":"nlx_143586","ParcellationScheme":["Paxinos"],"Is part of":"Cervical spinal cord gray matter","EfferentProjectionsPMID":"2456831,","Definition":"Columnar nucleus of spinal cord contained in lamina VII in the upper four cervical segments of the spinal cord. It is located lateral to the intermediomedial cell column ( Carpenter-1983 ). In the mouse it extends into the medulla ( Paxinos-2001 ). (Adapted from Brain Info)"}},{"Central cervical nucleus of PHT00":{"CurationStatus":"uncurated","PartiallyOverlapsWith":["Central cervical nucleus"],"ISBN":"123582555","PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Curator":"CoCoMac{{PONS brain region","Id":"nlx_br_227","Authors":["George Paxinos","Xu-Feng Huang"],"Species":"Macaque","Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","DefiningCitation":"ISBN 0123582555","Abbrev":"CeCv"}},{"Central cervical spinocerebellar tract":{"CurationStatus":"uncurated","EfferentProjections":["Vermic Lobule I","Vermic Lobule II","Vermic Lobule III","Vermic Lobule IV","Vermic Lobule V","Hemispheric Lobule VI","Vermic Lobule VI","Vermic Lobule VII","Vermic Lobule VIII","Vermic Lobule IX","Hemispheric Lobule VIIA","Hemispheric Lobule VIIBi"],"SuperCategory":"Regional part of brain","Id":"nlx_41715","Is part of":"Spinocerebellar tract","AfferentProjections":"Cervical spinal cord","Definition":"Afferents from the neck and head to the cerebellum."}},{"Central dorsal nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-05","Synonym":["nucleus centralis superior lateralis thalami","nucleus circularis","nucleus centralis superior lateralis"],"NeuronamesID":"302","CurationStatus":"uncurated","Umlscui":"C0752053","SuperCategory":"Regional part of brain","Id":"birnlex_956","Is part of":"Rostral intralaminar nuclei,","Abbrev":"CD"}},{"Central gray substance of medulla":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":"central gray matter","NeuronamesID":"753","CurationStatus":"uncurated","Umlscui":"C0262207","SuperCategory":"Regional part of brain","Id":"birnlex_2638","Abbrev":"CGM"}},{"Central gray substance of pons":{"Created":"2006-07-15","Synonym":["Central gray of pons","pontine central gray"],"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_799","Is part of":"Pons","Abbrev":"CGPn"}},{"Central lateral nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-05","Synonym":["central lateral nucleus of thalamus","central lateral thalamic nucleus","nucleus centralis lateralis of thalamus","nucleus centralis lateralis thalami"],"NeuronamesID":"303","CurationStatus":"uncurated","Umlscui":"C0228355","SuperCategory":"Regional part of brain","Id":"birnlex_961","Is part of":"Rostral intralaminar nuclei,","Abbrev":"CL"}},{"Central lateral nucleus of the thalamus of ABA 2009":{"PartiallyOverlapsWith":"Central lateral nucleus of the thalamus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153321","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Central linear nucleus raphe of ABA 2009":{"PartiallyOverlapsWith":"Central linear nucleus raphe","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153189","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Central lobule":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Lobular parts of the cerebellar cortex","Id":"birnlex_920"}},{"Central lobule of ABA 2009":{"PartiallyOverlapsWith":"Central lobule","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153581","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Central medial nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-05","EditorialNote":"Note that this BAMS ID assignment should be vetted further, but I do think this is the ID for the BAMS equivalent of this structural region (BB: 2007-03-05).","Synonym":["nucleus centralis medialis thalami","central medial thalamic nucleus","central medial nucleus thalamus (Rioch 1928)","central medial nucleus of thalamus"],"NeuronamesID":"304","CurationStatus":"uncurated","Umlscui":"C0920328","SuperCategory":"Regional part of brain","Id":"birnlex_971","Is part of":"Rostral intralaminar nuclei,","Abbrev":"CM"}},{"Central medial nucleus of the thalamus of ABA 2009":{"PartiallyOverlapsWith":"Central medial nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153270","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Central nervous system":{"Created":"2006-07-15","Synonym":"Myencephalon","CurationStatus":"uncurated","Umlscui":"C0927232","Comment":["This definition was contributed to by Maryann Martone","Onard Mejino","Paul Katz","David Osumi-Sutherland","Mihai Bota","Chris Mungall","Melissa Haendel","Laszlo Zaborszky","Doug Bowden","Alan","Ruttenberg"],"SuperCategory":"Regional part of nervous system","Id":"birnlex_1099","Has role":"CUMBO term","Is part of":"Nervous system","Abbrev":"CNS","Definition":"The central nervous system (CNS) is the part of the nervous system which includes the brain, spinal cord, and nerve cell layer of the retina.In animals with bilateral symmetry, it is a topographic division that is a  condensation of the nervous system in the longitudinal plane, lying on or near the median plane. For invertebrates the longitudinal division consists of one or more nerve cords, whereas for vertebrates it consists of a single, hollow, and dorsal cerebrospinal axis.In adult Echinoderms, which are radially symmetrical, a presumptive CNS is formed by a circular cord with associated radial cords. However, there is no ganglion that could be considered as brain in invertebrate When a CNS is present, its obligate companion topographic division is a peripheral nervous system.The term, as it currently defined, was first used by Meckel (1817)."}},{"Central Nervous System Bacterial Infection":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Central Nervous System Infection","Id":"birnlex_12682","Definition":"Bacterial infections of the brain, spinal cord, and meninges, including infections involving the perimeningeal spaces (MeSH)."}},{"Central nervous system depressant":{"Synonym":["CNS depressants","CNS depressant","central nervous system depressants","sedative"],"CurationStatus":"uncurated","SuperCategory":"Drug","Id":"CHEBI:35488","Definition":"A loosely defined group of drugs that tend to reduce the activity of the central nervous system."}},{"Central Nervous System Fungal Infection":{"Synonym":["Acute Stress Disorder"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Central Nervous System Infection","Id":"birnlex_12683","Definition":"MYCOSES of the brain, spinal cord, and meninges which may result in ENCEPHALITIS; MENINGITIS, FUNGAL; MYELITIS; BRAIN ABSCESS; and EPIDURAL ABSCESS. Certain types of fungi may produce disease in immunologically normal hosts, while others are classified as opportunistic pathogens, causing illness primarily in immunocompromised individuals (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME) (MeSH)."}},{"Central Nervous System Infection":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Nervous system disease","Id":"birnlex_12681","Definition":"Pathogenic infections of the brain, spinal cord, and meninges. DNA VIRUS INFECTIONS; RNA VIRUS INFECTIONS; BACTERIAL INFECTIONS; MYCOPLASMA INFECTIONS; SPIROCHAETALES INFECTIONS; fungal infections; PROTOZOAN INFECTIONS; HELMINTHIASIS; and PRION DISEASES may involve the central nervous system as a primary or secondary process (MeSH)."}},{"Central nervous system of primate":{"CurationStatus":"uncurated","SuperCategory":"Central nervous system","Id":"nlx_20785"}},{"Central nervous system of rodent":{"CurationStatus":"uncurated","SuperCategory":"Central nervous system","Id":"nlx_53588","Species":["Rodent"],"Definition":"The central nervous system of rodents"}},{"Central Nervous System Parasitic Infection":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Central Nervous System Infection","Id":"birnlex_12684","Definition":"Infections of the brain, spinal cord, and meninges caused by parasites, primarily PROTOZOA and HELMINTHS (MeSH)."}},{"Central nervous system stimulant":{"Synonym":["central stimulant","CNS stimulant"],"CurationStatus":"uncurated","SuperCategory":"Drug","Id":"CHEBI:35337"}},{"Central Nervous System Viral Infection":{"Synonym":"Viral CNS Infection","Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Central Nervous System Infection","Id":"birnlex_12685","Definition":"Viral infections of the brain, spinal cord, meninges, or perimeningeal spaces (MeSH)."}},{"Central nucleus of inferior colliculus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"470","CurationStatus":"uncurated","Umlscui":"C0175371","SuperCategory":"Regional part of brain","Id":"birnlex_1035","Is part of":"Inferior colliculus","Abbrev":"CIC"}},{"Central oculomotor nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"490","CurationStatus":"uncurated","Umlscui":"C0175384","SuperCategory":"Regional part of brain","Id":"birnlex_786","Is part of":"Oculomotor nuclear complex","Abbrev":"C3"}},{"Central pattern generator":{"CurationStatus":"uncurated","SuperCategory":"Biological process","Id":"oen_0001121","Has role":"Electrophysiology concept","Abbrev":"CPG","Definition":"A network of neurons capable of generating rhythmic motor activity without any afferent activity or other source of rhythmic external drive., A network of neurons capable of generating rhythmic motor activity without any afferent activity or other source of rhythmic external drive., A network of neurons capable of generating rhythmic motor activity without any afferent activity or other source of rhythmic external drive."}},{"Central Pontine Myelinolysis":{"Synonym":["Extrapontine Myelinolysis"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Demyelinating disease","Id":"birnlex_12552","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"A demyelinating condition affecting the PONS and characterized clinically by an acute progressive QUADRIPLEGIA; DYSARTHRIA; DYSPHAGIA; and alterations of consciousness. Pathologic features include prominent demyelination in the central PONS with sparing of axons and neurons. This condition is usually associated with systemic disorders such as HYPONATREMIA; chronic ALCOHOLISM; LIVER FAILURE; severe BURNS; malignant NEOPLASMS; hemorrhagic PANCREATITIS; HEMODIALYSIS; and SEPSIS. The rapid medical correction of hyponatremia has been cited as a cause of this condition (MeSH)."}},{"Central retina":{"PMID":"10524333,10975879,2794114,3294924,15952169,3667989,2229487,15803509,3884672,18671302,8308170,11056467,8847405,21192081,15164429,7410600","SuperCategory":"Brain Subdivisions based on automated term selection","Id":"nlx_11609","Is part of":"Retina"}},{"Central sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["sulcus centralis (Rolandi)","central sulcus of Rolando","Sulcus centralis cerebri","Sulcus centralis","fissure of Rolando","central fissure"],"CurationStatus":"uncurated","NeuronamesID":"29","Umlscui":["C0228188"],"SuperCategory":"Sulcus","Id":"birnlex_4035","Is part of":"Cerebral cortex","Abbrev":"cs"}},{"Central tegmental tract":{"NeuronamesID":"2204","CurationStatus":"uncurated","SuperCategory":"Nerve tract","Id":"nlx_32981","Is part of":["Midbrain tegmentum","Pontine tegmentum"],"Abbrev":"ctg","Definition":"A pathway containing fibers from midbrain nuclei that project to the inferior olivary complex, as well as fibers originating in the pontine reticular formation and the medullary reticular formation that project to several nuclei of the thalamus. It can be identified in the midbrain and the pons (Adapted from Brain Info)."}},{"Central tegmental tract of midbrain":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","CurationStatus":"uncurated","NeuronamesID":"519","Umlscui":"C0152364","SuperCategory":"Regional part of brain","Id":"birnlex_1081","Is part of":["Central tegmental tract"],"Abbrev":"ctgmb"}},{"Central tegmental tract of pons":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"596","CurationStatus":"uncurated","Umlscui":"C0228443","SuperCategory":"Regional part of brain","Id":"birnlex_1683","Is part of":["Central tegmental tract"]}},{"Centriole":{"CurationStatus":"uncurated","SuperCategory":"Non-membrane bound organelle","Id":"GO:0005814","Definition":"A cellular organelle, found close to the nucleus in many eukaryotic cells, consisting of a small cylinder with microtubular walls, 300-500 nm long and 150-250 nm in diameter. It contains nine short, parallel, peripheral microtubular fibrils, each fibril consisting of one complete microtubule fused to two incomplete microtubules. Cells usually have two centrioles, lying at right angles to each other. At division, each pair of centrioles generates another pair and the twin pairs form the pole of the mitotic spindle (Gene Ontology)."}},{"Centromedian nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-05","Synonym":["nucleus centralis thalami (Hassler)","centrum medianum","central magnocellular nucleus of thalamus","nucleus centri mediani thalami","nucleus centrum medianum","centromedian thalamic nucleus","nucleus centromedianus","nucleus centromedianus thalami","centre median nucleus","central nucleus-1","nucleus centralis centralis","centrum medianum thalami"],"CurationStatus":"uncurated","NeuronamesID":"306","Umlscui":"C0228351","SuperCategory":"Regional part of brain","Id":"birnlex_805","Is part of":"Intralaminar nuclear group,","Abbrev":"CMn"}},{"Centromedian thalamic nucleus medial part of PHT00":{"Synonym":["centromedian thalamic nucleus"],"CurationStatus":"uncurated","ISBN":"123582555","Curator":"CoCoMac{{PONS brain region","Authors":["George Paxinos","Xu-Feng Huang"],"Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"CMnM","PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Id":"nlx_br_17","Is part of":"Centromedian thalamic nucleus of PHT00","ParcellationScheme":["Paxinos"],"Species":"Macaque","DefiningCitation":"ISBN 0123582555"}},{"Centromedian thalamic nucleus of PHT00":{"Synonym":"centromedian thalamic nucleus","CurationStatus":"uncurated","ISBN":"123582555","Curator":"CoCoMac{{PONS brain region","Authors":["George Paxinos","Xu-Feng Huang"],"Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"CMn","PartiallyOverlapsWith":["Centromedian nucleus"],"PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Id":"nlx_br_16","Is part of":"Thalamus of PHT00","ParcellationScheme":["Paxinos"],"Species":"Macaque","DefiningCitation":"ISBN 0123582555"}},{"Centrosome":{"RelatedTo":"Microtubule organizing center","CurationStatus":"uncurated","SuperCategory":"Non-membrane bound organelle","Id":"GO:0005813","Definition":"A structure comprised of a core structure (in most organisms, a pair of centrioles) and peripheral material from which a microtubule-based structure, such as a spindle apparatus, is organized. Centrosomes occur close to the nucleus during interphase in many eukaryotic cells, though in animal cells it changes continually during the cell-division cycle."}},{"Cephalexin":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":["CEX","Cefalessina (DCIT)","Cefalexin","Cefalexin Sodium","Cefalexina (INN-Spanish)","Cefalexine (INN-French)","Cefalexinum (INN-Latin)","Cephalexin 1-hydrate","Cephalexin hydrate","Cephalexin monohydrate","Cephalexine","Cephalexinum","Alcephin","Alexin","Alsporin","Biocef","Carnosporin","Cefa-iskia","Cefablan","Cefadal","Cefadin","Cefadina","Cefaleksin","Cefalin","Cefaloto","Cefaseptin","Cefax","Ceforal","Cefovit","Celexin","Cepastar","Cepexin","Cephacillin","Cephanasten","Cephaxin","Cephin","Cepol","Ceporex","Ceporex Forte","Ceporexin","Ceporexin-E","Ceporexine","Check","Cophalexin","Durantel","Durantel DS","Ed A-Ceph","Erocetin","Factagard","Felexin","Fexin","Ibilex","Ibrexin","Inphalex","Kefalospes","Keflet","Keflex","Kefolan","Keforal","Keftab","Kekrinal","Kidolex","L-Keflex","Lafarine","Larixin","Lenocef","Lexibiotico","Lonflex","Lopilexin","Madlexin","Mamalexin","Mamlexin","Medoxine","Neokef","Neolexina","Novolexin","Nufex","Oracef","Oriphex","Oroxin","Ortisporina","Ospexin","Palitrex","Panixine Disperdose","Pectril","Pyassan","Roceph","Sanaxin","Sartosona","Sencephalin","Sepexin","Servispor","Sialexin","Sinthecillin","Sporicef","Sporidex","Syncl","Syncle","Synecl","Tepaxin","Tokiolexin","Uphalexin","Voxxim","Winlex"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00567","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00567","Definition":"A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of cephaloridine or cephalothin, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. (PubChem) Pharmacology: Cephalexin (also called Cefalexin) is a first generation cephalosporin antibiotic. It is one of the most widely prescribed antibiotics, often used for the treatment of superficial infections that result as complications of minor wounds or lacerations. It is effective against most gram-positive bacteria. Mechanism of action: Cephalexin, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cephalexin interferes with an autolysin inhibitor. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Cephalosporins"}},{"Cephaloglycin":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":[", CEG","Cefaloglicina (INN-Spanish)","Cefaloglycin","Cefaloglycine (INN-French)","Cefaloglycinum (INN-Latin)","Cephaloglycin anhydrous","Cephaloglycine","Cephaoglycin acid","D-Cephaloglycine","Kafocin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00689","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00689","Definition":"A cephalorsporin antibiotic. (PubChem) Pharmacology: Cephaloglycin is an antibiotic related to cephalosporin but no longer in common use. It is an orally absorbed derivative of cephalosporin C. Mechanism of action: The bactericidal activity of cephaloglycin results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Cephalosporins"}},{"Cephalopods":{"Created":"2007-08-15","CurationStatus":"pending_final_vetting","Umlscui":"C0324027","SuperCategory":"Mollusc","Id":"birnlex_519"}},{"Cephapirin":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":["Cefapirin","Cefapirina (INN-Spanish)","Cefapirine (INN-French)","Cefapirinum (INN-Latin)","Cefaprin","Cefaprin sodium","Cephapirin Sodium","Cephapirine","Ambrocef","Cefa","Cefadyl","Cefatrex"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01139","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01139","Definition":"Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms. (PubChem) Pharmacology: Cephapirin is a first-generation cephalosporin that has a wide spectrum of activity against gram-positive and gram-negative organisms. Cephapirin is more resistant to beta-lactamases than are the penicillins and so is effective against staphylococci, with the exception of methicillin-resistant staphylococci. Mechanism of action: The bactericidal activity of cephapirin results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Cephalosporins"}},{"Cercocebus":{"EditorialNote":"This class is not intended to present a normative,          comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of          the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","CurationStatus":"raw_import","Umlscui":"C0085226","SuperCategory":"Cercopithecinae","Id":"birnlex_7301","Definition":"* A genus of the subfamily CERCOPITHECINAE inhabiting the African forests. They are also known as mangabeys. (MSH) * a genus of Old World monkeys. (CSP)"}},{"Cercocebus torquatus":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2006-10-07","CurationStatus":"raw_import","Umlscui":"C0085227","SuperCategory":"Cercocebus","Id":"birnlex_7302"}},{"Cercopithecidae":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2006-10-07","CurationStatus":"raw_import","Umlscui":"C0007752","SuperCategory":"Cercopithecoidea","Id":"birnlex_463"}},{"Cercopithecinae":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2006-10-07","CurationStatus":"raw_import","Umlscui":"C0085225","SuperCategory":"Cercopithecidae","Id":"birnlex_524"}},{"Cercopithecoidea":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2006-10-07","CurationStatus":"raw_import","Umlscui":"C1675847","SuperCategory":"Catarrhini","Id":"birnlex_468"}},{"Cercopithecus campbelli":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","CurationStatus":"raw_import","Umlscui":"C0324842","SuperCategory":"Guenon","Id":"birnlex_7299"}},{"Cercopithecus cephus":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","CurationStatus":"raw_import","Umlscui":"C0324842","SuperCategory":"Guenon","Id":"birnlex_7298"}},{"Cercopithecus diana":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","CurationStatus":"raw_import","Umlscui":"C0324840","SuperCategory":"Guenon","Id":"birnlex_7297"}},{"Cercopithecus hamlyni":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","CurationStatus":"raw_import","Umlscui":"C0324846","SuperCategory":"Guenon","Id":"birnlex_7296"}},{"Cercopithecus neglectus":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","CurationStatus":"raw_import","Umlscui":"C0324844","SuperCategory":"Guenon","Id":"birnlex_7295"}},{"Cercopithecus nictitans":{"Created":"2007-08-04","EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","CurationStatus":"uncurated","Umlscui":"C0324839","SuperCategory":"Guenon","Id":"birnlex_543"}},{"Cercopithecus pogonias":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","CurationStatus":"raw_import","Umlscui":"C1047128","SuperCategory":"Guenon","Id":"birnlex_7294"}},{"Cercopithecus sclateri":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","CurationStatus":"raw_import","SuperCategory":"Guenon","Id":"birnlex_7293"}},{"Cerebellar Afferents From The Lateral Reticular Nucleus":{"CurationStatus":"uncurated","SuperCategory":"Afferent","Id":"nlx_13841","Is part of":"Cerebellar mossy fiber"}},{"Cerebellar Afferents From The Paramedian Reticular Nucleus":{"CurationStatus":"uncurated","SuperCategory":"Afferent","Id":"nlx_61869","Is part of":"Reticular Mossy Fibers"}},{"Cerebellar Afferents From The Pontine Reticulotegmental Nucleus":{"CurationStatus":"uncurated","SuperCategory":"Afferent","Id":"nlx_27964","Is part of":"Reticular Mossy Fibers"}},{"Cerebellar Afferents From The Prepositus Nuclear Complex":{"CurationStatus":"uncurated","SuperCategory":"Afferent","Id":"nlx_11784","Is part of":"Vestibular Mossy Fibers"}},{"Cerebellar Ataxia":{"Synonym":["Cerebellar Incoordination","Adiadochokinesis","Cerebellar Dysmetria","Dysmetria"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Ataxia","Id":"birnlex_12647","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"Incoordination of voluntary movements that occur as a manifestation of CEREBELLAR DISEASES. Characteristic features include a tendency for limb movements to overshoot or undershoot a target (dysmetria), a tremor that occurs during attempted movements (intention TREMOR), impaired force and rhythm of diadochokinesis (rapidly alternating movements), and GAIT ATAXIA (MeSH)."}},{"Cerebellar cortex":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","CurationStatus":"uncurated","NeuronamesID":"644","Umlscui":["C1284087"],"SuperCategory":"Regional part of brain","Id":"birnlex_1566","Is part of":"Cerebellum,","Definition":"The superficial gray matter of the cerebellum. It consists of three main layers, the molecular layer, the Purkinje cell layer and the granule cell layer, and the white matter laminae lying deep to the granule cell layer."}},{"Cerebellar cortex granular layer of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Granular layer of cerebellar cortex","Comment":["Note that this term does not appear in the 2012 version of the Allen Brain Atlas in the Scalable Brain Atlas viewer","only the cross products between lobules and granular/molecular layer.  However"],"SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153786","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Cerebellar cortex of ABA 2009","Organism":"mouse","Species":"Mouse","Abbrev":"CBXgr"}},{"Cerebellar cortex of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Cerebellar cortex","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153438","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Cerebellum of ABA 2009","Species":"Mouse"}},{"Cerebellar cortex Purkinje layer of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Purkinje cell layer of cerebellar cortex","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153342","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Cerebellar cortex of ABA 2009","Organism":"mouse","Species":"Mouse","Abbrev":"CBXpu"}},{"Cerebellar Corticopontine Projection":{"EditorialNote":"This category is incorrect.  The term doesn't appear in the literature as the projection from the cortex to the cerebellum is via the pontine nuclei.  The proper term is \"pontinecerebellar projection\"","CurationStatus":"graph position temporary","SuperCategory":"Afferent","Id":"nlx_71654","Is part of":"Cerebellum"}},{"Cerebellar deep nucleus principal neuron":{"Located in":["Deep cerebellar nuclear complex"],"CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_151895","Species":"Vertebrata"}},{"Cerebellar hemisphere":{"Created":"2006-07-15","Synonym":"Intermediate zone","CurationStatus":"uncurated","SuperCategory":"Cerebellar cortex","Id":"birnlex_1575"}},{"Cerebellar mossy fiber":{"Synonym":"mossy fiber","MolecularConstituents":["Glutamate","Aspartate","Acetylcholine"],"CurationStatus":"uncurated","SuperCategory":"Afferent","Id":"nlx_260","Locaton":"cerebellum","Definition":"Axon arising from cerebellar projecting cells in the cochlea, vestibular nuclei, spinal cord, reticular formation, cerebellar nuclei and basilar pontine nuclei.  Mossy fibers enter through all three cerebellar peduncles and send collaterals to the deep cerebellar nuclei, then branch in the white matter and terminate in the granule cell layer.  Through this branching, a given mossy fiber can innervate several folia.  Mossy fibers synapse on granule cells.  The synaptic contacts are made at enlargements along the length of the mossy fiber called mossy fiber rosettes.  The enlargements of the rosettes give the axons as \"mossy\" appearance in Golgi stained preparations. (adapted from Shepherd, G. M.  The synaptic organization of the brain, 5th ed.  New York:  Oxford University Press, 2004)."}},{"Cerebellar Noradrenergic Afferents":{"CurationStatus":"uncurated","SuperCategory":"Afferent","Id":"nlx_88603","Definition":"Axons arising from noradrenergic cells in the medulla that project to the cerebellum"}},{"Cerebellar nuclei of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Deep cerebellar nuclear complex","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153386","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Cerebellum of ABA 2009","Species":"Mouse"}},{"Cerebellar Paravermis":{"Synonym":"Intermediate zone","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_anat_20081236","Is part of":"Cerebellar cortex","Definition":"A region on either side of the midline of the cerebellum that lies lateral to the vermis and medial to the hemisphere. It contains the cerebellar cortical zones C1, C2 and C3 and receives climbing fibre input from the inferior olive and projects to the nucleus interpositus. Here, the term is used to denote the functionally related C1, C3 and Y (but not the C2) zones (Nature glossary: http://www.nature.com/nrn/journal/v6/n4/glossary/nrn1646.html#df1)."}},{"Cerebellar penducular complex":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-09","EditorialNote":"UMLS uses the preferred term \"cerebellar peduncles and decussations\", NeuroNames uses the preferred term \"cerebellar peduncles\", but I'm trying to avoid plurals.  NN & UMLS preferred terms included as a synonym.","Synonym":["cerebellar peduncles and decussations"],"CurationStatus":"uncurated","NeuronamesID":"206","Umlscui":"C0228514","SuperCategory":"Regional part of cerebellar white matter","Id":"birnlex_970","Is part of":"White matter"}},{"Cerebellar Pontocerebellar Projection":{"CurationStatus":"uncurated","SuperCategory":"Afferent","Id":"nlx_67357","Is part of":"Cerebellum"}},{"Cerebellar Primary Vestibular Afferents":{"CurationStatus":"uncurated","SuperCategory":"Afferent","Id":"nlx_58835","Is part of":"Vestibular Mossy Fibers"}},{"Cerebellar Secondary Vestibular Afferents":{"CurationStatus":"uncurated","SuperCategory":"Afferent","Id":"nlx_31314","Is part of":"Vestibular Mossy Fibers"}},{"Cerebellar Serotonergic Afferents":{"Neurotransmitter":"Serotonin,","CurationStatus":"uncurated","SuperCategory":"Afferent","Id":"nlx_77690","Is part of":"Cerebellum","Definition":"Exert a diffuse, modulatory influence on the activity of cerebellar neurons"}},{"Cerebellar white matter":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"688","CurationStatus":"uncurated","Umlscui":"C0152381","SuperCategory":"Composite part spanning multiple base regional parts of brain","Id":"birnlex_1562","Definition":"Regional part of cerebellum consisting of the myelinated axons lying deep to the granule cell layer, excluding the deep cerebellar nuclei and the cerebellar peduncles."}},{"Cerebellum":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID"," limit":"1000"," ]]* Definition Source: [[definitionSource::FMC]]Non structured information for this region can be found http://en.wikipedia.org/wiki/Cerebellum":"Download All Parts of Cerebellum","Synonym":["Parencephalon"],"CurationStatus":"uncurated","ISBN":"0849394902"," format":"CSV","Authors":["Joseph Altman"],"Title":["Development of the cerebellar system: in relation to its evolution","structure"],"Created":"2006-07-15","DefiningCriteria":["cyto-architecture"],"NeuronamesID":"640","Umlscui":["C0007765"],"PublicationDate":"1997","SuperCategory":"Regional part of brain","Id":"birnlex_1489","Is part of":"Cerebrospinal axis","Species":"Vertebrata,","Definition":"Part of the rhombencephalon that lies in the posterior cranial fossa behind the brain stem, consisting of the cerebellar cortex, deep cerebellar nuclei and cerebellar white matter.A portion of the brain that helps regulate posture, balance, and coordination. (NIDA Media Guide Glossary)The dorsal topographic division of the hindbrain, connected to the ventral  division-the pons-by a white matter tract, the middle cerebellar peduncle. The cerebellum was discovered and named by Aristotle (De Partibus Animalium) based on macrodissection of a variety of animals not including humans; see translation by Thompson (1910, 494b 30). Older synonyms include parencephalon (Aristotle), hindbrain (Galen, c192). "}},{"Cerebellum basket cell":{"Located in":"Molecular layer of cerebellar cortex,","AxonLength":"up to 500 um","Synonym":"Cerebellar basket cell","CurationStatus":"uncurated","Comment":"Image from CCDB may actually be a candelabrum cell.  Needs verification.","Has role":"Intrinsic neuron role","OriginOfAxon":"soma","LocationOfAxonArborization":"Purkinje cell layer of cerebellar cortex,","CellularSynapticTarget":"Cerebellum Purkinje cell,","DefiningCriteria":"The axon terminals form a \"pinceau\" around the Purkinje cell body and axonal initial segment","Neurotransmitter":"GABA","SubcellularSynapticTarget":"The axon terminals from up to 50 different basket cells converge to form a \"pinceau\" around each Purkinje cell body and axonal initial segment","SuperCategory":"Neuron","NumberOfPrimaryDendrites":"4-8","Id":"sao666951243","Polarity":"Multipolar","Species":"Vertebrata","DendriteThickness":"up to several um","Definition":"Intrinsic cell residing in the inner third of the molecular layer of the cerebellar cortex.  Axons extend laterally, transverse to the folium, and densely innervate the somata of Purkinje neurons.  Axon collaterals of the basket cell axon form the specialized terminal plexus, the \"pinceau\", around the Purkinje cell axon initial segment. Llinas, Walton and Lang.  In: The Synaptic Organization of the Brain.  5th ed. 2004."}},{"Cerebellum candelabrum cell":{"Located in":["Cerebellum"],"Synonym":["candelabrum cell"],"CurationStatus":"uncurated","Pages":"159-73","JournalVolume":"339","Curator":"Mihail Bota","Authors":["Laine J"],"Title":"The candelabrum cell: a new interneuron in the cerebellar cortex.","PMID":"8300903","EditorialNote":"http://onlinelibrary.wiley.com/doi/10.1002/cne.903390202/pdf","PublicationDate":"1994","ExampleImage":"Cerebellum candelabrum cell.JPG,","SuperCategory":"Neuron","PublicationName":"Journal of Comparative Neurology","NumberOfPrimaryDendrites":"1 or 2","Id":"BAMSC981","JournalNumber":"2","Species":["Rat"],"DefiningCitation":"Laine and Axelrad","SpeciesPMID":"16784818","Definition":"Neuron with perikaryon located inside the Purkinje cell layer. It is squeezed, either between the bulging parts of the PC somata or in the space left free between their upper poles, just at the level of the lower border of the molecular layer."}},{"Cerebellum Golgi cell":{"Located in":"Granular layer of cerebellar cortex,","AxonLength":"200-300 um","Synonym":["Cerebellar Golgi neuron"],"CurationStatus":"uncurated","OriginOfAxon":"soma","LocationOfAxonArborization":"Granular layer of cerebellar cortex,","CellularSynapticTarget":["superior olive cells","Granular layer of cerebellar cortex"],"EditorialNote":"http://www.neuroscience.cam.ac.uk/directory/profile.php?th247","DefiningCriteria":["Large stiff dendrites traversing the cerebellar cortical layers"],"Neurotransmitter":"GABA","ExampleImage":"Cerebellum Golgi cell.jpg,","SubcellularSynapticTarget":["Granule cell dendritic claws"],"SuperCategory":"Neuron","NumberOfPrimaryDendrites":"8-12","Id":"sao1415726815","Polarity":"Multipolar","CellSomaShape":"Spherical","Species":"Vertebrata","DendriteThickness":"2-4 um","Definition":"Large intrinsic neuron located in the granule layer of the cerebellar cortex that extends its dendrites into the molecular layer where they receive contact from parallel fibers.  The axon of the Golgi cell enters ramifies densely in the granule layer and enters into a complex arrangement with mossy fiber terminals and granule cell dendrites to form the cerebellar glomerulus. Llinas, Walton and Lang. In The Synaptic Organization of the Brain. 5th ed. 2004."}},{"Cerebellum granule cell":{"Located in":"Granular layer of cerebellar cortex","AxonLength":"Mouse: up to 4 mm.  Rat: up to 5 mm.","Synonym":["Cerebellar granule neuron"],"CurationStatus":"uncurated","Comment":"This is a duplicate with ID: sao1736323572","NeurotransmitterReceptors":"Glutamate-gated cationic channel,","OriginOfAxon":"soma","LocationOfAxonArborization":"Molecular layer of cerebellar cortex","CellularSynapticTarget":["Cerebellum Purkinje cell","Cerebellum stellate cell"],"Created":"2007-09-05","EditorialNote":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","DefiningCriteria":"Small soma with short claw-like dendrites","Neurotransmitter":"Glutamate,","ExampleImage":"Cerebellar granule cell.gif,","SubcellularSynapticTarget":"Dendritic spine","SuperCategory":"Neuron","NumberOfPrimaryDendrites":"3-5","Id":"nifext_128","Polarity":"Multipolar","Species":"Vertebrata","DendriteThickness":"Mouse: 1-2 um.  Rat: 1-2 um.","Definition":"Small, numerous neuron in the granule cell layer of the vertebrate cerebellar cortex, characterized by a very small soma and several short dendrites which terminate with claw-shaped endings.  In the transmission electron microscope, these cells are characterized by a darkly stained nucleus surrounded by a thin rim of cytoplasm.  The axon ascends into the molecular layer where it bifurcates to form parallel fibers which run parallel to the long axis of the folium.  Llinas, Walton and Lang. Cerebellum. In The Synaptic Organization of the Brain. 5th ed. 2004."}},{"Cerebellum granule cell axon":{"CurationStatus":"uncurated","SuperCategory":"Axon","Id":"nlx_152974","Is part of":"Cerebellum granule cell","Definition":"The axon of a cerebellum granule cell, comprising both ascending and parallel fibers"}},{"Cerebellum Lugaro cell":{"Located in":["Cerebellum","Purkinje cell layer of cerebellar cortex"],"CellularSynapticTarget":["Cerebellum Golgi cell","Cerebellum stellate cell"],"EditorialNote":"http://researchlsd.blogspot.com/2008/07/lugaro-cells.html","CurationStatus":"uncurated","MolecularConstituents":"GABA,","Neurotransmitter":"GABA,","ExampleImage":"Cerebellum Lugaro cell.jpg,","SuperCategory":"Neuron","Id":"nifext_133","Species":"Vertebrata","Definition":"Type of neuron found in cerebellar granule cell layer characterized by a fusiform cell body with thick, horizontally oriented dendrites. Lugaro cells are located in or slightly below the Purkinje cell layer outermost edge of the granular layer."}},{"Cerebellum nucleus reciprocal projections neuron":{"Located in":["Cerebellum"],"Synonym":["reciprocal projections neuron"],"CurationStatus":"uncurated","Pages":"251-256","JournalVolume":"99","Curator":"Mihail Bota","Authors":["Batini C","Buisseret-Delmas C","Compoint C"],"Title":"The GABAergic neurones of the cerebellar nuclei in the rat: projections to the cerebellar cortex.","PMID":"2471118","PublicationDate":"1989","SuperCategory":"Neuron","PublicationName":"Neuroscience Letters","Id":"BAMSC1042","JournalNumber":"3","Species":"Vertebrata","DefiningCitation":"Batini et al. 1989","Definition":"...perfectly matched those (2) described previously reciprocal, non to reciprocal and symmetrical projections were found. Collator note: this neurons receive projections from Purkinke cells and send feedback axons to the same cerebellar cortex neurons. From"}},{"Cerebellum of ABA 2009":{"PartiallyOverlapsWith":"Cerebellum","CurationStatus":"uncurated","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153185","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse","Species":"Mouse"}},{"Cerebellum of CIVM postnatal rat brain atlas":{"AtlasImage":["cerebellum p0.png"],"CurationStatus":"uncurated","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151520","Is part of":"Hindbrain of CIVM postnatal rat brain atlas","Definition":"Segmentation of the cerebellum is straightforward and can be done on virtually any MR contrast in the coronal and/or sagittal plane. A majority of the border between the cerebellum and the rest of the hindbrain is defined by ventricle. The major difficulty is in deciding how to apportion the territory of the cerebellar peduncles, which traverse the cerebellum/hindbrain border. One solution is to follow a best-fit line between the vestibular nuclei medially and the cochlear nuclei laterally and use that as a dividing line between cerebellum and hindbrain."}},{"Cerebellum of WHS11":{"AtlasImage":"Cerebellum of WHS11.png,","EditorialNote":"Current delineation looks like it includes the dorsal cochlear nucleus in the medulla on the more anterior sections.  Needs review","PartiallyOverlapsWith":"Cerebellum","CurationStatus":"uncurated","SuperCategory":"Waxholm 2011 parcellation scheme region","Id":"nlx_143760","ParcellationScheme":"Waxholm 2011 parcellation scheme","Is part of":"Hindbrain of WHS11","Species":"Mouse","Definition":"Delineation of cerebellum in Waxholm mouse brain atlas, as seen in T1 and T2* weighted volumes.  As seen in transverse: texture, intensity and apparent line separates cerebellum from other anatomy.  Includes cerebellar cortex and deep cerebellar nuclei;  does not include cerebellar peduncles within the brainstem."}},{"Cerebellum Purkinje cell":{"Located in":"Purkinje cell layer of cerebellar cortex","BranchingMetrics":"unipolar","AxonLength":"Mouse: up to 2 mm.  Rat: up to 3 mm.","Synonym":["Purkinje neuron","Purkinje's corpuscles","Cerebellar Purkinje neuron","Purkinje Cell","Purkyne cell","Corpuscles of Purkinje"],"CurationStatus":"uncurated","FiringPatterns":"Regular firing and bursting","SpontaneousFiringPatterns":"Regular firing and bursting","CellSomaSize":"Large soma","LocationOfAxonArborization":"Deep cerebellar nuclear complex,","SpineDensityOnDendrites":"spiny high density","DefiningCriteria":"Morphology;  Connectivity; Biochemical","LocationOfLocalAxonArborization":"Purkinje cell layer of cerebellar cortex","Neurotransmitter":"GABA","SuperCategory":"Neuron","CellSomaShape":"Spherical","Species":"Mammal","DendriteThickness":["Mouse: thick trunk (2-5 um); thin branches (0.5-1 um).  Rat: Thick trunk (3-6 um)"],"AxonProjectionLaterality":"ipsilateral","SenseLabId":"271","Has role":"Principal neuron role","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel","GABA-gated anionic channel"],"OriginOfAxon":"soma","Xref":"BAMSC977","CellularSynapticTarget":["Cerebellum Purkinje cell"],"EditorialNote":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","ExampleImage":"Cerebellum Purkinje cell.gif,","SubcellularSynapticTarget":"Local: cell bodies; distant: cell bodies and dendrites","NumberOfPrimaryDendrites":"1 (rarely 2)","AxonMyelination":"myelinated","Id":"sao471801888","Polarity":["Bipolar"],"SpontaneousFiringRate":"Rapid firing","Definition":"Principal neuron (projection neuron) of the cerebellar cortex; cell bodies arranged in a single layer; characterized by a pear-shaped cell body, 1 (rarely 2) primary dendrites and an elaborate dendritic tree heavily invested with dendritic spines."}},{"Cerebellum stellate cell":{"Located in":"Cerebellum,Molecular layer of cerebellar cortex","Synonym":["Cerebellar stellate neuron"],"CurationStatus":"uncurated","LocationOfAxonArborization":"Molecular layer of cerebellar cortex","CellularSynapticTarget":["Purkinje cell layer of cerebellar cortex"],"EditorialNote":"http://en.wikipedia.org/wiki/File:Pyramsdal-and-Spiny-stellate-cell.JPG","Neurotransmitter":"GABA","ExampleImage":"Cerebellum stellate cell.GIF,","SuperCategory":"Neuron","HasRole":"Intrinsic neuron role","Id":"nifext_130","Polarity":"Multipolar","Species":"Vertebrata","Definition":"Multipolar neuron found in cerebellar molecular layer."}},{"Cerebellum unipolar brush cell":{"Located in":"Granular layer of cerebellar cortex,","Located_in":"Cerebellum,Granular layer of cerebellar cortex","Synonym":["Unipolar brush neuron"],"CurationStatus":"uncurated","LocationOfAxonArborization":"Granular layer of cerebellar cortex","PMID":"8300904","Created":"2007-09-05","DefiningCriteria":"Morphology + calretinin immunoreactivity","Neurotransmitter":"Glutamate","SuperCategory":"Neuron","Species":"Mammal","DefiningCitation":["Kalinchichenko","S. G. and Okhotin","V. E.  Unipolar brush cells-a new type of excitatory interneuron in the cerebellar cortex and cochlear nuclei of the brainstem.  Neuroscience and Behavioral Physiology","25 (1)","21-26"],"MolecularConstituents":"Calretinin","Comment":"There are apparently two distinct populations of UBC's staining for calretinin and mGluR1 alpha respectively","Has role":"Intrinsic neuron role","OriginOfAxon":"soma","Abbrev":"UBC","CellularSynapticTarget":["Cerebellum granule cell"],"EditorialNote":"http://onlinelibrary.wiley.com/doi/10.1002/cne.903390203/pdf","ExampleImage":"Cerebellum unipolar brush cell.JPG,","SubcellularSynapticTarget":"axons of Golgi cells;  dendrodendritic synapses with granule cells","NumberOfPrimaryDendrites":"1","Id":"nifext_132","Polarity":"Bipolar","Definition":"A type of cell in the cerebellar cortex, first described in 1977 by Altman and Bayer, characterized by a single dendrite ending in a small brush consisting of a number of small dendrites called dendrioles.  Unipolar brush cells are found in primarily in the granular cell layer and most concentrated in lobule IX, the flocculus, the nodulus and the ventromedial zone of the paraflocculus.  Their somata are larger than granule cells but smaller than Golgi cells.  They are known to stain for calretinin."}},{"Cerebral aqueduct":{"Created":"2006-07-15","Synonym":"aqueduct of Sylvius","CurationStatus":"uncurated","Umlscui":"C0007769","SuperCategory":"Regional part of brain","Id":"birnlex_1261","Is part of":["Cerebral ventricular cavity"],"Definition":"Part of ventricular system of brain consisting of a narrow channel in the midbrain connecting the third and fourth ventricles.  (Maryann Martone)"}},{"Cerebral cortex":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["Cortex"],"CurationStatus":"uncurated","Is_part_of":"Telencephalon","Abbrev":"Cx","Created":"2006-07-15","DefiningCriteria":["cyto-architecture","connectivity"],"NeuronamesID":"20","Umlscui":"C0007776","SuperCategory":"Regional part of brain","Id":"birnlex_1494","Is part of":"Cerebrospinal axis","Definition":"The thin layer of gray matter on the surface of the cerebral hemisphere that develops from the telencephalon.  It consists of the neocortex (6 layered cortex or isocortex), the hippocampal formation and the olfactory cortex.The '''cerebral cortex''' is a sheet of neural tissue that is outermost to the cerebrum of the mammalian brain. It plays a key role in memory, attention, perceptual awareness, thought, language, and consciousness. It is constituted of up to six horizontal layers, each of which has a different composition in terms of neurons and connectivity.One of the 10 basic divisions of the cerebrospinal axi. The cerebral cortex is the dorsal topographic division of the endbrain (Kuhlenbeck, 1927), with a basically radial, laminated architecture. The cerebral cortex was described and illustrated for macrodissected adult humans by Vesalius (1543), and the term itself was introduced for macrodissected adult humans by Bauhin (1605)."}},{"Cerebral cortex layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Cerebral cortex  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153095","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cerebral cortex layer 2 of ABA 2009":{"PartiallyOverlapsWith":"Cerebral cortex  layer 2","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153135","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cerebral cortex layer 2-3 of ABA 2009":{"PartiallyOverlapsWith":"Cerebral cortex  layer 2-3","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153404","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cerebral cortex layer 3 of ABA 2009":{"PartiallyOverlapsWith":"Cerebral cortex  layer 3","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153173","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cerebral cortex layer 4 of ABA 2009":{"PartiallyOverlapsWith":"Cerebral cortex  layer 4","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153721","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cerebral cortex layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Cerebral cortex  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152946","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cerebral cortex layer 6 of ABA 2009":{"PartiallyOverlapsWith":"Cerebral cortex  layer 6","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153049","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cerebral cortex layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Cerebral cortex  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153560","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cerebral cortex layers 1-6b of ABA 2009":{"PartiallyOverlapsWith":"Cerebral cortex  layers 1-6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153354","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cerebral cortex of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Cerebral cortex","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_151353","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Cerebrum of ABA 2009","Species":"Mouse","Definition":"Super-parcellation of Allen Brain Atlas reference atlas comprising cortical plate (isocortex, olfactory areas and hippocampal formation) and and cortical subplate structures (claustrum, endopiriform cortex and some amygdaloid nuclei)"}},{"Cerebral cortex of PHT00":{"CurationStatus":"uncurated","ISBN":"123582555","Curator":"CoCoMac{{PONS brain region","Authors":["George Paxinos","Xu-Feng Huang"],"Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"Cx","PartiallyOverlapsWith":["neocortex","hippocampal formation","olfactory bulb","Prepyriform area","septohippocampal nucleus"],"PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Id":"nlx_br_246","ParcellationScheme":["Paxinos"],"Species":"Macaque","DefiningCitation":"ISBN 0123582555"}},{"Cerebral crus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","CurationStatus":"uncurated","NeuronamesID":"530","Umlscui":"C0175414","SuperCategory":"Regional part of brain","Id":"birnlex_1218","Is part of":["White matter"],"Abbrev":"ccr"}},{"Cerebral Hemorrhage":{"Synonym":["Intracerebral Hemorrhage","Cerebral Brain Hemorrhage","Cerebral Parenchymal Hemorrhage"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Cerebrovascular Disorder","Id":"birnlex_12795","Definition":"Bleeding into a cerebral hemisphere of the brain, including lobar, subcortical white matter, and basal ganglia hemorrhages. Commonly associated conditions include HYPERTENSION; INTRACRANIAL ARTERIOSCLEROSIS; INTRACRANIAL ANEURYSM; CRANIOCEREBRAL TRAUMA; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; CEREBRAL AMYLOID ANGIOPATHY; and CEREBRAL INFARCTION (MeSH)."}},{"Cerebral Infarction":{"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Brain Infarction","Id":"birnlex_12791","Definition":"The formation of an area of necrosis in the cerebrum caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction) (MeSH)."}},{"Cerebral nuclei":{"Synonym":["Basal ganglia (Warwick & Williams","1973)","Cerebral ganglia (Reil","1809)","Corpus striatum (Willis"],"DefiningCriteria":["cyto-architecture","connectivity"],"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_158496","Is part of":"Cerebrospinal axis","ParcellationSchemePMID":["Swanson"],"Species":"Vertebrata","Abbrev":"CNU","Definition":"The ventral topographic division of the endbrain, with a basically nonlaminated architecture (Swanson, 2000).The general outlines of the cerebral nuclei were described for macrodissected adult humans by Bartholin (1651), and a basic distinction during embryogenesis between cerebral cortex and cerebral nuclei was stressed by Baer (1837) and Reichert (1859-1861). The most common synonym today for cerebral nuclei, which was clearly defined by Swanson (2000), is basal ganglia (Warwick & Williams, 1973)."}},{"Cerebral nuclei of ABA 2009":{"PartiallyOverlapsWith":"Cerebral nuclei","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153222","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cerebral palsy":{"Synonym":["cerebral palsy","Spastic paralysis","Spastic hemiplegia","Spastic diplegia"],"CurationStatus":"uncurated","SuperCategory":"Neurodegenerative disease","Id":"DOID:1969","Definition":"A group of disorders that involve brain and nervous system functions including movement, learning, hearing, seeing, and thinking. (adapted PubMed Health)"}},{"Cerebral peduncle":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","EditorialNote":"Cerebral peduncle seems to be used differently in different nomenclatures.  In the rodent (and other non-human species), it seems to refer to the crus cerebri, while in human, it's the entire ventral midbrain.  Need to reconcile/clarify","DefiningCriteria":"topography","CurationStatus":"uncurated","NeuronamesID":"478","Umlscui":"C0007793","SuperCategory":"Regional part of brain","Id":"birnlex_1202","Abbrev":"CP","Definition":"Synonym for macrodissected adult human tegmentum (Vicq d'Azyr, 1784; Swanson, 2000); pp. 555-556. Later used thus by for example His (1893b, p. 178), Herrick (1915, p. 160), Strong & Elwyn (1943, p. 17), Carpenter (1976, p. 367), Williams & Warwick (1980, p. 935)."}},{"Cerebral Spinal Fluid":{"Created":"2007-10-18","Synonym":"Cerebrospinal fluid","CurationStatus":"uncurated","Umlscui":"C0007806","SuperCategory":"Bodily fluid","Id":"birnlex_1798","Abbrev":"CSF","Definition":"The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord. (NCI)  Transudate contained in the subarachnoid space. (UWDA)   clear colorless liquid secreted by the choroid plexus of the lateral, third, and fourth ventricles, and contained within the ventricular system of the brain and spinal cord and within the subarachnoid space. (CSP)"}},{"Cerebral white matter":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-04","NeuronamesID":"171","CurationStatus":"uncurated","Umlscui":["C0152295"],"SuperCategory":"Regional part of brain","Id":"birnlex_711","Definition":"White matter is one of the two main solid components of the central nervous system. It is composed of myelinated nerve cell processes, or axons, which connect various grey matter areas (the locations of nerve cell bodies) of the brain to each other and carry nerve impulses between neurons. Cerebral and spinal white matter do not contain dendrites, which can only be found in grey matter along with neural cell bodies and shorter axons (Christine Fennema-Notestine)."}},{"Cerebrospinal axis":{"DefiningCriteria":"topography","CurationStatus":"uncurated","TomoDefiningCriteria":"lies in the medial plane of the bodydorsal to the notochord","SuperCategory":"Regional part of brain","Id":"nlx_158477","ParcellationScheme":"Swanson-04","Is part of":"Nervous system","Species":"Vertebrata","Abbrev":"CSA","Definition":"The hollow tubular division of the nervous system that lies in the median plane, dorsal to a notochord and flanked by a bilateral series of segmental muscles.It is the topographic division that corresponds to the vertebrate central nervous system."}},{"Cerebrovascular Accident":{"Synonym":["Cerebral Stroke","Cerebrovascular Apoplexya","Cerebrovascular Stroke","Apoplexy"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Cerebrovascular Disorder","Id":"birnlex_12783","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"A sudden, nonconvulsive loss of neurologic function due to an ischemic or hemorrhagic intracranial vascular event. In general, cerebrovascular accidents are classified by anatomic location in the brain, vascular distribution, etiology, age of the affected individual, and hemorrhagic vs. nonhemorrhagic nature (MeSH)."}},{"Cerebrovascular Disorder":{"EditorialNote":"Note BIRNLex seeks to evolve a core subsumptive disease hierarchy based first on the effected function, then the effected structure, the latter for those categories of nervous system disease that have typically been associated with structural abnormalities or trauma (e.g., Motor neuron diseases, cerebrovascular trauma, etc.). Disease causation is in fact the ultimate goal of much biomedical research, and our recognitition of ALL the driving causes of a particular disease - and the ways in which these causes inter-relate with each other and with effected structures to cause a change in normal function is a critical representational task BIRNlex will increasingly take on to provide an evolving, nuanced functional reconstruction of disease as a process and an outcome.  These relations will be represented using OWL ObjectProperties.  Function is the most sensible context to drive the asserted subsumptive hierarchy for representing nervous system disease, since it is with the clinical description of altered, impaired, decreased, or lost function that the diagnosis - and the research - of disease is rooted.  Much has already been described regarding both the effected biomaterial entities and the causes of disease.  However, it is because understanding of such relations still is far from comprehensive, that biomedical investigation into nervous system disease continues.  Finally, given the \"realist\" ontology design approach being used to construct BIRNLex, function must be represented as inhering in some biomaterial entity from molecules and their controlling elements on up through gross anatomical structures.  Over time, BIRNLex will provide the required relations to depict these functionally-related structures for both the normal and pathological function of the nervous system.  This will be true both for the causes and for the outcomes of nervous system disease.  Initial work to extend this expressive representation will focus on the neurodegenerative diseases being studied by BIRN researchers.  Though this will be te case, BIRNLex still needs to provide a core asserted hierarchy for a broad swarth of nervous system disease, so as to enable BIRN researchers to link to the breadth of disorders that may impact or relate to those directly under study.","Synonym":["Intracranial Vascular Disorder","Brain Vascular Disorder"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Nervous system disease","Id":"birnlex_12780","Definition":"A broad category of disorders characterized by impairment of blood flow in the arteries and veins which supply the brain. These include CEREBRAL INFARCTION; BRAIN ISCHEMIA; HYPOXIA, BRAIN; INTRACRANIAL EMBOLISM AND THROMBOSIS; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; and VASCULITIS, CENTRAL NERVOUS SYSTEM. In common usage, the term cerebrovascular disorders is not limited to conditions that affect the cerebrum, but refers to vascular disorders of the entire brain including the DIENCEPHALON; BRAIN STEM; and CEREBELLUM (MeSH)."}},{"Cerebrovascular Trauma":{"Synonym":["Vascular Brain Injury"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Nervous System Trauma","Id":"birnlex_12666","Definition":"Penetrating and nonpenetrating traumatic injuries to an extracranial or intracranial blood vessel that supplies the brain. This includes the CAROTID ARTERIES, vertebral arteries ( VERTEBRAL ARTERY), and intracranial arteries, veins, and venous sinuses (MeSH)."}},{"Cerebrum":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","EditorialNote":"It is definitely correct to sub-class Cerebrum as a Regional_part_of_forebrain.  It isn't clear all would agree Cerebrum and Telencephalon are equivalent.  Is this what we want to declare for BIRNLex? (BB).Nolte (The Human Brain:  An Introduction to its Functional Neuroanatomy, 6th ed pg 72, presents a hierarchy where the cerebrum consists of the cerebral hemispheres (plus subcortical structures) and the diencephalon.  This is not a term that has much scientific validity, nor, in my opinion, is it worth declaring a definition one way or the other (MM)","NeuronamesID":"223","CurationStatus":"uncurated","Umlscui":"C0242202","SuperCategory":"Regional part of brain","Id":"birnlex_1042","Definition":"Gross division of the brain.  The term cerebrum has several definitions ranging in generality from equivalence to the term \"brain\" to the sum of the left cerebral hemisphere and right hemisphere, to a composite structure consisting of the cerebral cortex and adjacent cerebral white matter. A thorough discussion of the nature and history of the different definitions is presented in Anthoney-94 (NeuroNames)."}},{"Cerebrum of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Telencephalon","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152949","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Species":"Mouse"}},{"Cerivastatin":{"RelatedTo":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","Synonym":["Cerivastatin sodium","Cerivastatin","sodium salt","Baycol","Lipobay"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00439","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00439","Definition":"On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market. Pharmacology: Cerivastatin, a competitive HMG-CoA reductase inhibitor effective in lowering LDL cholesterol and triglycerides, is used to treat primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb). Mechanism of action: Cerivastatin competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the hepatic enzyme responsible for converting HMG-CoA to mevalonate. As mevalonate is a precursor of sterols such as cholesterol, this results in a decrease in cholesterol in hepatic cells, upregulation of LDL-receptors, and an increase in hepatic uptake of LDL-cholesterol from the circulation. Drug type: Small Molecule. Withdrawn. Drug category: Anticholesteremic Agents. Antilipemic Agents. Hydroxymethylglutaryl-CoA Reductase Inhibitors"}},{"Cerulenin":{"RelatedTo":["3-oxoacyl-(acyl-carrier-protein) synthase 3","3-oxoacyl-(acyl-carrier-protein) synthase 2","3-oxoacyl-(acyl-carrier-protein) synthase 1"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01034","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01034","Definition":"Cerulenin is an antifungal antibiotic that inhibits sterol and fatty acid biosynthesis. In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity. It is also shown to inhibit feeding and induce dramatic weight loss in mice. It is found naturally in the Cephalosporium caerulensfungus. (Wikipedia) Pharmacology: Cerulenin is an antifungal antibiotic isolated from Cephalosporium caerulens. It interrupts fungal growth by inhibiting the biosynthesis of sterols and fatty acids (inhibits bacterial fatty acid synthesis). It also inhibits HMG-CoA synthetase activity. Cerulenin produces metabolic effects similar to effects of leptin, but through mechanisms that are independent of, or down-stream from, both leptin and melanocortin receptors. Mechanism of action: Irreversibly binds to fatty acid synthase, specifically b-ketoacyl-acyl carrier protein synthase (FabH, FabB and FabF condensation enzymes). A number of tumor cells and cell lines have been observed to have highly upregulated expression and activity of fatty acid synthase (FAS). Inhibition of FAS by cerulenin leads to cytotoxicity and apoptosis in human cancer cell lines, an effect believed to be mediated by the accumulation of malonyl-coenzyme A in cells with an upregulated FAS pathway. Drug type: Approved. Small Molecule. Drug category: Antibiotics, Antifungal. Fatty Acid Synthesis Inhibitors"}},{"Ceruletide":{"RelatedTo":"Cholecystokinin type A receptor","SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00403","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00403","Definition":"Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. Pharmacology: Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. Mechanism of action: Caerulein acts according to its similarity to the natural gastrointestinal peptide hormone cholecystokinin. Cholecystokinin is a peptide hormone of the gastrointestinal system responsible for stimulating the digestion of fat and protein. Cholecystokinin is secreted by the duodenum, the first segment of the small intestine, and causes the release of digestive enzymes and bile from the pancreas and gall bladder, respectively. It also acts as a hunger suppresant. Cholecystokinin is secreted by the duodenum when fat- or protein-rich chyme leaves the stomach and enters the duodenum. The hormone acts on the pancreas to stimulate the secretion of the enzymes lipase, amylase, trypsin, and chymotrypsin. Together these pancreatic enzymes catalyze the digestion of fat and protein. Cholecystokinin also stimulates both the contraction of the gall bladder, and the relaxtion of the Sphincter of Oddi (Glisson's Sphinctor), which delivers, (not secretes) bile into the small intestine. Bile salts serve to emulsify fats, thereby increasing the effectiveness with which enzymes can digest them. Drug type: Approved. Small Molecule. Drug category: Diagnostic aids"}},{"Cervical dorsal root ganglion":{"Created":"2007-08-28","CurationStatus":"uncurated","Umlscui":"C0457466","SuperCategory":"Dorsal root ganglion","Id":"birnlex_2599"}},{"Cervical spinal cord":{"Created":"2007-08-18","CurationStatus":"uncurated","Umlscui":["C1278837"],"SuperCategory":"Regional part of spinal cord","Id":"birnlex_1499","Is part of":"Spinal cord"}},{"Cervical spinal cord central canal":{"Created":"2007-08-18","CurationStatus":"uncurated","Umlscui":"C0228620","SuperCategory":"Regional part of spinal cord","Id":"birnlex_1511","Is part of":"Spinal cord central canal","Definition":"Part of central canal contained within the cervical spinal cord.  It is continuous caudally with the thoracic spinal cord central canal and rostrally with the fourth ventricle of the brain via the obex (http://en.wikipedia.org/wiki/Central_canal_of_spinal_cord_"}},{"Cervical spinal cord dorsal column":{"Created":"2007-08-18","Synonym":"Cervical spinal cord posterior column","CurationStatus":"uncurated","Umlscui":"C0228617","SuperCategory":"Regional part of cervical spinal cord white matter","Id":"birnlex_736","Is part of":"Cervical spinal cord white matter"}},{"Cervical spinal cord dorsal horn":{"Created":"2007-08-18","Synonym":"Cervical spinal cord posterior horn","CurationStatus":"uncurated","Umlscui":"C0228611","SuperCategory":"Regional part of cervical spinal cord gray matter","Id":"birnlex_1673","Is part of":"Cervical spinal cord gray matter"}},{"Cervical spinal cord gray commissure":{"Created":"2007-08-18","CurationStatus":"uncurated","SuperCategory":"Regional part of cervical spinal cord gray matter","Id":"birnlex_1614","Is part of":"Cervical spinal cord gray matter"}},{"Cervical spinal cord gray matter":{"Created":"2007-08-18","CurationStatus":"uncurated","Umlscui":"C0228610","SuperCategory":"Regional part of spinal cord","Id":"birnlex_1521","Is part of":"Cervical spinal cord"}},{"Cervical spinal cord lateral column":{"Created":"2007-08-18","CurationStatus":"uncurated","Umlscui":"C0228618","SuperCategory":"Regional part of cervical spinal cord white matter","Id":"birnlex_729","Is part of":"Cervical spinal cord white matter"}},{"Cervical spinal cord lateral horn":{"Created":"2007-08-18","Synonym":"Cervical spinal cord intermediate horn","CurationStatus":"uncurated","Umlscui":["C1278739"],"SuperCategory":"Regional part of cervical spinal cord gray matter","Id":"birnlex_1665","Is part of":"Cervical spinal cord gray matter"}},{"Cervical spinal cord ventral column":{"Created":"2007-08-18","Synonym":"Cervical spinal cord anterior column","CurationStatus":"uncurated","Umlscui":["C0228619"],"SuperCategory":"Regional part of cervical spinal cord white matter","Id":"birnlex_1660","Is part of":"Cervical spinal cord white matter"}},{"Cervical spinal cord ventral commissure":{"Created":"2007-08-18","Synonym":["Cervical spinal cord anterior commissure"],"CurationStatus":"uncurated","SuperCategory":"Regional part of cervical spinal cord white matter","Id":"birnlex_1552","Is part of":["Cervical spinal cord white matter"]}},{"Cervical spinal cord ventral horn":{"Created":"2007-08-18","Synonym":"Cervical spinal cord anterior horn","CurationStatus":"uncurated","Umlscui":["C0228615"],"SuperCategory":"Regional part of cervical spinal cord gray matter","Id":"birnlex_1680","Is part of":"Cervical spinal cord gray matter"}},{"Cervical spinal cord white matter":{"Created":"2007-08-18","CurationStatus":"uncurated","Umlscui":"C0228616","SuperCategory":"Regional part of cervical spinal cord","Id":"birnlex_1531","Is part of":["Cervical spinal cord"]}},{"Cestoda":{"Created":"2007-11-30","CurationStatus":"pending_final_vetting","Umlscui":"C0007892","SuperCategory":"Platyhelminthes","Id":"birnlex_7200"}},{"Cetacea":{"Created":"2007-10-06","CurationStatus":"pending_final_vetting","Umlscui":"C0007896","SuperCategory":"Cetartiodactyla","Id":"birnlex_647"}},{"Cetartiodactyla":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C1041118","SuperCategory":"Laurasiatheria","Id":"birnlex_517"}},{"Cetirizine":{"RelatedTo":"Histamine H1 receptor","Synonym":["Cetirizina (Spanish)","Cetirizinum (Latin)","Cetrizine Hcl","Alerlisin","Cetryn","Formistin","Hitrizin Film Tablet","Reactine","Setir","Virlix","Ziptek","Zirtek","Zyrlex"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3561","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00341","Definition":"A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects. (PubChem) Pharmacology: Cetirizine, the active metabolite of the piperazine H1-receptor antagonist hydroxyzine, is used to treat chronic idiopathic urticaria, perennial allergic rhinitis, seasonal allergic rhinitis, allergic asthma, physical urticaria, and atopic dermatitis. Mechanism of action: Cetirizine competes with histamine for binding at H1-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The low incidence of sedation can be attributed to reduced penetration of cetirizine into the CNS as a result of the less lipophilic carboxyl group on the ethylamine side chain. Drug type: Approved. Small Molecule. Drug category: Anti-Allergic Agents. Antihistamines. Histamine H1 Antagonists, Non-Sedating"}},{"Cetrorelix":{"RelatedTo":["Lutropin-choriogonadotropic hormone receptor"],"Synonym":["Cetrorelix Acetate","Cetrorelixum (INN-Latin)","SB 75","SB-75"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00050","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00050","Definition":"Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released. Cetrorelix does not allow the premature release of these eggs to occur. Pharmacology: Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. Mechanism of action: Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. Drug type: Approved. Biotech. Investigational. Drug category: Hormone Antagonists. Infertility Agents"}},{"Cetuximab":{"RelatedTo":["High affinity immunoglobulin gamma Fc receptor I","Epidermal growth factor receptor","Low affinity immunoglobulin gamma Fc region receptor III-B","Complement C1s subcomponent","Complement C1r subcomponent","Complement C1q subcomponent subunit A","Complement C1q subcomponent subunit B","Complement C1q subcomponent subunit C","Low affinity immunoglobulin gamma Fc region receptor III-A","Low affinity immunoglobulin gamma Fc region receptor II-a","Low affinity immunoglobulin gamma Fc region receptor II-b"],"Synonym":["Anti EGFR","IMC-C225","cetuximab","Erbitux"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00002","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00002","Definition":"Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions. Pharmacology: Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factoralpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production. Mechanism of action: Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread. Drug type: Biotech. Drug category: Antineoplastic Agents"}},{"Cevimeline":{"RelatedTo":["Cholinergic system","Muscarinic acetylcholine receptor M3"],"Synonym":["Cevimeline hydrochloride","Cevimeline hydrochloride hemihydrate","Cevimeline hydrochloride hydrate","Evoxac"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3568","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00185","Definition":"Cevimeline is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjgren's syndrome. (Wikipedia) Pharmacology: Cevimeline is a cholinergic agonist which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and urinary tracts. Mechanism of action: Muscarinic agonists such as cevimeline bind and activate the muscarinic M1 and M3 receptors. The M1 receptors are common in secretory glands (exocrine glands such as salivary and sweat glands), and their activation results in an increase in secretion from the secretory glands. The M3 receptors are found on smooth muscles and in many glands which help to stimulate secretion in salivary glands, and their activation generally results in smooth muscle contraction and increased glandular secretions. Therefore, as saliva excretion is increased, the symptoms of dry mouth are relieved. Drug type: Approved. Small Molecule. Drug category: Muscarinic Agonists. Parasympathomimetics"}},{"Chandelier Cell Morphology":{"Created":"2007-09-05","Modified":"2009-05-31","SuperCategory":"Cell Morphological Quality","Id":"nifext_4","Definition":"axons forms rows of boutons making symmetric synapses exclusively on axon initial segments"}},{"Channel Baseline":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0213","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149672","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Offset of encoded sample value 0 from actual 0 using the units defined in the Channel Sensitivity Units Sequence (003A,0211). Required if Channel Sensitivity (003A,0210) is present."}},{"Channel Definition Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0200","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149673","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence of one or more Items, with one Item per channel. Ordering of Items in thisSequence is significant for reference to specific channels."}},{"Channel Derivation Description":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_020C","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149674","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Additional description of waveform channel derivation."}},{"Channel Description Code Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0022_001A","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149675","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Describes the light color used for each channel to generate the image. Required if this differs from the natural interpretation. Shall have the same number of items as the Value of Samples per Pixel Used (0028,0003) if present."}},{"Channel Label":{"ValueRepresentation":"SH","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0203","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149676","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"Text label for channel which may be used for display purposes."}},{"Channel Length":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0284","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149677","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Length of Channel (mm). If specified, the Channel Length (300A,0284) shall be the sum of the Source Applicator Length (300A,0296) and Transfer Tube Length (300A,02A4)."}},{"Channel Maximum Value":{"ValueRepresentation":"OB or OW","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:5400_0112","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149678","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"OB or OW","Definition":"Maximum valid sample value as limited by the acquisition equipment."}},{"Channel Minimum Value":{"ValueRepresentation":"OB or OW","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:5400_0110","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149679","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"OB or OW","Definition":"Minimum valid sample value as limited by the acquisition equipment."}},{"Channel Number":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0282","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149680","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Identification number of the Channel. The value of Channel Number (300A,0282) shall be unique within the Application Setup in which it is created."}},{"Channel Offset":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0218","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149681","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Additional offset of first sample of channel to be used in aligning multiple channels for presentation or analysis, in seconds."}},{"Channel Sample Skew":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0215","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149682","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Offset of first sample of channel from waveform multiplex group start time, in samples. Required if Channel Time Skew is not present."}},{"Channel Sensitivity":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0210","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149683","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Nominal numeric value of unit quantity of sample. Required if samples represent defined (not arbitrary) units."}},{"Channel Sensitivity Correction Factor":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0212","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149684","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Multiplier to be applied to encoded sample values to match units specified in Channel Sensitivity (003A,0210) (e.g., based on calibration data)  Required if Channel Sensitivity (003A,0210) is present."}},{"Channel Sensitivity Units Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0211","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149685","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"A coded descriptor of the Units of measure for the Channel Sensitivity. Only a single Item shall be permitted in this sequence. Required if Channel Sensitivity (003A,0210) is present."}},{"Channel Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0280","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149686","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Introduces sequence of Channels for current Application Setup. One or more items may be included in this sequence."}},{"Channel Shield ID":{"ValueRepresentation":"SH","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_02B3","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149687","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"User or machine supplied identifier for Channel Shield. Required if Channel Shield Sequence (300A,02B0) is sent."}},{"Channel Shield Name":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_02B4","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149688","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"User-defined name for Channel Shield."}},{"Channel Shield Nominal Thickness":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_02B8","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149689","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Nominal Thickness of Channel Shield (mm)."}},{"Channel Shield Nominal Transmission":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_02BA","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149690","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Nominal Transmission of Channel Shield (between 0 and 1)."}},{"Channel Shield Number":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_02B2","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149691","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Identification number of the Channel Shield. The value of Channel Shield Number (300A,02B2) shall be unique within the Channel in which it is created. Required if Channel Shield Sequence (300A,02B0) is sent."}},{"Channel Shield Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_02B0","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149692","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Introduces sequence of Channel Shields associated with current Channel. One or more items may be included in this sequence."}},{"Channel Source Modifiers Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0209","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149693","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence of one or more Items which further qualify the Waveform Source. Required if Channel Source Sequence (003A,0208) does not fully specify the semantics of the source. Ordering of Items in this Sequence may be semantically significant."}},{"Channel Status":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0205","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149694","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"One or more values for the status of this channel within this SOP Instance. Precise location of a change in status may be noted in an Annotation."}},{"Channel Time Skew":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0214","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149695","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Offset of first sample of channel from waveform multiplex group start time, in seconds Required if Channel Sample Skew is not present."}},{"Channel Total Time":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0286","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149696","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Total amount of time between first and final Control Points of the Brachy Control Point Sequence (300A,02D0) for current Channel (sec). Channel Total Time calculation is based upon the Reference Air Kerma Rate (300A,022A) of the Referenced Source Number (300C, 000E)."}},{"Charcot Marie Tooth disease":{"RelatedTo":"Peripheral nervous system","Synonym":["hereditary motor and sensory neuropathy"],"CurationStatus":"uncurated","SuperCategory":"Nervous system disease","Id":"nlx_dys_100316","PublicationLink":"http://www.ninds.nih.gov/disorders/charcot_marie_tooth/charcot_marie_tooth.htm","Abbrev":["CMT"],"Definition":"A common inherited neurological disorders, affecting approximately 1 in 2,500 people in the United States, comprising a group of disorders caused by mutations in genes that affect the normal function of the peripheral nerves.  A typical feature includes weakness of the foot and lower leg muscles, which may result in foot drop and a high-stepped gait with frequent tripping or falls. Foot deformities, such as high arches and hammertoes (a condition in which the middle joint of a toe bends upwards), are also characteristic due to weakness of the small muscles in the feet. In addition, the lower legs may take on an \"inverted champagne bottle\" appearance due to the loss of muscle bulk. Later in the disease, weakness and muscle atrophy may occur in the hands, resulting in difficulty with fine motor skills. (adapted from NINDS disease pages) "}},{"Chelicerata":{"EditorialNote":"listed both as an unconfirmed phylum (16208273) and class (16185420)","Created":"2007-08-20","CurationStatus":"pending_final_vetting","Umlscui":"C0998333","SuperCategory":"Arthropoda","Id":"birnlex_7000"}},{"Chemical compositional analysis instrument":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Measurement device","Id":"birnlex_2397"}},{"Chemical quantification instrument":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Measurement device","Id":"birnlex_2451"}},{"Chemical sensation":{"Created":"2007-08-22","Synonym":"chemosensory perception","CurationStatus":"uncurated","Umlscui":"C1154586","SuperCategory":"Sensory perception","Id":"birnlex_1889","Definition":"The series of events required for an organism to receive a sensory chemical stimulus, convert it to a molecular signal, and recognize and characterize the signal.  Definition Source: Gene Ontology"}},{"Chemical separation instrument":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Measurement device","Id":"birnlex_2398","Has role":"Instrument role","Definition":"Instruments that separate chemicals."}},{"Chemical Shift Reference":{"ValueRepresentation":"FD","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9053","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149697","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FD","Definition":"The chemical shift at the transmitter frequency in ppm. Required if Image Type (0008,0008) Value 1 is ORIGINAL or MIXED. May be present otherwise."}},{"Chemical Shift Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9084","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149698","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"The list of frequencies that were used to create the Metabolite Map. One or more Items may be included in this sequence."}},{"Chemical Shifts Maximum Integration Limit in Hz":{"RelatedTo":"BIRN-INCF Derived Data Project","SuperCategory":"DICOM term","Id":"nlx_149699","Is part of":"Resource:DICOM standard","Definition":"no def needed"}},{"Chemical Shifts Maximum Integration Limit in ppm":{"RelatedTo":"BIRN-INCF Derived Data Project","SuperCategory":"DICOM term","Id":"nlx_149700","Is part of":"Resource:DICOM standard","Definition":"no def needed"}},{"Chemical Shifts Minimum Integration Limit in Hz":{"RelatedTo":"BIRN-INCF Derived Data Project","SuperCategory":"DICOM term","Id":"nlx_149701","Is part of":"Resource:DICOM standard","Definition":"no def needed"}},{"Chemical Shifts Minimum Integration Limit in ppm":{"RelatedTo":"BIRN-INCF Derived Data Project","SuperCategory":"DICOM term","Id":"nlx_149702","Is part of":"Resource:DICOM standard","Definition":"no def needed"}},{"Chemical stimulus transduction":{"Synonym":["sensory detection of chemical stimulus"],"Created":"2008-03-13","CurationStatus":"graph_position_temporary","Umlscui":"C1327496","SuperCategory":"Sensory stimulus transduction","Id":"birnlex_15002","Definition":"* The series of events in which a sensory chemical stimulus is received and converted into a molecular signal. (GO:ai) (GO) * Sensory transduction where the binding of a specific molecular species is the direct stimulus being."}},{"Chemical structural analysis instrument":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Measurement device","Id":"birnlex_2429"}},{"Chemical supplier":{"CurationStatus":"uncurated","SuperCategory":"Reagent supplier","Id":"nlx_res_090915","Definition":"A material resource that provides chemicals e.,g., drugs, probes, salts, small molecules"}},{"Chemical Synapse":{"SuperCategory":"Synapse","Id":"sao289211478"}},{"Chemical Synapse Quality":{"SuperCategory":"Morphological Quality","Id":"sao1746643703"}},{"Chemistry":{"RelatedTo":"Neurochemistry","CurationStatus":"uncurated","SuperCategory":"Scientific_discipline","Id":"nlx_inv_100618","Definition":"Branch of science concerned with properties of matter.(from Egyptian kme (chem), meaning \"earth\") is the science concerned with the composition, structure, and properties of matter, as well as the changes it undergoes during chemical reactions. It is a physical science for studies of various atoms, molecules, crystals and other aggregates of matter whether in isolation or combination, which incorporates the concepts of energy and entropy in relation to the spontaneity of chemical processes. Modern chemistry evolved out of alchemy following the chemical revolution (1773).Scientific_disciplines within chemistry are traditionally grouped by the type of matter being studied or the kind of study. These include inorganic chemistry, the study of inorganic matter; organic chemistry, the study of organic matter; biochemistry, the study of substances found in biological organisms; physical chemistry, the energy related studies of chemical systems at macro, molecular and submolecular scales; analytical chemistry, the analysis of material samples to gain an understanding of their chemical composition and structure. Many more specialized disciplines have emerged in recent years, e.g. neurochemistry the chemical study of the nervous system (see subdisciplines). - definition adapted from Wikipedia"}},{"Chemoarchitectural part":{"SuperCategory":"Regional part of brain","Id":"nlx_anat_20090501","Definition":"Regional part of an anatomical region that is revealed by the use of a stain that reveals chemoarchitecture."}},{"Chemoarchitectural part of neostriatum":{"SuperCategory":"Chemoarchitectural part","Id":"nlx_anat_20090502"}},{"Chemokine":{"CurationStatus":"uncurated","SuperCategory":"Peptide","Id":"nifext_5065"}},{"Chemokine receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5408"}},{"Chemokine receptor - unspecified 1":{"EditorialNote":"Binds chemokine ligands but has not been shown to signal, may function as a binding protein","Created":"2007-09-19","SuperCategory":"Chemokine receptor","Id":"nifext_5409"}},{"Chemokine receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"Chemokine receptor","Id":"nifext_5511"}},{"Chemokine receptor - unspecified 3":{"EditorialNote":"Binds chemokine ligands but has not been shown to signal, may function as a binding protein","Created":"2007-09-19","SuperCategory":"Chemokine receptor","Id":"nifext_5568"}},{"Chemokine receptor - unspecified 4":{"EditorialNote":"Binds chemokine ligands but has not been shown to signal, may function as a binding protein","Created":"2007-09-19","SuperCategory":"Chemokine receptor","Id":"nifext_6366"}},{"Chemoreceptor":{"SuperCategory":"Sensory reception role","Id":"nlx_367"}},{"Chemosensory neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Sensory neuron (FBbt Term)","Id":"nlx_147907","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00005922","Definition":"Any neuron (FBbt_00005106) that functions in (some) detection of chemical stimulus involved in sensory perception (GO:0050907)."}},{"Chemosensory neuron of adult labial sensillum 7":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-03-11T04:39:43Z","Contributor":"sr544","SuperCategory":"Gustatory receptor neuron","Id":"nlx_148465","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100098","Fasciculates_with":"accessory pharyngeal nerve","Definition":"One of seven chemosensory neuron innervating the adult labial sensillum 7 (Nayak and Singh, 1983)."}},{"Chemosensory neuron of adult labial sensillum 8":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-03-11T04:32:11Z","Contributor":"sr544","SuperCategory":"Gustatory receptor neuron","Id":"nlx_148462","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100095","Fasciculates_with":"accessory pharyngeal nerve","Definition":"Chemosensory neuron innervating the adult labial sensillum 8 (Nayak and Singh, 1983)."}},{"Chemosensory neuron of adult labial sensillum 9":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-03-11T04:35:16Z","Contributor":"sr544","SuperCategory":"Gustatory receptor neuron","Id":"nlx_148464","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100097","Fasciculates_with":"accessory pharyngeal nerve","Definition":"Chemosensory neuron innervating the adult labial sensillum 9 (Nayak and Singh, 1983)."}},{"Chemotropism":{"Synonym":"Chemoattraction","CurationStatus":"uncurated","SuperCategory":"Neural coding","Id":"oen_0001122","Definition":"The hypothesis that developing axons are attracted toward diffusible factors secreted by particular groups of target cells."}},{"Cherax":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1081057","SuperCategory":"Parastacidae","Id":"birnlex_373"}},{"Cherax destructor":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998239","SuperCategory":"Cherax","Id":"birnlex_390"}},{"Cherax quadricarinatus":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1001475","SuperCategory":"Cherax","Id":"birnlex_384"}},{"Chewing-swallowing":{"Created":"4/27/2011 15:50","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00732","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Chewing-swallowing","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145954","Definition":"Subjects chew an oral stimulus that is not food (e.g., gum) or swallow their own saliva.  If the oral stimulus is food or liquid that is swallowed, then the correct paradigm class is Eating-Drinking."}},{"Chiasmatic cistern":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["Cisterna chiasmatica"],"NeuronamesID":"11","CurationStatus":"uncurated","Umlscui":"C0228152","SuperCategory":"Superficial feature part of forebrain","Id":"birnlex_4003","Abbrev":"ccis"}},{"Chicken":{"Created":"2007-06-03","Synonym":["Gallus gallus","Gallus gallus domesticus"],"CurationStatus":"uncurated","Umlscui":"C0008051","SuperCategory":"Gallus","Id":"birnlex_267"}},{"Child":{"CurationStatus":"uncurated","SuperCategory":"Age","Id":"nlx_154732"}},{"Childhood disintegrative disorder":{"CurationStatus":"uncurated","SuperCategory":"Pervasive Development Disorder","Id":"nlx_143846","Abbrev":"CDD","Definition":"A pediatric disorder characterized by normal development for at least the first two years of life followed by a severe regression in language, social interaction, bowel or bladder control, and/or motor skills. The affected individual may also exhibit repetitive and stereotyped patterns of behavior similar to autism. (NCI Thesaurus)"}},{"Chimeric animal stroop task":{"Created":"2/23/2010 12:11","CurationStatus":"uncurated","Contributor":"Deanna Lau","CAO_Id":"CAO_00713","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Chimeric_animal_stroop_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145929","Definition":"A task in which participants are shown pictures of chimeric animals (such as a duckand#39;s head attached to a cowand#39;s body) and asked to name animal that the head belongs to while ignoring the identity of the body, or vice versa."}},{"Chimpanzee":{"Created":"2007-08-03","EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Synonym":"Pan troglodytes","CurationStatus":"uncurated","Umlscui":"C0008111","SuperCategory":"Pan","Id":"birnlex_300"}},{"Chiroptera":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C0008139","SuperCategory":"Laurasiatheria","Id":"birnlex_217"}},{"Chlorambucil":{"RelatedTo":"DNA","Synonym":["Chlocambucil","Chloraminophen","Chloraminophene","Chlorbutin","Chlorbutine","Chloroambucil","Chlorobutin","Chlorobutine","Phenylbutyric Acid Nitrogen Mustard","Ambochlorin","Amboclorin","Ecloril","Elcoril","Leukeran","Leukeran Tablets","Leukersan","Leukoran","Linfolizin","Linfolysin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:28830","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00291","Definition":"A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed) Pharmacology: Chlorambucil is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death. Mechanism of action: Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. Drug type: Approved. Small Molecule. Drug category: Antineoplastic Agents. Antineoplastic Agents, Alkylating"}},{"Chloramphenicol":{"RelatedTo":["50S ribosomal protein L10","Complement decay-accelerating factor","Chloramphenicol acetyltransferase","Chloramphenicol 3-O phosphotransferase","Chloramphenicol acetyltransferase 3"],"Synonym":["CAF","CAM","CAP","CPh","Chloramfenikol","Chloramphenicole","Chloroamphenicol","Cloroamfenicolo","D-Chloramphenicol","Ak-Chlor Ophthalmic Ointment","Ak-Chlor Ophthalmic Solution","Ak-chlor","Alficetyn","Ambofen","Amphenicol","Amphicol","Amseclor","Anacetin","Aquamycetin","Austracil","Austracol","Biocetin","Biophenicol","Catilan","Chemicetin","Chemicetina","Chlomin","Chlomycol","Chlora-Tabs","Chloracol Ophthalmic Solution","Chloramex","Chloramficin","Chloramfilin","Chloramsaar","Chlorasol","Chloricol","Chlornitromycin","Chloro-25 vetag","Chlorocaps","Chlorocid","Chlorocid S","Chlorocide","Chlorocidin C","Chlorocidin C tetran","Chlorocol","Chlorofair","Chlorofair Ophthalmic Ointment","Chlorofair Ophthalmic Solution","Chloroject L","Chloromax","Chloromycetin Hydrocortisone","Chloromycetin Ophthalmic Ointment","Chloromycetin Palmitate","Chloromycetin for Ophthalmic Solution","Chloromycetny","Chloromyxin","Chloronitrin","Chloroptic","Chloroptic Ophthalmic Solution","Chloroptic S,O,P,","Chloroptic-P S,O,P,","Chlorovules","Cidocetine","Ciplamycetin","Cloramfen","Cloramficin","Cloramicol","Cloramidina","Clorocyn","Cloromisan","Clorosintex","Comycetin","Cylphenicol","Desphen","Detreomycin","Detreomycine","Dextromycetin","Doctamicina","Econochlor","Econochlor Ophthalmic Ointment","Econochlor Ophthalmic Solution","Elase-Chloromycetin","Embacetin","Emetren","Enicol","Enteromycetin","Erbaplast","Ertilen","Farmicetina","Farmitcetina","Fenicol","Fenicol Ophthalmic Ointment","Globenicol","Glorous","Halomycetin","Hortfenicol","I-Chlor Ophthalmic Solution","Intramycetin","Isicetin","Ismicetina","Isophenicol","Isopto fenicol","Juvamycetin","Kamaver","Kemicetina","Kemicetine","Klorita","Klorocid S","Leukamycin","Leukomyan","Leukomycin","Levomicetina","Levomitsetin","Levomycetin","Loromisan","Loromisin","Mastiphen","Mediamycetine","Medichol","Micloretin","Micochlorine","Micoclorina","Microcetina","Mychel","Mychel-Vet","Mycinol","Normimycin V","Novochlorocap","Novomycetin","Novophenicol","Ocu-Chlor Ophthalmic Ointment","Ocu-Chlor Ophthalmic Solution","Oftalent","Oleomycetin","Opclor","Opelor","Ophtho-Chloram Ophthalmic Solution","Ophthochlor","Ophthochlor Ophthalmic Solution","Ophthoclor","Ophthocort","Ophtochlor","Optomycin","Otachron","Otophen","Pantovernil","Paraxin","Pentamycetin","Pentamycetin Ophthalmic Ointment","Pentamycetin Ophthalmic Solution","Quemicetina","Rivomycin","Romphenil","Ronphenil","Septicol","Sificetina","Sintomicetina","Sintomicetine R","Sno-Phenicol","Sopamycetin Ophthalmic Ointment","Sopamycetin Ophthalmic Solution","Spectro-Chlor Ophthalmic Ointment","Spectro-Chlor Ophthalmic Solution","Stanomycetin","Synthomycetin","Synthomycetine","Synthomycine","Tega-Cetin","Tevcocin","Tevcosin","Tifomycin","Tifomycine","Tiromycetin","Treomicetina","Tyfomycine","Unimycetin","Veticol"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI_17698","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00446","Definition":"An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) Pharmacology: Chloramphenicol is a broad-spectrum antibiotic that was derived from the bacterium Streptomyces venezuelae and is now produced synthetically. Chloramphenicol is effective against a wide variety of microorganisms, but due to serious side-effects (e.g., damage to the bone marrow, including aplastic anemia) in humans, it is usually reserved for the treatment of serious and life-threatening infections (e.g., typhoid fever). Chloramphenicol is bacteriostatic but may be bactericidal in high concentrations or when used against highly susceptible organisms. Chloramphenicol stops bacterial growth by binding to the bacterial ribosome (blocking peptidyl transferase) and inhibiting protein synthesis. Mechanism of action: Chloramphenicol is lipid-soluble, allowing it to diffuse through the bacterial cell membrane. It then reversibly binds to the 50S subunit of bacterial ribosomes where transfer of amino acids to growing peptide chains is prevented (perhaps by suppression of peptidyl transferase activity), thus inhibiting peptide bond formation and subsequent protein synthesis. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Protein Synthesis Inhibitors"}},{"Chlordane":{"Synonym":["gamma-chlordan","gamma-chlordane,.gamma.-chlordan","1,3,4,7,8,9,10,10-octachlorotricyclo[5.2.1.0(2,6)]dec-8-ene","1068 Steral","Alpha-chlordan","Alpha-chlordane","Aspon-chlordane","BELT","C orodane","C-chlordane","Caswell No. 174","Caswell No. 174E","Chloordaan","Chlor kil","Chlor kill","Chlordan","Chlordane (alpha and gamma isomers)","Chlordane (analytical grade)","Chlordane (avg cis-,trans-)","Chlordane (technical grade)","Chlordane (technical mixture and metabolites)","Chlordane (technical mixture)","Chlordane (trans)","Chlordane alpha & gamma isomers","Liquid Chlordane","Chlordane liquid (dot)","Technical Chlordane","Chlorindan","Chlorodane","Chlorotox","Chlortox","Cis-chlordane","Cis-photochlordane","Clordan","Clordano","Compound k","Corodane","Cortilan-neu","Dichlorochlordene","Dow-klor","Dowchlor","Gold cres","Intox","Intox 8","Kilex lindane","Kypchlor","Latka 1068","Niran","Octa-klor","Octach lorohexahydromethanoindene","Octachlor","Octachlordane","Octachloro-4,7-methanohydroindane","Octachloro-4,7-methanotetrahydroindane","Octachlorodihydrodicyclopentadiene","Octachlorohexahydromethanoindene","Oindane","Oktaterr","Ortho-klor","Photochlordane","RCRA waste no. U036","Shell sd-5532","Starchlor","Steraskin","Syndane","Synklor","T-chlordane","Tat Chlor 4","Technical chlordane","Termex","Termi-ded","Topichlor 20","Topiclor","Topiclor 20","Toxichlor","Trans-chlordan","Trans-chlordane","Unexan-koeder"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0020","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0020","Abbrev":"C10H6Cl8","Definition":"Organic Compound;Pesticide;Organochloride; Chlordane is a manufactured chemical that was used as a pesticide in the United States from 1948 to 1988. Chlordane occurs in two isomers, called cis-chlordane (alpha-chlordane) and trans-chlordane (gamma-chlordane)."}},{"Chlordane, cis-":{"Synonym":["Alpha-chlordane","Chlordan","cis-","Chlordane cis","Cis-chlordan","a-chlordan"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0059","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0059","Abbrev":"C10H6Cl8","Definition":"Organic Compound;Pesticide;Organochloride; cis-Chlordane, also known as alpha-chlordane, is one of two isomers of chlordane. Chlordane is a manufactured chemical that was used as a pesticide in the United States from 1948 to 1988."}},{"Chlordane, trans-":{"Synonym":["Beta-chlordane","Chlordan","trans-","Chlordane gamma (trans)","Trans-gamma-chlordane","Trans-chlordan","Trans-gamma-chlordane","b-chlordan"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0064","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0064","Abbrev":"C10H6Cl8","Definition":"Organic Compound;Pesticide;Organochloride; Trans-chlordane, also known as gamma-chlordane, is one of two isomers of chlordane. Chlordane is a manufactured chemical that was used as a pesticide in the United States from 1948 to 1988."}},{"Chlordiazepoxide":{"RelatedTo":"Gamma-aminobutyric-acid receptor subunit alpha-1","Synonym":["A-Poxide","Abboxide","Apo-Chlordiazepoxide","Chloradiazepoxide","Chlordiazachel","Chlordiazepoxid","Chlordiazepoxide Base","Chlordiazepoxide Hcl","Chlordiazepoxidum","Chloridazepoxide","Chloridiazepide","Chloridiazepoxide","Chlorodiazepoxide","Chlozepid","Clopoxide","Clordiazepossido","Contol","Decacil","Elenium","Helogaphen","Ifibrium","Kalmocaps","Librax","Librelease","Librinin","Libritabs","Librium","Limbitrol","Limbitrol Ds","Lygen","Menrium","Mesural","Methaminodiazepoxide","Mildmen","Multum","Napoton","Napton","Novo-Poxide","Psicosan","Radepur","Risolid","Silibrin","Tropium"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3611","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB00475","Abbrev":"CDP","Definition":"An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. (PubChem) Pharmacology: Chlordiazepoxide has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The precise mechanism of action is not known. The drug blocks EEG arousal from stimulation of the brain stem reticular formation. The drug has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses. Hostile monkeys were made tame by oral drug doses which did not cause sedation. Chlordiazepoxide revealed a \"taming\" action with the elimination of fear and aggression. The taming effect of chlordiazepoxide was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals. Mechanism of action: Chlordiazepoxide binds to stereospecific benzodiazepine (BZD) binding sites on GABA (A) receptor complexes at several sites within the central nervous system, including the limbic system and reticular formation. BZDs enhance GABA-mediated chloride influx through GABA receptor channels, causing membrane hyperpolarization. The net neuro-inhibitory effects result in the observed sedative, hypnotic, anxiolytic, and muscle relaxant properties. Drug type: Approved. Illicit. Small Molecule. Drug category: Adjuvants, Anesthesia. Anti-anxiety Agents. Benzodiazepines. GABA Modulators. Hypnotics and Sedatives"}},{"Chlorhexidine":{"Synonym":["Chlorhexidin (Czech)","Chlorhexidine Base","Chlorhexidine Gluconate","Chlorhexidinum (INN-Latin)","Cloresidina (DCIT)","Clorhexidina (INN-Spanish)","Decanoylacetaldehyde Sodium Sulfide","Bioscrub","Brian Care","Cida-Stat","Dyna-Hex","Exidine","Fimeil","Hexadol","Hibiclens","Hibidil","Hibiscrub","Hibisol","Hibispray","Hibistat","Hibitane","Microderm","Nolvasan","Oro-Clense","Peridex","Periochip","Periogard","Pharmaseal Scrub Care","Prevacare R","Rotersept","Savloclens","Savlon Babycare","Sodium Houttuyfonamide","Soretol","Steri-Stat","Sterido","Sterilon","Superspray"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3614","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00878","Definition":"A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque. (PubChem) Pharmacology: Chlorhexidine, a topical antimicrobial agent, is bactericidal. Because of its positive charge, the chlorhexidine molecule reacts with the microbial cell surface to destroy the integrity of the cell membrane. This novel mechanism of action makes it highly unlikely for the development of bacterial resistance. Mechanism of action: Chlorhexidine's antimicrobial effects are associated with the attractions between chlorhexidine (cation) and negatively charged bacterial cells. After chlorhexidine is absorpted onto the organism's cell wall, it disrupts the integrity of the cell membrane and causes the leakage of intracellular components of the organisms. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Anti-Infective Agents, Local. Anti-Infectives. Disinfectants. Mouthwashes"}},{"Chloride":{"Synonym":["chloride(1-)","chloride-","Cl(-)","Cl-","chloride(-)","chloride anion","chloride ion"],"CurationStatus":"uncurated","SuperCategory":"Anion","Id":"CHEBI:17996","Has role":"Current carrier","DefiningCitation":["Thomas M. Jessell","Eric R. Kandel","James H. Schwartz","Essentials of Neuroscience and Behavior,Appleton & Lange","Norwalk","CT","1995"],"Abbrev":"Cl(-)","Definition":"A monoatomic chlorine that has formula Cl. An essential constituent of the nervous system. The concentration of the negatively charged Cl- ions outside the resting neuron is higher than that inside the cell. Inward flux of Cl- through thransmittergated Cl- channels is a common inhibitory mechanism."}},{"Chloride current":{"Synonym":["Cl- current","I.Cl current","I Cl"],"CurationStatus":"uncurated","SuperCategory":"Transmembrane ionic current","Id":"nlx_78116"}},{"Chlormerodrin":{"RelatedTo":["Succinate semialdehyde dehydrogenase","mitochondrial"],"Synonym":[", Chlormerodrine","Chlormeroprin","Chloromeridin","Chloromerodrin","Diurone","Hg-203 chlormerodrin","Katonil","Mercardox","Mercloran","Mercoral","Merculest","Merilid","Neogidrin","Neohydrin","Oricur","Percapyl","Promeran"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00534","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00534","Definition":"Chlormerodrin is a mercurial compound with toxic side effects that was previously used as a diuretic. The radiolabeled form has been used as a diagnostic and research tool. It is no longer used and has been replaced with new classes of diuretic drugs. Pharmacology: Chlormerodrin is a mercurial compound with toxic side effects. It is no longer used and has been replaced with new classes of diuretic drugs. Mechanism of action: Chlormerodrin most likely acts by a direct renal action. Mercurial diuresis is presumed to occur through inhibition of reabsorption of water and electrolytes in the convoluted tubules, although the problem of whether the locus of action is primarily on the proximal or distal portion has not yet been settled. There is also evidence that mercurials interfere with the permeability of the membrane of tubular cells by increasing passive influx of Na+ ion, Cl- ion and water into the cells, without interfering with the active extrusion of Na+ ion. Lastly, there is some evidence that chlormerodrin inhibits succinic dehydrogenase, but the clinical significance of this binding is not known. Drug type: Approved. Small Molecule. Drug category: Diagnostic aids. Mercurial Diuretics"}},{"Chlormezanone":{"RelatedTo":"Translocator protein","Synonym":["Chlormethazanone","Chlormethazone","Chlormezanon","Chlormezanone (BAN:INN:JAN)","Chlormezanonum (INN-Latin)","Clormetazanone","Clormetazon","Clormezanona (INN-Spanish)","Clormezanone (DCIT)","Dichloromethazanone","Dichloromezanone","dl-Chlormezanone","Alinam","Banabil-sintyal","Banabin","Banabin-Sintyal","Banabin-syntyal","Bisina","Chlomedinon","Clorilax","Lobak","Mio-Sed","Miorilax","Muskel","Muskel-Trancopal","Myolespen","Phenarol","Rexan","Rilansyl","Rilaquil","Rilasol","Rilassol","Rilax","Rillasol","Supotran","Suprotan","Tanafol","Trancopal","Trancote","Tranrilax"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01178","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01178","Definition":"A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. (PubChem) Pharmacology: Chlormezanone is a non-benzodiazepine muscle relaxant. It was discontinued worldwide in 1996 by its manufacturer due to confirmed serious and rare cutaneous reactions (toxic epidermal necrolysis). Mechanism of action: Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways. Drug type: Approved. Small Molecule. Withdrawn. Drug category: Anti-anxiety Agents. Antipsychotics. Benzodiazepines. Muscle Relaxants, Central"}},{"Chlorocebus aethiops":{"Synonym":["african green monkey"],"CurationStatus":"graph position temporary","SuperCategory":"Cercopithecinae","Id":"NCBITaxon:9534"}},{"Chloroform":{"Synonym":["1,1,1-Trichloromethane","Deutarated Chloroform 99%","Caswell No. 192","Chloroform UN1888","Chloroforme","Cloroformio","Formyl trichloride","Freon 20","HSDB 56","Methane trichloride","Methenyl chloride","Methenyl trichloride","Methyl trichloride","R 20","RCRA waste no. U044","Refrigerant R20","TCM","Trichloormethaan","Trichlormethan","Trichloroform"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0011","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0011","Abbrev":"CHCl3","Definition":"Organic Compound;Solvent;Reagent;Organochloride; Chloroform is a chemical compound produced by heating a mixture of chlorine and either chloromethane or methane. It was originally used as an anaesthetic, but is now used mainly in refridgerants and as a solvent or reagent in the synthesis of other chemicals."}},{"Chloroprocaine":{"RelatedTo":["Sodium channel protein type 10 subunit alpha","5-hydroxytryptamine 3 receptor","Neuronal acetylcholine receptor subunit alpha-10","Glutamate (NMDA) receptor subunit 3A"],"Synonym":["Chloroprocain","Chloroprocaine hydrochloride","Chlorprocaine","Halestyn","Nesacaine-CE"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01161","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01161","Definition":"Chloroprocaine hydrochloride is a local anesthetic given by injection during surgical procedures and labor and delivery. Chloroprocaine, like other local anesthetics, blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. Pharmacology: Chloroprocaine is an anesthetic agent indicated for production of local or regional anesthesia, particularly for oral surgery. Chloroprocaine (like cocaine) has the advantage of constricting blood vessels which reduces bleeding, unlike other local anesthetics like lidocaine. Chloroprocaine is an ester anesthetic. Mechanism of action: Chloroprocaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Chloroprocaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex. Drug type: Approved. Small Molecule. Drug category: Anesthetics, Local"}},{"Chloroquine":{"RelatedTo":["Hemoglobin subunit alpha","Tumor necrosis factor","Toll-like receptor 9"],"Synonym":["Chloraquine","Chlorochine","Chloroquina","Chloroquine Phosphate","Chloroquinium","Chlorquin","Clorochina","Hydroxychloroquine Sulfate","3377 RP opalate","Amokin","Aralen","Aralen HCl","Arechin","Arthrochin","Artrichin","Avlochlor","Avloclor","Bemaco","Bemaphate","Bemasulph","Benaquin","Bipiquin","Capquin","Chemochin","Chingamin","Chlorochin","Cidanchin","Cocartrit","Delagil","Dichinalex","Elestol","Gontochin","Heliopar","Imagon","Iroquine","Klorokin","Lapaquin","Malaquin","Malaren","Malarex","Mesylith","Neochin","Nivachine","Nivaquine","Nivaquine B","Pfizerquine","Plaquenil","Quinachlor","Quinagamin","Quinagamine","Quinercyl","Quingamine","Quinilon","Quinoscan","Resochen","Resochin","Resoquina","Resoquine","Reumachlor","Reumaquin","Roquine","Sanoquin","Silbesan","Siragan","Solprina","Sopaquin","Tanakan","Tresochin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3638","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00608","Definition":"The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. (PubChem) Pharmacology: Chloroquine is the prototype anti malarial drug, most widely used to treat all types of malaria except for disease caused by chloroquine resistant Plasmodium falciparum. It is highly effective against erythrocytic forms of Plasmodium vivax, Plasmodium ovale and Plasmodium malariae, sensitive strains of Plasmodium falciparum and gametocytes of Plasmodium vivax. Being alkaline, the drug reaches high concentration within the food vacuoles of the parasite and raises its pH. It is found to induce rapid clumping of the pigment. Chloroquine inhibits the parasitic enzyme heme polymerase that converts the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. It may also interfere with the biosynthesis of nucleic acids. Mechanism of action: The mechanism of plasmodicidal action of chloroquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. Drug type: Approved. Small Molecule. Drug category: Amebicides. Antimalarials. Antirheumatic Agents"}},{"Chlorothiazide":{"RelatedTo":["Carbonic anhydrase 1","Carbonic anhydrase 2","Solute carrier family 12 member 3","Carbonic anhydrase 4"],"Synonym":["Chlorothiazid","Chlorthiazide","Chlortiazid","Aldoclor","Alurene","Chloriazid","Chlorosal","Chlorurit","Chlotride","Chlrosal","Clotride","Diupres","Diuresal","Diuril","Diuril Boluses","Diurilix","Diurite","Diutrid","Esidrix","Flumen","Hydro-D","Hydrodiuril","Microzide","Minzil","Neo-Dema","Oretic","Salisan","Salunil","Saluretil","Saluric","Sk-Chlorothiazide","Thiazide","Urinex","Warduzide","Yadalan"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00880","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00880","Definition":"A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) Pharmacology: Like other thiazides, chlorothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral doses, 10-15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk. Mechanism of action: As a diuretic, chlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like chlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of chlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. Drug type: Approved. Small Molecule. Drug category: Antihypertensive Agents. Diuretics. Diuretics, Thiazide. Sodium Chloride Symporter Inhibitors"}},{"Chlorotrianisene":{"RelatedTo":"Estrogen receptor","Synonym":["CTA","Chloortrianisestrol","Chlorestrolo","Chlorotrianisenum (INN-Latin)","Chlorotrianisine","Chlorotrianizen","Chlortrianisen","Chlortrianisene","Chlortrianisenum","Chlortrianisestrol","Chlortrianisoestrolum","Chlortrianizen","Clorotrianiseno (INN-Spanish)","Anisene","Chlorotrisin","Clorestrolo","Clorotrisin","Hormonisene","Khlortrianizen","Merbentul","Metace","Rianil","Tace","Tace-Fn"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3641","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00269","Definition":"A powerful synthetic, non-steroidal estrogen. (PubChem) Pharmacology: Chlorotrianisene is a nonsteroidal synthetic estrogen. After menopause, when the body no longer produces estrogen, chlorotrianisene is used as a simple replacement of estrogen. The estrogen-stimulated endometrium may bleed within 48-72 hours after discontinuance of estrogen therapy. Paradoxically, prolonged estrogen therapy may cause shrinkage of the endometrium and an increase in size of the myometrium. Estrogens have a weak anabolic effect and may cause sodium retention with associated fluid retention and edema. Estrogens may also decrease elevated blood cholesterol and phospholipid concentrations. Estrogens affect bone by increasing calcium deposition and accelerating epiphyseal closure, following initial growth stimulation. During the preovulatory or nonovulatory phase of the menstrual cycle, estrogen is the principal determinant in the onset of menstruation. A decline of estrogenic activity at the end of the menstrual cycle also may induce menstruation; however, the cessation of progesterone secretion is the most important factor during the mature ovulatory phase of the menstrual cycle. The benefit derived from estrogen therapy in the prevention of postpartum breast engorgement must be carefully weighed against the potentialincreased risk of puerperal thromboembolismassociated with the use of large doses of estrogens. Mechanism of action: Chlorotrianisene binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. Drug type: Approved. Small Molecule. Drug category: Antineoplastic Agents. Antineoplastic Agents, Hormonal. Estrogens, Non-Steroidal"}},{"Chloroxine":{"Synonym":["CHQ","Chloroxyquinoline","Chlorquinol","Dichlorohydroxyquinoline","Dichloroquinolinol","Dichloroxin","Dikhloroskin","Capitrol","Chlofucid","Clofuzid","Endiaron","Quesyl","Quinolor"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01243","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01243","Definition":"Chloroxine is a synthetic antibacterial compound. Chloroxine is a compound used in some shampoos for the treatment of dandruff and seborrheic dermatitis of the scalp. Pharmacology: Chloroxine has an antibacterial action, inhibiting the growth of gram-positive as well as some gram-negative organisms. Also, chloroxine has shown some antifungal activity against certain dermatophytes and yeasts. Mechanism of action: Although the mechanism of action is not understood, chloroxine may slow down mitotic activity in the epidermis, thereby reducing excessive scaling associated with dandruff or seborrheic dermatitis of the scalp. Drug type: Approved. Small Molecule. Drug category: Antiseborrheic"}},{"Chlorphenesin":{"Synonym":["Chlorophenesin","Chlorphenesine (INN-French)","Chlorphenesinum (INN-Latin)","Clorfenesina (INN-Spanish)","alpha-Glyceryl ether","p-Chlorophenyl","p-Chlorophenyl glyceryl ether","Adermykon","Demykon","Gechophen","Gecophen","Maolate"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00856","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00856","Definition":"A centrally acting muscle relaxant. Its mode of action is unknown. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1203) Pharmacology: Chlorphenesin is a muscle relaxant. It works by blocking nerve impulses (or pain sensations) that are sent to your brain. Mechanism of action: The mechanism of action of chlorphenesin is not well defined, and its effects are measured mainly by subjective responses. It is known that chlorphenesin acts in the central nervous system (CNS) rather than directly on skeletal muscle. Drug type: Approved. Small Molecule. Drug category: Muscle Relaxants, Central"}},{"Chlorpheniramine":{"RelatedTo":"Histamine H1 receptor","Synonym":["Chloropheniramine","Chlorophenylpyridamin","Chlorophenylpyridamine","Chloroprophenpyridamine","Chlorphenamine","Chlorpheniramine Maleate","Chlorprophenpyridamine","Clorfeniramina","Dexchlorpheniramine","Dexchlorpheniramine Maleate","Aller-Chlor","Allergican","Allergisan","Antagonate","Chlo-Amine","Chlor-Trimeton","Chlor-Trimeton Allergy","Chlor-Trimeton Repetabs","Chlor-Tripolon","Chlorate","Chloropiril","Cloropiril","Efidac 24 Chlorpheniramine Maleate","Gen-Allerate","Haynon","Histadur","Kloromin","Mylaramine","Novo-Pheniram","Pediacare Allergy Formula","Phenetron","Piriton","Polaramine","Polaronil","Pyridamal 100","Telachlor"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:52010","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01114","Definition":"A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. (PubChem) Pharmacology: In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Chlorpheniramine, is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. Mechanism of action: Chlorpheniramine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Drug type: Approved. Small Molecule. Drug category: Anti-Allergic Agents. Antihistamines. Antipruritics. Histamine H1 Antagonists"}},{"Chlorpromazine":{"RelatedTo":["5-hydroxytryptamine 2A receptor","Serum albumin"],"Synonym":[", Chlorpromanyl-20","Chlorpromanyl-40","Chlorpromazine Hydrochloride Intensol","Largactil Liquid","Largactil Oral Drops","Novo-Chlorpromazine"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3647","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB00477","Definition":"The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. (PubChem) Pharmacology: Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Mechanism of action: Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. This action could also account for psychomotor agitation and amplification of psychosis (very rarely noted in clinical use). Drug type: Approved. Small Molecule. Drug category: Antiemetics. Antipsychotic Agents. Antipsychotics. Dopamine Antagonists. Phenothiazines"}},{"Chlorpropamide":{"RelatedTo":"ATP-sensitive inward rectifier potassium channel 1","Synonym":[", Adiaben","Apo-Chlorpropamide","Asucrol","Catanil","Chlorodiabina","Chloronase","Chloropropamide","Chlorpropamid","Chlorpropamide Bp/ Usp","Clorpropamide","Diabaril","Diabechlor","Diabenal","Diabenese","Diabeneza","Diabet-Pages","Diabetoral","Diabinese","Diamel Ex","Dynalase","Glisema","Glucamide","Insulase","Meldian","Melitase","Mellinese","Millinese","Novo-Propamide","Oradian"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00672","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00672","Definition":"A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277) Pharmacology: Chlorpropamide, a second-generation sulfonylurea antidiabetic agent, is used with diet to lower blood glucose levels in patients with diabetes mellitus type II. Chlorpropamide is twice as potent as the related second-generation agent glipizide. Mechanism of action: Sulfonylureas such as Chlorpropamide likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. Drug type: Approved. Small Molecule. Drug category: Hypoglycemic Agents. Sulfonylureas"}},{"Chlorprothixene":{"RelatedTo":["D(1A) dopamine receptor","5-hydroxytryptamine 2B receptor","Histamine H1 receptor","5-hydroxytryptamine 2A receptor","5-hydroxytryptamine 2C receptor","D(3) dopamine receptor"],"Synonym":["Alpha-Chlorprothixene","CPT","CPX","Chloroprothixene","Chlorprothixen","Chlorprothixine","Chlorprotixen","Chlorprotixene","Chlorprotixine","Chlothixen","Cis-Chlorprothixene","Iaractan","Paxyl","Rentovet","Tactaran","Taractan","Tarasan","Tardan","Traquilan","Trictal","Truxal","Truxaletten","Truxil"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3651","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB01239","Definition":"Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. Pharmacology: Chlorprothixene is a typical antipsychotic drug of the thioxanthine class. It has a low antipsychotic potency (half to 2/3 of chlorpromazine). An intrinsic antidepressant effect of chlorprothixene has been discussed, but not proven yet. Likewise, it is unclear, if chlorprothixene has genuine analgesic effects. An antiemetic effect, as with most antipsychotics, exists. It is used in the treatment of nervous, mental, and emotional conditions. Improvement in such conditions is thought to result from the effect of the medicine on nerve pathways in specific areas of the brain. Chlorprothixene has a strong sedative activity with a high incidence of anticholinergic side-effects. Chlorprothixene is structurally related to chlorpromazine, with which it shares in principal all side effects. Allergic side-effects and liver damage seem to appear with an appreciable lower frequency. Mechanism of action: Chlorprothixene blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. Drug type: Approved. Small Molecule. Drug category: Antipsychotic Agents. Antipsychotics. Dopamine Antagonists"}},{"Chlorthalidone":{"RelatedTo":"Solute carrier family 12 member 1","Synonym":["Chlorothalidone","Chlorphthalidolone","Chlorphthalidone","Chlortalidone","Chlorthalidon","Clodronic Acid","Higroton","Hydro-Long","Hygroton","Igroton","Isoren","Natriuran","Oradil","Phthalamodine","Phthalamudine","Renon","Saluretin","Tenoretic","Thalitone"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3654","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00310","Definition":"A benzenesulfonamide-phthalimidine that tautomerizes to a benzophenones form. It is considered a thiazide-like diuretic. (PubChem) Pharmacology: Chlorthalidone, a monosulfonamyl diuretic, differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Chlorthalidone is used alone or with atenolol in the management of hypertension and edema. Mechanism of action: Chlorthalidone inhibits sodium ion transport across the renal tubular epithelium in the cortical diluting segment of the ascending limb of the loop of Henle. By increasing the delivery of sodium to the distal renal tubule, Chlorthalidone indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Drug type: Approved. Small Molecule. Drug category: Antihypertensive Agents. Diuretics. Sodium Chloride Symporter Inhibitors"}},{"Chlorzoxazone":{"RelatedTo":"Calcium-activated potassium channel subunit alpha 1","Synonym":["Chloroxazone","Chlorzoxane","Chlorzoxazon","Biomioran","EZE-DS","Escoflex","Flexazone","Mioran","Miotran","Myoflexin","Myoflexine","Neoflex","Paraflex","Parafon Forte Dsc","Pathorysin","Relaxazone","Remular","Remular-S","Solaxin","Strifon Forte Dsc"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00356","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00356","Definition":"A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) Pharmacology: Chlorzoxazone, a synthetic compound, inhibits antigen-induced bronchospasms and, hence, is used to treat asthma and allergic rhinitis. Chlorzoxazone is used as an ophthalmic solution to treat conjunctivitis and is taken orally to treat systemic mastocytosis and ulcerative colitis. Chlorzoxazone is also a centrally-acting agent for painful musculoskeletal conditions. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex a.c. involved in producing and maintaining skeletal muscle spasm of varied etiology. The clinical result is a reduction of the skeletal muscle spasm with relief of pain and increased mobility of the involved muscles. Mechanism of action: Chlorzoxazone inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), mediators of type I allergic reactions. Chlorzoxazone also may reduce the release of inflammatory leukotrienes. Chlorzoxazone may act by inhibiting calcium influx. Drug type: Approved. Small Molecule. Drug category: Muscle Relaxants, Central"}},{"Choice reaction time task":{"Created":"4/15/2011 12:04","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00810","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Choice_reaction_time_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146032","Definition":"Choice reaction time tasks require distinct responses for each possible class of stimulus. For example, the subject might be asked to press one button if a red light appears and a different button if a yellow light appears."}},{"Choice task between risky and non-risky options":{"Created":"6/1/2011 16:02","CurationStatus":"uncurated","Contributor":"Carinna Torgerson","CAO_Id":"CAO_00898","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Choice_task_between_risky_and_non-risky_options","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146122","Definition":"a choice made between two or more options when one of those options has some probability"}},{"Cholecalciferol":{"RelatedTo":["Cytochrome P450 2R1","Cytochrome P450 27","mitochondrial"],"Synonym":["CC, Cholecalciferol","D3","Colecalciferol","Vitamin D3","Calciol","Delsterol","Delta-D","Deparal","Ebivit","Micro-Dee","Oleovitamin D3","Provitamin D3","Provitamine","Provitina","Ricketon","Trivitan","Vigantol"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00169","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00169","Definition":"Derivative of 7-dehydroxycholesterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from ergocalciferol in having a single bond between C22 and C23 and lacking a methyl group at C24. (PubChem) Pharmacology: Cholecalciferol (vitamin D3) is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of Vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma. Mechanism of action: The first step involved in the activation of vitamin D3 is a 25-hydroxylation which is catalysed by the 25-hydroxylase in the liver and then by other enzymes. The mitochondrial sterol 27-hydroxylase catalyses the first reaction in the oxidation of the side chain of sterol intermediates. The active form of vitamin D3 (calcitriol) binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein. Drug type: Approved. Nutraceutical. Small Molecule. Drug category: Antihypocalcemic Agents. Antihypoparathyroid Agents. Bone Density Conservation Agents. Essential Vitamin. Vitamins. Vitamins (Vitamin D)"}},{"Cholecystokinin":{"Created":"2007-09-19","CurationStatus":"uncurated","SuperCategory":"Peptide","Id":"nifext_5068","Has role":"Neuropeptide,","Abbrev":"CCK"}},{"Cholecystokinin receptor":{"Created":"2007-09-19","CurationStatus":"uncurated","SuperCategory":"G-protein coupled receptor","Id":"nifext_6396"}},{"Cholera toxin B-chain":{"RelatedTo":"Neuronal tract tracing","Synonym":["Cholera toxin B"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"nlx_152233","Has role":"Tracing role","Is part of":"Cholera toxin","Abbrev":"CTB","Definition":"A protein complex secreted by the bacterium Vibrio cholerae, comprising an oligomeric complex made up of six protein subunits: a single copy of the A subunit (part A, enzymatic), and five copies of the B subunit (part B, receptor binding), denoted as AB5.  Cholera toxin acts by the B subunit ring of the cholera toxin binding to GM1 gangliosides on the surface of target cells. Once bound, the entire toxin complex is endocytosed by the cell and the cholera toxin A1 (CTA1) chain is released by the reduction of a disulfide bridge. (adapted from Wikipedia:  http://en.wikipedia.org/wiki/Cholera_toxin)"}},{"Cholic":{"Synonym":"Bile acid","Created":"2007-09-19","SuperCategory":"Fatty acid","Id":"nifext_5159"}},{"Choline":{"RelatedTo":["Choline/ethanolamine kinase (Includes: Choline kinase beta","Acetylcholinesterase","Choline-phosphate cytidylyltransferase B","Choline O-acetyltransferase","Choline-phosphate cytidylyltransferase A","Choline dehydrogenase","mitochondrial","High-affinity choline transporter 1","Choline kinase alpha","Choline transporter-like protein 1","Phospholipase D2","Cholinesterase","Phospholipase D1","Choline transporter-like protein 4","Choline transporter-like protein 2","Choline transporter-like protein 3","Phosphatidylcholine:ceramide cholinephosphotransferase 2","Phosphoethanolamine/phosphocholine phosphatase","Phospholipase D4"],"Synonym":["(2-Hydroxyethyl)trimethylammonium","2-Hydroxy-N,N,N-trimethylethanaminium","Bilineurine","Choline cation","Choline ion"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:15354","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00122","Definition":"A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism. (PubChem) Pharmacology: This compound is needed for good nerve conduction throughout the CNS (central nervous system) as it is a precursor to acetylcholine (ACh). Choline is also needed for gallbladder regulation, liver function and lecithin (a key lipid) formation. Choline also aids in fat and cholesterol metabolism and prevents excessive fat build up in the liver. Choline has been used to mitigate the effects of Parkinsonism and tardive dyskinesia. Choline deficiencies may result in excessive build-up of fat in the liver, high blood pressure, gastric ulcers, kidney and liver dysfunction and stunted growth. Mechanism of action: Choline is a major part of the polar head group of phosphatidylcholine. Phosphatidylcholine's role in the maintenance of cell membrane integrity is vital to all of the basic biological processes: information flow, intracellular communication and bioenergetics. Inadequate choline intake would negatively affect all these processes. Choline is also a major part of another membrane phospholipid, sphingomyelin, also important for the maintenance of cell structure and function. It is noteworthy and not surprising that choline deficiency in cell culture causes apoptosis or programmed cell death. This appears to be due to abnormalities in cell membrane phosphatidylcholine content and an increase in ceramide, a precursor, as well as a metabolite, of sphingomyelin. Ceramide accumulation, which is caused by choline deficiency, appears to activate Caspase, a type of enzyme that mediates apoptosis. Betaine or trimethylglycine is derived from choline via an oxidation reaction. Betaine is one of the factors that maintains low levels of homocysteine by resynthesizing L-methionine from homocysteine. Elevated homocysteine levels are a significant risk factor for atherosclerosis, as well as other cardiovascular and neurological disorders. Acetylcholine is one of the major neurotransmitters and requires choline for its synthesis. Adequate acetylcholine levels in the brain are believed to be protective against certain types of dementia, including Alzheimer's disease. Drug type: Approved. Nutraceutical. Small Molecule. Drug category: Dietary supplement. Lipotropic Agents. Micronutrient. Nootropic Agents"}},{"Choline Acetyltransferase":{"Synonym":"Choline acetylase","CurationStatus":"uncurated","SuperCategory":"Protein","Id":"sao722953401","Has role":"Synthetic Enzyme","Is part of":"Cholinergic system","Abbrev":"ChAT","Definition":"A synthetic enzyme that catalyzes the formation of acetylcholine from acetyl-CoA and choline. EC 2.3.1.6 (MSH)."}},{"Cholinergic agonist role":{"CurationStatus":"uncurated","SuperCategory":"Agonist role","Id":"nlx_157291","Definition":"Role of a molecule that has an affinity for and stimulates physiologic activity at cell receptors normally stimulated by acetylcholine (modified from http://medical-dictionary.thefreedictionary.com/cholinergic+agonist+(2))"}},{"Cholinergic neuron (FBbt Term)":{"Has_role":"Fly_Anatomy_Ontology","Created":"2008-05-15T03:05:53Z","Contributor":"camcur","SuperCategory":"Neuron","Id":"nlx_148005","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007173","Definition":"Any neuron (FBbt_00005106) that releases as a neurotransmitter, some acetylcholine (CHEBI:15355)."}},{"Cholinergic receptor, nicotinic, alpha 5":{"RelatedTo":["Acetylcholine"],"Synonym":["CHOLINERGIC RECEPTOR","NEURONAL NICOTINIC","ALPHA POLYPEPTIDE 5; ACETYLCHOLINE RECEPTOR","NEURONAL NICOTINIC","ALPHA-5 SUBUNIT"],"CurationStatus":"graph position temporary","SuperCategory":"Protein","Curator":"Maryann Martone,","Id":"PRO:000005458","Has role":["Acetylcholine Receptor"],"Is part of":"Cholinergic system","DefiningCitation":"PRotein Ontology","Abbrev":"CHRNA5","Definition":"A protein that is a translation product of the CHRNA5 gene or a 1:1 ortholog thereof. Nicotinic acetylcholine receptors (nAChRs), such as CHRNA5, are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are thought to be (hetero)pentamers composed of homologous subunits. See MIM 118508 for additional background information on AChRs.(adapted from OMIM). "}},{"Cholinergic system":{"Synonym":["Acetylcholine system"],"CurationStatus":"uncurated","SuperCategory":"Molecular system","Id":"nlx_anat_1005028","Definition":"any molecule, protein, cell, tissue or organ that is related to acetylcholine."}},{"Chondroitin sulfate proteoglycan":{"Created":"2007-09-05","SuperCategory":"Proteoglycan","Id":"nifext_9"}},{"Chordata":{"Created":"2007-06-03","CurationStatus":"pending_final_vetting","Umlscui":"C0920312","SuperCategory":"Deuterostomia","Id":"birnlex_589"}},{"Chordin":{"Synonym":"CHRD","CurationStatus":"uncurated","Database_Reference":"PIRSF002496","Comment":"Category","SuperCategory":"Protein","Id":"PRO:000000010","Definition":"A protein that is a translation product of the CHRD gene or a 1:1 ortholog thereof. Chordin regulates signaling by BMP pathway. (PRO:CNA)"}},{"Chordoma":{"Synonym":"notochordoma","CurationStatus":"uncurated","SuperCategory":"Primary nervous system neoplastic disease","Id":"DOID:3302","Definition":"A notochordal cancer that derives_from cellular remnants of the notochord."}},{"Chorea":{"Synonym":["Choreiform Movement"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Dyskinesia","Id":"birnlex_12654","Definition":"Involuntary, forcible, rapid, jerky movements that may be subtle or become confluent, markedly altering normal patterns of movement. Hypotonia and pendular reflexes are often associated. Conditions which feature recurrent or persistent episodes of chorea as a primary manifestation of disease are referred to as CHOREATIC DISORDERS. Chorea is also a frequent manifestation of BASAL GANGLIA DISEASES (MeSH)."}},{"Choriogonadotropin alfa":{"RelatedTo":["Lutropin-choriogonadotropic hormone receptor"],"Synonym":["CG-beta","Choriogonadotropin beta chain precursor","Chorionic gonadotrophin beta subunit","Novarel","Ovidrel","Pregnyl"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00097","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00097","Definition":"Recombinant human chorionic gonadotropin with 2 subunits, alpha "}},{"Chorionic gonadotropin":{"Created":"2007-09-19","CurationStatus":"uncurated","SuperCategory":"Peptide","Id":"nifext_5021"}},{"Choroid Epithelial Cell":{"SuperCategory":"Ependymoglial Cell","Id":"sao1541570510","Definition":"Cuboidal shaped epithelial cell forming one of the components of the choroid plexus (Peters, Palay and Webster, 1991)."}},{"Choroid plexus":{"RelatedTo":"Cerebral Spinal Fluid","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"UBERON:0001886","Definition":"a structure consisting of modified ependymal cells in the ventricles of the brain responsible for the production of cerebral spinal fluid (CSFF)."}},{"Choroid plexus of fourth ventricle":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_27388","Is part of":["Choroid plexus"],"Definition":"Choroid plexus of the fourth ventricle"}},{"Choroid plexus of lateral ventricle":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_32548","Is part of":["Choroid plexus"],"Definition":"Part of choroid plexus contained in the lateral ventricle"}},{"Choroid plexus of third ventricle":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_18606","Is part of":["Choroid plexus"],"Definition":"Part of choroid plexus contained in the third ventricle"}},{"Chromadorea":{"Synonym":"Adenophorea","Created":"2007-06-03","CurationStatus":"pending_final_vetting","Umlscui":"C0162600","SuperCategory":"Nematoda","Id":"birnlex_571"}},{"Chromaffin cell":{"SuperCategory":"Nervous System Cell","Id":"nlx_297","Definition":" A cell located primarily in the adrenal medulla and paraganglia of the sympathetic nervous system that stores epinephrine secretory vesicles. Their name derives from their ability to stain a brownish color with chromic salts. , A cell located primarily in the adrenal medulla and paraganglia of the sympathetic nervous system that stores epinephrine secretory vesicles. Their name derives from their ability to stain a brownish color with chromic salts. , A cell located primarily in the adrenal medulla and paraganglia of the sympathetic nervous system that stores epinephrine secretory vesicles. Their name derives from their ability to stain a brownish color with chromic salts."}},{"Chromagen":{"CurationStatus":"uncurated","SuperCategory":"Detector role","Id":"nlx_inv_20090601","Definition":"A substance giving origin to a coloring matter that is detectable by eye in a chemical reaction."}},{"Chromatic property":{"SuperCategory":"Optical quality","Id":"PATO_0001301","Definition":"An optical quality that is the mixture, purity, or pattern of wavelengths of light perceived by the observer."}},{"Chromatin":{"SuperCategory":"Nuclear Subcomponent","Id":"sao1615953555","Definition":"The ordered and organized complex of DNA and protein that forms the chromosome (Gene Ontology)."}},{"Chromatin immunoprecipitation assay":{"Synonym":"Chromatin immunoprecipitation","CurationStatus":"uncurated","SuperCategory":"Immunoprecipitation assay","Id":"OBI_0000716","DefiningCitation":"Ontology for BIomedical Investigation","Definition":"is an assay which aims at identifying protein binding sites in genomic DNA and determining how protein may regulate gene transcription by relying on immunoprecipitation of DNA bound protein, creation of a library of corresponding DNA fragments (either single or paired-end fragments) and subsequent sequencing using parallelized sequencing methods."}},{"Chromium(VI) oxide":{"Synonym":["Amperit 704.0","Anadonis green","Anhydride chromique","Anidride cromica","C-grun","C.I. Pigment Green 17","Casalis green","Chrom(vi)-oxid","Chrome","Chrome (trioxyde de)","Chrome Green F 3","Chrome bronze","Chrome green","Chrome ocher","Chrome ochre","Chrome oxide","Chrome oxide (Cr2O3)","Chrome oxide green BX","Chrome oxide green GN-m","Chrome oxide green GP","Chromia","Chromia (CrO3)","Chromic (vi) Acid","Chromic Acid,","Chromic Acid green","Chromic Acid mixture","Chromic Acid on Amberlyst A-26","Chromic Acid","chromium salt","Chromic Acid","polymer-supported","Chromic Acid","solid","Chromic anhydride","Chromic oxide","Chromic oxide [chromium and chromium compounds]","Chromic trioxide","Chromic(vi) Acid","Chromicum Acidum","Chromium Oxide X1134","Chromium Tab 500mcg","Chromium anhydride","Chromium oxide","Chromium oxide (Cr2O3)","Chromium oxide (Cr4O12)","Chromium oxide (Cr8O12)","Chromium oxide (CrO3)","Chromium oxide green","Chromium oxide greens","Chromium oxide hydrate","Chromium oxide pigment","Chromium oxide tetrahydrate","Chromium sesquioxide","Chromium trioxide (chemical mixture study)","Chromium trioxide [chromium and chromium compounds]","Chromium trioxide","anhydrous [UN1463]","Chromium trioxide","sintered","Chromium(3+) oxide","Chromium(3+) trioxide","Chromium(6+) trioxide","Chromium(III) oxide","Chromium(III) oxide (2:3)","Chromium(III) sesquioxide","Chromium(VI) oxide (1:3)","Chromium(vi) oxide","Chromium(vi) trioxide","Chromosulfuric Acid","Chromous trioxide","Chromsaeureanhydrid","Chromtrioxid","Chroomtrioxyde","Chroomzuuranhydride","Cosmetic hydrophobic Green 9409","Cosmetic micro blend chrome oxide 9229","CrO3","Cromo(triossido di)","Dichromium trioxide","Green chrome oxide","Green chromic oxide","Green chromium oxide","Green cinnabar","Green oxide of chromium","Green oxide of chromium OC-31","Green rouge","Kromex U 1","Leaf green","Levanox green ga","Monochromium oxide","Monochromium trioxide","OKhP1","Oil green","Oxide of chromium","Pigment green 17","Puratronic chromium trioxide","Pure Chromium Oxide Green 59","Red oxide of chromium","Sintered chromium trioxide","Trioxochromium","Trioxyde de chrome","[CrO3]","chromium oxide","51Cr-labeled"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0065","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0065","Abbrev":"CrO3","Definition":"Inorganic Compound;Chromium Compound; Chromium(VI) oxide is a chemical compound of hexavalent chromium. It is used mainly in electroplating. Hexavalent chromium is more toxic than other oxidation states of the chromium atom because of its greater ability to enter cells and higher redox potential."}},{"Chromium, hexavalent":{"Synonym":["CR(vi)","Chromium (cr(sup 6+))","Chromium (hexavalent compounds)","Chromium (vi)","Chromium hexavalent ion","Chromium(6+)","Chromium(6+)ions","Chromium(vi)","Chromium(vi) cation","Chromium(vi) compounds","Chromium(vi) ions","Chromium hexavalent (CR(vi))","Chromium ion (Cr 6+)"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0018","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0018","Abbrev":"[Cr]6+","Definition":"Inorganic Compound;Metal;Chromium Compound; Hexavalent chromium refers to chemical compounds that contain the element chromium in the +6 oxidation state. Chromium(VI) is more toxic than other oxidation states of the chromium atom because of its greater ability to enter cells and higher redox potential."}},{"Chromotography instrument":{"Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Chemical separation instrument","Id":"birnlex_2402"}},{"Chronic":{"SuperCategory":"Process quality","Id":"PATO_0001863","Definition":"Having slow progressive course of indefinite duration."}},{"Chronic binge drug administration paradigm":{"Synonym":["Chronic binge","Chronic binge administration paradigm"],"CurationStatus":"uncurated","SuperCategory":"Chronic drug administration paradigm","Id":"nlx_inv_100810","Has role":"NIF annotation standard for treatment type","Definition":"A drug administration paradigm where multiple doses of a drug are given within a day lasting longer than one experimental session over the course of multiple days."}},{"Chronic drug administration paradigm":{"Synonym":["chronic drug","chronic drug administration","chronic"],"CurationStatus":"uncurated","SuperCategory":"Drug administration paradigm","Id":"nlx_inv_1005003","Has role":"NIF annotation standard for treatment type","Definition":"A drug administration paradigm where the drug is given for more than one experimental session over the course of several days, to mimic the effects of chronic drug administration."}},{"Chronic Inflammatory Demyelinating Polyradiculoneuropathy":{"Synonym":["Chronic Inflammatory Polyradiculoneuropathy","Chronic Inflammatory Demyelinating Polyneuropathy"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Polyradiculoneuropathy","Id":"birnlex_12563","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"A slowly progressive autoimmune demyelinating disease of peripheral nerves and nerve roots. Clinical manifestations include weakness and sensory loss in the extremities and enlargement of peripheral nerves. The course may be relapsing-remitting or demonstrate a step-wise progression. Protein is usually elevated in the spinal fluid and cranial nerves are typically spared. GUILLAIN-BARRE SYNDROME features a relatively rapid progression of disease which distinguishes it from this condition (MeSH)."}},{"Chronic Progressive Multiple Sclerosis":{"Synonym":["Progressive Relapsing Multiple Sclerosis"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Multiple Sclerosis","Id":"birnlex_12515","DefiningCitation":["Ann Neurol 1994;36 Suppl:S73-S79; Adams et al.","Principles of Neurology","6th ed"],"Definition":"A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form (MeSH)."}},{"Chronic tic disorder":{"CurationStatus":"uncurated","SuperCategory":"Tic Disorder","Id":"nlx_dys_100302","DefiningCitation":["Evidente VG. \"Is it a tic or Tourette's? Clues for differentiating simple from more complex tic disorders\". Postgraduate medicine108 (5): 175-6"],"Definition":"Chronic tic disorder is either single or multiple motor or phonic tics, but not both, which are present for more than a year."}},{"Chronic Wasting Disease":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Prion Disease","Id":"birnlex_12695","Definition":"A transmissible spongiform encephalopathy (prion disease) of DEER and elk characterized by chronic weight loss leading to death. It is thought to spread by direct contact between animals or through environmental contamination with the prion protein ( PRIONS) (MeSH)."}},{"Chronological age":{"SuperCategory":"Age","Id":"PATO_0001486","Definition":"Age measured by the time (years and months) something or someone has existed."}},{"Chx10":{"Synonym":["Chx10","Hox10"],"CurationStatus":"uncurated","SuperCategory":"Gene","Id":"nlx_27323","Definition":"C. elegans ceh-10 homeo domain containing homolog"}},{"Cibarial pump muscle neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Motor neuron (FBbt Term)","Id":"nlx_147733","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004023","Fasciculates_with":"pharyngeal nerve"}},{"Ciclopirox":{"RelatedTo":["Prostaglandin G/H synthase 1","Prostaglandin G/H synthase 2"],"Synonym":["CPO","Ciclopirox Olamin","Ciclopirox-Olamin","Ciclopiroxum (INN-Latin)","HOE 296b","HOE-296b","ciclopirox","ciclopiroxolamine","Loprox","Loprox Shampoo","Penlac","Penlac Nail Lacquer"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01188","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01188","Definition":"Ciclopirox (also called Loprox, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic use. (Wikipedia) Pharmacology: Ciclopirox is a broad-spectrum antifungal medication that also has antibacterial and anti-inflammatory properties. Its main mode of action is thought to be its high affinity for trivalent cations, which inhibit essential co-factors in enzymes. Ciclopirox exhibits either fungistatic or fungicidal activity in vitro against a broad spectrum of fungal organisms, such as dermatophytes, yeasts, dimorphic fungi, eumycetes, and actinomycetes. In addition to its broad spectrum of action, ciclopirox also exerts antibacterial activity against many Gram-positive and Gram-negative bacteria. Furthermore, the anti-inflammatory effects of ciclopirox have been demonstrated in human polymorphonuclear cells, where ciclopirox has inhibited the synthesis of prostaglandin and leukotriene. Ciclopirox can also exhibit its anti-inflammatory effects by inhibiting the formation of 5-lipoxygenase and cyclooxygenase. Mechanism of action: Unlike antifungals such as itraconazole and terbinafine, which affect sterol synthesis, ciclopirox is thought to act through the chelation of polyvalent metal cations, such as Fe3+ and Al3+. These cations inhibit many enzymes, including cytochromes, thus disrupting cellular activities such as mitochondrial electron transport processes and energy production. Ciclopirox also appears to modify the plasma membrane of fungi, resulting in the disorganization of internal structures. The anti-inflammatory action of ciclopirox is most likely due to inhibition of 5-lipoxygenase and cyclooxygenase. Drug type: Approved. Investigational. Small Molecule. Drug category: Antifungal Agents"}},{"Cidofovir":{"RelatedTo":"DNA polymerase","Synonym":["CDV","Cidofovir Anhydrous","HPMPC"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00369","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00369","Definition":"Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA synthesis. (Wikipedia) Pharmacology: Cidofovir is a new anti-viral drug. It is classified as a nucleotide analogue and is active against herpes cytomegalovirus (CMV) retinitis infection. Most adults are infected with CMV. Cidofovir suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis. Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Cidofovir diphosphate inhibits herpesvirus polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerase alpha, beta, and gamma(1,2,3). Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis. Mechanism of action: Cidofovir acts through the selective inhibition of viral DNA polymerase. Drug type: Approved. Small Molecule. Drug category: Anti-HIV Agents. Antineoplastic Agents. Antiviral Agents. Radiation-Sensitizing Agents"}},{"Cilastatin":{"RelatedTo":"Dipeptidase 1","SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01597","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01597","Definition":"A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4. (PubChem) Pharmacology: Cilastatin is a chemical compound which inhibits the human enzyme dehydropeptidase. Dehydropeptidase is found in the kidney and is responsible for degrading the antibiotic imipenem. Cilastatin is therefore combined intravenously with imipenem in order to protect it from dehydropeptidase and prolong its antibacterial effect. However, cilastatin in and of itself does not have any antibacterial activity. Mechanism of action: Cilastatin is a renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4. Drug type: Approved. Small Molecule. Drug category: Protease Inhibitors"}},{"Ciliary displacement stimulus transduction":{"Created":"2008-03-13","CurationStatus":"graph_position_temporary","SuperCategory":"Mechanical stimulus transduction","Id":"birnlex_15016","Definition":"Energy transfer between some physical force and primary sensory cilia displacement which to stimulation of the neurons (BB: 2008-03-13)"}},{"Ciliary ganglion cell":{"Located in":"Ciliary ganglion","Located_in":"Ciliary ganglion","Synonym":"Ciliary ganglion neuron","CurationStatus":"uncurated","Neurotransmitter":"Acetylcholine","ExampleImage":"Ciliary ganglion cell.JPG,","SuperCategory":"Neuron","Polarity":"Unipolar","Id":"sao1366775348","Species":"Vertebrata","OriginOfAxon":"soma"}},{"Ciliated photoreceptor cell":{"Has_role":"Fly_Anatomy_Ontology","Created":"2008-11-03T01:08:18Z","Contributor":"david","SuperCategory":"Photoreceptor cell (FBbt Term)","Id":"nlx_148045","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007252"}},{"Ciliatedness":{"SuperCategory":"Cellular quality","Id":"PATO_0001408","Definition":"A cellular quality inhering in a bearer by virtue of having thin, tail-like projections extending outwards from the cell body."}},{"Cilium":{"CurationStatus":"uncurated","SuperCategory":"Cellular component","Id":"sao787716553","Definition":"Cilia arising from neurons have been described in many different regions of the nervous system.  Neuronal cilia have a \"9+0\" pattern, that is, they are missing the central pair of microtubules that characterizes most cilia (Peters, Palay and Webster, 1991)."}},{"Cilium basal body":{"Synonym":"ciliary basal body","CurationStatus":"uncurated","SuperCategory":"Cellular component","Id":"GO:0036064","Definition":"A membrane-tethered derivative of the centriole, and the site of assembly and remodelling of the cilium. As well as anchoring the cilium, the basal body is thought to provide a selective gateway regulating the entry of ciliary proteins and vesicles by intraflagellar transport."}},{"Cilostazol":{"RelatedTo":["cGMP-inhibited 3',5'-cyclic phosphodiesterase A","cAMP-specific 3',5'-cyclic phosphodiesterase 4B"],"Synonym":["Cilostazole","Cilostazolum (INN-Latin)","Pletaal"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01166","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01166","Definition":"Cilostazol is a medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral vascular disease. It is manufactured by Otsuka Pharmaceutical Co. under the trade name Pletal. Although drugs similar to cilostazol have increased the risk of death in patients with congestive heart failure, studies of significant size have not addressed people without the disease. (Wikipedia) Pharmacology: Cilostazol is a quinolinone derivative indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance. Intermittent claudication is pain in the legs that occurs with walking and disappears with rest. The pain occurs due to reduced blood flow to the legs. Mechanism of action: The mechanism of the effects of cilostazol on the symptoms of intermittent claudication is not fully understood. Cilostazol and several of its metabolites are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation. Drug type: Approved. Small Molecule. Drug category: Bronchodilator Agents. Fibrinolytic Agents. Neuroprotective Agents. Phosphodiesterase Inhibitors. Platelet Aggregation Inhibitors. Vasodilator Agents"}},{"Cimetidine":{"RelatedTo":["Histamine H2 receptor"],"Synonym":["Cimetidine A/AB","Cimetidine Hcl","Acibilin","Acinil","Cimal","Cimetag","Cimetum","Dyspamet","Edalene","Eureceptor","Gastromet","Peptol","Tagamet","Tagamet HB","Tagamet HB 200","Tametin","Tratul","Ulcedin","Ulcedine","Ulcerfen","Ulcimet","Ulcofalk","Ulcomedina","Ulcomet"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3699","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00501","Definition":"A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. (PubChem) Pharmacology: Cimetidine is a histamine H2-receptor antagonist. It reduces basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. It is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Cimetidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Cimetidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Mechanism of action: Cimetidine binds to an H2-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity. Drug type: Approved. Small Molecule. Drug category: Adjuvants. Analgesics. Anti-Ulcer Agents. Enzyme Inhibitors. Histamine Antagonists. Histamine H2 Antagonists"}},{"Cinacalcet":{"RelatedTo":"Extracellular calcium-sensing receptor","CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:48390","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01012","Definition":"Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure. Pharmacology: Cinacalcet is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues). Secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) is a progressive disease, associated with increases in parathyroid hormone (PTH) levels and derangements in calcium and phosphorus metabolism. Increased PTH stimulates osteoclastic activity resulting in cortical bone resorption and marrow fibrosis. The goals of treatment of secondary hyperparathyroidism are to lower levels of PTH, calcium, and phosphorus in the blood, in order to prevent progressive bone disease and the systemic consequences of disordered mineral metabolism. In CKD patients on dialysis with uncontrolled secondary HPT, reductions in PTH are associated with a favorable impact on bone-specific alkaline phosphatase (BALP), bone turnover and bone fibrosis. Cinacalcet reduces calcium levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium. Mechanism of action: The calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of parathyroid hormone secretion. Cinacalcet directly lowers parathyroid hormone levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium. The reduction in parathyroid hormone is associated with a concomitant decrease in serum calcium levels. Drug type: Approved. Small Molecule. Drug category: Calcimimetics"}},{"Cinalukast":{"RelatedTo":"Cysteinyl leukotriene receptor 1","SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00587","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00587","Definition":"Used in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Cinalukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus. Pharmacology: Used in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Cinalukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus. Mechanism of action: Binds to the cysteinyl leukotriene receptor. The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene receptors (CysLT) found in the human airway. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Drug type: Approved. Small Molecule. Drug category: Antiarrhythmic Agents"}},{"CINERGI Resource Descriptor":{"CurationStatus":"uncurated","SuperCategory":"Continuant","Id":"nlx_158156","Is part of":"Resource:CINERGI","DefiningCitation":"http://neurolex.org/wiki/CINERGI_Resource_Types","Definition":"Any class that describes a resource for the CINERGI Project."}},{"Cingulate cortex":{"Created":"2006-10-08","EditorialNote":"The only elements labelled \"cingulate cortex\" in neuronames related to mouse brain parcellations both from Swanson and from Paxinos.  No \"cingulate cortex\" is listed for primates.  There are the many cortical areas defined by Brodmann's parcellation scheme present in NeuroNames, and they are obviously the mans by which cortical parenchyma regions are accessed. (BB).","CurationStatus":"uncurated","Umlscui":"C0598179","SuperCategory":"Regional part of brain","Id":"birnlex_934","Is part of":"Cingulate gyrus"}},{"Cingulate gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","EditorialNote":"Will keep the NN \"gyri\" distinct from the BIRN \"cortex\" regions.  Should we later decide the intended meanings are the same, we can set the corresponding classes to be equivalent.  In the end, any such correspondence really would depend on how the various cortical areas defined by Brodmann or some other parcellation scheme as defined for the NN gyri relate to those cortical areas assigned to the BIRN coritical regions (BB)., UMLS includes a CUI for \"Cingulate cortex\" (C0598179) separate from this other for \"Cingulate gyrus\"., Note that in BrainMap.org, they mere list LimbicLobe.AnteriorCingulate.GrayMatter under which they included Brodmann areas 10, 24, 25, 32, & 33 and LimbicLobe.CingulateGyrus.GrayMatter under which they include Brodmann areas 23, 24, 31, and 32.  This indicates not all gray matter contained within the cingulate cortex lies within the cingulate gyrus - at least it doesn't according to BrainMap.org's parcellation., Now I see where my confusion derives from.  It relates to the fact this distinction between surface and volumetric, parenchymal structures is a bit unclear in NeuroNames.  There sulci are clearly listed as \"superficial\" (i.e., defining surfaces), whereas gyri as listed as \"volumetric structures\".  The organization of the parenchyma within the lobes of the cerebral cortex are largely given according to complex structures lumped into the \"ancillary terms\" - e.g., all of the Brodmann areas.  The implication for listing \"gyri\" as volumetric is that the cortical parenchyma lying underneath the gyral surface are also included in these gyral regions.  Therefore, it may in fact be correct to set the BIRN \"cingulate cortex\" ","Synonym":["cingulate region"],"CurationStatus":"uncurated","NeuronamesID":"141","Umlscui":"C0018427","SuperCategory":"Regional part of brain","Id":"birnlex_798","Is part of":"Limbic lobe","Species":"Human","Abbrev":"CG","Definition":"One of the convolutions on the medial surface of the cerebral hemisphere. It surrounds the rostral part of the brain and interhemispheric commissure and forms part of the limbic system. (MSH)  One of three essential structures comprising the limbic lobe, the other two being the hippocampus and parahippocampal gyrus. (CSP)"}},{"Cingulate sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","Synonym":["callosomarginal fissure","calloso-marginal sulcus","Sulcus cingulatus","Sulcus callosomarginalis","cingulate fissure","callosomarginal sulcus"],"CurationStatus":"uncurated","NeuronamesID":"24","Umlscui":"C0228189","SuperCategory":"Sulcus","Id":"birnlex_1468","Is part of":"Cerebral cortex"}},{"Cingulum of CIVM postnatal rat brain atlas":{"AtlasImage":["cingulum p0.png"],"CurationStatus":"uncurated","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151546","Is part of":"Major White Matter Structures of CIVM postnatal rat brain atlas","Definition":"The cingulum is easily segmented on coronal T2-weighted MRI and/or a directionally encoded color fractional anisotropy image if one exists. On T2-weighted MRI the cingulum is a dark crescentic structure just dorsal to the corpus callosum. The dorsal border with the much brighter appearing cortex is straightforward. The ventral border with the corpus callosum is defined by a fine, bright line that fades laterally as the two structures merge. This border is trivially easy to distinguish on color fractional anisotropy images as these two white matter tracts course virtually perpendicular to each other. The rostral extent of the cingulum is a small sliver just medial to the forceps minor of the corpus callosum. The caudal extent is a semicircular shell around the medial aspect of the forceps major of the corpus callosum."}},{"Cinnarizine":{"RelatedTo":["Voltage-dependent P/Q-type calcium channel subunit alpha-1A","Histamine H1 receptor"],"Synonym":[", Abitrate","Aplactan","Aplexal","Apotomin","Artate","Carecin","Cerebolan","Cerepar","Cinaperazine","Cinazyn","Cinnacet","Cinnageron","Cinnarizine Stugeron","Corathiem","Denapol","Dimitron","Dimitronal","Eglen","Folcodal","Giganten","Glanil","Hilactan","Ixertol","Katoseran","Labyrin","Lazeta","Marisan","Midronal","Mitronal","Olamin","Processine","Sedatromin","Sepan","Siptazin","Spaderizine","Stugeron","Stutgeron","Stutgin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:31403","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00568","Definition":"Cinnarizine is an anti-histaminic drug which is mainly used for the control of vomiting due to motion sickness. Cinnarizine was first synthesized by Janssen Pharmaceutica in 1955.It acts by interfering with the signal transmission between vestibular apparatus of the inner ear and the vomiting centre of the hypothalamus. The disparity of signal processing between inner ear motion receptors and the visual senses is abolished, so that the confusion of brain whether the individual is moving or standing is reduced. Vomiting in motion sickness is actually a physiological compensatory mechanism of the brain to keep the individual from moving so that it can adjust to the signal perception.Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. It is also effectively combined with other nootropics, primarily piracetam; in such combination each drug potentiate the other in boosting brain oxygen supply. Pharmacology: Cinnarizine is an antihistamine and a calcium channel blocker. Histamines mediate a number of activities such as contraction of smooth muscle of the airways and gastrointestinal tract, vasodilatation, cardiac stimulation, secretion of gastric acid, promotion of interleukin release and chemotaxis of eosinophils and mast cells. Competitive antagonists at histamine H1 receptors may be divided into first (sedating) and second (non-sedating) generation agents. Some, such as Cinnarizine also block muscarinic acetylcholine receptors and are used as anti-emetic agents. Cinnarizine through its calcium channel blocking ability also inhibits stimulation of the vestibular system. Mechanism of action: Binds to the Histamine H1 receptor and to muscarinic acetylcholine receptors. Cinnarizine also inhibits contractions of vascular smooth muscle cells by blocking L type calcium channels. Cinnarizine has also been implicated in binding to dopamine D2 receptors. Drug type: Approved. Small Molecule. Drug category: Anti-Allergic Agents. Calcium Channel Blockers. Histamine H1 Antagonists"}},{"Cinolazepam":{"RelatedTo":"Translocator protein","Synonym":["Cinolazepamum (inn-latin)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01594","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01594","Definition":"Cinolazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Cinolazepam is not approved for sale in the United States or Canada. Pharmacology: Cinolazepam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Cinolazepam is not approved for sale in the United States or Canada. Mechanism of action: Cinolazepam binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways. Drug type: Approved. Small Molecule. Drug category: Anticonvulsants. Benzodiazepines. Sedatives and Hypnotics"}},{"Cinoxacin":{"RelatedTo":"DNA","SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00827","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00827","Definition":"Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. (PubChem) Pharmacology: Cinoxacin is a synthetic antibacterial agent with in vitro activity against many gram-negative aerobic bacteria, particularly strains of the Enterobacteriaceae family. Cinoxacin inhibits bacterial deoxyribonucleic acid (DNA) synthesis, is bactericidal, and is active over the entire urinary pH range. Cross resistance with nalidixic acid has been demonstrated. Mechanism of action: Evidence exists that cinoxacin binds strongly, but reversibly, to DNA, interfering with synthesis of RNA and, consequently, with protein synthesis. Drug type: Approved. Small Molecule. Drug category: Anti-Infective Agents"}},{"Ciprofloxacin":{"RelatedTo":["DNA gyrase subunit A","DNA topoisomerase 4 subunit A","Serum albumin","DNA topoisomerase 2-alpha"],"Synonym":["Ciprofloxacin HCl","Ciprofloxacin dihydrochloride","Ciprofloxacin hydrochloride","Ciprofloxacin monohydrochloride","Ciprofloxacina","ciprofloxacin","Bacquinor","Baycip","Bernoflox","Ciflox","Cifloxin","Ciloxan","Ciprinol","Cipro","Cipro I,V,","Cipro XL","Cipro XR","Ciprobay","Ciprocinol","Ciprodar","Cipromycin","Ciproquinol","Ciproxan","Ciproxin","Flociprin","Floxin","Ocuflox","Proquin XR","Septicide"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00537","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00537","Definition":"A broad-spectrum antimicrobial carboxyfluoroquinoline. (PubChem) Pharmacology: Ciprofloxacin is a broad-spectrum antiinfective agent of the fluoroquinolone class. Ciprofloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. The mechanism of action of quinolones, including ciprofloxacin, is different from that of other antimicrobial agents such as beta-lactams, macrolides, tetracyclines, or aminoglycosides; therefore, organisms resistant to these drugs may be susceptible to ciprofloxacin. There is no known cross-resistance between ciprofloxacin and other classes of antimicrobials. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Mechanism of action: The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-Infective Agents. Anti-Infectives. Nucleic Acid Synthesis Inhibitors. Quinolones"}},{"CIRAD":{"RelatedTo":"Agropolis Foundation","Synonym":["Centre de Cooperation Internationale en Research Agronomique pour le Development","Centre de coopration internationale en recherche agronomique pour le dvelopement"],"CurationStatus":"curated","SuperCategory":"Institute","Id":"nlx_158285","Is part of":["French Ministry of Higher Education and Research"],"DefiningCitation":"http://www.cirad.fr/en/","Abbrev":"CIRAD","Definition":"A French research center working with developing countries to tackle international agricultural and development issues. They are a public industrial and commercial enterprise (EPIC) under the joint authority of the Ministry of Higher Education and Research and the Ministry of Foreign Affairs.CIRAD works with the whole range of developing countries to generate and pass on new knowledge, support agricultural development and fuel the debate on the main global issues concerning agriculture. They are a targeted research organization, and base their operations on development needs, from field to laboratory and from a local to a global scale.CIRAD's activities involve the life sciences, social sciences and engineering sciences, applied to agriculture, food and rural territories. They work hand-in-hand with local people and the local environment, on complex, ever-changing issues: food security, ecological intensification, emerging diseases, the future of agriculture in developing countries, etc."}},{"Circadian rhythm":{"RelatedTo":"Suprachiasmatic nucleus","CurationStatus":"uncurated","SuperCategory":"Biological rhythm","Id":"GO:0007623","Definition":"A biological activity that occurs in approximately 24-hour periods or cycles.  The \"clock\" resides in the suprachiasmatic nucleus."}},{"Circinate":{"SuperCategory":"Curled","Id":"PATO_0001964","Definition":"A shape inhering in a bearer by virtue of the edges of its surface are rolled spirally downwards."}},{"Circling":{"SuperCategory":"Behavioral quality","Id":"PATO_0001911","Definition":"A behavioral quality in which an organism moves in a circular course."}},{"Circling direction":{"SuperCategory":"Direction","Id":"PATO_0001904","Definition":"A direction approximating the shape of a circle."}},{"Circuit part of central nervous system":{"Created":"2007-08-25","CurationStatus":"uncurated","Comment":"I don't understand this category?  What is it meant to describe?  We already have categories for intrinsic neurons and principle neurons.","SuperCategory":"Central nervous system","Id":"birnlex_2513","Is part of":"Central nervous system"}},{"Circular sulcus of insula":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","Synonym":["Sulcus marginalis insulae","circuminsular sulcus","circular fissure","ciruclar insular sulcus","marginal insular sulcus","Sulcus circularis insulae","circular sulcus (of Reil)"],"CurationStatus":"uncurated","NeuronamesID":"32","Umlscui":"C0228258","SuperCategory":"Sulcus","Id":"birnlex_1475","Is part of":"Insula","Species":"Human","Abbrev":"crs"}},{"Circumference":{"SuperCategory":"Perimeter","Id":"PATO_0001648","Definition":"The length of the closed curve of a circle."}},{"Circumvallate papilla":{"Synonym":"Vallate papilla","Created":"2008-03-22","CurationStatus":"uncurated","Umlscui":["C1182961","C1267555"],"SuperCategory":"Lingual papilla","Id":"birnlex_4106_2"}},{"Circumventricular organ":{"CurationStatus":"pending final vetting","SuperCategory":"Regional part of brain","Id":"nlx_anat_20090312","Abbrev":"CVO","Definition":"Brain region located around or in relation to the ventricular system that is highly vascularized and distinguished by the lack of a blood brain barrier."}},{"Cis Face of Golgi Apparatus":{"Synonym":["cis Golgi network","Golgi cis face","Golgi cis-face","forming face"],"CurationStatus":"uncurated","SuperCategory":"Membrane bound organelle","Id":"GO:0005801","Xref":"sao632188024","Definition":"The network of interconnected tubular and cisternal structures located at the convex side of the Golgi apparatus, which abuts the endoplasmic reticulum."}},{"Cisapride":{"RelatedTo":["5-hydroxytryptamine 4 receptor","Potassium voltage-gated channel subfamily H member 2","5-hydroxytryptamine 3 receptor"],"Synonym":["cisapride","Acenalin","Alimix","Cipril","Enteropride","Kinestase","Prepulsid","Pridesia","Propulsid","Propulsid Quicksolv","Propulsin","Risamal"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00604","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00604","Definition":"In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. Pharmacology: Cisapride is a parasympathomimetic which acts as a serotonin 5-HT4 agonist. Stimulation of the serotonin receptors increases acetylcholine release in the enteric nervous system. Cisapride stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Cisapride increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. It increases the resting tone of the lower esophageal sphincter. It has little, if any, effect on the motility of the colon or gallbladder. Cisapride does not induce muscarinic or nicotinic receptor stimulation, nor does it inhibit acetylcholinesterase activity. Mechanism of action: Cisapride acts through the stimulation of the serotonin 5-HT4 receptors which increases acetylcholine release in the enteric nervous system (specifically the myenteric plexus). This results in increased tone and amplitude of gastric (especially antral) contractions, relaxation of the pyloric sphincter and the duodenal bulb, and increased peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. Drug type: Approved. Investigational. Small Molecule. Withdrawn. Drug category: Anti-Ulcer Agents. Gastrointestinal Agents. Prokinetic Agents. Serotonin Agonists"}},{"Cisatracurium Besylate":{"RelatedTo":"Neuronal acetylcholine receptor subunit alpha-2","Synonym":[", Atracurium Besylate","Atracurium Besylate Preservative Free","Nimbex"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00565","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00565","Definition":"Cisatracurium Besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration. Cisatracurium Besylate acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. The neuromuscular block produced by cisatracurium besylate is readily antagonized by anticholinesterase agents once recovery has started. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at the time of reversal, the longer the time required for recovery of neuromuscular function. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. Pharmacology: Cisatracurium Besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration. Cisatracurium Besylate acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. The neuromuscular block produced by cisatracurium besylate is readily antagonized by anticholinesterase agents once recovery has started. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at the time of reversal, the longer the time required for recovery of neuromuscular function. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. Mechanism of action: Cisatracurium Besylate binds to the nicotinic acetycholine (cholinergic) receptors in the motor endplate and blocks access to the receptors. In the process of binding, the receptor is actually activated - causing a process known as depolarization. Since it is not degraded in the neuromuscular junction, the depolarized membrane remains depolarized and unresponsive to any other impulse, causing muscle paralysis. Drug type: Approved. Small Molecule. Drug category: Neuromuscular Blocking Agents"}},{"Cisplatin":{"RelatedTo":"DNA","Synonym":["CACP","CPDC","CPDD","Cis-DDP","Cis-Diaminedichloroplatinum","Cis-Diamminedichloroplatinum","DDP","DDPT","Diamminedichloroplatinum","Platinum Ammine Chloride","Platinum Ammonium Chloride","Platinum Diamine Dichloride","Trans-DDP","Trans-Diaminedichloroplatinum","Trans-Diamminedichloroplatinum","Trans-Dichlorodiammine Platinum","Trans-Platinumdiammine Dichloride","Abiplatin","Biocisplatinum","Briplatin","Carboquone","Cis Pt II","Cismaplat","Cisplatine","Cisplatyl","Citoplationo","Lederplatin","Neoplatin","Plastin","Platamine","Platiblastin","Platidiam","Platinex","Platinol","Platinol-AQ","Platinoxan"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:27899","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00515","Definition":"Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. Pharmacology: Cisplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death. Mechanism of action: Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. Drug type: Approved. Small Molecule. Drug category: Antineoplastic Agents. Cross-Linking Reagents. Radiation-Sensitizing Agents"}},{"Cistern of lamina terminalis":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["Cisterna lamina terminalis"],"NeuronamesID":"10","CurationStatus":"uncurated","Umlscui":"C0228153","SuperCategory":"Superficial feature part of forebrain","Id":"birnlex_4002","Abbrev":"cislt"}},{"Citalopram":{"RelatedTo":"Sodium-dependent serotonin transporter","Synonym":["Citalopram Hydrobromide","Citalopramum (INN-Latin)","Celexa","Cipram"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3723","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00215","Definition":"A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition. (PubChem) Pharmacology: Citalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of Citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that Citalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Citalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of Citalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Citalopram does not inhibit monoamine oxidase. Mechanism of action: The antidepressant, antiobsessive-compulsive, and antibulimic actions of Citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Citalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs. Drug type: Approved. Small Molecule. Drug category: Antidepressants. Antidepressive Agents, Second-Generation. Selective Serotonin Reuptake Inhibitors (SSRIs). Serotonin Uptake Inhibitors"}},{"Citation record":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Information content entity","Id":"birnlex_2387"}},{"Citation record element":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Information content entity","Id":"birnlex_2376","Definition":"Those elements defined as a part of the PubMed DTD and used by many literature citation databases"}},{"CIVM postnatal rat brain atlas parcellation scheme":{"EditorialNote":"All of the categories that were originally listed under this category are now found under CIVM postnatal rat brain atlas parcellation scheme region","CurationStatus":"uncurated","SuperCategoryPMID":"23246176","SuperCategory":"Parcellation scheme","Id":"nlx_151513","Species":"Rat","HasRolePMID":"23246176","DefinitionPMID":"23246176","Definition":"Parcellation scheme for the CIVM postnatal rat brain atlas, designed as a developmental neuro-ontology for tracking regional changes in MR biomarkers throughout postnatal neurodevelopment."}},{"CIVM postnatal rat brain atlas parcellation scheme region":{"CurationStatus":"uncurated","SuperCategory":"Parcellation scheme parcel","Id":"nlx_153850","Is part of":"CIVM postnatal rat brain atlas parcellation scheme","Species":"Rat","DefinitionPMID":"23246176","Definition":"Brain regions defined in the CIVM postnatal rat brain atlas parcellation scheme and criteria for their identification in MRI images"}},{"Cladodromous":{"SuperCategory":"Branched (PATO 0000402)","Id":"PATO_0001971","Definition":"A shape inhering in a bearer by virtue of having secondary branches freely branching toward the margin."}},{"Cladribine":{"RelatedTo":["Purine nucleoside phosphorylase","DNA"],"Synonym":["2-CdA","2-Chloro-2'-deoxy-beta-adenosine","2-Chloro-2'-deoxyadenosine","2-Chlorodeoxyadenosine","Chlorodeoxyadenosine","cladribine","Leustatin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00242","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00242","Definition":"An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. (PubChem) Pharmacology: Cladribine is a synthetic antineoplastic agent with immunosuppressive effects. Cladribine is one of a group of chemotherapy drugs known as the anti-metabolites.Anti-metabolites stop cells making and repairing DNA. Cancer cells need to make and repair DNA in order to grow and multiply. Mechanism of action: Cladribine is structurally related to fludarabine and pentostatin but has a different mechanism of action. It is phosphorylated to its corresponding nucleotide CdATP, which accumulates and is incorporated into the DNA of cells such as lymphocytes. High levels of CdATP lead to DNA strand breaks, inhibition of DNA synthesis, and cell death. Unlike other antimetabolite drugs, cladribine has cytotoxic effects on resting as well as proliferating lymphocytes. However, it does cause cells to accumulate at the G1/S phase junction, suggesting that cytotoxicity is associated with events critical to cell entry into S phase. It also binds purine nucleoside phosphorylase (PNP), however no relationship between this binding and a mechanism of action has been established. Drug type: Approved. Investigational. Small Molecule. Drug category: Antineoplastic Agents. Immunosuppressive Agents"}},{"Clarithromycin":{"RelatedTo":"50S ribosomal protein L10","Synonym":["CLA","Clarithromycine","Clathromycin","Biaxin","Biaxin XL","Klacid","Klaricid","Macladin","Naxy","Veclam"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01211","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01211","Definition":"A semisynthetic macrolide antibiotic derived from erythromycin that is active against a variety of microorganisms. It can inhibit protein synthesis in bacteria by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation. (PubChem) Pharmacology: Clarithromycin, a macrolide antibiotic similar to erythromycin and azithromycin, is effective against Mycobacterium avium complex (MAC) and is used for the treatment of Helicobacter pylori-associated peptic ulcer disease, community-acquired pneumonia, sinusitis, and chronic bronchitis. Clarithromycin is also used to treat respiratory tract, sexually transmitted, otitis media, and AIDS-related infections. Mechanism of action: Clarithromycin is first metabolized to 14-OH clarithromycin. Like other macrolides, it then binds to the 50 S subunit of the 70 S ribosome of the bacteria, blocking RNA-mediated bacterial protein synthesis. Clarithromycin also inhibits the hepatic microsomal CYP3A4 isoenzyme and P-glycoprotein, an energy-dependent drug efflux pump. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Macrolides. Other Macrolides. Protein Synthesis Inhibitors"}},{"Clarity":{"RelatedTo":"Resource:Clarity resources","Synonym":"Clarity protocol","CurationStatus":"uncurated","SuperCategory":"Specimen preparation protocol","Id":"nlx_152560","DefinitionPMID":"23575631","Definition":"A method for the transformation of intact tissue into a nanoporous hydrogel-hybridized form (crosslinked to a three-dimensional network of hydrophilic polymers) that is fully assembled but optically transparent andmacromolecule-permeable."}},{"Clark WELeG 1951 Parcellation scheme":{"CurationStatus":"uncurated","PublicationDate":"1951","SuperCategory":"Parcellation scheme","Id":"nlx_155471","Authors":"Clark WELeG","Title":"Central nervous system","Definition":"Parcellations or definitions of nervous system structures from Clark WELeG (1951): Central nervous system. In Cunningham's Text-Book of Anatomy, 9th edn, ed Brash JC (Oxford University Press, London), pp 835-1008."}},{"Clark WELeG 1951 Parcellation scheme region":{"CurationStatus":"uncurated","SuperCategory":"Parcellation scheme region","Id":"nlx_155472","Is part of":"Clark WELeG 1951 Parcellation scheme","Definition":"Nervous system structure definitions from Clark WELeG (1951): Central nervous system. In Cunningham's Text-Book of Anatomy, 9th edn, ed Brash JC (Oxford University Press, London), pp 835-1008."}},{"Clarke's Nucleus":{"PMID":"4173077","EditorialNote":"This class was originally entered as a plural (Clarke's nuclei) and so was entered as a duplicate class as a singular (nlx_12).  However, as ontology classes should be singular and as the singular is the more common form, I am going to merge the two classes, retain the original identifier but make the singular the preferred name.","Synonym":["nucleus dorsalis"],"CurationStatus":"graph position temporary","SuperCategory":"Regional part of spinal cord","Curator":"Maryann Martone,","Id":"nlx_anat_20090102","Is part of":["Lumbar spinal cord dorsal horn"],"DefiningCitation":"Boehme CC. 1968. The Neural Structure of Clarke's Nucleus of the Spinal Cord. J. Comp. Neur. 132:445-462. PMID: 4173077","Definition":"A rounded collection of cells locat4ed on the medial surface of the base of the posterior horn. Considered by many to be a part of the posterior horn. Two column-shaped nuclear masses formed by large cells. Clarke's nuclei are located in the regions dorsolateral to the central canal in the thoratic and upper lumbar segments."}},{"Class 1 small leucine-rich proteoglycan":{"RelatedTo":" ","Synonym":" ","Umlscui":" ","Database Reference":"PIRSF002490","SuperCategory":"Protein","Comment":"Category","Id":"PRO:000000011","Definition":"A protein with a core domain composition consisting of eight to ten tandem leucine-rich repeat sequences that are flanked at either end by cysteine rich disulfide loops. [PMID:14562268]"}},{"Class I dendritic arborizing neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2008-11-04T10:59:06Z","Synonym":"class I dendritic arborising neuron","Contributor":"david","SuperCategory":"Dendritic arborizing neuron","Id":"nlx_148056","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007272","Definition":"A dendritic arborizing md sensory neuron with a long, dorsally directed primary dendrite which branches repeatedly along its length into antero-posteriorly oriented secondary dendrites. The dendrites are smooth and their branching pattern is relatively simple, with few side branches or varicosities."}},{"Class II dendritic arborizing neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2008-11-04T11:04:12Z","Synonym":"class II da","Contributor":"david","SuperCategory":"Dendritic arborizing neuron","Id":"nlx_148057","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007273","Definition":"A dendritic arborizing md sensory neuron with multiple long and sinuous dendrites. Their branching pattern is relatively symmetrical. Higher order branches are generally short stubs extending from the major trunks."}},{"Class III dendritic arborizing neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2008-11-04T11:06:05Z","Synonym":"class III da","Contributor":"david","SuperCategory":"Dendritic arborizing neuron","Id":"nlx_148058","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007274","Definition":"A dendritic arborizing md sensory neuron with long primary and secondary dendrites that have spiked protrusions along most of their length and at the ends of major branches."}},{"Class IV dendritic arborizing neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2008-11-04T11:06:51Z","Synonym":"class IV da","Contributor":"david","SuperCategory":"Dendritic arborizing neuron","Id":"nlx_148059","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007275","Definition":"A dendritic arborizing md sensory neuron with a highly complex branching pattern that completely fills large regions of the body wall with its arbors. Each cell may have 800-900 terminal branches and more than 6 branch orders."}},{"Class project":{"CurationStatus":"uncurated","SuperCategory":"Project role","Id":"nlx_152229","Definition":"A project conducted by students as part of a course or program of study."}},{"Classic Globoid Cell Leukodystrophy":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Globoid Cell Leukodystrophy","Id":"birnlex_12534"}},{"Classic Pelizaeus-Merzbacher Disease":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Pelizaeus-Merzbacher Disease","Id":"birnlex_12547"}},{"Classical conditioning":{"Created":"6/1/2011 16:14","CurationStatus":"uncurated","Contributor":"Carinna Torgerson","CAO_Id":"CAO_00733","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Classical_conditioning","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145955","Definition":"Subjects are presented with paired stimuli in an attempt to study associative learning or get a subject to react to the conditioned stimulus in the same manner as the unconditioned stimulus, demonstrating a learned association between the two."}},{"Classical conditioning paradigm":{"Created":"2006-06-01","CurationStatus":"uncurated","SuperCategory":"Conditioning paradigm","Id":"birnlex_2017","Definition":"A behavioral paradigm in which subjects are presented with paired stimuli (usually involving presentation of an eye puff with an auditory tone) in an attempt to study associative learning."}},{"Classical Lewy Body":{"Synonym":"Brainstem Lewy Body","CurationStatus":"uncurated","SuperCategory":"Lewy Body","Id":"sao4749542545","Definition":"Eosinophilic cytoplasmic lesion, 5 to 15 micrometers in diameter, with a dense eosinphilic core surrounded by a halo of 10 to 20 nm wide radially oriented alpha-synuclein fibrils."}},{"Clathrin":{"SuperCategory":"Protein","Id":"sao5277619","Definition":"Major protein of the polyhedral coat of coated pits and vesicles (EMBL-EBI)."}},{"Clathrin Coat":{"SuperCategory":"Vesicle Coat","Id":"sao879919129","Definition":"A membrane coat found on coated pits and some coated vesicles; consists of polymerized clathrin triskelions, each comprising three clathrin heavy chains and three clathrin light chains, linked to the membrane via one of the AP adaptor complexes (Gene Ontology)."}},{"Clathrin Coated Endocytic Vesicle":{"SuperCategory":"Endocytic Vesicle","Id":"sao1243595998","Definition":"A clathrin-coated, membrane-bounded intracellular vesicle formed by invagination of the plasma membrane around an extracellular substance (Gene Ontology)."}},{"Claude Syndrome":{"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Brain Stem Infarction","Id":"birnlex_12786","Definition":"Anatomical location: Midbrain Tegmentum; Vasculature: Posterior cerebral artery; Symptoms: Ataxia - arm and leg - also Oculomotor palsy with contralateral tremor and ataxia"}},{"Claustral amygdaloid area":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-04","NeuronamesID":"233","CurationStatus":"uncurated","Umlscui":"C0262214","SuperCategory":"Regional part of brain","Id":"birnlex_1515","Is part of":"Telencephalon"}},{"Claustrum":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["insular claustrum"],"AtlasImage":"Brainmaps Claustrum.jpg,","CurationStatus":"uncurated","EfferentProjections":["Frontal cortex","Premotor cortex","Pre-supplementary motor area","Supplementary motor cortex","Area 46","Somatosensory cortex"],"Comment":"Essay on claustrum for class project:  http://neurolex.org/wiki/What_is_the_claustrum","Is_part_of":"Basal nuclear complex","Abbrev":"Cl","Created":"2006-10-04","NeuronamesID":"234","Umlscui":"C0008910","SuperCategory":"Regional part of brain","Id":"birnlex_1522","Is part of":["Telencephalon"],"Species":["Mammal"],"Definition":"Lamina of gray matter in the forebrain separated from the cortex in most species by the extreme capsule. (Brodal, Neurological Anatomy, 3rd Ed., 1981, pg 225).","EfferentProjectionsPMID":"12412139"}},{"Claustrum of ABA 2009":{"PartiallyOverlapsWith":"Claustrum","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153425","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Claustrum of PHT00":{"Synonym":"claustrum","CurationStatus":"uncurated","ISBN":"123582555","Curator":"CoCoMac{{PONS brain region","Authors":["George Paxinos","Xu-Feng Huang"],"Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"Cl","PartiallyOverlapsWith":"Claustrum","PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Id":"nlx_br_253","ParcellationScheme":["Paxinos"],"Species":"Macaque","DefiningCitation":"ISBN 0123582555"}},{"Clavate":{"Synonym":"Club-shaped","SuperCategory":"Concave 3-D shape","Id":"PATO_0001883","Definition":"Gradually becoming thicker towards the end; club shaped."}},{"Clavulanate":{"RelatedTo":"Beta-lactamase","Synonym":["Clavulanic Acid"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00766","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00766","Definition":"Clavulanic acid and its salts and esters. The acid is a suicide inhibitor of bacterial beta-lactamase enzymes from Streptomyces clavuligerus. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with beta-lactam antibiotics prevents antibiotic inactivation by microbial lactamase. (PubChem) Pharmacology: Clavulanic acid, produced by the fermentation of Streptomyces Clavuligerus, is a beta-lactam structurally related to the penicillins. Clavulanic acid is used in conjunction with amoxicillin for the treatment of bronchitis and urinary tract, skin, and soft tissue infections caused by beta-lactamase producing organisms. Mechanism of action: Clavulanic acid competitively and irreversibly inhibits a wide variety of beta-lactamases, commonly found in microorganisms resistant to penicillins and cephalosporins. By inactivating beta-lactamase (the bacterial resistance protein), the accompanying penicillin/cephalosporin drugs may be made more potent. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Enzyme Inhibitors"}},{"Cleavage cat":{"Synonym":"Cat cleavage","CurationStatus":"uncurated","SuperCategory":"Embryonic cat","Id":"nlx_organ_109134","Definition":"The division of cells in the early embryo, 17 to 24 hours. Cleavage ends with the formation of the blastula. (Adapted from Wikipedia)"}},{"Cleavage dog":{"Synonym":"Dog cleavage","CurationStatus":"uncurated","SuperCategory":"Embryonic dog","Id":"nlx_organ_109137","Definition":"The division of cells in the early embryo, days 4 to 8. Cleavage ends with the formation of the blastula. (Adapted from Wikipedia)"}},{"Cleavage ferret":{"Synonym":"Ferret cleavage","CurationStatus":"uncurated","SuperCategory":"Embryonic ferret","Id":"nlx_organ_109144","Definition":"The division of cells in the early embryo (50 hours to 4.5 days). Cleavage ends with the formation of the blastula. (Adapted from Wikipedia)"}},{"Cleavage human":{"Synonym":"Human cleavage","CurationStatus":"uncurated","SuperCategory":"Embryonic human","Id":"nlx_organ_109113","Definition":"The division of cells in the early embryo, days 1 to 3. Cleavage ends with the formation of the blastula. (Adapted from Wikipedia)"}},{"Cleavage mouse":{"Synonym":"Mouse cleavage","CurationStatus":"uncurated","SuperCategory":"Embryonic mouse","Id":"nlx_organ_109120","DefiningCitation":"http://genex.hgu.mrc.ac.uk/Databases/Anatomy/new/home.shtml","Definition":"The division of cells in the early embryo, days 1 to 3. Cleavage ends with the formation of the blastula. (Adapted from Wikipedia)"}},{"Cleavage rat":{"Synonym":"Rat cleavage","CurationStatus":"uncurated","SuperCategory":"Embryonic rat","Id":"nlx_organ_109127","Definition":"The division of cells in the early embryo, days 1 to 3. Cleavage ends with the formation of the blastula. (Adapted from Wikipedia)"}},{"Cleavage xenopus":{"Synonym":"Xenopus cleavage","CurationStatus":"uncurated","SuperCategory":"Embryonic xenopus","Id":"nlx_organ_109161","Definition":"The division of cells in the early embryo, 1 to 3 hours. Cleavage ends with the formation of the blastula. (Adapted from Wikipedia) Alternate Definition: The stages from 2-cell to 64-cell embryo, during which the zygote undergoes synchronous divisions into 2, 4, 8, 16, etc. blastomeres. (Xenopus anatomy and development: http://purl.org/obo/owl/XAO#XAO_1000004)"}},{"Cleft":{"Synonym":"Bifid","SuperCategory":"Concave","Id":"PATO_0000403","Definition":"Concave shape that is partially split or divided."}},{"Clemastine":{"RelatedTo":"Histamine H1 receptor","Synonym":["Clemastina (INN-Spanish)","Clemastine Fumarate","Clemastinum (INN-Latin)","Meclastin","Mecloprodin","Tavist"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00283","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00283","Definition":"A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. (PubChem) Pharmacology: Clemastine is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines competitively antagonize various physiological effects of histamine including increased capillary permeability and dilatation, the formation of edema, the \"flare\" and \"itch\" response, and gastrointestinal and respiratory smooth muscle constriction. Within the vascular tree, H1- receptor antagonists inhibit both the vasoconstrictor and vasodilator effects of histamine. Depending on the dose, H1- receptor antagonists can produce CNS stimulation or depression. Most antihistamines exhibit central and/or peripheral anticholinergic activity. Antihistamines act by competitively blocking H1- receptor sites. Antihistamines do not pharmacologically antagonize or chemically inactivate histamine, nor do they prevent the release of histamine. Mechanism of action: Clemastine is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Drug type: Approved. Small Molecule. Drug category: Anti-Allergic Agents. Antipruritics. Histamine H1 Antagonists"}},{"Clenbuterol":{"RelatedTo":["Beta-2 adrenergic receptor","Tumor necrosis factor"],"Synonym":["Clenbuterolum (inn-latin)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01407","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01407","Definition":"A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. (PubChem) Pharmacology: Clenbuterol is a substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. Although approved for use in some countries, as of fall, 2006, clenbuterol is not an ingredient of any therapeutic drug approved by the U.S. Food and Drug Administration. Mechanism of action: Not Available Drug type: Approved. Small Molecule. Drug category: Adrenergic beta-Agonists. Bronchodilator Agents. Sympathomimetics"}},{"Clicks":{"PMID":"11742243.","CurationStatus":"uncurated","SuperCategory":"Stimulus type","Curator":"Jessica Turner","Id":"COGPO:00153","DefiningCitation":["Rate-dependent activation of a prefrontal-insular-cerebellar network during passive listening to trains of click stimuli: an fMRI study. Ackermann H","Riecker A","Mathiak K","Erb M","Grodd W"],"Definition":"Repeated ticking sounds made by a mechanical or electrical instrument at given frequency (e.g., metronome clicks)."}},{"Clidinium":{"RelatedTo":["Cholinergic system"],"Synonym":"Quarzan","CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"DB00771","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00771","Definition":"Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. Pharmacology: Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. Mechanism of action: Inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. Drug type: Approved. Small Molecule. Drug category: Antiarrhythmic Agents. Anticholinergic Agents. Antispasmodics. Parasympatholytics"}},{"Client program":{"Synonym":"software client","Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Data access protocol","Id":"birnlex_2825"}},{"Climbing fiber":{"Synonym":"Climbing fibre","CurationStatus":"uncurated","SuperCategory":"Axon","Id":"nlx_subcell_20090203","Definition":"Axon of inferior olive neuron that projects to the cerebellar cortex, largely via the inferior cerebellar peduncle.  They range in diameter from 1-3 um and are myelinated until they enter the granule cell layer.  They give off collaterals to the deep cerebellar nuclei.  They synapse extensively with the dendrites of Purkinje cells in the molecular layer, where each fiber branches repeatedly to \"climb\" along the Purkinje cell dendritic tree.  Each Purkinje cell is innervated by only a single climbing fiber."}},{"Clindamycin":{"RelatedTo":"50S ribosomal protein L10","Synonym":["Clindamicina (INN-Spanish)","Clindamycin Hcl","Clindamycin Hydrochloride","Clindamycin Phosphate","Clindamycine (French)","Clindamycine (INN-French)","Clindamycinum (INN-Latin)","clindamycin","Chlolincocin","Cleocin","Cleocin Hcl","Cleocin Pediatric","Cleocin Phosphate","Cleocin T","Cleocin T Gel","Cleocin T Lotion","Cleocin T Topical Solution","Clinda-Derm","Clindagel","Clindesse","Clindets","Clinimycin","Dalacin","Dalacin C","Dalacin C Flavored Granules","Dalacin C Phosphate","Dalacin T Topical Solution","Evoclin","ResiDerm A","Sobelin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3745","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01190","Definition":"An antibacterial agent that is a semisynthetic analog of lincomycin. (PubChem) Pharmacology: Clindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal. Mechanism of action: Systemic/Vaginal-Clindamycin inhibits protein synthesis of bacteria by binding to the 50 S ribosomal subunits of the bacteria. Topical-Clindamycin reduces free fatty acid concentrations on the skin and to suppress the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-Bacterial Agents. Lincomycins. Protein Synthesis Inhibitors"}},{"Clinical dementia rating scale":{"Related disease":"Dementia","CurationStatus":"uncurated","SuperCategory":"Rating scale","Id":"SNOMED:273367002","Species":"Human","DefiningCitation":"http://alzheimer.wustl.edu/cdr/pdfs/cdr_overviewtranscript-revised.pdf","Abbrev":"CDR","Definition":"A rating scale for severity of dementia, ranging from 0 (normal) to 5 (severe dementia)"}},{"Clinical evaluation of language fundamentals-3":{"Created":"5/10/2011 15:00","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00811","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Clinical_evaluation_of_language_fundamentals-3","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146033","Definition":"3rd edition of an assessment used to evaluate the nature and extent of language difficulties in school children and adolescents."}},{"Clinical finding":{"EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","Created":"2007-10-05","CurationStatus":"graph_position_temporary","SuperCategory":"Narrative object","Id":"birnlex_11041"}},{"Clinical pathology":{"CurationStatus":"uncurated","SuperCategory":"Pathology","Id":"nlx_inv_100619","Abbrev":"Clin pathol,","Definition":"Branch of pathology dealing with clinical aspects of pathological examination of excisions and postmortem analysis."}},{"Clinical studies":{"CurationStatus":"uncurated","SuperCategory":"Medicine","Id":"nlx_inv_100620","Definition":"Branch of medicine which is concerned with human clinical trials.From BRO: studies or resources that help investigators do clinical studies or trials, including, epidemiology, outcome development, physiological human studies, interventional trials, etc"}},{"Clione":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C1028739","SuperCategory":"Clionidae","Id":"birnlex_7229","Definition":"A genus of small, shell-less, marine mollusks in the family Clione, superorder GASTROPODA. These pteropod (possessing a foot developed into wing-like organ for swimming) sea slugs feed exclusively on another pteropod mollusk, Limacina. (MSH)"}},{"Clione limacina":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C1032137","SuperCategory":"Clione","Id":"birnlex_7230"}},{"Clionidae":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C1032137","SuperCategory":"Gymnosomata","Id":"birnlex_7228"}},{"Clitellata":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1093346","SuperCategory":"Annelida","Id":"birnlex_364"}},{"Clivus of fovea centralis":{"Synonym":"clivus of macula lutea","Created":"2007-08-28","CurationStatus":["uncurated"],"Umlscui":["C0929760"],"SuperCategory":"Regional part of fovea","Id":"birnlex_2544"}},{"Clobazam":{"RelatedTo":"Gamma-aminobutyric-acid receptor subunit alpha-1","Synonym":["clobazam","Chlorepin","Clorepin","Frisium","Mystan","Urbadan"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00349","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00349","Definition":"Clobazam is a drug which is a benzodiazepine derivative. It has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984. (Wikipedia) Pharmacology: Clobazam is a barbiturate used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain. Mechanism of action: Clobazam binds at a distinct binding site associated with a Cl- ionopore at the GABA-A receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is prolonged as a result. Drug type: Approved. Illicit. Investigational. Small Molecule. Drug category: Anticonvulsants. Benzodiazepines"}},{"Clobetasol":{"RelatedTo":"Annexin A1","Synonym":[", Clobesol","Clobetasol Propionate","Clobetasol propionate (USAN:JAN)","Clobetasole propionate","Clobetasolpropionat mikron,","Clobex","Dermovate","Embeline","Embeline E","Olux","Temovate"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01013","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01013","Definition":"A derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity.  Absorbed through the skin faster than fluocinonide, it is used topically in treatment of psoriasis but may cause marked adrenocortical suppression. (PubChem) Pharmacology: Like other topical corticosteroids, clobetasol has anti-inflammatory, antipruritic, and vasoconstrictive properties. It is a very high potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved. Mechanism of action: The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Drug type: Approved. Small Molecule. Drug category: Anti-inflammatory Agents. Corticosteroids, topical. Glucocorticoids"}},{"Clocortolone":{"RelatedTo":"Annexin A1","Synonym":["Clocortolone pivalate"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00838","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00838","Definition":"Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp. Pharmacology: Like other topical corticosteroids, clocortolone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Clocortolone is a moderate potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved. Mechanism of action: The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Drug type: Approved. Small Molecule. Drug category: Corticosteroids, topical"}},{"Clodronate":{"RelatedTo":["ADP/ATP translocase 1","Tyrosine-protein phosphatase non-receptor type 1","ADP/ATP translocase 3","ADP/ATP translocase 2"],"Synonym":["clodronate","Acide Clodronique (INN-French)","Acido Clodronico (INN-Spanish)","Acidum Clodronicum (INN-Latin)","Bonefos","Clasteon","Dichloromethanediphosphonic acid","Dichloromethylidene diphosphonate","Loron"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00720","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00720","Definition":"A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. (PubChem) Pharmacology: Clodronate is a first generation (non-nitrogenous) bisphosphonate in the same family as etidronate and tiludronate. Clodronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the clodronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Clodronate has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia. Mechanism of action: The bisphosphonate group binds strongly to the bone mineral, hydroxyapatite. This explains the specific pharmacological action of these compounds on mineralized tissues, especially bone. The exact mechanism of action of clodronate is not known, however it is known that it does not inhibit protein isoprenylation but can be metabolized intracellularly to a --methylene (AppCp-type) analog of ATP (AppCCl2p), which is cytotoxic to macrophages in vitro. Inhibition of the ADP/ATP translocase by the metabolite AppCCl2p is a likely route by which clodronate causes osteoclast apoptosis and inhibits bone resorption. Recently, the slime mold Dictyostelium discoideum was shown to take up bisphosphonates by pinocytosis. In these cells, clodronate, but not other pharmacologically active bisphosphonates, was incorporated into adenine nucleotides, which could potentially explain why this bisphosphonate sometimes seems to act differently than the other bisphosphonates. Clodronate, like all biphosphonates, also binds protein-tyrosine-phosphatase. Drug type: Approved. Investigational. Small Molecule. Drug category: Antihypocalcemic Agents. Antineoplastic Agents. Bisphosphonates. Bone Density Conservation Agents. Osteoporosis Prophylactic"}},{"Clofarabine":{"RelatedTo":["Ribonucleoside-diphosphate reductase large subunit"],"Synonym":["clofarabine","Clolar"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00631","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00631","Definition":"Clofarabine is a substance that is being studied in the treatment of cancer. It is a purine nucleoside antimetabolite. It is marketed in the U.S. and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra.It is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if extends life expectancy. Some investigations of effectiveness in cases of acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) have been carried out. Pharmacology: Clofarabine is a purine nucleoside antimetabolite. Clofarabine seems to interfere with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells also may be affected by clofarabine, other effects also occur. Clofarabine prevents cells from making DNA and RNA by interfering with the synthesis of nucleic acids, thus stopping the growth of cancer cells. Mechanism of action: Clofarabine is metabolized intracellularly to the active 5-triphosphate metabolite. This metabolite inhibits DNA synthesis by decreasing cellular deoxynucleotide triphosphate pools through an inhibitory action on ribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair through incorporation into the DNA chain by competitive inhibition of DNA polymerases. The affinity of clofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosine triphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNA repair by incorporation into the DNA chain during the repair process. Clofarabine 5-triphosphate also disrupts the integrity of mitochondrial membrane, leading to the release of the pro-apoptotic mitochondrial proteins, cytochrome C and apoptosis-inducing factor, leading to programmed cell death. Drug type: Approved. Investigational. Small Molecule. Drug category: Antimetabolites. Antineoplastic Agents. Purine analogues"}},{"Clofazimine":{"RelatedTo":["Potassium transporter"],"Synonym":["Chlofazimine","Clofazimina (INN-Spanish)","Clofaziminum (INN-Latin)","Lampren"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00845","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00845","Definition":"A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619) Pharmacology: Clofazimine exerts a slow bactericidal effect on Mycobacterium leprae (Hansen's bacillus). Clofazimine inhibits mycobacterial growth and binds preferentially to mycobacterial DNA. Clofazimine also exerts antiinflammatory properties in controlling erythema nodosum leprosum reactions. Clofazimine is highly lipophilic and tends to be deposited predominantly in fatty tissue and in cells of the reticuloendothelial system. It is taken up by macrophages throughout the body. Measurement of the minimum inhibitory concentration (MIC) of clofazimine against leprosy bacilli in vitro is not yet feasible. In the mouse footpad system, the multiplication of M.leprae is inhibited by introducing 0.0001%- 0.001% clofazimine in the diet. Although bacterial killing may begin shortly after starting the drug, it cannot be measured in biopsy tissues taken from patients for mouse footpad studies until approximately 50 days after the start of therapy. Mechanism of action: Appears to preferentially bind to mycobacterial DNA leading to disruption of the cell cycle and eventually kills the bacterium. It may also bind to bacterial potassium transporters, thereby inhibiting their function. Lysophospholipids have been found to mediate the activity of this drug. Drug type: Approved. Small Molecule. Drug category: Anti-Inflammatory Agents, Non-Steroidal. Antimycobacterials. Coloring Agents. Dyes. Leprostatic Agents"}},{"Clomifene":{"RelatedTo":"Estrogen receptor","Synonym":["Chlomaphene","Chloramifene","Chloramiphene","Cisclomiphene","Clomifene citrate","Clomifeno","Clomiphene Citrate","Clomiphene citrate (Z,E)","Clomiphene dihydrogen citrate","Racemic clomiphene citrate","Zuclomiphene citrate","clomiphene","Androxal","Clomid","Clomifert","Clomiphene","Clomiphene B","Clomivid","Clomphid","Clostilbegyt","Dyneric","Genozym","Ikaclomin","Milophene","Omifin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00882","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00882","Definition":"A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue. (PubChem) Pharmacology: Clomifene (previously clomiphene) is an orally administered, non steroidal, ovulatory stimulant that acts as a selective estrogen receptor modulator (SERM). Clomifene can lead to multiple ovulation, and hence increasing the risk of twins. In comparison to purified FSH, the rate of ovarian hyperstimulation syndrome is low. There may be an increased risk of ovarian cancer, and weight gain. Clomifene is capable of interacting with estrogen-receptor-containing tissues, including the hypothalamus, pituitary, ovary, endometrium, vagina, and cervix. It may compete with estrogen for estrogen-receptor-binding sites and may delay replenishment of intracellular estrogen receptors. Clomifene initiates a series of endocrine events culminating in a preovulatory gonadotropin surge and subsequent follicular rupture. The first endocrine event in response to a course of clomifene therapy, is an increase in the release of pituitary gonadotropins. This initiates steroidogenesis and folliculogenesis resulting in growth of the ovarian follicle and an increase in the circulating level of estradiol. Following ovulation, plasma progesterone and estradiol rise and fall as they would in a normal ovulatory cycle. Mechanism of action: Clomifene acts by inhibiting the action of estrogen on the gonadotrope cells in the anterior pituitary gland. \"Sensing\" low estrogen levels, follicle-stimulating hormone release is increased, leading to a higher rate of ovulation and hence pregnancy. Clomifene has no apparent progestational, androgenic, or antrandrogenic effects and does not appear to interfere with pituitary-adrenal or pituitary-thyroid function. Drug type: Approved. Investigational. Small Molecule. Drug category: Estrogen Antagonists. Fertility Agents, Female. Selective Estrogen Receptor Modulators"}},{"Clomipramine":{"RelatedTo":["Glutathione S-transferase pi","5-hydroxytryptamine 2A receptor","Sodium-dependent noradrenaline transporter"],"Synonym":["3-Chloroimipramine","Chlorimipramine","Clomipramina (INN-Spanish)","Clomipramine HCL","Clomipraminum (INN-Latin)","Monochlorimipramine","Anafranil"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:47780","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01242","Definition":"A tricyclic antidepressant similar to imipramine that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine. (PubChem) Pharmacology: Clomipramine, a tricyclic antidepressant, is the 3-chloro derivative of Imipramine. It was thought that tricyclic antidepressants work exclusively by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: alpha-1 and beta-1 receptors are sensitized, alpha-2 receptors are desensitized (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. Mechanism of action: Clomipramine is a strong, but not completely selective Serotonic-Reuptake-Inhibitor (SRI), as the active main metabolite desmethyclomipramine acts preferably as an inhibitor of Noradrenaline-Reuptake. Alpha-1-Receptor blockage and beta-down-regulation have been noted and most likely play a role in the short term effects of clomipramine. A blockade of sodium-channels and NMDA-receptors might, as with other tricyclics, account for its effect in chronic pain, in particular the neuropathic type. Drug type: Approved. Small Molecule. Drug category: Antidepressive Agents, Tricyclic. Serotonin Uptake Inhibitors"}},{"Clomocycline":{"RelatedTo":["30S ribosomal protein S4","30S ribosomal protein S9"],"Synonym":["Chlormethylenecycline","Clomociclina (INN-Spanish)","Clomocyclinum (INN-Latin)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00453","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00453","Definition":"Clomocycline is a tetracycline antibiotic. Pharmacology: Clomocycline is a tetracycline antibiotic that is commonly prescribed by medical doctors for infections and to treat acne. It may also be used to treat urinary tract infections, gum disease, and other bacterial infections such as gonorrhea and chlamydia. Clomocycline is also used commonly as a prophylactic treatment for infection by Bacillus anthracis (anthrax). It is also effective against Yersinia pestis and malaria and is also prescribed for the treatment of Lyme disease. Clomocycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Cells become resistant to Clomocycline by at least two mechanisms: efflux and ribosomal protection. In efflux, a resistance gene encodes a membrane protein that actively pumps Clomocycline out of the cell. This is the mechanism of action of the tetracycline resistance gene on the artificial plasmid pBR322. In ribosomal protection, a resistance gene encodes a protein which binds to the ribosome and prevents Clomocycline from acting on the ribosome. Mechanism of action: Clomocycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Clomocycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Tetracyclines"}},{"Clonazepam":{"RelatedTo":["Serum albumin","Translocator protein"],"Synonym":["Chlonazepam","Clonazepamum","Antelepsin","Antilepsin","Cloazepam","Clonopin","Iktorivil","Klonopin","Klonopin Rapidly Disintegrating","Landsen"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01068","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01068","Definition":"An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses. (PubChem) Pharmacology: Clonazepam, a benzodiazepine, is used primarily as an anticonvulsant in the treatment of absence seizures, petit mal variant seizures (Lennox-Gastaut syndrome), akinetic and myoclonic seizures, and nocturnal myoclonus. Mechanism of action: Allosteric interactions between central benzodiazepine receptors and gamma-aminobutyric acid (GABA) receptors potentiate the effects of GABA. As GABA is an inhibitory neurotransmitter, this results in increased inhibition of the ascending reticular activating system. Benzodiazepines, in this way, block the cortical and limbic arousal that occurs following stimulation of the reticular pathways. Drug type: Approved. Illicit. Small Molecule. Drug category: Anticonvulsants. Benzodiazepines. GABA Modulators"}},{"Clonidine":{"RelatedTo":["Alpha-2A adrenergic receptor"],"Synonym":["Chlornidinum","Clonidin","Clonidine HCl","Clonidinhydrochlorid","Clonidinum (INN-Latin)","ST 155BS","Adesipress","Catapres","Catapres-TTS","Catapresan","Catapressan","Catarpres","Catarpresan","Clonistada","Dixarit","Duraclon","Duraclont","Ipotensium","Isoglaucon"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:46631","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00575","Definition":"An alpha-2 adrenergic agonist that crosses the blood-brain barrier. Clonidine acts centrally by reducing sympathetic tone, resulting in a fall in diastolic and systolic blood pressure and a reduction in heart rate. It also acts peripherally, and this peripheral activity may be responsible for the transient increase in blood pressure seen during rapid intravenous administration. (From Martindale, the Extra Pharmacopoeia, 30th ed, p350) Pharmacology: Clonidine is an antihypertensive agent and an epidural agent for refractory cancer pain. Similar to guanabenz in mechanism of action, clonidine is used in the treatment of hypertension, opiate and nicotine withdrawal, vascular headaches, diabetic diarrhea, glaucoma, ulcerative colitis, Gilles de la Tourette's syndrome, menopause symptoms, severe pain in cancer patients refractory to opiate agonists, and neuropathic pain and in the diagnosis of pheochromocytoma. Mechanism of action: Clonidine acts as an agonist at presynaptic alpha(2)-receptors in the nucleus tractus solitarius of the medulla oblongata. Stimulation of these receptors results in the supression of efferent sympathetic pathways and the subsequent decrease in blood pressure and vascular tone in the heart, kidneys, and peripheral vasculature. Clonidine is also a partial agonist at presynaptic alpha(2)-adrenergic receptors of peripheral nerves in vascular smooth muscle. Drug type: Approved. Small Molecule. Drug category: Adrenergic alpha-Agonists. Analgesics. Antihypertensive Agents. Central Alpha-Agonists. Sympatholytics"}},{"Clopidogrel":{"RelatedTo":["P2Y purinoceptor 12","Cytochrome P450 3A3"],"Synonym":[", Clopidogrel (Ban:Inn)","Clopidogrel sulfate"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:37941","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00758","Definition":"Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to reduce atherosclerotic events such as myocardial infarction, stroke, and vascular death in patients who have had a recent stroke, recent MI, or have established peripheral vascular disease. Pharmacology: Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to reduce atherosclerotic events such as myocardial infarction, stroke, and vascular death in patients who have had a recent stroke, recent MI, or have established peripheral vascular disease. Mechanism of action: The active metabolite of clopidogrel prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of clopidogrel. Drug type: Approved. Small Molecule. Drug category: Antiplatelet Agents. Fibrinolytic Agents. Platelet Aggregation Inhibitors"}},{"Clorazepate":{"RelatedTo":["Translocator protein"],"Synonym":[", Chlorazepate","Chlorazepic acid","Clorazepate dipotassium","Clorazepic acid","Clorazepic acid (BAN)","Gen-xene"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00628","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00628","Definition":"A water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions. (PubChem) Pharmacology: Clorazepate is a member of the group of drugs called benzodiazepines. Pharmacologically, clorazepate has the characteristics of the benzodiazepines. It has depressant effects on the central nervous system. The primary metabolite, nordiazepam, quickly appears in the blood stream. Studies in healthy men have shown that clorazenate has depressant effects on the central nervous system. Since orally administered clorazepate dipotassium is rapidly decarboxylated to form nordiazepam, there is essentially no circulating parent drug. Mechanism of action: Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Drug type: Approved. Illicit. Small Molecule. Drug category: Anti-anxiety Agents. Anticonvulsants. GABA Modulators"}},{"Closed":{"SuperCategory":"Closure","Id":"PATO_0000608","Definition":"blocked passage or view."}},{"Closed-source license":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"License","Id":"birnlex_2352","Definition":"Any non open source license with restrictions on the source code. "}},{"Closure":{"SuperCategory":"Morphology","Id":"PATO_0000136","Definition":"A morphological quality pertaining to the degree to which an object contains an opening, aperture, orifice, or vent."}},{"Closure incomplete":{"SuperCategory":"Open","Id":"PATO_0000609","Definition":"Not completed blocked passage or view."}},{"Clotrimazole":{"RelatedTo":["Cytochrome P450 51"],"Synonym":["Chlotrimazole","Clotrimazol","Canesten","Canesten 1-Day Cream Combi-Pak","Canesten 1-Day Therapy","Canesten 3-Day Therapy","Canesten 6-Day Therapy","Canesten Combi-Pak 1-Day Therapy","Canesten Combi-Pak 3-Day Therapy","Canesten Cream","Canesten Solution","Canestine","Canifug","Cimitidine","Clotrimaderm","Empecid","FemCare","Gyne lotrimin","Gyne-Lotrimin 3","Gyne-Lotrimin 3 Combination Pack","Gyne-Lotrimin Combination Pack","Gyne-lotrimin","Gynix","Lotrimin","Lotrimin AF Cream","Lotrimin AF Jock-Itch Cream","Lotrimin AF Lotion","Lotrimin AF Solution","Lotrimin Af","Lotrimin Cream","Lotrimin Lotion","Lotrimin Solution","Mono-baycuten","Mycelax","Mycelex","Mycelex 7","Mycelex Cream","Mycelex G","Mycelex Solution","Mycelex Troches","Mycelex Twin Pack","Mycelex-7","Mycelex-7 Combination Pack","Mycelex-G","Myclo Cream","Myclo Solution","Myclo Spray Solution","Myclo-Gyne","Mycosporin","Mykosporin","Neo-Zol Cream","Trimysten","Trivagizole 3"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3764","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00257","Definition":"An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. (PubChem) Pharmacology: Clotrimazole, an imidazole derivative with a broad spectrum of antimycotic activity, inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections. In studies in fungal cultures, the minimum fungicidal concentration of clotrimazole caused leakage of intracellular phosphorous compounds into the ambient medium with concomitant breakdown of cellular nucleic acids, and accelerated potassium etflux. Both of these events began rapidly and extensively after addition of the drug to the cultures. The primary action of clotrimazole is against dividing and growing organisms. Mechanism of action: Clotrimazole interacts with yeast 14- demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the membrane. In this way, clotrimazole inhibits ergosterol synthesis, resulting in increased cellular permeability. Clotrimazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms and the uptake of purine, impair triglyceride and/or phospholipid biosynthesis, and inhibit the movement of calcium and potassium ions across the cell membrane by blocking the ion transport pathway known as the Gardos channel. Drug type: Approved. Small Molecule. Drug category: Anti-Infective Agents, Local. Antifungal Agents. Growth Inhibitors"}},{"Cloxacillin":{"RelatedTo":["Serum albumin","Penicillin-binding proteins 1A/1B"],"Synonym":["Cloxacillin Sodium","Novo-Cloxin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:49566","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01147","Definition":"A semi-synthetic antibiotic that is a chlorinated derivative of oxacillin. (PubChem) Pharmacology: Cloxacillin is a semisynthetic antibiotic in the same class as penicillin. Cloxacillin is for use against staphylococci that produce beta-lactamase. Mechanism of action: By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, cloxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cloxacillin interferes with an autolysin inhibitor. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Penicillins"}},{"Clozapine":{"RelatedTo":["D(1A) dopamine receptor","Histamine H4 receptor","5-hydroxytryptamine 1A receptor","D(4) dopamine receptor","Histamine H1 receptor","5-hydroxytryptamine 2A receptor","5-hydroxytryptamine 2C receptor","D1 dopamine receptor-interacting protein calcyon"],"Synonym":["Clozapin","Asaleptin","Clozaril","Fazaclo ODT","Iprox","Leponex"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3766","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB00363","Definition":"A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. (PubChem) Pharmacology: Clozapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Clozapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Clozapine acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Clozapine. Clozapine's antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects. Clozapine's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Clozapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug. Mechanism of action: The mechanism of action of Clozapine, as with other drugs used to treat schizophrenia, is unknown. However, it has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism. Drug type: Approved. Small Molecule. Drug category: Antipsychotic Agents. Antipsychotics. GABA Antagonists. Serotonin Antagonists"}},{"Club drug":{"Synonym":"Drugs of abuse","CurationStatus":"uncurated","SuperCategory":"Drug of abuse role","Id":"nlx_89990","Definition":"A drug of abuse that is used by teenagers and young adults at bars, nightclubs, concerts, and parties. Club drugs include GHB, Rohypnol, ketamine, and others. [MDMA (Ecstasy), Methamphetamine, and LSD (Acid), are considered club drugs and are covered in their individual drug summaries. - adapted from NIDA"}},{"Clubbed":{"Comment":["This term was moved from \"shape\" to a kind of \"inverted\" to better reflect its definition and its current usage (cf Mammalian Phenotype Ontology"],"SuperCategory":"Shape","Id":"PATO_0001797","Definition":"A shape quality inhering in a bearer by virtue of being gradually enlarged towards one end.  For example, platarflexed."}},{"Clupeocephala":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C1210429","SuperCategory":"Elopocephala","Id":"birnlex_515"}},{"Clustered Anatomical Configuration":{"SuperCategory":"Configuration","Id":"sao1475145503"}},{"CNGA1":{"RelatedTo":["Calcium(2+)","Sodium(+)","Potassium(+)","Lithium(+)","Rubidium(+)"],"Synonym":["CNG1","CNGa1"],"Created":"2007-09-06","SuperCategory":"Cyclic-nucleotide gated channel - type A","Id":"nifext_3035","DefiningCitation":["http://omim.org/entry/123825"]}},{"CNGA2":{"Synonym":["OCNC1","CNGa3"],"Created":"2007-09-06","SuperCategory":"Cyclic-nucleotide gated channel - type A","Id":"nifext_3040","DefiningCitation":["http://omim.org/entry/300338"]}},{"CNGA3":{"Synonym":["CNGa2","CNG3"],"Created":"2007-09-06","SuperCategory":"Cyclic-nucleotide gated channel - type A","Id":"nifext_3044","DefiningCitation":["http://omim.org/entry/600053"]}},{"CNGA4":{"Synonym":["OCNC2","CNG5","CNGB2"],"Created":"2007-09-06","SuperCategory":"Cyclic-nucleotide gated channel - type A","Id":"nifext_3048","DefiningCitation":["http://omim.org/entry/609472"]}},{"CNGB1":{"Synonym":["CNG4","RCNC2"],"Created":"2007-09-06","SuperCategory":"Cyclic-nucleotide gated channel - type B","Id":"nifext_3053","DefiningCitation":["http://omim.org/entry/600724"]}},{"CNGB3":{"Synonym":["CNG6","CCNC2"],"Created":"2007-09-06","SuperCategory":"Cyclic-nucleotide gated channel - type B","Id":"nifext_3057","DefiningCitation":["http://omim.org/entry/605080"]}},{"CNQX":{"PMID":"2898377","Synonym":["6-cyano-7-nitroquinoxaline-2,3-dione","7-nitro-2,3-dioxo-1,4- dihydroquinoxaline-6-carbonitrile"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"nlx_14886","Has role":["Antagonist role","Drug"],"Definition":"competitive AMPA/kainate receptor antagonist."}},{"Co-expression":{"CurationStatus":"uncurated","SuperCategory":"Expression level","Id":"nlx_qual_1010004","Has role":"NIF annotation standard for differential expression","Definition":"Expression level indicated that two or more signals are expressed together in the same structure"}},{"Co-investigator":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Investigator","Id":"birnlex_2199"}},{"Co-staining":{"CurationStatus":"uncurated","SuperCategory":"Staining","Id":"nlx_66639","Has role":"NIF annotation standard for differential expression"}},{"Coagulation Factor IX":{"RelatedTo":["Coagulation factor VIII","Prothrombin","Coagulation factor X","Coagulation factor VII","Vitamin K-dependent gamma-carboxylase","Coagulation factor XI"],"Synonym":["Christmas factor","Coagulation factor IX precursor","PTC","Plasma thromboplastin component"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00100","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00100","Definition":"Human Factor IX protein, produced by recombinant DNA technology for use in therapy of factor IX deficiency, known as hemophilia B or Christmas disease. Coagulation Factor IX (Recombinant) is a glycoprotein with an approximate molecular mass of 55,000 Da consisting of 415 amino acids in a single chain. It has a primary amino acid sequence that is identical to the Ala 148 allelic form of plasma-derived factor IX. Pharmacology: Binds vitamin K and factor VIIIa. Cleaves the Arg-Ile bond in factor X to form active factor Xa. Plays a key role in blood coagulation and clotting. Injections of factor IX are used to treat hemophilia B, which is sometimes called Christmas disease. AlphaNine is injected to increase plasma levels of Factor IX and can temporarily correct this coagulation defect. Mechanism of action: Cleaves the Arg-Ile bond in Factor X to form active factor Xa leading to coagulation and clotting. Drug type: Approved. Biotech. Drug category: Coagulants. Thrombotic Agents"}},{"Coagulation factor VIIa":{"RelatedTo":["Coagulation factor X","Coagulation factor VII","Vitamin K-dependent gamma-carboxylase","Tissue factor pathway inhibitor","Tissue factor"],"Synonym":["Coagulation factor VII precursor","Eptacog alfa","Proconvertin","SPCA","Serum prothrombin conversion accelerator"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00036","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00036","Definition":"Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade.1 NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form. Pharmacology: Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting. Mechanism of action: NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin. Drug type: Approved. Biotech. Drug category: Coagulants. Thrombotic Agents"}},{"Coarse":{"SuperCategory":"Texture","Id":"PATO_0000700"}},{"Coasting":{"PMID":"15939771","RelatedTo":["Drifting","Creeping"],"CurationStatus":"uncurated","SuperCategory":"Swimming activity","Id":"nlx_151973","Species":"Zebrafish","DefinitionPMID":"15939771","Definition":"Passive sliding without body/fin movements (i.e., after the fish stopped swimming actively) similar to drifting (also see creeping, which involves slow swimming with only pectoral fin use)."}},{"Coated pit":{"CurationStatus":"uncurated","SuperCategory":"Cellular component","Id":"GO:0005905","Is part of":"Endomembrane system","Definition":"A part of the endomembrane system in the form of an invagination of a membrane upon which a clathrin coat forms, and that can be converted by vesicle budding into a clathrin-coated vesicle. Coated pits form on the plasma membrane, where they are involved in receptor-mediated selective transport of many proteins and other macromolecules across the cell membrane, in the trans-Golgi network, and on some endosomes."}},{"Coated Tip":{"SuperCategory":"Endosomal Subcomponent","Id":"sao694815499","Definition":"Coated tips of tubular endosomes that appear to be vesicles in the process of budding off (Clooney et al., 2002)."}},{"Coating":{"SuperCategory":"Texture","Id":"PATO_0002012"}},{"Cobalt":{"Synonym":["Aquacat","Cobalt Oligosol Liq 0.45mg/2ml","Cobalt atomic absorption standard solution","Cobalt icp/DCP standard solution","Cobalt solution","Cobalt standard for ic","Cobalt(II) nitrate solution","Cobalt-59","Cobalt-liq","Cobaltum Dps 4ch-30ch","Cobaltum metallicum","Cobaltum muriaticum","Cobaltum nitricum","Cobatope-57","Kobalt","Oligostim Cobalt - Tab 6dh","Raney-cobalt"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0049","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0049","Abbrev":"[Co]2+","Definition":"Inorganic Compound;Metal;Cobalt Compound; Cobalt is a metallic element with the atomic number 27. It is found naturally in rocks, soil, water, plants, and animals, and is mainly used to produce alloys and pigments. In small amounts cobalt is an essential element for life, as it is part of vitamin B12. However, excess exposure is known to exhibit toxic effects. Cobalt also exists in the toxic radioactive form Cobalt-60."}},{"Cocaine":{"RelatedTo":["D(1A) dopamine receptor","Sodium channel protein type 10 subunit alpha","Sodium channel protein type 11 subunit alpha","Sodium channel protein type 5 subunit alpha","Sodium- and chloride-dependent GABA transporter 1","Sodium-dependent noradrenaline transporter","D(3) dopamine receptor","Kappa-type opioid receptor","Sodium-dependent dopamine transporter"],"Synonym":["Benzoylethylecgonine","Benzoylmethylecgonine","Beta-Cocain","Cocain","Cocaina","Cocaine-M","D-pseudococaine","Delcaine","Depsococaine","Dextrocaine","Eritroxilina","Erytroxylin","Isocaine","Isococain","Isococaine","L-Cocain","L-Cocaine","Methyl Benzoylecgonine","Neurocaine","Cocaine hydrochloride"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:27958","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB00907","Abbrev":"COC","Definition":"An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake. (PubChem) Pharmacology: Cocaine is a local anesthetic indicated for the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities. Mechanism of action: Cocaine produces anesthesia by inhibiting excitation of nerve endings or by blocking conduction in peripheral nerves. This is achieved by reversibly binding to and inactivating sodium channels. Sodium influx through these channels is necessary for the depolarization of nerve cell membranes and subsequent propagation of impulses along the course of the nerve. Cocaine is the only local anesthetic with vasoconstrictive properties. This is a result of its blockade of norepinephrine reuptake in the autonomic nervous system. Cocaine binds differentially to the dopamine, serotonin, and norepinephrine transport proteins and directly prevents the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons. Cocaine also produces a number of indirect actions, which alter other neuromodulatory systems (i.e., opioidergic, glutamatergic, and GABAergic systems). Drug type: Approved. Illicit. Small Molecule. Drug category: Anesthetics. Anesthetics, Local. Dopamine Uptake Inhibitors. Local Anesthetics. Vasoconstrictor Agents"}},{"Cocaine-Related Disorder":{"Created":"2007-10-08","Synonym":["Cocaine addiction","Cocaine Abuse","Cocaine Usage"],"CurationStatus":"uncurated","Comment":["We should probably add \"addiction\" as a synonym to all the drug related disorders"],"SuperCategory":"Substance-Related Disorder","Curator":"Bill Bug","Id":"birnlex_12710"}},{"Cochlea":{"RelatedTo":"Auditory sensation","Created":"2007-08-20","CurationStatus":"uncurated","Umlscui":["C0009195"],"SuperCategory":"Regional part of body","Id":"birnlex_1190","Is part of":["Inner ear"],"Definition":"Component of the inner ear, tonotopically organized to aid transduction of sound.  * The part of the internal ear that is concerned with hearing. It forms the anterior part of the labyrinth, is conical, and is placed almost horizontally anterior to the vestibule. (MSH) * The part of the internal ear that is concerned with hearing. It forms the anterior part of the labyrinth, is conical, and is placed almost horizontally anterior to the vestibule. (NCI) * part of the internal ear that is concerned with hearing; forms the anterior part of the labyrinth, is conical, and is placed almost horizontally anterior to the vestibule. (CSP)"}},{"Cochlea duct":{"Synonym":["Reissners canal"],"Created":"2007-08-28","CurationStatus":"uncurated","Umlscui":["C1323110"],"SuperCategory":"Duct part of cochlear canal","Id":"birnlex_2562","DefiningCitation":["Stevens","S.S. & Warshofsky"]}},{"Cochlea inner hair cell":{"Located in":"Spiral organ of Corti,","Synonym":["Cochlear Inner Hair Cell","Inner Hair Cell"],"CurationStatus":"uncurated","MolecularConstituents":["Otoferlin"],"NeurotransmitterReceptors":"AMPA-type glutamate-gated cationic channel,","Has role":"Principal neuron role","NeurotransmitterReceptorsPMID":"22715884","OriginOfAxon":"no axon","Abbrev":"IHC","CellSomaSize":"Small soma","SpineDensityOnDendrites":"Smooth","EditorialNote":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912990/figure/Fig1/","MolecularConstituentsPMID":["22959777"],"NeurotransmitterPMID":"12965293","Neurotransmitter":"Glutamate","SuperCategory":"Neuron","Id":"sao429277527","CellSomaShape":"Pear-shaped","Species":"Mammal","Definition":"A pear-shaped epithelial cell that is medially placed re: the inner pillar and forms a single row within the organ of Corti. Resting potential is modulated by perturbations in stereocilia located at the apical pole of the cell. In contrast to outer hair cells, the inner hair cells are fewer in number, have fewer stereocilia, and are less differentiated. They do, however, receive ~95% of the auditory-nerve dendrites.  Although a single auditory nerve fiber innervates several outer hair cells, each inner hair cell receives several more heavily myelinated, auditory-nerve dendrites.  Neurotransmitter release activates the auditory nerve, which leads to the cochlear nucleus within the central auditory pathway.(MSH)","DefinitionPMID":"18619539,3909832"}},{"Cochlea outer hair cell":{"Located in":["Cochlea"],"Located_in":"Spiral organ of Corti","Synonym":["Cochlear Outer Hair Cell"],"CurationStatus":"graph position temporary","MolecularConstituents":"Prestin","Comment":["Note that transmitter is Glutamate OR Aspartate"],"CellSomaShapeOther":"Columnar","Curator":["Maryann Martone"],"NeurotransmitterReceptors":"Acetylcholine","Has role":"Principal neuron role","NeurotransmitterReceptorsPMID":"10402196","OriginOfAxon":"no axon","Abbrev":"OHC","CellSomaSize":"Small soma","MolecularConstituentsPMID":"10821263","NeurotransmitterPMID":"22715884","SynonymPMID":"18195086","Neurotransmitter":["Glutamate","Aspartate"],"SuperCategory":"Neuron","Id":"sao1582628662","CellSomaShape":"Other","Species":"Mammal","Definition":"In mammals, the outer hair cells are arranged in three rows that are further removed from the modiolus than the single row of inner hair cells. Although receiving only ~5% of the innervating auditory nerve dendrites, the motile properties of the outer hair cells actively contribute to the sensitivity and frequency selectivity of the cochlea. The process of somatic electromotility, due to the presence of the motor protein, prestin, is essential for normal cochlear function.  Outer hair cell function is also directly influenced by efferent input from the medial superior olivary complex. (MSH)","DefinitionPMID":"20624897"}},{"Cochlear canal":{"Synonym":"Spiral canal of cochlea","Created":"2007-08-28","CurationStatus":"raw_import","Umlscui":["C0009198"],"SuperCategory":"Organ cavity","Id":"birnlex_2553"}},{"Cochlear nuclear complex":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-07","EditorialNote":"BFO includes a \"snap:ObjectAggregate\".  That would probably be more appropriate for these sort of aggregate structures (BB).","Synonym":["Cochlear nucleus"],"CurationStatus":"uncurated","NeuronamesID":"717","Umlscui":"C0152411","SuperCategory":"Regional part of brain","Id":"birnlex_1151","Has role":"Cranial nerve nucleus","Is part of":"Medulla oblongata,","Species":"Mammal,"}},{"Cochlear nuclei of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Cochlear nuclear complex","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152905","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Medulla sensory related of ABA 2009","Organism":"mouse","Species":"Mouse"}},{"Cochlear nucleus (dorsal) cartwheel cell":{"AxonProjectionLateralityPMID":"8389821,1862946","Located in":"Somas lie at the superficial side of the pyramidal (fusiform) cell layer of the dorsal cochlear nucleus.","Located_in":"Molecular layer of dorsal cochlear nucleus","BranchingMetrics":"stellate","Synonym":"Cartwheel neuron","CurationStatus":"uncurated","FiringPatterns":"bursting","SpontaneousFiringPatterns":"Bursting","CellSomaSize":"Medium soma","RelatedTo":"Cerebellum Purkinje cell","SpineDensityOnDendrites":"spiny high density","Created":"2007-09-05","MolecularConstituentsPMID":"1862946,3449006,3317418,23486948","SpineDensityOnDendritesPMID":"4134212,8389821,7814691","Neurotransmitter":["Glycine"],"LocationOfLocalAxonArborization":["Pyramidal cells","giant cells"],"CellSomaShapePMID":"8389821,7814691","SuperCategory":"Neuron","CellSomaShape":"Spherical","Species":"Mammal","DefiningCitation":"4134212","AxonProjectionLaterality":"ipsilateral","DendriteLocation":"Molecular layer of dorsal cochlear nucleus","MolecularConstituents":["PEP19","Cerebellin","GAD"],"RelatedToPMID":"2077109,3449006,3317418","AxonMyelinationPMID":"21040850,22063631","NeurotransmitterReceptors":"MGluR1alpha","Has role":"Intrinsic neuron role","DendriteLocationPMID":"8389821","CellSomaSizePMID":"8389821,7814691","OriginOfAxon":"soma","LocationOfLocalAxonArborizationPMID":"1862946,21791289","CellularSynapticTarget":"Cochlear_(dorsal)_nucleus_pyramidal_neuron","OriginOfAxonPMID":"8389821,7814691","NeurotransmitterPMID":"23486948,21791289","LocatedInPMID":"4134212,8389821,7814691","Id":"nifext_76","BranchingMetricsPMID":"4134212,8389821,7814691","AxonMyelination":"myelinated","SpontaneousFiringRate":"Rapid firing","HasRolePMID":"2077109","DefinitionPMID":"4134212,8389821,7814691","Definition":"Cartwheel cell bodies lie on the superficial side of the pyramidal (or fusiform) cell layer of the dorsal cochlear nucleus. Their spiny dendrites receive input from the axons of granule cells (parallel fibers) and their axons release GABA and glycine onto cartwheel, pyramidal and giant cell targets. Cartwheel cells share many of the features, molecular and electrophysiological, of cerebellar Purkinje neurons."}},{"Cochlear nucleus (dorsal) giant cell":{"Located in":"deep layer of the dorsal cochlear nucleus","Located_in":"Cochlear nuclear complex,","BranchingMetrics":"multipolar","Synonym":"None","CurationStatus":"graph position temporary","NeurotransmitterReceptorsPMID":"9242277","LocationOfAxonArborization":"Inferior colliculus","CellSomaSize":"Large soma","SpineDensityOnDendrites":"spiny low density","Created":"2007-09-05","SpineDensityOnDendritesPMID":"9242277","Neurotransmitter":"Likely glutamate","LocationOfLocalAxonArborization":"no local arborization","LocationOfAxonArborizationPMID":"15669051","SuperCategory":"Neuron","CellSomaShape":"Multipolar","Species":"Vertebrata","DefiningCitation":"7240455","AxonProjectionLaterality":"contralateral","DendriteLocation":["Dendrites spread from the cell body in all directions.  Dendrites are smooth where they lie in the deep layer but where the dendrites cross the pyramidal (fusiform) cell layer into the molecular layer"],"Curator":"Maryann Martone","NeurotransmitterReceptors":"Glycine-gated chloride channel,","Has role":"Principal neuron role","DendriteLocationPMID":"7240455,9242277,15669051,7760132","CellSomaSizePMID":"7240455,","OriginOfAxon":"soma and sometimes dendrite","LocationOfLocalAxonArborizationPMID":"15669051","Abbrev":"GC","EditorialNote":"We are having trouble adding multiple references to this entry;  the titles of the papers get mixed up.  As a temporary fix, I removed the multiple references but this needs to be fixed.Definition:,7240455,9242277,15669051Soma location:9242277,15669051Soma Size: 9242277,15669051","LocatedInPMID":"7240455,","Id":"nifext_75","BranchingMetricsPMID":"7240455,","AxonMyelination":"myelinated","HasRolePMID":"7240455","DefinitionPMID":"5801446","Definition":"Large multipolar cells located in the deep layer of the dorsal cochlear nucleus.  Like the pyramidal (fusiform) cells, a principal neuron of the DCN.  Their dendrites, branching sparsely across isofrequency bands, are smooth until they reach the molecular layer, where the tips are spiny.  The axons join pyramidal cell axons to form the DAS (dorsal acoustic stria) through which they project to the contralateral inferior colliculus."}},{"Cochlear nucleus (dorsal) Golgi cell":{"Located in":"Dorsal cochlear nucleus","Located_in":"Cochlear nuclear complex,","Created":"2007-09-05","Synonym":["deep cerebellar nucleus GABAergic cell","DCN Gabaergic cell"],"CurationStatus":"uncurated","Neurotransmitter":"GABA","Comment":"Should the anatomical location be changed to Dorsal cochlear nucleus?","SuperCategory":"Neuron","Id":"nifext_136","Species":"Vertebrata"}},{"Cochlear nucleus (dorsal) pyramidal neuron":{"Located in":"Cochlear nuclear complex,","DendriteLength":"Rat: apical 150-200 um; basal 200-250um","Located_in":"Pyramidal (fusiform) cell body layer","Synonym":["fusiform cell"],"CurationStatus":"uncurated","LocationOfAxonArborization":"Rat: axon collaterals to other pyramidal cells.  Mouse: no axon collaterals.  Exit through the dorsal and intermediate acoustic striae to terminate in the contralateral inferior colliculus","Created":"2007-09-05","DefiningCriteria":"Spiny apical and smooth basal dendrites; fusiform cell body shape; in pyramidal cell body layer","Neurotransmitter":"Excitatory neurotransmitter","SuperCategory":"Neuron","Species":"Mammal","DefiningCitation":["Kane","1974; Young and Oertel","2004 (in Shepherd"],"DendriteThickness":"Rat: apical 2-5 um; basal 2-6 um","AxonProjectionLaterality":"contralateral","Comment":"Should be \"Cochlear nucleus dorsal pyramidal neuron\"","Is_part_of":"cochlear (dorsal) nucleus","OriginOfAxon":"soma","Abbrev":"py","CellularSynapticTarget":"Rat: axon collaterals to other pyramidal cells.  Mouse: no axon collaterals.  Axon terminates in the contralateral inferior colliculus","EditorialNote":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","ExampleImage":"Cochlear nucleus pyramidal neuron.gif,","NumberOfPrimaryDendrites":"Rat: apical 5-7; basal 2-4","Id":"nifext_74","Polarity":"Bipolar","Definition":"Bipolar neuron in dorsal cochlear nucleus, whose cell bodies form a band in the pyramidal cell layer.  Characterized by a spiny apical dendritic tree in the molecular layer and a smooth basal dendritic tree in the deep layer.  The apical dendrites have many branches which are contacted by parallel fibers from granule cells, whereas the basal dendrites have few branches and receive inputs from the auditory nerve."}},{"Cochlear nucleus (dorsal) stellate cell":{"Located in":"Dorsal cochlear nucleus","CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_153843","Species":"Vertebrata"}},{"Cochlear nucleus (dorsal) unipolar brush cell":{"AxonProjectionLateralityPMID":"7472327","Located in":"dorsal cochlear nucleus","Located_in":"Cochlear nuclear complex,","BranchingMetrics":"unipolar","Synonym":["DCN glutamatergic cell"],"CurationStatus":"uncurated","AbbrevPMID":"20937306","NeurotransmitterReceptorsPMID":"18343594,7673463","LocationOfAxonArborization":"none","CellSomaSize":"Small soma","RelatedTo":"Cerelllum unipolar brush cell","SpineDensityOnDendrites":"Smooth","Created":"2007-09-05","MolecularConstituentsPMID":"18343594,11044898","Neurotransmitter":"Glutamate","LocationOfLocalAxonArborization":"within the same granule cell domain as the cell body","CellSomaShapePMID":"18343594","SuperCategory":"Neuron","CellSomaShape":"Spherical","Species":"Vertebrata","DefiningCitation":"8106879","AxonProjectionLaterality":"ipsilateral","DendriteLocation":"Brush of dendrites is short and lies near the cell body","MolecularConstituents":["Calretinin","MGluR1alpha","Epidermal growth factor substrate 8 (Eps8)","T-box gene (Tbr2)","Alpha 6 GABA-A receptor"],"RelatedToPMID":"20937306","CellSomaShapeOther":"Oval","AxonMyelinationPMID":"10891606","NeurotransmitterReceptors":["GluR2","GluR3","GluR5/6/7","NR1"],"Has role":"Intrinsic neuron role","DendriteLocationPMID":"18343594","CellSomaSizePMID":"18343594","OriginOfAxon":"soma","LocationOfLocalAxonArborizationPMID":"7472327","Abbrev":"UBC","OriginOfAxonPMID":"7472327","NeurotransmitterPMID":"7472327","LocatedInPMID":"18343594","AxonMyelination":"unmyelinated","BranchingMetricsPMID":"18343594,7472327","Id":"nifext_135","HasRolePMID":"7472327","DefinitionPMID":"8106879,7978355,8059339,8300904,7472327","Definition":"Unipolar brush cells are characterized by having one dendrite that terminates in a paintbrush-like structure of dendrioles that receives input from a single mossy fiber terminal.  The axon usually emanates from the opposite pole, branches 1-3 times and ends in mossy terminals.  They were defined by E. Mugnaini and his colleagues in the 1990s."}},{"Cochlear nucleus (dorsal) vertical cell":{"Located in":"Dorsal cochlear nucleus deep layer","Located_in":"Dorsal cochlear nucleus,","Synonym":["tuberculoventral cell","vertical cell"],"CurationStatus":"uncurated","NeurotransmitterReceptorsPMID":"8389823","LocationOfAxonArborization":"ventral cochlear nucleus","CellSomaSize":"Medium soma","RelatedTo":["\"type II\" responses to sound"],"SpineDensityOnDendrites":"Smooth","Created":"2007-09-05","Neurotransmitter":"Glycine,","LocationOfLocalAxonArborization":"dorsal cochlear nucleus","CellSomaShapePMID":"8389823","LocationOfAxonArborizationPMID":["PMID: 8389823 (Zhang and Oertel"],"SuperCategory":"Neuron","CellSomaShape":"Multipolar","Species":"Vertebrata","DefiningCitation":["Lorente de No","1933"],"AxonProjectionLaterality":"ipsilateral","RelatedToPMID":["7061349"],"NeurotransmitterReceptors":"AMPA-type glutamate-gated cationic channel,","Has role":"Intrinsic neuron role","DendriteLocationPMID":"3360996,8389823","OriginOfAxon":"soma and sometimes dendrite","LocationOfLocalAxonArborizationPMID":["PMID: 8389823 (Zhang and Oertel","1993); PMID: 10444694  (Rhode"],"OriginOfAxonPMID":["PMID: 8389823 (Zhang and Oertel","1993); PMID: 10444694  (Rhode"],"NeurotransmitterPMID":"1972392","SynonymPMID":["Lorente de No","1981","The Primary Acoustic Nuclei","Raven","NY; PMID: 3360996 (Wickesberg","Oertel"],"LocatedInPMID":["Lorente de No","1933"],"Id":"nifext_73","BranchingMetricsPMID":["PMID: 8389823 (Zhang and Oertel","1993); PMID: 10444694  (Rhode"],"AxonMyelination":"myelinated","HasRolePMID":"7061349,1972392,10444694","DefinitionPMID":["Lorente de No","1933"],"Definition":"Intrinsic neuron found in the deep layer of the dorsal cochlear nucleus, whose cell bodies and dendrites are intermingled among the basal dendritic trees of pyramidal cells.  Their dendrites are smooth and lie in the plane of an isofrequency sheet; in sections in standard planes, parts of the dendrites are cut so they appear to be oriented vertically, perpendicular to the plane of the layers.  They are inhibitory and use glycine as a neurotransmitter."}},{"Cochlear nucleus (ventral) globular bushy cell":{"Located in":"ventral cochlear nucleus","AxonProjectionLateralityPMID":["PMID: 6298659 (Tolbert et al.","1982); PMID: 3215304 (Friauf","Ostwald","1988); PMID: 3693616 (Smith","Rhode"],"CurationStatus":"uncurated","CellSomaSize":"Large soma","LocationOfAxonArborization":["medial nucleus of trapezoid body"],"RelatedTo":"Primary-like responses to tones","SpineDensityOnDendrites":"Smooth","Created":"2007-09-05","Neurotransmitter":"Glutamate,","LocationOfLocalAxonArborization":"none","CellSomaShapePMID":["PMID: 5801446 (Osen"],"LocationOfAxonArborizationPMID":["PMID: 5801446 (Osen","1969); PMID: 6298659 (Tolbert et al.","1982); PMID: 3693616 (Smith","Rhode"],"SuperCategory":"Neuron","CellSomaShape":"Oval","Species":"Vertebrata","DefiningCitation":["PMID: 5801446 (Osen","1969); PMID: 6298659 (Tolbert et al."],"AxonProjectionLaterality":"contralateral","RelatedToPMID":["PMID: 3693616 (Smith","Rhode"],"AxonMyelinationPMID":["PMID: 1156852 (Brownell"],"NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel"],"Has role":"Principal neuron role","CellSomaSizePMID":["PMID: 5801446 (Osen","1969); PMID: 7162626 (Tolbert","Morest"],"OriginOfAxon":"soma","Abbrev":"GBC","NeurotransmitterPMID":["PMID: 8096081 (Forsythe","Barnes-Davies"],"LocatedInPMID":["PMID: 5801446 (Osen","1969); PMID: 4134212 (Brawer","Morest","Kane"],"Id":"nifext_70","AxonMyelination":"myelinated","HasRolePMID":["PMID: 6298659 (Tolbert et al.","1982); PMID: 3693616 (Smith","Rhode"],"DefinitionPMID":["PMID: 5801446 (Osen","1969); PMID: 6298659 (Tolbert et al."],"Definition":"The distinction between globular and spherical bushy cells was originally reported by Osen on the basis of a difference in the shape of the cell bodies.  Globular bushy cells lie in and around the root of the auditory nerve.  Their axons project to the contralateral medial nucleus of the trapezoid body (MNTB), innervating principal cells with a calyx of Held."}},{"Cochlear nucleus (ventral) multipolar cell":{"Located in":["Cochlear nuclear complex"],"Located_in":"Ventral cochlear nucleus,","EditorialNote":"http://vanat.cvm.umn.edu/neurHistAtls/pages/neuron3.html","CurationStatus":"uncurated","ExampleImage":"Cochlear nucleus (ventral) multipolar cell.jpg,","SuperCategory":"Neuron","Id":"nlx_cell_20081202","Species":"Vertebrata","DefiningCitation":["Definition Source: Young and Oertel (2004). In Shepherd (ed.) The Synaptic Organization of the Brain","5th ed"],"Definition":"Multipolar neuron located in the ventral cochlear nucleus with multiple long dendrites extending from the cell soma.  Two subclasses (D and T) are recognzed based on their alignment with auditory nerve fibers. Both types have axon collaterals that terminate locally near the cell soma."}},{"Cochlear nucleus (ventral) multipolar D cell":{"AxonProjectionLateralityPMID":"6185548,3304530,12867521,15669051","Located in":"Ventral cochlear nucleus","Located_in":"Cochlear nuclear complex,","Synonym":["D multipolar cell","type II (Cant","1981)","onset-chopper responses to tones","radial stellate"],"CurationStatus":"uncurated","PublicationLink":"7322355,2341631","AbbrevPMID":"2723154,15669051","NeurotransmitterReceptorsPMID":"9425176,11549747","LocationOfAxonArborization":["Contralateral ventral cochlear nucleus"],"CellSomaSize":"Large soma","RelatedTo":"Inhibit T stellate cells","SpineDensityOnDendrites":"Smooth","Created":"2007-09-05","MolecularConstituentsPMID":"3304530,8132865","SpineDensityOnDendritesPMID":"2723154,2341631,9268126","Neurotransmitter":"Glycine,","LocationOfLocalAxonArborization":["Ipsilateral ventral cochlear nucleus"],"CellSomaShapePMID":"7322355,3304530,15669051","LocationOfAxonArborizationPMID":["PMID: 6185548 (Cant","Gaston","1982); PMID: 15669051 (Smith et al."],"SuperCategory":"Neuron","CellSomaShape":"Multipolar","Species":"Vertebrata","AxonProjectionLaterality":"bilateral","MolecularConstituents":"Glycine","RelatedToPMID":"9425176","CellSomaShapeOther":"Cell bodies densely innervated","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel","GABA A-gated anionic channel"],"Has role":"Intrinsic neuron role","CellSomaSizePMID":"7322355,3304530,2341631,15669051","OriginOfAxon":"soma","LocationOfLocalAxonArborizationPMID":["PMID: 2723154 (Smith","Rhode","1989); PMID: 2341631 (Oertel et al.","1990); PMID: 9268126 (Doucet","Ryugo"],"Abbrev":"Oc","OriginOfAxonPMID":"2723154,2341631,15669051","NeurotransmitterPMID":"3304530,9425176","SynonymPMID":"7322355,2723154,9268126","LocatedInPMID":"8132865","AxonMyelination":"myelinated","Id":"nifext_69","BranchingMetricsPMID":"2723154,2341631,9268126","HasRolePMID":"7931527,12867521","DefinitionPMID":"2341631","Definition":"One of two types of multipolar or stellate cells, D stellate cells are glycinergic inhibitory neurons named for having an axon that projects dorsalward into the dorsal cochlear nucleus and that exits through the intermediate acoustic stria to innervate the contralateral cochlear nucleus.  Axons have widespread collaterals in the ventral cochlear nucleus and in the deep layer of the dorsal cochlear nucleus."}},{"Cochlear nucleus (ventral) multipolar T cell":{"AxonProjectionLateralityPMID":["PMID: 759446 (Adams","1979); PMID: 9067830 (Schofield","Cant"],"Located in":"Ventral cochlear nucleus","Located_in":"Cochlear nuclear complex,","BranchingMetrics":"multipolar","Synonym":["T multipolar cell","T stellate cell","type I","chopper"],"CurationStatus":"uncurated","NeurotransmitterReceptorsPMID":["PMID: 9425176 (Ferragamo et al.","1998); PMID: 11549747 (Fujino","Oertel"],"LocationOfAxonArborization":["contralateral (uncommonly ipsilateral) inferior colliculus","ventral nuclei of the lateral lemniscus"],"CellSomaSize":"Large soma","RelatedTo":"chopper responses to tones","SpineDensityOnDendrites":"Smooth","Created":"2007-09-05","SpineDensityOnDendritesPMID":["PMID: 2341631 (Oertel et al.","1990); PMID: 2723154 (Smith","Rhode","1989); PMID: 9268126 (Doucet","Ryugo"],"Neurotransmitter":"Glutamate,","LocationOfLocalAxonArborization":["ipsilateral ventral cochler nucleus"],"LocationOfAxonArborizationPMID":["PMID: 759446 (Adams","1979); PMID: 1757599 (Thompson","Thompson"],"SuperCategory":"Neuron","CellSomaShape":"Multipolar","Species":"Vertebrata","DefiningCitation":["PMID: 2723154 (Smith","Rhode","1989); PMID: 2341631 (Oertel et al."],"AxonProjectionLaterality":"bilateral","DendriteLocation":"Dendrites lie parallel to auditory nerve fibers in the ventral cochlear nucleus","RelatedToPMID":["PMID: 2723154 (Smith","Rhode"],"AxonMyelinationPMID":["PMID: 1156852 (Brownell"],"NeurotransmitterReceptors":["Glycine-gated chloride channel","AMPA-type glutamate-gated cationic channel","NMDA-type glutamate-gated cationic channel","Acetylcholine-gated channel (nicotinic)"],"Has role":"Principal neuron role","DendriteLocationPMID":["PMID: 2341631 (Oertel et al.","1990); PMID: 2723154 (Smith","Rhode","1989); PMID: 9268126 (Doucet","Ryugo"],"CellSomaSizePMID":["PMID: 7322355 (Cant","1981); PMID: 2723154 (Smith","Rhode","1989); PMID: 7322355 (Cant","1981); PMID: 2341631 (Oertel et al.","1990); PMID: 9268126 (Doucet","Ryugo"],"OriginOfAxon":"soma","LocationOfLocalAxonArborizationPMID":["PMID: 2723154 (Smith","Rhode","1989); PMID: 2341631 (Oertel et al.","1990); PMID: 9268126 (Doucet","Ryugo"],"OriginOfAxonPMID":["PMID: 21056098 (Oertel et al."],"NeurotransmitterPMID":["PMID: 9425176 (Ferragamo et al."],"SynonymPMID":["PMID: 7322355 (Cant","1981); PMID: 2341631 (Oertel et al.","1990); PMID: 2723154 (Smith","Rhode","1989); PMID: 9268126 (Doucet","Ryugo"],"LocatedInPMID":["PMID: 759446 (Adams"],"Id":"nifext_68","BranchingMetricsPMID":["PMID: 2723154 (Smith","Rhode","1989); PMID: 2341631 (Oertel et al.","1990); PMID: 9268126 (Doucet","Ryugo"],"AxonMyelination":"myelinated","HasRolePMID":["PMID: 6164444 (Ryugo","Willard","Fekete","1981); PMID: 21056098 (Oertel et al."],"DefinitionPMID":["PMID: 5801446 (Osen","1969); PMID: 2341631 (Oertel et al."],"Definition":"Principal cells of the ventral cochlear nucleus are named for having the axon exit the cochlear nucleus through the Trapezoid body. A band of dendrites in an isofrequency lamina receives input from a small number of auditory nerve fibers.  Sharp tuning is enhanced by sideband inhibition.  The population of T stellate cells encodes the spectra of sounds."}},{"Cochlear nucleus (ventral) octopus cell":{"AxonProjectionLateralityPMID":"7499559","Located in":["Cochlear nuclear complex","ventral cochlear nucleus","octopus cell area","dorsal tail of ventral cochlear nucleus"],"Located_in":"Ventral cochlear nucleus,","Synonym":["Ventral cochlear nucleus octopus cell"],"CurationStatus":"graph position temporary","NeurotransmitterReceptorsPMID":"10516291,11549753","LocationOfAxonArborization":["Ventral nucleus of lateral lemniscus"],"CellSomaSize":"Large soma","PMID":"5801446","RelatedTo":"Onset responses to tones","SpineDensityOnDendrites":"Smooth","Created":"2007-09-05","MolecularConstituentsPMID":"15245481,18424000,8867285","SpineDensityOnDendritesPMID":"4134212,6300200,7722652","Neurotransmitter":"Glutamate,","LocationOfLocalAxonArborization":"In some species (mice) but not in others (cats) octopus cells have local collaterals in the octopus cell area and contact granule cells in the granule cell lamina.","CellSomaShapePMID":"5801446,4134212","LocationOfAxonArborizationPMID":"15669051","SuperCategory":"Neuron","CellSomaShape":"Oval","Species":"Mammal","AxonProjectionLaterality":"contralateral","MolecularConstituents":["KCNA","HCN1","Parvalbumin"],"RelatedToPMID":"1150921,6300200,15669051","SenseLabId":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","AxonMyelinationPMID":"7499559","NeurotransmitterReceptors":"AMPA-type glutamate-gated cationic channel,","Has role":"Principal neuron role","CellSomaSizePMID":"5801446,4134212","OriginOfAxon":"soma and sometimes dendrite","LocationOfLocalAxonArborizationPMID":"7722652","Abbrev":"OC","OriginOfAxonPMID":["7722652"],"EditorialNote":"I can't track down the reference to the nucleus interfascicularis.  The reference given doesn't mention the nucleus and according to Brain Info, there are two nuclei, one in the midbrain tegmentum and one associated with the hypoglossal nucleus, that go by that name.  Needs clarification","NeurotransmitterPMID":"7722652","LocatedInPMID":"5801446","ExampleImage":"Cochlear nucleus (ventral) octopus cell.gif,","Id":"nifext_72","BranchingMetricsPMID":"22764237","AxonMyelination":"myelinated","HasRolePMID":"7499559","DefinitionPMID":"5801446","Definition":"Large neuron located in the octopus cell area of the posterior division of the ventral cochlear nucleus (called dorsal tail of the ventral cochlear nucleus by Cajal and nucleus interfascicularis by Lorente de No), whose dendrites emanate from one side of the cell body, giving them a shape reminiscent of an octopus."}},{"Cochlear nucleus (ventral) spherical bushy cell":{"Located in":"Ventral cochlear nucleus","Located_in":"Ventral cochlear nucleus,","Synonym":["Bushy neuron","Bushy cell"],"CurationStatus":"uncurated","NeurotransmitterReceptorsPMID":"3746428","CellSomaSize":"Large soma","LocationOfAxonArborization":"superior olivary complex","RelatedTo":"Primary-like responses to tones","SpineDensityOnDendrites":"Smooth","LocationOfLocalAxonArborization":"none","Neurotransmitter":"Glutamate,","CellSomaShapePMID":"5801446","SuperCategory":"Neuron","CellSomaShape":"Oval","Species":"Vertebrata","DefiningCitation":["Smith","P. H. and Rhode","W. S. (1987)  Characterization of HRP-labeled globular bushy cells in the cat anteroventral cochlear nucleus.  J. Comp. Neurol.","266:  360-375 and Shepherd (2004) The Synaptic Organization of the Brain","5th ed"],"AxonProjectionLaterality":"bilateral","Comment":["To be consistent"],"CellSomaShapeOther":"Spherical bushy cells are round; globular bushy cells are oval","AxonMyelinationPMID":"1156852","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel","Glycine-gated chloride channel"],"Has role":"Principal neuron role","CellSomaSizePMID":"5801446","OriginOfAxon":"soma","Abbrev":["sSBC","lSBC"],"EditorialNote":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","LocatedInPMID":"5801446","ExampleImage":"Cochlear nucleus (ventral) bushy cell.gif,","Id":"nlx_cell_20081201","AxonMyelination":"myelinated","Definition":"Bushy cells in the anteroventral cochlear nucleus have one to four primary dendrites which branch profusely, giving them a \"bushy\" appearance.  They project to the superior olivary nuclei. They carry information that is used to localize sounds in the azimuthal plane.  Three types of bushy cells differ in the shapes of their somata and in their patterns of projection.  The cell somata of these neurons have been described as \"spherical\" in the anterior division of the AVCN and \"globular\" in the posterior division of the AVCN.  Large spherical bushy cells project to the medial superior olivary nuclei bilaterally, globular bushy cells project to the contralateral medial nucleus of the trapezoid body.  Small spherical bushy cells project to the vicinity of the ipsilateral lateral superior olivary nucleus but it is not yet clear which cells are their targets.  Their inputs from the spiral (cochlear) ganglion arise via the end bulbs of Held."}},{"Cochlear nucleus subpedunclular granular region of ABA 2009":{"PartiallyOverlapsWith":"Cochlear nucleus  subpedunclular granular region","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153265","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Code Meaning":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0104","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149703","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Required if (4008,0117) Interpretation Diagnosis Code Sequence is present."}},{"Code Profiler":{"CurationStatus":"uncurated","SuperCategory":"Software development tool","Id":"birnlex_2226","Definition":"A performance analysis tool that measures the behavior of a program as it executes, particularly the frequency and duration of function calls. The profiling process helps to determine which subroutines (or just snippets of code) take longest to execute and which subroutines are called most often. Code profilers are used when you suspect that some part of your code is called very often and maybe there is a need to optimize it, which could significantly improve the overall performance. Profilers use a wide variety of techniques to collect data, including hardware interrupts, code instrumentation, instruction set simulation, operating system hooks, and performance counters."}},{"Code testing framework":{"Created":"2007-03-07","CurationStatus":"uncurated","SuperCategory":"Software development tool","Id":"birnlex_2227","Definition":"A resource that provides a software environment created to investigate the quality of the product or service under test, with respect to the context in which it is intended to operate. This includes, but is not limited to, the process of executing a program or application with the intent of finding software bugs."}},{"Code Value":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0100","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149704","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"Required if (4008,0117) Interpretation Diagnosis Code Sequence is present."}},{"Codeine":{"RelatedTo":["Delta-type opioid receptor","Kappa-type opioid receptor"],"Synonym":["Codeine anhydrous","L-Codeine","Methylmorphine","Morphine monomethyl ether","Norcodeine","N-Methyl","Norcodine","N-Methyl","Codicept"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:16714","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB00318","Definition":"An opioid analgesic related to morphine but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough. (PubChem) Pharmacology: Codeine, an opiate agonist in the CNS, is similar to other phenanthrene derivatives such as morphine. Codeine, in combination with guaifenesin or iodinated glycerol, is used as a cough suppressant and, as a single agent or in combination with acetaminophen or other products, is used for pain control and as an antidiarrheal agent. Mechanism of action: Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Codeine's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. Drug type: Approved. Illicit. Small Molecule. Drug category: Analgesics. Analgesics, Opioid. Antitussive Agents. Antitussives. Narcotics. Opiate Agonists"}},{"Coding Scheme Designator":{"ValueRepresentation":"SH","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0102","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149705","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"Required if (4008,0117) Interpretation Diagnosis Code Sequence is present."}},{"Coding Scheme External ID":{"ValueRepresentation":"ST","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0114","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149706","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"ST","Definition":"The coding scheme identifier as defined in an external registry. Required if coding scheme is registered and Coding Scheme UID (0008,010C) is not present."}},{"Coding Scheme Identification Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0110","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149707","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence of items that map values of Coding Scheme Designator (0008,0102) to an external coding system registration, or to a private or local coding scheme. One or more items may be present in the sequence."}},{"Coding Scheme Name":{"ValueRepresentation":"ST","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0115","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149708","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"ST","Definition":"The coding scheme full common name."}},{"Coding Scheme Registry":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0112","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149709","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"The name of the external registry where further definition of the identified coding scheme may be obtained. Required if coding scheme is registered."}},{"Coding Scheme UID":{"ValueRepresentation":"UI","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_010C","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149710","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"UI","Definition":"The coding scheme UID identifier. Required if coding scheme is identified by an ISO 8824 object identifier compatible with the UI VR."}},{"Coding Scheme Version":{"ValueRepresentation":"SH","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0103","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149711","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"The coding scheme version associated with the Coding Scheme Designator (0008,0102)."}},{"Coelomata":{"Created":"2007-06-03","CurationStatus":"pending_final_vetting","Umlscui":"C1004414","SuperCategory":"Bilateria","Id":"birnlex_606"}},{"Coelurosauria":{"Created":"2007-06-03","CurationStatus":"pending_final_vetting","SuperCategory":"Theropoda","Id":"birnlex_243"}},{"Cognitive assessment":{"Created":"2006-06-01","CurationStatus":"uncurated","Umlscui":"C0870300","SuperCategory":"Assessment","Id":"birnlex_2021"}},{"Cognitive function":{"Created":"2007-03-05","EditorialNote":"The examples are derived from the Wikipedia page on 'Mental function.'  Perhaps a more narrow set of examples that specifically fit to our requirements in BIRN would be more appropriate.  A more authoritative neuropsychological source should also be used, as some of these examples may be considered by neuropsychologists to be degenerate - e.g., 'belief function' is_a 'imaginative function' (BB:2007-03-05).Note that we are distinguishing between processes and functions, so there will appear to be a set of duplicate classes.  The distinction as described by BFO, as we understand it, is that functions are end-directed activities of continuants.  So memory function is an end activity of a memory process.  We therefore measure memory function as an indicator of the effectiveness of the memory process.","CurationStatus":"uncurated","Umlscui":"C0392335","SuperCategory":"Behavioral system function","Id":"birnlex_1864"}},{"Cognitive process":{"Created":"2006-05-15","EditorialNote":"Note that we are distinguishing between processes and functions, so there will appear to be a set of duplicate classes.  The distinction as described by BFO, as we understand it, is that functions are end-directed activities of continuants.  So memory function is an end activity of a memory process.  We therefore measure memory function as an indicator of the effectiveness of the memory process.","CurationStatus":"uncurated","Umlscui":["C0025361"],"SuperCategory":"Behavioral process","Id":"birnlex_1800"}},{"Cognitive psychology":{"RelatedTo":["Cognition","Cognitive control","Cognitive development","Language","Syntax"],"CurationStatus":"uncurated","SuperCategory":"Psychology","Id":"nlx_inv_100621","Definition":"Branch of psychology concerned with the study of cognition"}},{"Cognitive state":{"EditorialNote":"Describes entities related to cognitive processes.  At some point, this will have to be merged with the OBR but for now I think it's best kept separate (MM).","Created":"2006-06-01","CurationStatus":"uncurated","SuperCategory":"Disposition","Id":"birnlex_1810"}},{"Coiled":{"Synonym":["Spiral","helix-shaped"],"SuperCategory":"Coiling","Id":"PATO_0000404","Definition":"Curled or wound (especially in concentric rings or spirals)."}},{"Coiling":{"SuperCategory":"Shape","Id":"PATO_0001794","Definition":"A shape quality inhering in a bearer by virtue of being wound in a continuous series of loops."}},{"Coincidence detection":{"Synonym":"Coincidence Detector","CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001082","DefiningCitation":"ModelDB:3632","Definition":"Process by which a neuron, neural circuit or neural model detects simultaneous but spatially separate synaptic inputs."}},{"Coincidence Window Width":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_1210","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149712","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"The width of the coincidence timing window, in nsec. The maximum time difference accepted between two single events."}},{"Colchicine":{"RelatedTo":["Tubulin beta-1 chain","Tubulin beta chain","Pyrin"],"Synonym":["Colchicin","Colchicina","Colchicinum","Col-probenecid","Colbenemid","Condylon"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:23359","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01394","Definition":"A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (periodic disease). (PubChem) Pharmacology: Colchicine is a highly poisonous alkaloid, originally extracted from plants of the genus Colchicum (Autumn crocus, also known as the \"Meadow saffron\"). Originally used to treat rheumatic complaints and especially gout, it was also prescribed for its cathartic and emetic effects. Its present medicinal use is mainly in the treatment of gout; as well, it is being investigated for its potential use as an anti-cancer drug. It can also be used as initial treatment for pericarditis and preventing recurrences of the condition. Mechanism of action: The precise mechanism of action has not been completely established. In patients with gout, colchicine apparently interrupts the cycle of monosodium urate crystal deposition in joint tissues and the resultant inflammatory response that initiates and sustains an acute attack. Colchicine decreases leukocyte chemotaxis and phagocytosis and inhibits the formation and release of a chemotactic glycoprotein that is produced during phagocytosis of urate crystals. Colchicine also inhibits urate crystal deposition, which is enhanced by a low pH in the tissues, probably by inhibiting oxidation of glucose and subsequent lactic acid production in leukocytes. Colchicine has no analgesic or antihyperuricemic activity. Colchicine inhibits microtubule assembly in various cells, including leukocytes, probably by binding to and interfering with polymerization of the microtubule subunit tubulin. Although some studies have found that this action probably does not contribute significantly to colchicine's antigout action, a recent in vitro study has shown that it may be at least partially involved. Drug type: Approved. Small Molecule. Drug category: Gout Suppressants. Tubulin Modulators"}},{"Cold":{"SuperCategory":"Temperature","Id":"PATO_0000677","Definition":"A temperature which is relatively low."}},{"Coleoidea":{"EditorialNote":"This is listed as an unconfirmed Cephalapod genus name in GBIF (GbifID:16149559)","Created":"2007-08-15","CurationStatus":"pending_final_vetting","Umlscui":"C1081048","SuperCategory":"Cephalopods","Id":"birnlex_525"}},{"Colesevelam":{"Synonym":["Colesevelam hydrochloride","CholestaGel"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00930","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00930","Definition":"Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol. Pharmacology: Colesevelam is a high capacity bile-acid binding molecule. Colesevelam binds to bile acids in the intestine which reduces the amount of bile acids that are returned to the liver via enterohepatic circulation. Clinical studies have demonstrated that elevated levels of total cholesterol (total-C), LDL-C, and apolipoprotein B (Apo B, a protein associated with LDL-C) are associated with an increased risk of atherosclerosis in humans. Similarly, decreased levels of high-density lipoprotein cholesterol (HDL-C) are associated with the development of atherosclerosis. Epidemiological investigations have established that cardiovascular morbidity and mortality vary directly with the levels of total-C and LDL-C, and inversely with the level of HDL-C. The combination of colesevelam and an HMG-CoA reductase inhibitor is effective in further lowering serum total-C and LDL-C levels beyond that achieved by either agent alone. Mechanism of action: Colesevelam is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption. As the bile acid pool becomes depleted, the hepatic enzyme, cholesterol 7-(alpha)-hydroxylase, is upregulated, which increases the conversion of cholesterol to bile acids. This causes an increased demand for cholesterol in the liver cells, resulting in the dual effect of increasing transcription and activity of the cholesterol biosynthetic enzyme, hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase, and increasing the number of hepatic low-density lipoprotein (LDL) receptors. These compensatory effects result in increased clearance of LDL cholesterol (LDL-C) from the blood, resulting in decreased serum LDL-C levels. Serum triglyceride levels may increase or remain unchanged. The end result is increased clearance of LDL-cholesterol from the blood with decreased serum LDL-cholesterol. Drug type: Approved. Small Molecule. Drug category: Anticholesteremic Agents. Bile acid sequestrants"}},{"Colestipol":{"Synonym":["Colestipolum (INN-Latin)","Cholestabyl"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00375","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00375","Definition":"Highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels. (PubChem) Pharmacology: Cholesterol is the major, and probably the sole precursor of bile acids. During normal digestion, bile acids are secreted via the bile from the liver and gall bladder into the intestines. Bile acids emulsify the fat and lipid materials present in food, thus facilitating absorption. A major portion of the bile acids secreted is reabsorbed from the intestines and returned via the portal circulation to the liver, thus completing the enterohepatic cycle. Only very small amounts of bile acids are found in normal serum. Colestipol hydrochloride binds bile acids in the intestine forming a complex that is excreted in the feces. This nonsystemic action results in a partial removal of the bile acids from the enterohepatic circulation, preventing their reabsorption. Since colestipol hydrochloride is an anion exchange resin, the chloride anions of the resin can be replaced by other anions, usually those with a greater affinity for the resin than the chloride ion. Mechanism of action: Colestipol is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption. As the bile acid pool becomes depleted, the hepatic enzyme, cholesterol 7-(alpha)-hydroxylase, is upregulated, which increases the conversion of cholesterol to bile acids. This causes an increased demand for cholesterol in the liver cells, resulting in the dual effect of increasing transcription and activity of the cholesterol biosynthetic enzyme, hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase, and increasing the number of hepatic low-density lipoprotein (LDL) receptors. These compensatory effects result in increased clearance of LDL cholesterol (LDL-C) from the blood, resulting in decreased serum LDL-C levels. Serum triglyceride levels may increase or remain unchanged. The end result is increased clearance of LDL-cholesterol from the blood with decreased serum LDL-cholesterol. Drug type: Approved. Small Molecule. Drug category: Anion Exchange Resins. Antilipemic Agents"}},{"Colistimethate":{"Synonym":["Colistimethale Sodium","Colistimethate sodium","Colistin methanesulfonate sodium salt","Colistin sodium methanesulfonate","Colistin sodium methanesulfonate from bacillus colistinus","Coly-Mycin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01111","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01111","Definition":"Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms. Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa. Pharmacology: Colistimethate is a polymyxin antibiotic agent. Originally, colistimethate sodium was thought to be less toxic than polymyxin B; however, if the drugs are administered at comparable doses, their toxicities may be similar. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins. Mechanism of action: Colistimethate is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistimethate is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes. Drug type: Approved. Small Molecule. Drug category: Antibacterial Agents"}},{"Colistin":{"Synonym":[", Colistin sulfate","Colistin sulfate","nonsterile","Colistin sulphate","Coly-mycin S","Polymyxin E sulfate","Polymyxin E"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00803","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00803","Definition":"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally. (PubChem) Pharmacology: Colistin is a polymyxin antibiotic agent. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins. Mechanism of action: Colistin is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistin is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents"}},{"Collaborating institution":{"Created":"2006-04-04","CurationStatus":"graph_position_temporary","SuperCategory":"Institution","Id":"birnlex_2096"}},{"Collaboration tool":{"CurationStatus":"uncurated","SuperCategory":"Software resource","Id":"nlx_158023","Keywords":"Resource:CINERGI","Definition":"A software resource that supports collaboration between a group of users in some activity."}},{"Collaborator":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Investigator","Id":"birnlex_2059","Definition":"Participant in a research project or experiment, who is not the primary investigator, who performs portions of the research project or who makes significant intellectual contributions to the research project."}},{"Collagen Fibril":{"SuperCategory":"Fibril","Id":"sao7547390221","Definition":"Delicate fibrils of collagen in connective tissue. It is composed of molecules of tropocollagen aggregated in linear array."}},{"Collagenase":{"RelatedTo":["Collagen alpha-1(I) chain","Collagen alpha-1(III) chain","Collagen alpha-1(II) chain"],"Synonym":["AA4500","collagenase","Cordase","Santyl (Advance Biofactures Corp)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00048","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00048","Definition":"The enzyme collagenase is derived from fermentation of Clostridium histolyticum Pharmacology: Used in the treatment of skin ulcers and sever burns, collagenase is able to digest collagen in necrotic tissue at physiological pH. Collagenase thus contributes towards the formation of granulation tissue and subsequent epithelization of dermal ulcers and severely burned areas. Mechanism of action: Collagenase is a protease that is specific to collagen. The triple helical region of interstitial collagens is highly resistant to most cell proteinases. However, during remodeling of the connective tissue in such processes as wound healing and metastasis, collagen becomes susceptible to cleavage by collagenases. Collagenase cleaves all 3 alpha helical chains of native Types I, II and III collagens at a single locus by hydrolyzing the peptide bond following the Gly residue of the sequence: Gly 775-(Ile or Leu) 776-(Ala or Leu) 777 located approximately three-fourths of the chain length from each N-terminus Drug type: Approved. Biotech. Investigational. Drug category: Anti-Ulcer Agents. Topical"}},{"Collapsed":{"SuperCategory":"Structure","Id":"PATO_0001478"}},{"Collateral sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","Synonym":["Sulcus collateralis"],"CurationStatus":"uncurated","NeuronamesID":"28","Umlscui":"C0228226","SuperCategory":"Sulcus","Id":"birnlex_1480","Is part of":"Cerebral cortex","Species":"Human","DefinitionPMID":"22512258","Definition":"Sulcus that runs from the anterior part of the human medial temporal lobe along the parahippocampal gyrus into the occipital lobe"}},{"Collation Flag":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2000_0063","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149713","Has role":"Non-imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Flag indicating that the films of the print request shall be collated."}},{"Collection":{"CurationStatus":"uncurated","SuperCategory":"Entity","Id":"nlx_158007","Has role":"CINERGI Resource Descriptor","Keywords":"Resource:CINERGI","DefiningCitation":"http://www.w3.org/ns/prov#Collection","Definition":"A collection is an entity that provides a structure to some constituents, which are themselves entities. These constituents are said to be member of the collections. (PROVO)"}},{"Colliculus Inferior GABAergic Principal Cell":{"DefiningCriteriaPMID":"19889997","Located in":"inferior colliculus","Located_in":"Inferior colliculus,","BranchingMetrics":"stellate","Synonym":"large GABAergic (LG) neurons","CurationStatus":"uncurated","AxonDiameterPMID":"9310410","PublicationLink":"http://www.ncbi.nlm.nih.gov/sites/entrez?Db","LocationOfAxonArborization":"medial geniculate body","CellSomaSize":"Large soma","PMID":"8755593","SpineDensityOnDendrites":"Smooth","MolecularConstituentsPMID":"19340418","DefiningCriteria":"large soma with dense VGLUT2+ endings","Neurotransmitter":"GABA","CellSomaShapePMID":"7909821","SuperCategory":"Neuron","AxonTract":"Brachium of the inferior colliculus","CellSomaShape":"Multipolar","Species":"Mammal","DefiningCitation":["Winer et al"],"AxonProjectionLaterality":"ipsilateral","DendriteLocation":"Inferior colliculus","MolecularConstituents":"Parvalbumin","AxonMyelinationPMID":"9310410","NeurotransmitterReceptors":["Glutamate-gated cationic channel","GABA-gated anionic channel"],"Has role":"Principal neuron role","DendriteLocationPMID":"19889997","SubcellularSynapticTargetPMID":"11036215","CellularSynapticTargetPMID":"11036215","CellSomaSizePMID":"19889997","AxonTractPMID":"9310410","AxonDiameter":"mean: 1.63 micrometer","OriginOfAxon":"soma","CellularSynapticTarget":"medial geniculate body stellate cell","NeurotransmitterPMID":"8755593","SynonymPMID":"22855671","LocatedInPMID":"19889997","SubcellularSynapticTarget":"dendrite","Id":"nlx_60854","AxonMyelination":"myelinated","HasRolePMID":"19889997","DefinitionPMID":"22855671","Definition":"Winer and colleagues (1996) first described that GABAergic neurons project to the medial geniculate body in cat. Peruzzi et al. (1997) showed that the cell type is also found in rats, and  sends action potentials more rapidly than glutamatergic IC neurons. Ito and colleagues (2009) showed that the cell type is the largest neuron in the IC and receives dense VGLUT2-positive axosomatic terminals on the cell body. Other cell types such as glutamatergic neurons and small GABAergic neurons do not have such endings."}},{"Colliculus inferior intrinsic cell":{"DefiningCriteriaPMID":"19889997","Located in":"Inferior colliculus","Located_in":"Inferior colliculus,","Synonym":"small GABAergic (SG) neurons","CurationStatus":"uncurated","PublicationLink":"http://www.ncbi.nlm.nih.gov/pubmed/19889997","CellSomaSize":"Small soma","PMID":"19889997","Created":"2007-09-05","MolecularConstituentsPMID":"19340418","DefiningCriteria":"small soma size and absense of excitatory axosomatic endings","Neurotransmitter":"GABA","SuperCategory":"Neuron","CellSomaShape":"Other","Species":"Vertebrata","DefiningCitation":["Ito et al."],"DendriteLocation":"inferior colliculus","MolecularConstituents":"Parvalbumin","Has role":"Intrinsic neuron role","NeurotransmitterReceptors":["Glutamate-gated cationic channel","GABA-gated anionic channel"],"CellSomaSizePMID":"19889997","OriginOfAxon":"soma","SynonymPMID":"22855671","NeurotransmitterPMID":"19889997","LocatedInPMID":"19889997","Id":"nifext_83","HasRolePMID":"22855671","DefinitionPMID":"19889997","Definition":"It is not established that there are \"pure\" local interneurons of which axons are restricted in the inferior colliculus (IC). However, even after a large injection of retrograde tracer into the medial geniculate body (MGB), a main target of IC projection, most small GABAergic neurons, which lack dense excitatory axosomatic terminals, were not labeled with the tracer. On the other hand, large GABAergic neurons send axons to the MGB."}},{"Colliculus inferior principal cell":{"AxonProjectionLateralityPMID":"6201779","Located in":"Inferior colliculus","Located_in":"Inferior colliculus,","BranchingMetrics":"other","Synonym":"Inferior colliculus principal neuron","CurationStatus":"uncurated","AxonDiameterPMID":"9310410","PublicationLink":"http://www.ncbi.nlm.nih.gov/pubmed/6201779","LocationOfAxonArborization":"medial geniculate body","CellSomaSize":"Medium soma","PMID":"6201779","Created":"2007-09-05","MolecularConstituentsPMID":"21165977","Neurotransmitter":"Glutamate","LocationOfAxonArborizationPMID":"6201779","SuperCategory":"Neuron","AxonTract":"Brachium of the inferior colliculus","CellSomaShape":"Oval","Species":"Vertebrata","DefiningCitation":["Oliver"],"AxonProjectionLaterality":"ipsilateral","DendriteLocation":"inferior colliculus","MolecularConstituents":"Vesicular glutamate transporter 2","AxonMyelinationPMID":"9310410","Has role":"Principal neuron role","DendriteLocationPMID":"6201779","SubcellularSynapticTargetPMID":"11036215","CellularSynapticTargetPMID":"11036215","CellSomaSizePMID":"6201779","AxonTractPMID":"9310410","AxonDiameter":"mean: 0.86 micrometer (including GABAergic axons)","OriginOfAxon":"soma","CellularSynapticTarget":["medial geniculate body tufted cell"],"NeurotransmitterPMID":"21165977","SynonymPMID":"    ","LocatedInPMID":"6201779","SubcellularSynapticTarget":"dendrite","Id":"nifext_82","BranchingMetricsPMID":"6201779","AxonMyelination":"myelinated","HasRolePMID":"6201779","DefinitionPMID":"6201779","Definition":"Around 80% of neurons in the inferior colliculus (IC) is glutamatergic (Ito and Oliver, 2012). They express vesicular glutamate transporter (VGLUT) 2 but not VGLUT1 or VGLUT3 (Ito and Oliver, 2010, 2011). Their main target is the medial geniculate body although they send axons to most auditory brainstem nuclei. Since majority of IC neurons are disc-shaped, which extend their dendrite parallel to isofrequency laminae (Oliver, 1984), majority of glutamatergic neurons are likely to be disc-shaped. Stellate neurons, which are less common and extend dendrite perpendicular to isofrequency laminae, also project to the medial geniculate body (Oliver, 1984)."}},{"Colliculus superior deep vertical fusiform cell":{"Located in":"Superior colliculus","Located_in":"Superior colliculus intermediate gray layer","Synonym":"deep vertical fusiform cell","CurationStatus":"uncurated","Pages":"418-35","JournalVolume":"158","Curator":"Mihail Bota","Authors":["Langer TP"],"Title":"The upper layers of the superior colliculus of the rat: a Golgi study.","PMID":"4615112","EditorialNote":"Appended Superior colliculus to name given by contributor to conform to Neurolex NIF naming conventions","PublicationDate":"1974","SuperCategory":"Neuron","PublicationName":"J Comp Neurol.","Id":"BAMSC1122","JournalNumber":"4","Species":"Vertebrata","DefiningCitation":"Langer and Lund 1974","Definition":"Deep vertical fusiform cells have cell bodies about 20 micrometers wide and their dendrites extend from the upper margin of the zone of vertical cells to the depth of the zone of optic fibers perhaps even deeper. The superficial and deep fields are usually notably different in the manner in which the dendrites branch and spread, the over to all size of the fields, the shapes of the fields, the type and density of spines, and the caliber of the dendrites."}},{"Colliculus superior intermediate vertical fusiform cell":{"Located in":"Superior colliculus","Located_in":"Superior colliculus optic layer","Synonym":"intermediate vertical fusiform cell","CurationStatus":"uncurated","Pages":"418-35","JournalVolume":"158","Curator":"Mihail Bota","Authors":["Langer TP"],"Title":"The upper layers of the superior colliculus of the rat: a Golgi study.","PMID":"4615112","EditorialNote":"Appended Superior colliculus to name given by contributor to conform to Neurolex NIF naming conventions","PublicationDate":"1974","SuperCategory":"Neuron","PublicationName":"J Comp Neurol.","Id":"BAMSC1121","JournalNumber":"4","Species":"Vertebrata","DefiningCitation":"Langer and Lund 1974","Definition":"The intermediate vertical fusiform cells have cell bodies 12 to 18 micrometers in diameter in the upper portion of the zone of vertical cells and their dendritic fields extend from the collicular surface to the deep margin of the zone of vertical cells (fig. 12b, 13). Intermediate vertical fusiform cells most often have a superficial field with relatively fewer spines, straighter, more even caliber dendrites that branch less often but more equally than those in the deep field of the same cell (figs. 12b, 13)."}},{"Colliculus superior inverted pyramidal cell":{"Located in":"Superior colliculus","Located_in":"Superior colliculus superficial gray layer","Synonym":"inverted pyramidal cell","CurationStatus":"uncurated","Pages":"418-35","JournalVolume":"158","Curator":"Mihail Bota","Authors":["Langer TP"],"Title":"The upper layers of the superior colliculus of the rat: a Golgi study.","PMID":"4615112","EditorialNote":"Appended Superior colliculus to name given by contributor to conform to Neurolex NIF naming conventions","PublicationDate":"1974","SuperCategory":"Neuron","PublicationName":"J Comp Neurol.","Id":"BAMSC1124","JournalNumber":"4","Species":"Vertebrata","DefiningCitation":"Langer and Lund 1974","Definition":"The inverted pyramidal cell is similar to the pyramidal cell except that the cell body lies within the deep portion of the zone of horizontal cells. The superficial field is a circumsomatic field and the deep field is elongated to reach into the deeper portion of the zone of vertical cells. The cell body is about the size of an intermediate vertical fusiform cell soma. The axon is similar, but more apt to have collaterals to the superficial zones. Inverted pyramidal cells fall within the definition of the narrow field vertical cells."}},{"Colliculus superior piriform cell":{"Located in":"Superior colliculus stratum opticum","Synonym":["piriform cell"],"CurationStatus":"uncurated","Pages":"418-35","JournalVolume":"158","Curator":"Mihail Bota","Authors":["Langer TP"],"Title":"The upper layers of the superior colliculus of the rat: a Golgi study.","PMID":"4615112","EditorialNote":"Appended Superior colliculus to name given by contributor to conform to Neurolex NIF naming conventions","PublicationDate":"1974","SuperCategory":"Neuron","PublicationName":"J Comp Neurol.","Id":"BAMSC1117","JournalNumber":"4","Species":"Vertebrata","DefiningCitation":"Langer and Lund 1974","Definition":"The piriform cells have ovoid or cup shaped cell bodies, 10 to 15 micrometers in diameter, located within a narrow lamina along the deep margin of the zone of horizontal cells. The restriction of the piriform cell somata to the boundary between the zone of horizontal cells and the zone of vertical cells is remarkably accurate and consistent. The piriform cells give rise to 2 to 5 dendrites from the superficial surface, which course through the zone of horizontal cells to terminate just beneath the surface. As the ascending dendrites approach the surface they branch more frequently, almost always by equipartition, to form a complicated intermingling bouquet of slowly tapering dendrites, 150 to 350 micrometers in width and slightly less than 200 micrometers in depth. The axon most frequently takes its origin from the base of the soma, but sometimes it arises from one of the low order dendrites. From its origin the axon runs immediately down through the zone of vertical cells, occasionally with collaterals which may arborize within the superficial laminae. The axon is thin and smooth, occasionally with en passant varicosities."}},{"Colliculus superior pyramidal cell":{"Located in":["Superior colliculus"],"Synonym":"pyramidal cell","CurationStatus":"uncurated","Pages":"418-35","JournalVolume":"158","Curator":"Mihail Bota","Authors":["Langer TP"],"Title":"The upper layers of the superior colliculus of the rat: a Golgi study.","PMID":"4615112","EditorialNote":"Appended Superior colliculus to name given by contributor to conform to Neurolex NIF naming conventions","PublicationDate":"1974","SuperCategory":"Neuron","PublicationName":"J Comp Neurol.","Id":"BAMSC1123","JournalNumber":"4","Species":"Vertebrata","DefiningCitation":"Langer and Lund 1974","Definition":"Pyramidal cells are similar to vertical fusiform cells in most respects. They have a vertically elongated cell body, about 15 micrometers in transverse diameter, in the deeper half of the zone of vertical cells. The dendritic field is narrow and cylindrical, 100 to 250 micrometer in diameter, and extends from the upper margin of the zone of horizontal cells to the lower margin of the zone of vertical cells, about 500 micrometers. Rather than having superficial and deep fields, the pyramidal cell has the deep field reduced to a circumsomatic field, or a diminuitive basal field, and the superficial field is relatively elongated to accord with the deeper cell body. Pyramidal cells are usually multipolar, with one or two thick apical dendrites, which branch several times on the way to the surface, particularly in the upper portion of the zone of horizontal cells, and several smaller dendrites which form a small field about the cell body. It is of interest that smooth pyramidal cells tend to have two primary dendrites, like smooth vertical fusiform cells. The axon takes its origin from the soma or a low order dendrite and runs down into the deep zones. It is smooth and thin, about like that of the vertical fusiform cells."}},{"Colliculus superior stellate neuron":{"Located in":"Superior colliculus","Synonym":"stellate neuron","CurationStatus":"uncurated","Pages":"418-35","JournalVolume":"158","Curator":"Mihail Bota","Has role":"Principal neuron role","Authors":["Langer TP"],"Title":"The upper layers of the superior colliculus of the rat: a Golgi study.","PMID":"4615112","EditorialNote":"Appended Superior colliculus to name given by contributor to conform to Neurolex NIF naming conventions","PublicationDate":"1974","SuperCategory":"Neuron","PublicationName":"J Comp Neurol.","Polarity":"Multipolar","Id":"BAMSC1129","JournalNumber":"4","Species":"Rat,","DefiningCitation":"Langer and Lund 1974","Definition":"The third major category of cells in the superior colliculus is the stellate cell. The cells are defined by the lack of overall orientation to the dendritic fields which extend symmetrically from the cell body. Stellate cells are multipolar with dendrites arising from any portion of the cell body. The dendrites may range anywhere from gnarled to radiate with the gnarled spiny cells most frequent in the zone of horizontal cells and the smooth radiate cells increasingly more frequent in the deeper zones until they are almost the only cell type in the zones below the stratum opticum. The dimensions of the cell bodies and dendritic fields are comparable to those of other cells in the same zone and the dendritic field is generally contained within the same zone as the cell body. The axons of stellate cells have both local and/or distant distributions and a morphology characteristic of intrinsic axons. As with all the other cell types, the axon may take its origin from the cell body or a low order dendrite."}},{"Colliculus superior type I ganglion cell":{"Located in":"Superior colliculus","Synonym":"type I ganglion cell","CurationStatus":"uncurated","Pages":"418-35","Comment":"Need to determine whether this should be listed as a synonym of piriform cell or if it is a separate class","JournalVolume":"158","Curator":"Mihail Bota","Authors":["Langer TP"],"Title":"The upper layers of the superior colliculus of the rat: a Golgi study.","PMID":"4615112","EditorialNote":"Appended Superior colliculus to name given by contributor to conform to Neurolex NIF naming conventions","PublicationDate":"1974","SuperCategory":"Neuron","PublicationName":"J Comp Neurol.","Id":"BAMSC1126","JournalNumber":"4","Species":"Rat","DefiningCitation":"Langer and Lund 1974","SpeciesPMID":"4615112","Definition":"Type I ganglion cells are the piriform cells."}},{"Colliculus superior wide field vertical cell":{"Located in":"Superior colliculus","Synonym":"wide field vertical cell","CurationStatus":"uncurated","Pages":"418-35","JournalVolume":"158","Curator":"Mihail Bota","Has role":"Principal neuron role","Authors":["Langer TP"],"Title":"The upper layers of the superior colliculus of the rat: a Golgi study.","PMID":"4615112","EditorialNote":"Appended Superior colliculus to name given by contributor to conform to Neurolex NIF naming conventions","PublicationDate":"1974","SuperCategory":"Neuron","PublicationName":"J Comp Neurol.","Id":"BAMSC1125","JournalNumber":"4","Species":"Rat,","DefiningCitation":"Langer and Lund 1974","Definition":"There are two similar populations in the group of wide field vertical cells. The first lies in the deep margin of the zone of vertical cells where it looks very similar to the piriform cells relative to the zone of horizontal cells. Cajal called these the ovoid or triangular cells. The second population has its cell bodies distributed primarily to the upper portion of the zone of optic fibers. Cajal called these triangular or stellate cells. Cajal's nomenclature is rather bulky and, though descriptive, somewhat confusing because stellate cells are a distinct cell type in the nomenclature of this paper and triangular occurs in both names. For reasons developed below, the ovoid or triangular cells or wide field cells of the zone of vertical cells will be called Type II ganglion cells and the triangular or stellate cells or wide field cells of the zone of optic fibers will be called Type III ganglion cells. Type I ganglion cells are the piriform cells. Collator note: we assumed this class of neurons as projection neurons, because at least several subpopulations project to visually related areas. See Sefton et al., 2005; Mason and Groos, 1981; Mackay to Sim et al. 1983; Okoyama and Kudo, 1987)."}},{"Collimator Left Vertical Edge":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1702","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149714","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Required if Collimator Shape (0018,1700) is RECTANGULAR. Location of the left edge of the rectangular collimator with respect to pixels in the image given as column."}},{"Collimator Lower Horizontal Edge":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1708","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149715","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Required if Collimator Shape (0018,1700) is RECTANGULAR. Location of the lower edge of the rectangular collimator with respect to pixels in the image given as row. "}},{"Collimator Right Vertical Edge":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1704","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149716","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Required if Collimator Shape (0018,1700) is RECTANGULAR. Location of the right edge of the rectangular collimator with respect to pixels in the image given as column."}},{"Collimator Shape":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1700","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149717","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Shape(s) of the collimator."}},{"Collimator Type":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1181","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149718","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Collimator type. Required if a sequence Item is present."}},{"Collimator Upper Horizontal Edge":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1706","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149719","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Required if Collimator Shape (0018,1700) is RECTANGULAR. Location of the upper edge of the rectangular collimator with respect to pixels in the image given as row."}},{"Color":{"SuperCategory":"Optical quality","Id":"PATO_0000014","Definition":"A composite chromatic quality composed of hue, saturation, and intensity parts."}},{"Color brightness":{"Synonym":["color lightness","color intensity"],"Comment":["Color brightness refers to the intensity"],"SuperCategory":"Optical quality","Id":"PATO_0000016","Definition":"A scalar optical property that is the intensity, value or amount of perceived light."}},{"Color hue":{"SuperCategory":"Chromatic property","Id":"PATO_0000015","Definition":"A chromatic scalar-circular quality inhering in an object that manifests in an observer by virtue of the dominant wavelength of visible light; may be subject to the fiat divisions, typically into 7 or 8 spectra."}},{"Color Image Printing Flag":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2000_0062","SuperCategory":"DICOM term","Id":"nlx_149720","Has role":"Non-imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD (retired)."}},{"Color pattern":{"SuperCategory":"Chromatic property","Id":"PATO_0000019","Definition":"A chromatic property that is the relative position of different hues or degrees of saturation."}},{"Color saturation":{"Comment":"Color saturation refers to the amount of white light or gray paint mixed in with the hue (single wavelength) and is a measure of color purity.","SuperCategory":"Chromatic property","Id":"PATO_0000017","Definition":"A scalar chromatic property that is the degree of purity of perceived light."}},{"Color trails test":{"Created":"4/13/2011 16:38","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00912","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Color_trails_test","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146136","Definition":"No definition submitted yet."}},{"Color-discrimination task":{"Created":"3/15/2011 9:24","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00812","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Color-discrimination_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146034","Definition":"is a behavioral task where a subject is to make specific responses when presented with particular colors.  The responses to the various colors are then evaluated to see if the subject was able to discern between different colors."}},{"Color-word stroop task":{"Created":"12/4/2009 11:52","CurationStatus":"uncurated","Contributor":"System Administrator","CAO_Id":"CAO_00707","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Color-word_stroop_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145923","Definition":"A task in which single words (including names of colors) are presented in colored ink, and the subject is asked to name the color of the ink as quickly as possible. The ink color may either match or conflict with the color name. Accuracy and response time are measured."}},{"Colored":{"Synonym":"Pigmented","SuperCategory":"Relative color","Id":"PATO_0000336","Definition":"Having color."}},{"Colorless":{"Synonym":"Unpigmented","SuperCategory":"Relative color","Id":"PATO_0000337","Definition":"Lacking color."}},{"Column Angulation":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1450","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149721","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Angle of the X-Ray beam in degree relative to an orthogonal axis to the detector plane. Positive values indicate that the tilt is towards the head of the table. Note: The detector plane is assumed to be parallel to the table plane."}},{"Columnar":{"CurationStatus":"uncurated","SuperCategory":"Shape","Id":"PATO_0002063","Definition":"A shape inhering in a bearer by virtue of the bearer's being elongated and cylindrical."}},{"Columns":{"ValueRepresentation":"US","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_0011","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149722","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of columns in the image."}},{"Coma":{"Created":"2007-10-08","Synonym":["Pseudocoma","Comatose"],"CurationStatus":"uncurated","SuperCategory":"Consciousness Disorder","Id":"birnlex_12773","Definition":"A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.  This includes Feigned coma or psychogenic coma. These patients appear comatose (i.e., unresponsive, unarousable, or both) but have no structural lesion, metabolic or toxic disorder (MeSH)."}},{"Combat Disorder":{"Synonym":["War Neurosis"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Traumatic Stress Disorder","Id":"birnlex_12678","Definition":"Neurotic reactions to unusual, severe, or overwhelming military stress (MeSH)."}},{"Comment":{"EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","Synonym":"Note","Created":"2007-10-10","CurationStatus":"graph_position_temporary","SuperCategory":"Narrative object","Id":"birnlex_11039"}},{"Comments":{"RelatedTo":"BIRN-INCF Derived Data Project","SuperCategory":"DICOM term","Id":"nlx_149723","Is part of":"Resource:DICOM standard","Definition":"no def needed"}},{"Comments on Radiation Dose":{"ValueRepresentation":"ST","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_0310","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149724","Has role":"Imaging procedure attribute","Is part of":"Resource:DICOM standard","Value_Representation":"ST","Definition":"User-defined comments on any special conditions related to radiation dose encountered during this Performed Procedure Step."}},{"Comments on the Performed Procedure Step":{"ValueRepresentation":"ST","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_0280","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149725","Has role":"Imaging procedure attribute","Is part of":"Resource:DICOM standard","Value_Representation":"ST","Definition":"User-defined comments on the Performed Procedure Step."}},{"Comments on the Scheduled Procedure Step":{"ValueRepresentation":"LT","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_0400","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149726","Has role":"Imaging procedure attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LT","Definition":"User-defined comments on the Scheduled Procedure Step. Note: The Comments attribute is intended to transmit non-structured information, which can be displayed to the operator of the Modality."}},{"Commercial license":{"Created":"2007-10-11","Synonym":["For purchase","License purchase required"],"CurationStatus":"uncurated","SuperCategory":"Closed-source license","Id":"birnlex_2353","Xref":"NITRC_610","Definition":"A legal instrument governing the usage or redistribution of software. <BR>NITRC definition"}},{"Commercial Organization":{"CurationStatus":"uncurated","SuperCategory":"Organization","Id":"nlx_152342"}},{"Commissural nucleus of thalamus of MAP2004":{"EditorialNote":"A brief review of Pub Med suggests that this term isn't used very much; thus I'm not creating a general brain category for it.","CurationStatus":"graph position temporary","PartiallyOverlapsWith":["Central medial nucleus"],"SuperCategory":"MAP2004 parcel","Curator":"Maryann Martone,","Id":"nlx_144260","ParcellationScheme":"MAP2004 parcellation scheme","Species":"Human,","Definition":"Part of central medial thalamic nucleus of thalamus"}},{"Commissural nucleus of the solitary tract":{"Synonym":"commissural nucleus tractus solitarius","SynonymPMID":"10657035","CurationStatus":"uncurated","PartiallyOverlapsWith":"Solitary nucleus commissural part of PHT00","SuperCategory":"Regional part of brain","Id":"nlx_144259","ParcellationScheme":["Paxinos"]}},{"Commissural nucleus of vagus nerve":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":"nucleus of inferior commisure","NeuronamesID":"751","CurationStatus":"uncurated","Umlscui":"C0175528","SuperCategory":"Regional part of brain","Id":"birnlex_2639","Is part of":"Medulla oblongata","Abbrev":"Cm10"}},{"Commissure":{"CurationStatus":"uncurated","SuperCategory":"Regional part of nervous system","Id":"nlx_110","Has role":"CUMBO term","Definition":"White matter fiber bundle that crosses the midline of the brain or spinal cord, that connects similar structures on both sides (Heimer, L. The Human Brain, 2nd ed., 1995, pg 6)."}},{"Commissure of fornix":{"Synonym":["dorsal hippocampal commissure","fornical commissure"],"CurationStatus":"uncurated","Umlscui":"C0228287","SuperCategory":"Commissure","Id":"birnlex_746","Is part of":"Fornix","Abbrev":"dhc"}},{"Commissure of inferior colliculus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"472","CurationStatus":"uncurated","Umlscui":"C0152367","SuperCategory":"Commissure","Id":"birnlex_935","Is part of":["Inferior colliculus"],"Abbrev":"cic"}},{"Commissure of superior colliculus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","CurationStatus":"uncurated","NeuronamesID":"466","Umlscui":"C0152366","SuperCategory":"Commissure","Id":"birnlex_1073","Is part of":["White matter"],"Abbrev":"csc"}},{"Common data element":{"CurationStatus":"uncurated","SuperCategory":"Standard specification","Id":"C19984","DefiningCitation":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C19984","Definition":"Data terms or concepts that have been determined to be identical between projects or contexts (from NCI Thesaurus)"}},{"Common spiny lobster":{"Synonym":"Palinurus elephas","Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998246","SuperCategory":"Palinurus","Id":"birnlex_144"}},{"Communication function":{"Created":"2007-08-22","CurationStatus":"uncurated","SuperCategory":"Behavioral system function","Id":"birnlex_1870"}},{"Community building portal":{" limit":"1000","Synonym":"Social Network","CurationStatus":"uncurated","SuperCategory":"Portal"," format":"CSV","Id":"nlx_inv_090905","Xref":"NITRC_521","Definition":"An environment that represents community involvement and participation to express and exchange ideas regarding a specific topic. (NITRC)"}},{"Compatibility":{"Comment":"Needs redefined or obsoleted. Is this the same as genetic incompatibility? Moved to organismal quality","SuperCategory":"Organismal quality","Id":"PATO_0000021","Definition":"A quality of having or lacking the ability to harmoniously coexist."}},{"Compatible":{"SuperCategory":"Compatibility","Id":"PATO_0000344","Definition":"A quality of being capable of harmonious coexistence."}},{"Compensator Columns":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00E8","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149727","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of columns in the compensator. Required if Compensator Sequence (300A,00E3) is sent."}},{"Compensator Divergence":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_02E0","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149728","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Indicates presence or absence of geometrical divergence of the compensator."}},{"Compensator ID":{"ValueRepresentation":"SH","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00E5","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149729","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"User-supplied identifier for compensator."}},{"Compensator Mounting Position":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_02E1","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149730","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Indicates on which side of the Compensator Tray the compensator is mounted."}},{"Compensator Number":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00E4","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149731","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Identification number of the Compensator. The value of Compensator Number (300A,00E4) shall be unique within the Beam in which it is created. Required if Number of Compensators (300A,00E0) is non-zero."}},{"Compensator Pixel Spacing":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00E9","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149732","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Physical distance (in mm) between the center of each pixel projected onto machine isocentric plane. Specified by a numeric pair - adjacent row spacing (delimiter) adjacent column spacing. Required if Compensator Sequence (300A,00E3) is sent."}},{"Compensator Position":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00EA","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149733","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"The x and y coordinates of the upper left hand corner (first pixel transmitted) of the compensator, projected onto the machine isocentric plane in the IEC BEAM LIMITING DEVICE coordinate system (mm). Required if Compensator Sequence (300A,00E3) is sent."}},{"Compensator Rows":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00E7","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149734","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of rows in the compensator. Required if Compensator Sequence (300A,00E3) is sent."}},{"Compensator Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00E3","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149735","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Introduces sequence of treatment compensators. Required if Number of Compensators (300A,00E0) is non-zero. One or more items may be included in this sequence."}},{"Compensator Thickness Data":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00EC","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149736","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"A data stream of the pixel samples which comprise the compensator, expressed as thicknesses (in mm). The order of pixels sent is left to right, top to bottom, i.e., the upper left pixel is sent first followed by the remainder of the first row , followed by the leftmost pixel of the second row."}},{"Compensator Transmission Data":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00EB","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149737","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"A data stream of the pixel samples which comprise the compensator, expressed as broad-beam transmission values (between 0 and 1) along a ray line passing through the pixel, at the beam energy specified by the Nominal Beam Energy (300A,0114)."}},{"Compensator Type":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3004_00EE","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149738","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Type of compensator (if any)."}},{"Compiler":{"Created":"2007-03-07","CurationStatus":"uncurated","SuperCategory":"Software development tool","Id":"birnlex_2225","Definition":"A resource that provides a computer program (or set of programs) that transforms source code written in a computer language (the source language) into another computer language (the target language, often having a binary form known as object code). The most common reason for wanting to transform source code is to create an executable program. A \\\\u201ccompiler\\\\u201d is primarily used for programs that translate source code from a high-level programming language to a lower level language (e.g., assembly language or machine language), and is likely to perform many or all of the following operations: lexical analysis, preprocessing, parsing, semantic analysis, code generation, and code optimization."}},{"Completion Flag":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_A491","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149739","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"The estimated degree of completeness of this SR Document with respect to externally defined criteria in a manner specified in the Conformance Statement. Note: It may be desirable to make these criteria adaptable to local policies or user decisions."}},{"Completion Flag Description":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_A492","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149740","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Explanation of the value sent in Completion Flag (0040,A491)."}},{"Complex":{"SuperCategory":"Complexity","Id":"PATO_0001504","Definition":"A complexity quality inhering in a bearer by virtue of its being intricate and compounded."}},{"Complex Image Component":{"ValueRepresentation":"cs","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_9208","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149741","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"cs","Definition":"Representation of complex data of frames in the SOP Instance."}},{"Complex laminated body":{"CurationStatus":"uncurated","SuperCategory":"Laminated Body","Id":"nlx_151681","Abbrev":"CLB","DefinitionPMID":"7188322","Definition":"Cytoplasmic organelles described in some lateral geniculate neurons composed of sheets of tubules (25 nm in diameter) separated by dense material (about 75 nm wide), which together with the tubules whorl give a structure resembling a 'finger-print '. In 2 um thick Epon-Araldite sections stained with methylene-blue and Azure II, CLBs are dark blue, round or oval bodies of the same order of size as the nucleolus."}},{"Complex Partial Epilepsy":{"Synonym":"Complex Partial Seizure Disorder","Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Partial Epilepsy","Id":"birnlex_12728","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"A disorder characterized by recurrent partial seizures marked by impairment of cognition. During the seizure the individual may experience a wide variety of psychic phenomenon including formed hallucinations, illusions, deja vu, intense emotional feelings, confusion, and spatial disorientation. Focal motor activity, sensory alterations and AUTOMATISM may also occur. Complex partial seizures often originate from foci in one or both temporal lobes. The etiology may be idiopathic (cryptogenic partial complex epilepsy) or occur as a secondary manifestation of a focal cortical lesion (symptomatic partial complex epilepsy) (MeSH)."}},{"Complex Regional Pain Syndrome":{"Synonym":"Autonomic Hyperreflexia","Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Autonomic Nervous System Disease","Curator":"Bill Bug","Id":"birnlex_12583","DefiningCitation":"Pain 1995 Oct;63(1):127-33"}},{"Complex span test":{"Created":"4/15/2011 8:57","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00916","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Complex_span_test","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146140","Definition":"No definition submitted yet."}},{"Complexity":{"Comment":"TODO: obsolete this","SuperCategory":"Quality of a single physical entity","Id":"PATO_0001502","Definition":"A monadic quality of continuant inhering in a bearer by virtue of its being intricate and compounded."}},{"Composite part spanning multiple base regional parts of brain":{"EditorialNote":"Note that many of these composite structures could be created by simply defining them as the union of their constituent parts - e.g., Medial_lemniscus ","Created":"2006-10-07","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1304"}},{"Composition":{"Comment":["For example calcium composition (which may inhere in bone)"],"SuperCategory":"Quality of a single physical entity","Id":"PATO_0000025","Definition":"A monadic quality of continuant inhering in an object by virtue of the quantities or relative ratios of subparts of the inhering entity."}},{"Compound acidity":{"SuperCategory":"Acidity","Id":"PATO_0001427","Definition":"A concentration quality inhering in a compound by virtue of its tendency to act as a hydron donor."}},{"Compressed":{"SuperCategory":"Structure","Id":"PATO_0001840"}},{"Compression Code":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_0060","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149742","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD (retired)."}},{"Compression Force":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_11A2","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149743","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"The compression force applied to the body part during exposure, measured in Newtons."}},{"Computational biology":{"RelatedTo":["Mathematics"],"CurationStatus":"uncurated","SuperCategory":"Scientific_discipline","Id":"nlx_inv_100622","Definition":"From BRO: is an interdisciplinary field that applies the techniques of computer science, applied mathematics and statistics to address biological problems. The main focus lays on developing mathematical modeling and computational simulation techniques. By these means it addresses scientific reaserch topics with their theoretical and experimental questions without a laboratory. - definition adapted from WikipediaNote: this class may need to be collapsed with bioinformatics -AB"}},{"Computational hosting":{"CurationStatus":"uncurated","SuperCategory":"Service resource","Id":"nlx_res_090925","Definition":"A computational environment that allows a database, database management system and / or complete application software to be installed on a host's hardware to perform storage and computation tasks."}},{"Computational Linguistics":{"CurationStatus":"uncurated","SuperCategory":"Scientific discipline","Id":"nlx_149629","Definition":"Computational linguistics is an interdisciplinary field dealing with the statistical or rule-based modeling of natural language from a computational perspective. (from Wikipedia)"}},{"Computational model":{"Created":"2007-10-10","CurationStatus":"uncurated","SuperCategory":"Algorithm","Id":"birnlex_2300","Has role":"Electrophysiology concept","DefiningCitation":"ModelDB:58584"}},{"Computer Axial Tomography imaging assay":{"Synonym":["CT scan","CAT scan"],"CurationStatus":"uncurated","SuperCategory":"Imaging assay","Id":"nlx_144406","Has role":"Neuroimaging"}},{"Computer Axial Tomography imaging protocol":{"Created":"2007-10-09","Synonym":["CAT imaging protocol"],"CurationStatus":"uncurated","SuperCategory":"X-ray imaging protocol","Id":"birnlex_2268"}},{"Concatenation Frame Offset Number":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_9228","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149744","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"UL","Definition":"Offset of the first frame in a multi-frame image of a concatenation. Logical frame numbers in a concatenation can be used across all its SOP instances. This offset can be applied to the implicit frame number  to find the logical frame number in a concatenation."}},{"Concatenation UID":{"ValueRepresentation":"UI","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_9161","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149745","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"UI","Definition":"Identifier of all SOP Instances that belong to the same concatenation. Required if a group of multi-frame image SOP Instances within a Series are part of a Concatenation."}},{"Concave":{"SuperCategory":"Concavity","Id":"PATO_0001857","Definition":"A shape quality inhering in a bearer by virtue of curving inward."}},{"Concave 3-D shape":{"SuperCategory":"Shape","Id":"PATO_0002008","Definition":"A complete three dimensional shape in which there is a line connecting pairs of points on the object that lies outside of the object.  Or a shape with cavities.  Contrast: Concave."}},{"Concavity":{"SuperCategory":"Surface shape","Id":"PATO_0002005","Definition":"Surface shape that refers to the inward or outward curvature of the surface."}},{"Concentrated":{"SuperCategory":"Population Quality","Id":"sao4152363223","Definition":"Indicates a group of objects exist in a large amount in a particular area."}},{"Concentrated (PATO 0001159)":{"SuperCategory":"Concentration of","Id":"PATO_0001159","Definition":"A concentration which is relatively high."}},{"Concentration of":{"Synonym":"concentration","SuperCategory":"Quality of related physical entities","Id":"PATO_0000033","Definition":"A physical quality inhering in a substance by virtue of the amount of it there is mixed with another substance."}},{"Condensed (PATO 0001485)":{"SuperCategory":"Structure","Id":"PATO_0001485"}},{"Condensed Chromatin":{"Synonym":"heterochromatin","SuperCategory":"Chromatin","Id":"sao581845896","Definition":"Chromatin that are agglomerated into irregular masses, some attached to the nuclear envelope., A compact and highly condensed form of chromatin (Gene Ontology)."}},{"Condensed Mitochondrial Quality":{"SuperCategory":"Mitochondrial Quality","Id":"sao1152497626","Definition":"Morphological state characterized by a contracted matrix and expanded intracristal space;  observed experimentally when added ADP is used up (Mannella et al., 2001)."}},{"Conditional stop signal task":{"Created":"10/6/2010 15:11","CurationStatus":"uncurated","Contributor":"Russ Poldrack","CAO_Id":"CAO_00794","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Conditional_stop_signal_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146016","Definition":"A task in which an external stimulus signals the participant to interrupt an already-initiated motor response, but only for a subset of possible responses."}},{"Conditioned place preference paradigm":{"Synonym":["environmental place conditioning","conditioned place preference"],"CurationStatus":"uncurated","SuperCategory":"Behavioral conditioning paradigm","Id":"nlx_444","Definition":"A behavioral conditioning paradigm where the animal is presented with a positive stimulus (e.g., food or the effects of a drug of abuse) paired with placement in a distinct environment containing various cues (e.g., tactile, visual, and/or olfactory). When later tested in the normal state, measures of the preference for the compartments previously associated with the positive stimulus, e.g., approaches or amount of time spent in the compartment,  serves as an indicator of preference and a measure of reward learning. This paradigm is commonly used in animal studies to evaluate preferences for environmental stimuli that have been associated with a positive or negative reward. The technique is often used to determine the addiction potential of drugs. (adapted from Wikipedia)"}},{"Conditioning paradigm":{"CurationStatus":"uncurated","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_220"}},{"Conductance":{"CurationStatus":"uncurated","SuperCategory":"Quality of related physical entities","Id":"oen_0001224","Has role":"Electrophysiology concept","Definition":"Measure of how easily electricity flows along a certain path through an electrical element. The SI derived unit of conductance is the siemens."}},{"Conduction":{"Comment":"Examples could be heat or electricity or sound.","SuperCategory":"Physical quality","Id":"PATO_0001585","Definition":"The transmission of an entity through a medium."}},{"Conduction failure":{"RelatedTo":["Action potential"],"CurationStatus":"uncurated","SuperCategory":"Nerve conduction","Id":"oen_0001080","Has role":"Electrophysiology concept","DefiningCitation":"ModelDB:114307","Definition":"A failure of the action potential to propagate down the axon."}},{"Conductivity":{"CurationStatus":"uncurated","SuperCategory":"Quality of related physical entities","Id":"oen_0001223","Definition":"A physical quality inhering in a bearer by virtue of the bearer's ability to transmit of an entity through a medium."}},{"Conenzyme A":{"Synonym":["Cholinergic system","Coenzym A","COENZYME A","Koenzym A","Coenzyme A","Free conenzyme A"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"CHEBI:15346","Has role":["Coenzyme","Precursor"],"Is part of":"Cholinergic system","DefiningCitation":"CHEBI and  NCI Thesaurus","Abbrev":["HSCoA","CoASH","CoA"],"Definition":"A coenzyme containing pantothenic acid, adenosine 3-phosphate 5-pyrophosphate, and cysteamine; involved in the transfer of acyl groups, notably in transacetylations (NCI Thesaurus)."}},{"Conference proceeding":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Narrative resource","Id":"birnlex_2357"}},{"Confidentiality Code":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_1008","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149746","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Confidentiality Constraints on the Requested Procedure by the party filling the order."}},{"Confidentiality Constraint on Patient Data Description":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_3001","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149747","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Special indication to the modality operator about confidentiality of patient information (e.g., that he should not use the patients name where other patients are present)."}},{"Configuration":{"Comment":["Refers to a specialized arrangements of a cellular component or other structure that is characteristic of a given region","e.g."],"SuperCategory":"Anatomical Pattern","Id":"sao18717211"}},{"Configuration Information Description":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2010_0152","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149748","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LT","Definition":"TBD."}},{"Confocal imaging protocol":{"Synonym":["confocal imaging"],"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Light emitting optical imaging protocol","Id":"birnlex_2258"}},{"Confocal microscope":{"Created":"2006-05-15","CurationStatus":"uncurated","SuperCategory":"Optical microscope","Id":"birnlex_2029"}},{"Congenital Myasthenic Syndrome":{"Synonym":"Congenital Myasthenia Gravis","Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Neuromuscular Junction Diseases","Id":"birnlex_12597","DefiningCitation":"Arch Neurol 1999 Feb;56(2):163-7","Definition":"A heterogeneous group of disorders characterized by a congenital defect in neuromuscular transmission at the NEUROMUSCULAR JUNCTION. This includes presynaptic, synaptic, and postsynaptic disorders (that are not of autoimmune origin). The majority of these diseases are caused by mutations of various subunits of the nicotinic acetylcholine receptor ( RECEPTORS, NICOTINIC) on the postsynaptic surface of the junction (MeSH)."}},{"Congenital retinoschisis":{"Synonym":"Congenital retinoschisis disorder","Created":"2007-11-18","CurationStatus":"uncurated","Umlscui":"C0344551","SuperCategory":"Retinoschisis","Id":"birnlex_12829"}},{"Congested":{"SuperCategory":"Structure","Id":"PATO_0001836"}},{"Conical":{"SuperCategory":"Convex 3-D shape","Id":"PATO_0002021","Definition":"A convex 3-D shape that resembles a cone (a 3-D shape with a round cross section that tapers)."}},{"Conical papilla":{"Created":"2008-03-22","CurationStatus":"uncurated","Umlscui":["C0226967"],"SuperCategory":"Lingual papilla","Id":"birnlex_4103"}},{"CONICET":{"Synonym":["National Council of Scientific and Technical Research (Argentina)","Consejo Nacional de Investigaciones Cientficas y Tcnicas"],"CurationStatus":"curated","ExampleImage":["CONICET.PNG"],"SuperCategory":"Government granting agency","Id":"nlx_143717","Keywords":"Grant sponsor","DefiningCitation":"http://www.conicet.gov.ar/","Abbrev":"CONICET","Definition":"The CONICET is the leading organization dedicated to the promotion of science and technology in Argentina. It operates in four major areas* agricultural sciences, engineering and materials * life sciences and health * natural sciences * Social Sciences and HumanitiesThe National Scientific and Technical Research Council (Spanish: Consejo Nacional de Investigaciones Cientficas y Tcnicas, CONICET) is an Argentine government agency which directs and co-ordinates most of the scientific and technical research done in universities and institutes. It was established on 5 February 1958 by a decree of the national government. Its first director was Medicine Nobel Prize Bernardo A. Houssay.Nowadays, it is governed by a board completely independent from the federal government. It funds scientific research in three basic ways. First, CONICET gives grants for collective work to research teams of well-recognized scientists of every discipline (including social sciences and humanities). Secondly, it has a roll of 6,500 researches and 2,500 technicians as employees in different categories, from \"investigador asistente\" to \"investigador principal\". And thirdly, it grants scolarships for doctoral and post-doctoral studies to 8,500 young researches from Argentina and other countries. (Wikipedia)"}},{"Conivaptan":{"RelatedTo":["Vasopressin V1a receptor"],"Synonym":["Conivaptan hydrochloride","YM 087","YM-087","conivaptan"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00872","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00872","Definition":"Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). Pharmacology: Conivaptan is a nonpeptide, dual antagonist of arginine vasopressin (AVP) V1A and V2 receptors. The level of AVP in circulating blood is critical for the regulation of water and electrolyte balance and is usually elevated in both euvolemic and hypervolemic hyponatremia. The AVP effect is mediated through V2 receptors, which are functionally coupled to aquaporin channels in the apical membrane of the collecting ducts of the kidney. These receptors help to maintain plasma osmolality within the normal range. The predominant pharmacodynamic effect of conivaptan in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water. The pharmacodynamic effects of conivaptan include increased free water excretion (i.e., effective water clearance (EWC)) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality. Mechanism of action: Conivaptan is a dual AVP antagonist with nanomolar affinity for human V1A and V2 receptors in vitro. This antagonism occurs in the renal collecting ducts, resulting in aquaresis, or excretion of free water. Drug type: Approved. Investigational. Small Molecule. Drug category: Aquaresis promoters"}},{"Conjugated Estrogens":{"RelatedTo":"Estrogen receptor","Synonym":["Estrogens","Estrone Estrone Hydrogen Sulfate","Estrone Hydrogen Sulfate","Estrone Sodium Sulfate","Estrone Sulfate","Estrone Sulfate Sodium","Estrone Sulphate","Estrone-sulfate","Oestrone Sulphate","Sodium Estrone Sulfate","Conestoral","Evex","Hyhorin","Morestin","Par Estro","Premarin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00286","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00286","Definition":"Conjugated estrogens, a mixture of the water-soluble salts of sulfate esters from estrone, equilin, 17 -dihydroequilin, and other related steroids, may be derived from pregnant equine urine or yam and soy plants. Estrogens are important in the development and maintenance of the female reproductive system and secondary sex characteristics. Pharmacology: Conjugated estrogens, a mixture of the water soluble salts of sulfate esters from estrone, equilin, 17 -dihydroequilin, and other related steroids, may be derived from pregnant equine urine or yam and soy plants. Estrogens are important in the development and maintenance of the female reproductive system and secondary sex characteristics. They promote growth and development of the vagina, uterus, and fallopian tubes, and enlargement of the breasts. Indirectly, they contribute to the shaping of the skeleton, maintenance of tone and elasticity of urogenital structures, changes in the epiphyses of the long bones that allow for the pubertal growth spurt and its termination, growth of axillary and pubic hair, and pigmentation of the nipples and genitals. Decline of estrogenic activity at the end of the menstrual cycle can bring on menstruation, although the cessation of progesterone secretion is the most important factor in the mature ovulatory cycle. However, in the preovulatory or nonovulatory cycle, estrogen is the primary determinant in the onset of menstruation. Estrogens also affect the release of pituitary gonadotropins. The pharmacologic effects of conjugated estrogens are similar to those of endogenous estrogens. Mechanism of action: Estrogens enter the cells of responsive tissues (e.g., female organs, breasts, hypothalamus, pituitary) where they interact with a protein receptor, subsequently increasing the rate of synthesis of DNA, RNA, and some proteins. Estrogens decrease the secretion of gonadotropin-releasing hormone by the hypothalamus, reducing the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary. Drug type: Approved. Small Molecule. Drug category: Estrogens"}},{"Connected spatiotemporal region":{"Comment":["Definition: A space time region (span:SpaceTimeRegion) that has temporal and spatial dimensions such that all points within the spatiotemporal region are mediately or immediately connected to all other points within the same space time region (span:SpaceTimeRegion).","Examples: the spatial and temporal location of an individual organism's life"],"SuperCategory":"Spatiotemporal region","Id":"ConnectedSpatiotemporalRegion"}},{"Connected temporal region":{"Comment":["Examples: the 1970s years","the time from the beginning to the end of a heart attack","the time taken up by cellular meiosis"],"SuperCategory":"Temporal region","Id":"ConnectedTemporalRegion"}},{"Connectional specificity":{"CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001129","Definition":"The principle that neurons form specific functional interconnections, based on three anatomical observations: 1. there is no cytoplasmic continuity between nerve cells; 2. neurons do not connect indiscriminately to one another or form random networks; 3. each cell communicates with specific postsynaptic cells but not with others, and always at specialized sites (synapses)."}},{"Connectionist model":{"Synonym":"Neural net model","CurationStatus":"uncurated","SuperCategory":"\tComputational model","Id":"oen_0001130","Has role":"Electrophysiology concept","Definition":"A model of neural function with parallel and distributed processing components.  Also neural net model."}},{"Connectivity matrix":{"CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001079","DefiningCitation":"ModelDB:114660"}},{"Connexin":{"SuperCategory":"Protein","Id":"sao2056711309","Definition":"A group of homologous proteins which form the intermembrane channels of gap junctions. The connexins are the products of an identified gene family which has both highly conserved and highly divergent regions. The variety contributes to the wide range of functional properties of gap junctions (MSH)."}},{"Connexin 32":{"SuperCategory":"Connexin","Id":"sao376700953"}},{"Connexin 43":{"SuperCategory":"Connexin","Id":"sao1089608116","Definition":"A 43 kD peptide which is a member of the connexin family of gap junction proteins. Connexin 43 is a product of a gene in the alpha class of connexin genes (the alpha-1 gene). It was first isolated from mammalian heart, but is widespread in the body including the brain (MSH)."}},{"Connexon":{"Synonym":["hemichannel"],"Comment":"Some people do not use hemichannel as synonymous with connexon","SuperCategory":"Subcellular entity","Id":"sao445019788","Definition":"Assembly of 6 connexins into a hemichannel that forms one half of an intercellular channel.  The intercellular channel is formed by the dimerization of the two connexons.  In some cells, the hemichannel is active as a conduit between the cytoplasm and the extracellular space."}},{"Consciousness":{"RelatedTo":["thalamus","behavior"],"Created":"4/28/2011 12:18","EditorialNote":"NIF categorized this as a cognitive process. OK?","Synonym":"dynamic core","CurationStatus":"graph position temporary","Contributor":"Brenda Gregory","CAO_Id":"CAO_00223","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Consciousness","SuperCategory":"Cognitive process","Id":"nlx_func_1005001","Has role":"Cognitive Atlas Concept","Definition":"the quality or state of being aware especially of something within oneself; the state or fact of being conscious of an external object, state, or fact; the state of being characterized by sensation, emotion, volition, and thought; the totality of conscious states of an individual; the normal state of conscious life,(regained consciousness); the upper level of mental life of which the person is aware as contrasted with unconscious processes."}},{"Consciousness Disorder":{"Created":"2007-10-08","Synonym":["Depressed Level of Consciousness"],"CurationStatus":"uncurated","Comment":["We have several types of altered states of consciousness","e.g.","unconsciousness"],"SuperCategory":"Nervous system disease","Curator":"Bill Bug","Id":"birnlex_12771","Definition":"Organic mental disorders in which there is impairment of the ability to maintain awareness of self and environment and to respond to environmental stimuli. Dysfunction of the cerebral hemispheres or brain stem RETICULAR FORMATION may result in this condition (MeSH"}},{"Consistency":{"SuperCategory":"Physical quality","Id":"PATO_0000037","Definition":"A physical quality that inheres in a continuant by virtue of density, firmness, or viscosity."}},{"Consortium":{"CurationStatus":"uncurated","SuperCategory":"Organization portal","Id":"nlx_158146","DefiningCitation":"http://vivoweb.org/ontology/core#Consortium","Definition":"Independent organizations formally working together toward a common goal, under an expressed agreement. (VIVO)"}},{"Conspicuous":{"SuperCategory":"Conspicuousness","Id":"PATO_0000463","Definition":"A quality inhering in a bearer by virtue of its being clearly visibile."}},{"Conspicuousness":{"Comment":["This term was created as a grouping term for the 2 terms \"conspicuous\" and \"inconspicuous\". However"],"SuperCategory":"Qualitative","Id":"PATO_0001998","Definition":"A quality inhering in a bearer by virtue of its visibility."}},{"Constant-pressure calorimetry instrument":{"Synonym":"Constant-pressure calorimeter","Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Calorimetry instrument","Id":"birnlex_2424"}},{"Constant-volume calorimetry instrument":{"Synonym":"Constant-volume calorimeter","Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Calorimetry instrument","Id":"birnlex_2425"}},{"Constitutional part of cell":{"Created":"2006-09-07","CurationStatus":"uncurated","SuperCategory":"Anatomical_entity","Id":"birnlex_10"}},{"Constraint Weight":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0021","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149749","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Relative importance of satisfying constraint, where high values represent more important constraints."}},{"Constricted":{"SuperCategory":"Structure","Id":"PATO_0001847"}},{"Consumption quality":{"Synonym":"propensity to consume","SuperCategory":"Quality of related processes","Id":"PATO_0000187","Definition":"A relational quality of occurrent inhering in a bearer by virtue of its ability to consume a resource."}},{"Contact Site":{"SuperCategory":"Mitochondrial Site","Id":"sao447856407","Definition":"Sites of close apposition of the inner and outer mitochondrial membrane (Perkins and Frey, 2000)."}},{"Contactin":{"SuperCategory":"Protein","Id":"sao1517449491"}},{"Content Creators Name":{"ValueRepresentation":"PN","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0084","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149750","Has role":"Scan-related personnel attribute","Is part of":"Resource:DICOM standard","Value_Representation":"PN","Definition":"Name of operator saving the presentation state (such as a technologist or physician)."}},{"Content Date":{"ValueRepresentation":"DA","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0023","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149751","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DA","Definition":"The date the image pixel data creation started. Required if image is part of a series in which the images are temporally related. Note: This Attribute was formerly known as Image Date."}},{"Content Description":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0081","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149752","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"A description of this presentation."}},{"Content Item Modifier Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_0441","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149753","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence that specifies modifiers for a Protocol Context Content Item. One or more items may be included in this sequence. See Section C.4.10.1."}},{"Content Label":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0080","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149754","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"label that is used to identify this presentation. Note: This value may be used by an application as a Defined Term in order to imply some grouping of different presentation states, i.e. it may have the same value for different presentation state instances."}},{"Content Qualification":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9004","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149755","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Content Qualification Indicator."}},{"Content Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_A730","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149756","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"A potentially recursively nested Sequence of Items that conveys content that is the Target of Relationships with the enclosing Source Content Item. One or more Items may be included in this sequence. Required if the enclosing Content Item has relationships. Notes: 1. If this Attribute is not present then the enclosing Item is a leaf. 2. The order of Items within this Sequence is semantically significant for presentation."}},{"Content Template Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_A504","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149757","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Template that describes the content of this Content Item. Only a single Item shall be permitted in this sequence. Required if a template was used to define the content of this Item and the template consists of a single CONTAINER with nested content and it is the outermost invocation of a set of nested templates that start with the same CONTAINER."}},{"Content Time":{"ValueRepresentation":"TM","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0033","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149758","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"TM","Definition":"The time the image pixel data creation started. Required if image is part of a series in which the images are temporally related."}},{"Context Group Extension Creator UID":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_010B","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149759","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD."}},{"Context Group Extension Flag":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0108","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149760","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD."}},{"Context Group Local Version":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0107","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149761","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DT","Definition":"TBD."}},{"Context Group Version":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0106","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149762","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DT","Definition":"TBD."}},{"Context Identifier":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_010F","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149763","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD."}},{"Continuant":{"Comment":["Synonyms: endurant"],"SuperCategory":"Entity","Id":"Continuant","Definition":"An entity (bfo:Entity) that exists in full at any time in which it exists at all, persists through time while maintaining its identity and has no temporal parts., Examples: a heart, a person, the color of a tomato, the mass of a cloud, a symphony orchestra, the disposition of blood to coagulate, the lawn and atmosphere in front of our building"}},{"Continuing medical education":{" limit":"1000","CurationStatus":"graph position temporary","SuperCategory":"Training resource"," format":"CSV","Id":"nlx_res_090921","Abbrev":"CME","Definition":"A type of continuing education (CE) that helps those in the medical field maintain competence and learn about new and developing areas of their field. These activities may take place as live events, written publications, online programs, audio, video, or other electronic media. Content for these programs is developed, reviewed, and delivered by faculty who are experts in their individual clinical areas. Similar to the process used in academic journals, any potentially conflicting financial relationships for faculty members must be both disclosed and resolved in a meaningful way.(adapted from Wikipedia)"}},{"Continuity Of Content":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_A050","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149764","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"This flag specifies for a CONTAINER whether or not its contained Content Items are logically linked in a continuous textual flow or are separate items. Required if Value Type (0040,A040) is CONTAINER. "}},{"Continuous":{"Synonym":"uninterrupted","SuperCategory":"Occurrence quality","Id":"PATO_0000689","Definition":"Uninterrupted in time, sequence, substance, or extent."}},{"Continuous performance task":{"Created":"8/10/2011 7:27","CurationStatus":"uncurated","Contributor":"Russ Poldrack","CAO_Id":"CAO_00708","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Continuous_performance_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145924","Definition":"A task in which subjects are presented with a stream of letters, and must respond to one of the letters and refrain from responding to any other letters."}},{"Continuous recognition paradigm":{"Created":"4/19/2011 12:06","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00813","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Continuous_recognition_paradigm","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146035","Definition":"In the continuous recognition paradigm, study and test phases are not separate entities, but rather, items are continuously presented and the participant is instructed to respond to an item as and#34;oldand#34; if it has been seen before (generally presented a second time) in this continual stream of item presentation. Items that were correctly called and#34;oldand#34; are the subsequently remembered trials, and items that were and#34;missedand#34; (not called old upon second presentation) make up the subsequently forgotten trials."}},{"Contour Data":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3006_0050","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149765","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Sequence of (x,y,z) triplets defining a contour in the patient based coordinate system described in mm. Required if Contour Sequence (3006,0040) is sent."}},{"Contour Geometric Type":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3006_0042","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149766","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Geometric type of contour. Required if Contour Sequence (3006,0040) is sent."}},{"Contour Image Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3006_0016","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149767","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Introduces sequence of items describing images in a given series used in defining the Structure Set (typically CT or MR images). Required if RT Referenced Series Sequence (3006,0014) is sent. One or more items may be included in this sequence."}},{"Contour Number":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3006_0048","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149768","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Identification number of the contour. The value of Contour Number (3006,0048) shall be unique within the Contour Sequence (3006,0040) in which it is defined. No semantics or ordering shall be inferred from this attribute."}},{"Contour Offset Vector":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3006_0045","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149769","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Vector (x,y,z) in the the patient based coordinate system described in mm which is normal to plane of Contour Data (3006,0050), describing direction and magnitude of the offset (in mm) of each point of the central plane of a contour slab."}},{"Contour Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3006_0040","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149770","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Introduces sequence of Contours defining ROI. One or more items may be included in this sequence."}},{"Contour Slab Thickness":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3006_0044","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149771","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FD","Definition":"Thickness of slab (in mm) represented by contour, where the Contour Data (3006,0050) defines a plane in the center of the slab, offset by the Contour Offset Vector (3006,0045) if it is present."}},{"Contour Uncertainty Radius":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0312","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149772","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FD","Definition":"TBD."}},{"Contractile":{"SuperCategory":"Contractility","Id":"PATO_0001690","Definition":"A contractility quality inhering in a bearer by virtue of its ability of contracting or being contracted."}},{"Contractile vacuole":{"CurationStatus":"uncurated","Id":"GO:0000331","Definition":"A specialized vacuole of eukaryotic cells, especially Protozoa, that fills with water from the cytoplasm and then discharges this externally by the opening of contractile vacuole pores. Its function is probably osmoregulatory."}},{"Contractility":{"SuperCategory":"Physical quality","Id":"PATO_0001579","Definition":"A monadic quality of continuant inhering in a bearer by virtue of its ability to shrink or contract."}},{"Contrast Administration Profile Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9340","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149773","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence that describes one or more phases of contrast administered. If present, shall contain one or more Items."}},{"Contrast agent":{"Created":"2006-05-15","CurationStatus":"uncurated","Umlscui":"C0009924","SuperCategory":"Detector role","Id":"birnlex_2037"}},{"Contrast Allergies":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0010_2110","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149774","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Description of prior reaction to contrast agents."}},{"Contrast enhancement protocol":{"RelatedTo":"Microscopy","Created":"2006-05-15","EditorialNote":"Should really be importing the FlyBase biological imaging ontology, now that it is so mature.  Unfortunately, this is currently only available in OBO format.  It really needs to be incorporated directly or through import into OBI (BB:2006-10-10).","CurationStatus":"uncurated","Comment":"I would change the label of this class to \"Contrast enhancement protocol\" because these techniques can be used without microscopy","SuperCategory":"Specimen preparation protocol","Id":"birnlex_2039","Definition":"Protocol designed to add contrast to a biological organism or specimen for the purposes of imaging"}},{"Contrast Frame Averaging":{"ValueRepresentation":"US","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_6112","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149775","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Specifies the number of contrast frames to average together before performing the mask operation. If the Attribute is missing, no averaging is performed."}},{"Contributing Equipment Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_A001","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149778","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":" A sequence that describes the equipment that contributed to the image."}},{"Contribution DateTime":{"ValueRepresentation":"DT","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_A002","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149779","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DT","Definition":"The Date and Time when the equipment contributed to the composite instance."}},{"Contribution Description":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_A003","Comment":"DICOM specific term","SuperCategory":"Imaging hardware attribute","Id":"nlx_149780","Has role":"DICOM term","Is part of":"Resource:DICOM standard","Value_Representation":"ST","Definition":"Description of the contribution the equipment made to the composite instance."}},{"Control Point 3D Position":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_02D4","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149781","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Coordinates (x, y, z) of Control Point in the patient based coordinate system (mm)."}},{"Control Point Delivery Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3008_0040","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149782","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Introduces sequence of beam control points for current treatment beam. The sequence may contain one or more items."}},{"Control Point Index":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0112","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149783","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Index of current Control Point, starting at 0 for first Control Point. Required if Control Point Sequence (300A, 0111) is sent."}},{"Control Point Relative Position":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_02D2","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149784","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Distance between current Control Point Position and the distal-most possible Source position in current Channel (mm)."}},{"Control Point Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0111","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149785","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Introduces sequence of machine configurations describing treatment beam. Two or more items may be included in this sequence."}},{"Control role":{"Created":"2007-10-05","EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","Synonym":"Control","CurationStatus":"uncurated","SuperCategory":"Role in protocol application","Curator":"Bill Bug","Id":"birnlex_11017"}},{"Controlled vocabulary":{"Synonym":["controlled terminology"],"CurationStatus":"uncurated","SuperCategory":"Data or information resource","Id":"birnlex_2335","Keywords":"Resource:CINERGI","Definition":"In library and information science controlled vocabulary is a carefully selected list of words and phrases, which are used to tag units of information (document or work) so that they may be more easily retrieved by a search. Controlled vocabularies solve the problems of homographs, synonyms and polysemes by ensuring that each concept is described using only one authorized term and each authorized term in the controlled vocabulary describes only one concept. In short, controlled vocabularies reduce ambiguity inherent in normal human languages where the same concept can be given different names and ensure consistency.  Controlled vocabulary schemes mandate the uses of predefined, authorized terms that have been preselected by the designer of the controlled vocabulary as opposed to natural language vocabularies where there is no restriction on the vocabulary that can be used. (definition Source:Wikipedia)"}},{"Convergence":{"CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001132","Definition":"A pattern of connections between neurons in which several presynaptic neurons make a synaptic connection onto a common postsynaptic cell."}},{"Conversion Type":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0064","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149786","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Describes the kind of image conversion."}},{"Convex":{"SuperCategory":"Concavity","Id":"PATO_0001355","Definition":"A shape quality that obtains by virtue of having inward facing edges; having a surface or boundary that curves or bulges outward, as the exterior of a sphere."}},{"Convex 3-D shape":{"Comment":"Use this term or an is_a child of this term when the entire shape of the object is known","SuperCategory":"Shape","Id":"PATO_0002007","Definition":"A complete three dimensional shape in which for every line connecting a pair of points on the object is within the object. Or: a shape lacking cavities.  Contrast: concave."}},{"Convex angle":{"SuperCategory":"Angular placement","Id":"PATO_0001053","Definition":"Angular placement that is at an angle which is less than 180 degrees."}},{"Convolute":{"SuperCategory":"Curled","Id":"PATO_0001966","Definition":"A shape inhering in a bearer by virtue of one edge of its surface being wholly rolled up in another."}},{"Convolution":{"Created":"2007-03-07","CurationStatus":"uncurated","SuperCategory":"Algorithm","Curator":["Jessica Turner"],"Id":"birnlex_2129"}},{"Coordinate System Axis Code Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_08DA","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149787","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Axis of a coordinate system. This sequence shall contain exactly one item."}},{"Copeptin":{"RelatedTo":"AVP","Synonym":"C-terminal pro-vasopressin","CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nlx_11137","Definition":"C-terminus of prohormone arginine vasopressin"}},{"Copula of the pyramis of PHT00":{"Synonym":"copula of the pyramis","CurationStatus":"uncurated","ISBN":"123582555","Curator":"CoCoMac{{PONS brain region","Authors":["George Paxinos","Xu-Feng Huang"],"Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"Cop","PartiallyOverlapsWith":"Copula pyramidis","PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Id":"nlx_br_260","Is part of":"#N/A","ParcellationScheme":["Paxinos"],"Species":"Macaque","DefiningCitation":"ISBN 0123582555"}},{"Copula pyramidis":{"Synonym":"Copula of the pyramis","CurationStatus":"graph position temporary","NeuronamesID":"1894","Comment":"I'm not sure whether this is synonymous with lobule VIII.  I don't think so;  I think it's the lateral part.  But needs checking by an expert.","SuperCategory":"Regional part of brain","Curator":"Maryann Martone,","Id":"nlx_153834","Is part of":"Hemispheric lobule VIII","Definition":"A part of the cerebellar hemisphere in the mouse ( Paxinos-2001 ) and the rat ( Swanson-1998 ) that corresponds laterally to the pyramis of the vermis of the cerebellum. It is regarded as the rodent homolog of the 'lateral belly' of the the biventer lobule of the human (Voogd-1990) (Adapted from NeuroNames:  http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID"}},{"Copula pyramidis of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Copula pyramidis","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153465","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Hemispheric regions of ABA 2009","Species":"Mouse"}},{"Cord blood stem cell":{"CurationStatus":"uncurated","Comment":"Umls Cui: C1636284","SuperCategory":"Somatic stem cell","Id":"419423006"}},{"Core facility":{"Synonym":["facility core"],"CurationStatus":"graph position temporary","SuperCategory":"Access service resource","Id":"nlx_293","Definition":"A centralized or shared resource that provides services including access to instruments in support of members of an organization."}},{"Core of nucleus accumbens":{"Synonym":"Nucleus accumbens core","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Is_part_of":"Nucleus accumbens","Id":"nlx_anat_20090306","Is part of":"Nucleus accumbens","Abbrev":"AcbC"}},{"Corona radiata":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_anat_090903","Is part of":["White matter"],"Definition":"Fan shaped white matter mass comprised of afferent and efferent fibers from the cerebral cortex arranged in radially arrayed bundles, converging towards the internal capsule (Carpenter, Core Text of Neuroanatomy, 3rd ed, 1985, pg. 30;  Heimer, The Human Brain and Spinal Cord, 2nd ed., 1995, pg 84)."}},{"Corpora quadrigema":{"Synonym":["Tectum"],"DefiningCriteria":"topography","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_158517","Species":["Vertebrata"],"Definition":"Synonym of the human macrodissected human tectum, described by Winslow (1733). In english: quadrigeminal body."}},{"Corpus callosum":{"Created":"2006-07-15","CurationStatus":"uncurated","Umlscui":"C0010090","SuperCategory":"Commissure","Id":"birnlex_1087","Is part of":["Telencephalon"],"Abbrev":"cc","Definition":"White matter structure containing massive numbers of commissural fibers connecting cortical areas in the two cerebral hemispheres.it is subdivided into a genu, a rostrum, a body, and a splenium.  (MM)"}},{"Corpus Callosum of CIVM postnatal rat brain atlas":{"AtlasImage":["corpus callosum p0.png"],"CurationStatus":"uncurated","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151547","Is part of":"Major White Matter Structures of CIVM postnatal rat brain atlas","Definition":"The corpus callosum, external capsule and deep cerebral white matter are most easily segmented on coronal T2-weighted MRI. This white matter structure is much darker that surrounding tissues and can be easily thresholded on a slice-by-slice basis. The dorsal border with the cingulum is defined by a fine, bright line that fades laterally as the two structures merge. This border is trivially easy to distinguish on color fractional anisotropy images as these two white matter tracts course virtually perpendicular to each other.  The rostral extent of the forceps minor is a comma-shaped dark region that appears in the center of the frontal cortex in the coronal plane. The caudal extent is a dark, diagonal strip just medial to the visual cortex."}},{"Corrected Image":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_0051","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149788","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"A value that indicates which, if any, corrections have been applied to the image. Corrections are applied to all frames in the image.                   Any type of normalization applied to correct for count loss in Time Slots."}},{"Cortical amygdalar area anterior part layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  anterior part  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153701","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area anterior part layer 2 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  anterior part  layer 2","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152930","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area anterior part layer 3 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  anterior part  layer 3","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153148","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area anterior part of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  anterior part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153765","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153669","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part lateral zone layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part  lateral zone  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153764","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part lateral zone layer 1-2 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part  lateral zone  layer 1-2","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153431","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part lateral zone layer 1-3 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part  lateral zone  layer 1-3","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153722","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part lateral zone layer 2 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part  lateral zone  layer 2","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153583","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part lateral zone layer 3 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part  lateral zone  layer 3","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153681","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part lateral zone of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part  lateral zone","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153184","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part medial zone layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part  medial zone  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153136","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part medial zone layer 1-2 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part  medial zone  layer 1-2","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153630","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part medial zone layer 1-3 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part  medial zone  layer 1-3","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153129","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part medial zone layer 2 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part  medial zone  layer 2","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152952","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part medial zone layer 3 of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part  medial zone  layer 3","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153084","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part medial zone of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part  medial zone","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153399","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdalar area posterior part of ABA 2009":{"PartiallyOverlapsWith":"Cortical amygdalar area  posterior part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153238","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical amygdaloid nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":["posterior amygdaloid area","posterior cortical nucleus"],"CurationStatus":"uncurated","NeuronamesID":"222","Umlscui":"C0175216","SuperCategory":"Regional part of brain","Id":"birnlex_2700","Is part of":"Corticomedial nuclear complex","Abbrev":"CoA","DefinitionPMID":"12843409","Definition":"Three layered structure that is located in the caudal aspect of the amygdala bordering the periamygdaloid cortex laterally."}},{"Cortical flat map":{"PMID":["7410593"],"Synonym":["Flat map","Flatmap","cortical map"],"CurationStatus":"uncurated","SuperCategory":"Map","Id":"nlx_158049","DefinitionPMID":["7410593"],"Definition":"A two-dimensional, unfolded representation of the cerebral cortex that displays the entire hemisphere in one view requiring artificial cuts that disrupt the continuity between nearby cortical locations. The flat map uses a technique based on information contained in outlines of histological sections and allows an entire hemisphere to be represented on a single cortical map. For an example see Figure 2E, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288593/figure/F2/"}},{"Cortical Lewy Body":{"Comment":"has Regional Part some Regional_Part_of_Lewy_Body restriction violated because Cortical Lewy Body lacks halo.","SuperCategory":"Lewy Body","Id":"sao4040591221","Definition":"Lesion that is less well defined than a Classical Lewy Body and lacks a halo."}},{"Cortical parcel":{"CurationStatus":"uncurated","SuperCategory":"Parcellation scheme parcel","Id":"nlx_12237","Definition":"Contiguous region of cortical gray matter that is defined and delineated by methods based on one or another of the following approaches:  architecture, function, pattern of connections (inputs and outputs), and/or topographic organization (mapping of a sensory sheet or a motor representation)."}},{"Cortical parcellation scheme":{"CurationStatus":"uncurated","SuperCategory":"Parcellation scheme","Id":"nlx_87354","Definition":"A parcellation scheme for cerebral cortex (neocortex, allocortex, olfactory areas)"}},{"Cortical plate of ABA 2009":{"PartiallyOverlapsWith":"Cortical plate","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153349","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cortical subplate of ABA 2009":{"PartiallyOverlapsWith":"Cortical subplate","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153117","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Corticomedial nuclear complex":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":["corticomedial nuclear group","pars corticomedialis (Corpus amygdaloideum)","amygdalar corticomedial nucleus"],"CurationStatus":"uncurated","NeuronamesID":"220","Umlscui":"C0175214","SuperCategory":"Regional part of brain","Id":"birnlex_2680","Is part of":"Amygdala","Abbrev":"CMA","DefinitionPMID":"12843409","Definition":"These structures are referred to as nuclei but have a layered cortical like structure. These areas include the anterior amygdaloid area, posterior amygdaloid area, the periamygdaloid cortex, and the bed nucleus of the accessory olfactory tract."}},{"Corticotectal tract":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","CurationStatus":"uncurated","NeuronamesID":"476","Umlscui":"C0262216","SuperCategory":"Regional part of brain","Id":"birnlex_1016","ConnDefiningCriteria":["The corticotectal tract originates in visual association areas 18 and 19 and terminates in the superior colliculus and other nuclei in the midbrain tectum (Strominger et al.","2012","Noback's Human Nervous System"],"Is part of":["White matter"]}},{"Corticotropin":{"RelatedTo":["Adrenocorticotropic hormone receptor"],"Synonym":["ACTH","Adrenocorticotopin","Adrenocorticotropic hormone","Corticotrophin","Cortrophin","ACTH","Acethropan","Acortan","Acthar","Exacthin","H,P","Acthar Gel","Isactid","Purified cortrophin gel","Reacthin","Solacthyl"],"Related disease":"Stress","CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"DB01285","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB01285","Definition":"Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. Pharmacology: Corticotropin acts through the stimulation of cell surface ACTH receptors, which are primarily located on the adrenocortical cells. Corticotropin stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens). Corticotropin is also related to the circadian rhythm in many organisms. Mechanism of action: As a diagnostic aid (adrenocortical function), corticotropin combines with a specific receptor on the adrenal cell plasma membrane. In patients with normal adrenocortical function, it stimulates the initial reaction involved in the synthesis of adrenal steroids (including cortisol, cortisone, weak androgenic substances, and a limited quantity of aldosterone) from cholesterol by increasing the quantity of cholesterol within the mitochondria. Corticotropin does not significantly increase serum cortisol concentrations in patients with primary adrenocortical insufficiency (Addison's disease). The mechanism of action of corticotropin in the treatment of infantile myoclonic seizures is unknown. Drug type: Approved. Biotech. Drug category: Diagnostic Agents"}},{"Corticotropin releasing factor":{"Synonym":"CRF","Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5137"}},{"Cortistatin":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5127"}},{"Cosyntropin":{"RelatedTo":"Adrenocorticotropic hormone receptor","Synonym":["Tetracosactide","Cortrosyn"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01284","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01284","Definition":"A synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Pharmacology: Cosyntropin exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N- terminal portion of the molecule and that the 1-20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residue. For example, the decrement from 20 to 19 results in a 70% loss of potency. The pharmacologic profile of Cosyntropin is similar to that of purified natural ACTH. It has been established that 0.25 mg of Cosyntropin will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. Cosyntropin has less immunogenic activity than ACTH because the amino acid sequence having most of the antigenic activity of ACTH, i.e., amino acids 25-39, is not present in cosyntropin. The extra-adrenal effects which natural ACTH and Cosyntropin have in common include increased melanotropic activity, increased growth hormone secretion and an adipokinetic effect. These are considered to be without physiological or clinical significance. Mechanism of action: Cosyntropin combines with a specific receptor in the adrenal cell plasma membrane and, in patients with normal adrenocortical function, stimulates the initial reaction involved in the synthesis of adrenal steroids (including cortisol, cortisone, weak androgenic substances, and a limited quantity of aldosterone) from cholesterol by increasing the quantity of the substrate within the mitochondria. Cosyntropin does not significantly increase plasma cortisol concentration in patients with primary or secondary adrenocortical insufficiency. Drug type: Approved. Biotech. Drug category: Diagnostic Agents"}},{"Coturnix":{"Created":"2007-06-03","CurationStatus":"pending_final_vetting","Umlscui":"C0010199","SuperCategory":"Phasianinae","Id":"birnlex_253"}},{"Count":{"SuperCategory":"Quantitative","Id":"PATO_0000053"}},{"Count in organism":{"Synonym":["presence","presence or absence in organism","count","quantitative"],"Comment":["This term was originally named \"presence\". It has been renamed to reduce ambiguity. Consider annotating with the reciprocal relation,PATO:0001555","has_number_of. For example"],"SuperCategory":"Qualitative","Id":"PATO_0000070","Definition":"The number of entities of this type that are part of the whole organism."}},{"Count Rate":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1243","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149789","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Maximum count rate achieved during the acquisition in counts/sec."}},{"Counting stroop task":{"Created":"4/13/2011 16:29","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00906","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Counting_stroop_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146130","Definition":"No definition submitted yet."}},{"Counting-calculation":{"Created":"4/27/2011 15:46","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00734","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Counting-calculation","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145956","Definition":"Subjects count, add, subtract, multiply, or divide various stimuli (numbers, bars, dots, etc)."}},{"Country of Residence":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0010_2150","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149790","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Country in which patient currently resides."}},{"Counts Accumulated":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0070","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149791","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Sum of all gamma events for all frames in the image."}},{"Counts Included":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_1400","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149792","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Type of counts included in this count rate data. Required if Axis Units (50xx,0030) contains CPS or CNTS."}},{"Counts Source":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_1002","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149793","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"The primary source of counts. The primary source leads to the underlying image Units (0054,1001), as opposed to secondary sources which are used during reconstruction correction."}},{"Coverage of k-Space":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9094","CurationStatus":"uncurated","SuperCategory":"DICOM term","Id":"nlx_149794","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Coverage of k-Space in the ky-kz plane. Required if Image Type (0008,0008) Value 1 is ORIGINAL or MIXED and MR Acquisition Type (0018,0023) equals 3D. "}},{"Covert braille reading paradigm":{"Created":"2006-06-01","CurationStatus":"pending_final_vetting","SuperCategory":"Reading paradigm","Id":"birnlex_2185","Definition":"A behavioral paradigm in which a subject reads aloud with fingers."}},{"Covert visual reading paradigm":{"Created":"2006-06-01","CurationStatus":"uncurated","SuperCategory":"Reading paradigm","Id":"birnlex_2179"}},{"Cranial ganglion part of peripheral nervous system":{"Created":"2007-08-28","CurationStatus":"graph_position_temporary","SuperCategory":"Ganglion part of peripheral nervous system","Id":"birnlex_2597"}},{"Cranial nerve nucleus":{"Synonym":"cranial nerve nuclei","CurationStatus":"uncurated","SuperCategory":"Nucleus of CNS","Id":"nlx_28532","Definition":"Nucleus that receives projections from or contains neurons that send projections through one of the cranial nerves"}},{"Cranial relay neuron":{"CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_152084","Species":"Vertebrata"}},{"Cranial Thermal Index":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_5026","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149795","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"The Cranial Thermal Index (TIC) measures the largest possible temperature increase in cranial bone. Used in ultrasound."}},{"Craniata":{"Created":"2007-06-03","CurationStatus":"pending_final_vetting","Umlscui":"C1039837","SuperCategory":"Chordata","Id":"birnlex_222"}},{"Craniocerebral Trauma":{"Created":"2007-10-05","Synonym":["Head Trauma","Head Injury","Craniocerebral Injury"],"CurationStatus":"uncurated","SuperCategory":"Nervous System Trauma","Id":"birnlex_12667","Definition":"Traumatic injuries involving the cranium and intracranial structures (i.e., BRAIN; CRANIAL NERVES; MENINGES; and other structures). Injuries may be classified by whether or not the skull is penetrated (i.e., penetrating vs. nonpenetrating) or whether there is an associated hemorrhage (MeSH)."}},{"Craniopharyngioma":{"Synonym":["Rathke Pouch Tumor"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Primary nervous system neoplastic disease","Id":"birnlex_12613","Definition":"A benign pituitary-region neoplasm that originates from Rathke's pouch. The two major histologic and clinical subtypes are adamantinous (or classical) craniopharyngioma and papillary craniopharyngioma. The adamantinous form presents in children and adolescents as an expanding cystic lesion in the pituitary region. The cystic cavity is filled with a black viscous substance and histologically the tumor is composed of adamantinomatous epithelium and areas of calcification and necrosis. Papillary craniopharyngiomas occur in adults, and histologically feature a squamous epithelium with papillations (MeSH)."}},{"Craspedodromous":{"SuperCategory":"Branched (PATO 0000402)","Id":"PATO_0001969","Definition":"A shape inhering in a bearer by virtue of having secondary branches terminating at the margin."}},{"Cre-recombinase":{"Synonym":["Cre"],"CurationStatus":"uncurated","SuperCategory":"Enzyme","Id":"nlx_152724","Is part of":"CRE-lox recombination system","Species":"Bacteria","Definition":"A tyrosine recombinase enzyme derived from the P1 Bacteriophage. The enzyme uses a topoisomerase I like mechanism to carry out site specific recombination events. The enzyme (38kDa) is a member of the Integrase family of site specific recombinase and it is known to catalyse the site specific recombination event between two DNA recognition sites (loxP sites).  Cre recombinase is a widely used tool in the field of molecular biology. The enzyme's unique and specific recombination system is exploited to manipulate genes and chromosomes in a huge range of research, such as gene knock out or knock in studies. The enzyme's ability to operate efficiently in a wide range of cellular environments (including mammals, plants, bacteria, and yeast) enables the Cre-Lox recombination system to be used in a vast number of organisms, making it a particularly useful tool in scientific research (Adapted from Wikipedia:  http://en.wikipedia.org/wiki/Cre_recombinase)"}},{"Creatine":{"RelatedTo":["Creatine kinase B-type","Creatine kinase","ubiquitous mitochondrial","Glycine amidinotransferase","mitochondrial","Sodium- and chloride-dependent creatine transporter 1","Creatine kinase","sarcomeric mitochondrial","Guanidinoacetate N-methyltransferase"],"Synonym":["(alpha-Methylguanido)acetic acid","Creatine (8CI)","Creatine","hydrate","Methylguanidoacetic acid","N-Amidinosarcosine","N-Methyl-N-guanylglycine","Cosmocair C 100","Creatin","Kreatin","Krebiozon","Phosphagen"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:16919","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00148","Definition":"An amino acid that occurs in vertebrate tissues and in urine.  In muscle tissue, creatine generally occurs as phosphocreatine.  Creatine is excreted as creatinine in the urine. (PubChem) Pharmacology: Creatine is a essential, non-proteinaceous amino acid found in all animals and, in some plants. Creatine is synthesized in the kidney, liver and pancreas from L-arginine, glycine and L-methionine. Following its biosynthesis, creatine is transported to the skeletal muscle, heart, brain and other tissues. Most of the creatine is metabolized in these tissues to phosphocreatine (creatine phosphate). Phosphocreatine is a major energy storage form in the body. Supplemental creatine may have an energy-generating action during anaerobic exercise and may also have neuroprotective and cardioprotective actions. Mechanism of action: In the muscles, a fraction of the total creatine binds to phosphate - forming creatine phosphate. The reaction is catalysed by creatine kinase, and the result is phosphocreatine (PCr). Phosphocreatine binds with adenosine diphosphate to convert it back to ATP (adenosine triphosphate), an important cellular energy source. Drug type: Approved. Nutraceutical. Small Molecule. Drug category: Dietary supplement. Micronutrient"}},{"Creation Date":{"ValueRepresentation":"DA","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2100_0040","EditorialNote":"Would like to change the name of this category to \"Creation date of print job\" to distinguish it from the more general Dublin Core property CreateDate.","CurationStatus":"graph position temporary","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149796","Has role":"Non-imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DA","Definition":"Date of print job creation."}},{"Creation Time":{"ValueRepresentation":"TM","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2100_0050","CurationStatus":"uncurated","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149797","Has role":"Non-imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"TM","Definition":"Time of print job creation."}},{"Creative Commons Attribution License":{"Synonym":["Creative Commons Attribution 3.0 Unported","Creative Commons Attribution License","Creative Commons Attribution","Creative Commons Attribution 3.0 License"],"CurationStatus":"uncurated","ExampleImage":["CC BY.PNG"],"SuperCategory":"Creative Commons License","Id":"nlx_152583","Keywords":"Attribution","DefiningCitation":"http://creativecommons.org/licenses/by/3.0/","Abbrev":["CC BY","CC BY 3.0"],"Definition":"License that lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they attribute the work in the manner specified. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. Notice - For any reuse or distribution, you must make clear to others the license terms of this work. The best way to do this is with a link to the CC BY web page. "}},{"Creative Commons Attribution-NoDerivs License":{"Synonym":["Creative Commons Attribution-NoDerivs 3.0 Unported","Creative Commons Attribution-NoDerivs"],"CurationStatus":"uncurated","ExampleImage":["CC BY-ND.PNG"],"SuperCategory":"Creative Commons License","Id":"nlx_152584","Keywords":["Derivative"],"DefiningCitation":"http://creativecommons.org/licenses/by-nd/3.0/","Abbrev":["CC BY-ND"],"Definition":"License that allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to you in the manner specified.Notice - For any reuse or distribution, you must make clear to others the license terms of this work. The best way to do this is with a link to the CC BY-ND web page. "}},{"Creative Commons Attribution-NonCommercial License":{"Synonym":["Creative Commons Attribution-NonCommercial 3.0 Unported","Creative Commons Attribution-NonCommercial"],"CurationStatus":"uncurated","ExampleImage":["CC BY-NC.PNG"],"SuperCategory":"Creative Commons License","Id":"nlx_152587","Keywords":["Attribution"],"DefiningCitation":"http://creativecommons.org/licenses/by-nc/3.0/","Abbrev":["CC BY-NC"],"Definition":"License that lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you in the manner specified and be non-commercial, they don't have to license their derivative works on the same terms. Notice - For any reuse or distribution, you must make clear to others the license terms of this work. The best way to do this is with a link to the CC BY-NC web page."}},{"Creative Commons Attribution-NonCommercial-NoDerivs License":{"Synonym":["Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported","Creative Commons Attribution-NonCommercial-NoDerivs"],"CurationStatus":"uncurated","ExampleImage":["CC BY-NC-ND.PNG"],"SuperCategory":"Creative Commons License","Id":"nlx_152588","Keywords":["Attribution","Non-commercial"],"DefiningCitation":"http://creativecommons.org/licenses/by-nc-nd/3.0/","Abbrev":["CC BY-NC-ND"],"Definition":"License that is the most restrictive of the six Creative Commons main licenses, only allowing others to download your works and share them with others as long as they credit you in the manner specified, but they can't change them in any way or use them commercially. Notice - For any reuse or distribution, you must make clear to others the license terms of this work. The best way to do this is with a link to the CC BY-NC-ND web page."}},{"Creative Commons Attribution-NonCommercial-ShareAlike License":{"Synonym":["Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported","Creative Commons Attribution-NonCommercial-ShareAlike","Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License"],"CurationStatus":"uncurated","ExampleImage":"CC BY-NC-SA.PNG,","SuperCategory":"Creative Commons License","Id":"nlx_152585","Keywords":["Attribution","Non-commercial"],"AltURL":["http://creativecommons.org/licenses/by-nc-sa/3.0/","http://creativecommons.org/licenses/by-nc-sa/2.5/","http://creativecommons.org/licenses/by-nc-sa/2.0/"],"DefiningCitation":"http://creativecommons.org/licenses/by-nc-sa/4.0/","Abbrev":["CC BY-NC-SA"],"Definition":"License that lets others remix, tweak, and build upon your work non-commercially, as long as they credit you n the manner specified and license their new creations under the identical terms. Notice - For any reuse or distribution, you must make clear to others the license terms of this work. The best way to do this is with a link to the CC BY-NC-SA web page."}},{"Creative Commons Attribution-ShareAlike License":{"RelatedTo":"Open-source license","Synonym":["Creative Commons Attribution-ShareAlike 3.0 Unported","Creative Commons Attribution-ShareAlike","Creative Commons Attribution-ShareAlike 3.0 License"],"CurationStatus":"uncurated","ExampleImage":["CC BY-SA.PNG"],"SuperCategory":"Creative Commons License","Id":"nlx_152586","Keywords":["Attribution"],"DefiningCitation":"http://creativecommons.org/licenses/by-sa/3.0/","Abbrev":["CC BY-SA"],"Definition":"License that lets others remix, tweak, and build upon your work even for commercial purposes, as long as they credit you in the manner specified and license their new creations under the identical terms. This license is often compared to \"copyleft\" free and open source software licenses. All new works based on yours will carry the same license, so any derivatives will also allow commercial use. This is the license used by Wikipedia, and is recommended for materials that would benefit from incorporating content from Wikipedia and similarly licensed projects. Notice - For any reuse or distribution, you must make clear to others the license terms of this work. The best way to do this is with a link to the CC BY-SA web page. "}},{"Creative Commons License":{"tweets.background":"#F6F6F6","count":"5","CurationStatus":"uncurated","tweets.links":"#013C41","Abbrev":"CC","tweets.color":"#605C4F","shell.background":"#013C41","SuperCategory":"Open-source license","Id":"nlx_152581","Is part of":"Creative Commons","user":"{{#show: {{FULLPAGENAME ","DefiningCitation":"http://creativecommons.org/","Definition":"One of several public copyright licenses that allow the distribution of copyrighted works. A Creative Commons license is used when an author wants to give people the right to share, use, and even build upon a work that they have created. CC provides an author flexibility (for example, they might choose to allow only non-commercial uses of their own work) and protects the people who use or redistribute an author's work, so they don't have to worry about copyright infringement, as long as they abide by the conditions the author has specified.There are several types of CC licenses. The licenses differ by several combinations that condition the terms of distribution. They were initially released on December 16, 2002 by Creative Commons, a U.S. non-profit corporation founded in 2001. (Wikipedia, http://en.wikipedia.org/wiki/Creative_Commons_license)"}},{"Creative Commons Zero License":{"Synonym":["Creative Commons Zero"],"CurationStatus":"uncurated","SuperCategory":"Creative Commons License","Id":"nlx_152582","DefiningCitation":"http://creativecommons.org/choose/zero/","Abbrev":"CC0","Definition":"Universal tool if you are a holder of copyright or database rights, and you wish to waive all your interests in your work worldwide. Using CC0, you can waive all copyrights and related or neighboring rights that you have over your work, such as your moral rights (to the extent waivable), your publicity or privacy rights, rights you have protecting against unfair competition, and database rights and rights protecting the extraction, dissemination and reuse of data.You cannot waive rights to a work that you do not own unless you have permission from the owner. You may use this tool even if your work is free of copyright in some jurisdictions, if you want to ensure it is free everywhere. Creative Commons does not recommend this tool for works that are already in the public domain worldwide, instead use the Public Domain Mark for such works."}},{"Creator-Version UID":{"ValueRepresentation":"UI","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_9123","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149798","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"UI","Definition":"Unique identification of the equipment and version of the software that has created the Raw Data information. The UID allows one to avoid attempting to interpret raw data with an unknown format."}},{"Creeping":{"PMID":"21333690","RelatedTo":["Coasting","Drifting"],"Synonym":["Coasting"],"CurationStatus":"uncurated","SuperCategory":"Swimming activity","Id":"nlx_151975","Species":"Zebrafish","DefinitionPMID":"21333690","Definition":"Very slow swimming during which only the pectoral fins propel the fish forward; also see coasting/drifting (passive sliding without fin use)."}},{"Crescent-shaped":{"Synonym":["lunate"],"CurationStatus":"uncurated","SuperCategory":"2-D shape","Id":"PATO_0001870","Definition":"A shape produced when a circular disk has a segment of another circle removed from its edge, so that what remains is a shape enclosed by two circular arcs of different diameters which intersect at two points (usually in such a manner that the enclosed shape does not include the center of the original circle)."}},{"Creutzfeldt-Jakob Syndrome":{"Synonym":["Creutzfeldt-Jakob Disease","Jakob-Creutzfeldt Disease"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Prion Disease","Id":"birnlex_12687","DefiningCitation":["N Engl J Med"],"Definition":"A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS (MeSH)."}},{"Cricetidae":{"Created":"2007-10-14","CurationStatus":"raw_import","SuperCategory":"Muroidea","Id":"birnlex_675"}},{"Cricetinae":{"Synonym":"hamster","Created":"2007-10-14","CurationStatus":"raw_import","SuperCategory":"Cricetidae","Id":"birnlex_676"}},{"Cricetulus":{"Created":"2007-10-14","CurationStatus":"raw_import","SuperCategory":"Cricetinae","Id":"birnlex_679"}},{"Cricetulus griseus":{"Synonym":"Cricetulus aureus","Created":"2007-10-14","CurationStatus":"raw_import","SuperCategory":"Cricetulus","Id":"birnlex_680"}},{"Cricothyroid muscle":{"CurationStatus":"uncurated","SuperCategory":"Muscle organ","Id":"nlx_143570","Is part of":"Larynx","DefinitionPMID":"19426785","Definition":"Muscle of the larynx that influences glottic position by tilting the thyroid cartilage on the cricoid cartilage"}},{"Crista Junction":{"CurationStatus":"uncurated","SuperCategory":"Mitochondrial Site","Id":"sao1825845900","Definition":"Tubular structures of relatively uniform size that connect mitochondrial cristae to the inner mitchondrial membrane (Perkins and Ellisman, 2003)."}},{"Cristae Quality":{"SuperCategory":"Morphological Quality","Id":"sao1843037539","Definition":"Refers to the morphology of mitochondrial cristae."}},{"Critical period":{"Created":"5/16/2011 11:59","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00244","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Critical_period","SuperCategory":"Duration","Id":"CAO_00244","Definition":"a limited time in which an event can occur, usually to result in some kind of transformation; in developmental psychology and developmental biology, it is a time in the early stages of an organisma's life during which it displays a heightened sensitivity to certain environmental stimuli, and develops in particular ways due to experiences at this time."}},{"Crockerinus":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1689164","SuperCategory":"Orconectes","Id":"birnlex_260"}},{"Cromoglicate":{"RelatedTo":["Calcium-activated potassium channel subunit alpha 1"],"Synonym":["Acide Cromoglicique (INN-French)","Acido Cromoglicico (INN-Spanish)","Acidum Cromoglicicum (INN-Latin)","Cromoglicic Acid","Cromoglycate","Cromoglycic Acid","Cromolyn","Aarane","Alercom","Alerion","Allergocrom","Apo-Cromolyn","Children's Nasalcrom","Colimune","Crolom","Cromolyn Nasal Solution","Cromoptic","Cromovet","Fivent","Gastrocrom","Gastrofrenal","Gen-Cromoglycate","Inostral","Intal","Intal Inhaler","Intal Syncroner","Introl","Irtan","Lomudal","Lomupren","Lomusol","Lomuspray","Nalcrom","Nalcron","Nasalcrom","Nasmil","Opticrom","Opticron","Rynacrom","Sofro","Vistacrom"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01003","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01003","Definition":"A chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack. (PubChem) Pharmacology: Cromoglicate or cromolyn (USAN), a synthetic compound, inhibits antigen-induced bronchospasms and, hence, is used to treat asthma and allergic rhinitis. Cromoglicate is used as an ophthalmic solution to treat conjunctivitis and is taken orally to treat systemic mastocytosis and ulcerative colitis. Mechanism of action: Cromoglicate inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), mediators of type I allergic reactions. Cromoglicate also may reduce the release of inflammatory leukotrienes. Cromoglicate may act by inhibiting calcium influx. Drug type: Approved. Small Molecule. Drug category: Anti-Asthmatic Agents"}},{"Cross Section Diameter Major":{"SuperCategory":"Measurement","Id":"sao824839913","Definition":"Maximum diameter of a cross section through structure, assumed to be the maximum diameter in the case of spherical structures like vesicles.  Use this field when entering only a single cross section value where the structure is assumed to be spherical."}},{"Cross Section Diameter Minor":{"SuperCategory":"Measurement","Id":"sao136816674","Definition":"Minimum diameter of a cross section through structure."}},{"Crotamiton":{"Synonym":["Crotaglin","Crotalgin","Crotamitone","Crotamitex","Crotan","Eurasil","Eurax","Eurax Cream","Eurax Lotion","Euraxil"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00265","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00265","Definition":"Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol. Pharmacology: Crotamiton is usually used to treat pruritis (itching of the skin) caused by scabies or sunburn. Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching. Due to this cooling effect it is also effective for the relief of sunburn. The drug is also believed to kill scabies through an unknown mechanism. Mechanism of action: Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching. Drug type: Approved. Small Molecule. Drug category: Antiparasitic Agents. Antipruritics. Pesticides. Scabicides"}},{"Crowded":{"SuperCategory":"Position","Id":"PATO_0000619","Definition":"A quality inhering in a bearer by virtue of being overfilled."}},{"Crus 1 of ABA 2009":{"PartiallyOverlapsWith":"Crus 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153333","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Crus 2 of ABA 2009":{"PartiallyOverlapsWith":"Crus 2","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153649","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Crustacea":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0010395","SuperCategory":"Pancrustacea","Id":"birnlex_278"}},{"Cryptenamine":{"RelatedTo":["Cholinergic system","Muscarinic acetylcholine receptor M3","Muscarinic acetylcholine receptor M1","Muscarinic acetylcholine receptor M5","Muscarinic acetylcholine receptor M4"],"Synonym":"Unitensen","CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"DB00785","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00785","Definition":"Cryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known. Pharmacology: Cryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. Mechanism of action: Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known. Some evidence has suggested that cryptenamine acts in a similar fashion to atropine, which lowers the \"rest and digest\" activity of all muscles and glands regulated by the parasympathetic nervous system. This occurs because atropine is a competitive inhibitor of the muscarinic acetylcholine receptors (acetylcholine is the neurotransmitter used by the parasympathetic nervous system). Therefore muscarinic acetylcholine receptors will be listed as experimental targets for cryptenamine. Drug type: Approved. Small Molecule. Drug category: Antihypertensive Agents"}},{"CSIRO":{"tweets.background":"#F6F6F6","Synonym":["Commonwealth Scientific and Industrial Research Organisation","Commonwealth Scientific and Industrial Research Organization","CSIRO - Commonwealth Scientific and Industrial Research Organisation"],"count":"5","CurationStatus":"uncurated","tweets.links":"#013C41","Abbrev":"CSIRO","tweets.color":"#605C4F","shell.background":"#013C41","SuperCategory":"Government granting agency","Id":"nlx_149457","user":"{{#show: {{FULLPAGENAME ","DefiningCitation":"http://www.csiro.au/","Definition":"CSIRO, the Commonwealth Scientific and Industrial Research Organisation, is Australia's national science agency and one of the largest and most diverse research agencies in the world.National Research Flagships: Large-scale, long-term, multidisciplinary science to address Australia's major national challenges and opportunities.Divisions: CSIRO expertise is organised into 14 research areas:* Animal, Food and Health Sciences* Astronomy and Space Science* Earth Science and Resource Engineering* Ecosystem Sciences* Energy Technology* Food & Nutritional Sciences* ICT Centre* Land and Water* Livestock Industries* Marine and Atmospheric Research* Materials Science & Engineering* Mathematics, Informatics and Statistics* Plant Industry* Process Science and EngineeringNational Facilities: CSIRO manages national facilities and collections that are opened to researchers around Australia and overseas."}},{"CT-proET-1":{"RelatedTo":"ET1","Synonym":"C-terminal pro-endothelin-1","CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nlx_12319","Definition":"Carboxy terminus of prohormone endothelin-1"}},{"Ctenosquamata":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C1059402","SuperCategory":"Eurypterygii","Id":"birnlex_287"}},{"CTnI":{"RelatedTo":["cTnT","cTnC"],"Synonym":["Cardiac troponin I"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nlx_54310","DefinitionPMID":"8661099","Definition":"CTnI is one of the subunits in the troponin complex, expressed only in cardiac muscle"}},{"Cuban Flower Bat":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C1669041","SuperCategory":"Phyllonycteris","Id":"birnlex_336"}},{"Cuboid":{"Synonym":"Cuboidal","SuperCategory":"Convex 3-D shape","Id":"PATO_0001872","Definition":"A convex 3-D shape that resembles a cube (a 3-D shape with a square cross section)."}},{"Cued explicit recognition":{"Created":"4/27/2011 15:45","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00735","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Cued_explicit_recognition","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145957","Definition":"Subjects view a list of items (words, pictures, sounds, or abstract patterns) prior to scanning.  During scanning, probe words are presented and subject recall if the words are familiar or unfamiliar."}},{"Cuff-electrode recording protocol":{"Created":"2007-10-09","Synonym":"Suction electrode recording protocol","CurationStatus":"uncurated","SuperCategory":"Macro-electrode recording protocol","Id":"birnlex_2291","Has role":"Electrophysiology concept"}},{"Cullin":{"RelatedTo":" ","Synonym":" ","Umlscui":" ","Database Reference":"PIRSF017874","SuperCategory":"Protein","Comment":"Category","Id":"PRO:000000013","Definition":"A protein with a core domain composition consisting of a cullin domain that functions as a molecular scaffold responsible for assembling the ROC1/Rbx1 RING-based E3 ubiquitin ligases. [PIRSF:PIRSF017874]"}},{"Culmen":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Lobular parts of the cerebellar cortex","Id":"birnlex_926"}},{"Culmen of ABA 2009":{"PartiallyOverlapsWith":"Culmen","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153343","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"CUMBO term":{"CurationStatus":"uncurated","SuperCategory":"Project role","Id":"nlx_64503","Definition":"A term that is defined through the Common Upper Mammalian Brain Ontology (CUMBO), a project of the International Neuroinformatics Coordinating Facility (INCF:  http://incf.org)."}},{"Cumulative Dose Reference Coefficient":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_010C","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149799","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Coefficient used to calculate cumulative dose contribution from this Beam to the referenced Dose Reference at the current Control Point. Required if Referenced Dose Reference Sequence (300C,0050) is sent."}},{"Cumulative Dose to Dose Reference":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3008_0052","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149800","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Cumulative Dose delivered to Dose Reference (Gy). Required if reatment Summary Dose Reference Sequence (3008,00E0) is sent."}},{"Cumulative Meterset Weight":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0134","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149801","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Cumulative weight to current control point. Cumulative Meterset Weight for the first item in Control Point Sequence shall always be zero. Cumulative Meterset Weight for the final item in Control Point Sequence shall always be equal to Final Cumulative Meterset Weight (300A, 010E)."}},{"Cumulative Time Weight":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_02D6","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149802","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Cumulative time weight to current Control Point (where the weighting is proportional to time values delivered). Cumulative Time Weight for first item in Brachy Control Point Sequence (300A,02D0) is always zero."}},{"Cuneate":{"Synonym":"Wedge-shaped","SuperCategory":"Triangular","Id":"PATO_0001955","Definition":"Narrowly triangular, wider at the apex and tapering toward the base."}},{"Cuneate fasciculus of medulla":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"876","Umlscui":"C0228521","SuperCategory":"Regional part of brain","Id":"birnlex_1242","Is part of":["Medulla oblongata"],"Abbrev":"cu","Definition":"Part of cuneate fasciculus found in the medulla"}},{"Cuneate fasciculus of spinal cord":{"Synonym":"fasiculus cuneatus of spinal cord","CurationStatus":"uncurated","SuperCategory":"Regional part of spinal cord","Id":"nlx_143971","Is part of":"Dorsal column of spinal cord","Definition":"Part of cuneate fasciulus located in dorsal funiculus of the spinal cord"}},{"Cuneate nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":["Burdachs nucleus"],"CurationStatus":"uncurated","NeuronamesID":"764","Umlscui":"C0587939","SuperCategory":"Nucleus of CNS","Id":"birnlex_2640","Is part of":["Medulla oblongata"],"Abbrev":"Cu"}},{"Cuneate nucleus of ABA 2009":{"PartiallyOverlapsWith":"Cuneate nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153195","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cuneiform nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","CurationStatus":"uncurated","NeuronamesID":"493","Umlscui":"C0175396","SuperCategory":"Regional part of brain","Id":"birnlex_1430","Is part of":"Midbrain reticular formation","Abbrev":"CnF"}},{"Cuneiform nucleus of ABA 2009":{"PartiallyOverlapsWith":"Cuneiform nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153670","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Cuneocerebellar tract":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":"cuneocerebellar fibers","Pages":"212","CurationStatus":"uncurated","ISBN":"0-89004-106-7","Authors":"Masao Ito","DOI":"10.1007/BF00234336","Title":"The Cerebellum and neural control","Abbrev":"CCT","Created":"2006-10-08","NeuronamesID":"800","Umlscui":"C0175556","SuperCategory":"Regional part of brain","Id":"birnlex_1238","Is part of":["White matter"],"Definition":"White matter tract that originates from the cuneate and external cuneate nuclei.  It relays ascending spinal fibers in the dorsal funiculus and conveys information from forelimbs to the cerebellum."}},{"Cuneus cortex":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","EditorialNote":"UMLS and NeuroNames use the preferred name \"cuneus\".","Synonym":["cuneate lobule","cuneus gyrus","cuneus of hemisphere"],"CurationStatus":"uncurated","NeuronamesID":"139","Umlscui":"C0152307","SuperCategory":"Regional part of brain","Id":"birnlex_1396","Is part of":"Occipital lobe","Species":"Human","Abbrev":"CuG","Definition":"Component of the occipital lobe.  The rostral boundary was the first coronal slice above the calcarine sulcus where the cuneus cortex becomes visible whereas the caudal boundary was the last slice where the calcarine sulcus was visualized. The medial boundary was the most medial portion of the occipital and parietal cortices. The superio-lateral boundary was the parieto-occipital fissure whereas the inferolateral boundary was the pericalcarine cortex (Christine Fennema-Notestine)."}},{"Cups task":{"Created":"8/10/2011 7:39","CurationStatus":"uncurated","Contributor":"Russ Poldrack","CAO_Id":"CAO_00814","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Cups_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146036","Definition":"On each trial, participants choose between a risky and safe option. Each trial involves either gains or losses. The options are presented as a choice of cups. The risky option involves two to five cups, one containing a gain (loss) of $2, $3 or $5, and the others containing $0. If the latter option is selected, the payoff from one cup is selected at random. The safe cup offers a sure gain (loss) $1."}},{"Cupula of the cochlear canal":{"Created":"2007-08-28","CurationStatus":"raw_import","Umlscui":"C0458764","SuperCategory":"Regional part of cochlear canal","Id":"birnlex_2557"}},{"Curled":{"SuperCategory":"Shape","Id":"PATO_0000405","Definition":"A shape or quality of having parallel chains in undulate fashion on the border."}},{"Current carrier":{"Synonym":["Current carrier molecule","Charge carrier"],"CurationStatus":"uncurated","SuperCategory":"Physical quality","Id":"nlx_70102"}},{"Current clamp voltage recording protocol":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Intracellular electrode recording protocol","Id":"birnlex_2278","Has role":"\tElectrophysiology concept"}},{"Current Fraction Number":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3008_0022","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149803","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Fraction number for this beam administration."}},{"Current Patient Location":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0038_0300","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149804","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Describes the current known location of the patient."}},{"Current Requested Procedure Evidence Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_A375","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149805","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"List of all Composite SOP Instances referenced in the Content Sequence (0040,A730). One or more Items shall be included in this sequence. Note: In the context of the Key Object Selection the current evidence is considered to be only the set of instances referenced within the Key Object Selection."}},{"Current Treatment Status":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3008_0200","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149806","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Status of the Treatment at the time the Treatment Summary was created."}},{"Curriculum material":{"Synonym":["Curriculum materials"],"CurationStatus":"uncurated","SuperCategory":"Training material","Id":"nlx_res_20090431","Definition":"A resource that provides curriculum that relates to teaching, such as introductory neurobiology."}},{"Curvature":{"SuperCategory":"Surface shape","Id":"PATO_0001591","Definition":"A shape quality inhering in a bearer by virtue of the curving of a line or surface."}},{"Curve Activation Layer":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:50xx_1001","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149807","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"The layer (defined in Graphic Layer (0070,0002) of the Graphic Layer Module C.10.7) in which the Curve described in group 50xx shall be displayed. If no layer is specified (zero length) then the curve shall not be displayed.Required if Group 50xx is present."}},{"Curve Data":{"ValueRepresentation":"OW or OB","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:50xx_3000","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149808","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"OW or OB","Definition":"TBD (retired)."}},{"Curve Dimensions":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:50xx_0005","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149809","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of dimensions for these data. The dimensions may be any number from 1 to n.  If the Type of Data (50xx,0020) is SYSRATE, then the Curve Dimensions (50xx,0005) shall equal 2. "}},{"Curved":{"Synonym":["bowing"],"SuperCategory":"Curvature","Id":"PATO_0000406","Definition":"A curvature quality inhering in a bearer by virtue of having or marked by a curve or smoothly rounded bend."}},{"Curved caudal":{"Synonym":"Curved Posterior","SuperCategory":"Curved","Id":"PATO_0001467","Definition":"A curvature quality inhering in a bearer by virtue of being curved towards the part of the body from which the tail arises."}},{"Curved dorsal":{"SuperCategory":"Curved","Id":"PATO_0001468","Definition":"A curvature quality inhering in a bearer by virtue of being curved towards the back or upper surface of an organism."}},{"Curved lateral":{"SuperCategory":"Curved","Id":"PATO_0001649","Definition":"A curvature quality inhering in a bearer by virtue of being curved towards the side."}},{"Curved rostral":{"Synonym":"Curved anterior","SuperCategory":"Curved","Id":"PATO_0001466","Definition":"A curvature quality inhering in a bearer by virtue of being curved towards the front of an organism."}},{"Curved ventral":{"SuperCategory":"Curved","Id":"PATO_0001469","Definition":"A curvature quality inhering in a bearer by virtue of being curved towards the abdomen of an organism."}},{"Cuspidate":{"SuperCategory":"Tapered","Id":"PATO_0001973","Definition":"Tapering gradually into a rigid point."}},{"Cut":{"SuperCategory":"Shape","Id":"PATO_0001978","Definition":"Regularly divided by deep incisions."}},{"Cut open oocyte voltage clamp recording protocol":{"CurationStatus":"uncurated","SuperCategory":"Multiple-electrode voltage clamp recording protocol","Id":"oen_0001314","Has role":"Electrophysiology concept","Definition":"A technique to measure the ion currents across the membrane of oocytes, while holding the membrane voltage at a set level, while using two electrodes, one holds the membrane potential steady while the other measures current and the feedback circuit used to bridge the electrodes."}},{"CX3C Chemokine":{"Created":"2007-09-19","SuperCategory":"Chemokine","Id":"nifext_5063"}},{"CX3CL1":{"Created":"2007-09-19","SuperCategory":"CX3C Chemokine","Id":"nifext_5064"}},{"CX3CR1 receptor":{"Synonym":"CX3CR1","Created":"2007-09-19","SuperCategory":"Chemokine receptor","Id":"nifext_7737"}},{"CXC Chemokine":{"Created":"2007-09-19","SuperCategory":"Chemokine","Id":"nifext_5056"}},{"CXCL1":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5259"}},{"CXCL10":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5257"}},{"CXCL11":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5258"}},{"CXCL12":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5060"}},{"CXCL13":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5061"}},{"CXCL14":{"Created":"2007-09-19","CurationStatus":"uncurated","SuperCategory":"CXC Chemokine","Id":"nifext_5262"}},{"CXCL15":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5263"}},{"CXCL16":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5062"}},{"CXCL2":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5260"}},{"CXCL3":{"Created":"2007-09-19","CurationStatus":"uncurated","SuperCategory":"CXC Chemokine","Id":"nifext_5261"}},{"CXCL5":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5058"}},{"CXCL6":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5255"}},{"CXCL7":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5256"}},{"CXCL8":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5057"}},{"CXCL9":{"Created":"2007-09-19","SuperCategory":"CXC Chemokine","Id":"nifext_5059"}},{"CXCR1 receptor":{"Synonym":"CXCR1","Created":"2007-09-19","SuperCategory":"Chemokine receptor","Id":"nifext_6572"}},{"CXCR2 receptor":{"EditorialNote":"macrophage derived lectin is a proposed ligand, single publication","Synonym":"CXCR2","Created":"2007-09-19","SuperCategory":"Chemokine receptor","Id":"nifext_7024"}},{"CXCR3 receptor":{"Synonym":"CXCR3","Created":"2007-09-19","SuperCategory":"Chemokine receptor","Id":"nifext_6502"}},{"CXCR4 receptor":{"Synonym":"CXCR4","Created":"2007-09-19","SuperCategory":"Chemokine receptor","Id":"nifext_6653"}},{"CXCR5 receptor":{"Synonym":"CXCR5","Created":"2007-09-19","SuperCategory":"Chemokine receptor","Id":"nifext_7447"}},{"Cyan":{"SuperCategory":"Color","Id":"PATO_0000319","Definition":"A color consisting of green and blue hue."}},{"Cyan fluorescent protein":{"CurationStatus":"uncurated","SuperCategory":"Fluorescent protein","Id":"nlx_mol_20090608","Abbrev":["CFP","ECFP","Cerulean"]}},{"Cyanide":{"Synonym":["CN(-)","CYN","Carbon nitride ion","Carbon nitride ion (CN(sup 1-))","Carbon nitride ion (cn1-)","Chuck norrisium","Cyanide (CN(sup 1-))","Cyanide (anion)","Cyanide (cn1-)","Cyanide ion","Cyanide(1-)","Free Cyanide","Cyano","Cyanure","Hydrocyanic Acid ion(1-)","Hydrocyanic Acid ion(1-)-","Isocyanide","NME","Nitrile anion","Potassium cyanide","Prussiate","Zyanid"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0028","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0028","Abbrev":"[CN]-","Definition":"Organic Compound;Cyanide Compound;Nitrile; Certain bacteria, fungi, and algae can produce cyanide, and cyanide is found in a number of foods and plants. Cyanides also occur naturally as part of sugars or other naturally-occurring compounds."}},{"Cyanocobalamin":{"RelatedTo":["Transcobalamin-1","Methylmalonic aciduria type A protein","mitochondrial","Amnionless protein","Transcobalamin-2","Cob(I)yrinic acid a,c-diamide adenosyltransferase","mitochondrial","Methionine synthase reductase","mitochondrial","Methylmalonyl-CoA mutase","mitochondrial","Cubilin","Vitamin B12 transporter btuB","Vitamin B12-binding protein"],"Synonym":["Cyanocob(III)alamin","Vitamin B12","Vitamin B12 complex","Anacobin","Bedoz","Berocca PN","Berubigen","Betalin 12","Cernevit-12","Cobavite","Cobex","Cobolin-M","Crystamine","Crysti-12","Cyanocobalamin Co 57 Schilling Test Kit","Cyanoject","Cyomin","Depinar","Dicopac","Dicopac Kit","Infuvite Pediatric","M,V,I","Pediatric","Nascobal","Neuroforte-R","Primabalt","Redisol","Rubivite","Rubramin PC","Rubratope-57 Kit","Rubratope-60 Kit","Ruvite","Shovite","Vi-Twel","Vibal","Vibisone","Vitabee 12"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00115","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00115","Definition":"Cyanocobalamin (commonly known as Vitamin B12) is the most chemically complex of all the vitamins. Cyanocobalamin's structure is based on a corrin ring, which, although similar to the porphyrin ring found in heme, chlorophyll, and cytochrome, has two of the pyrrole rings directly bonded. The central metal ion is Co (cobalt). Cyanocobalamin cannot be made by plants or by animals, as the only type of organisms that have the enzymes required for the synthesis of cyanocobalamin are bacteria and archaea. Higher plants do not concentrate cyanocobalamin from the soil and so are a poor source of the substance as compared with animal tissues. Cyanocobalamin is naturally found in foods including meat (especially liver and shellfish), eggs, and milk products. (HMDB) Pharmacology: Cyanocobalamin (Vitamin B12) is a water-soluble organometallic compound with a trivalent cobalt ion bound inside a corrin ring. It is needed for nerve cells and red blood cells, and to make DNA. Vitamin B12 deficiency is the cause of several forms of anemia. Mechanism of action: Vitamin B12 is used in the body in two forms: Methylcobalamin and 5-deoxyadenosyl cobalamin. The enzyme methionine synthase needs methylcobalamin as a cofactor. This enzyme is involved in the conversion of the amino acid homocysteine into methionine. Methionine in turn is required for DNA methylation. 5-Deoxyadenosyl cobalamin is a cofactor needed by the enzyme that converts L-methylmalonyl-CoA to succinyl-CoA. This conversion is an important step in the extraction of energy from proteins and fats. Furthermore, succinyl CoA is necessary for the production of hemoglobin, the substances that carries oxygen in red blood cells. Drug type: Approved. Nutraceutical. Small Molecule. Drug category: Antianemic Agents. Essential Vitamin. Vitamins (Vitamin B Complex)"}},{"Cyclacillin":{"RelatedTo":["Penicillin-binding proteins 1A/1B","Oligopeptide transporter"],"Synonym":["Aminocyclohexylpenicillin","Ciclacilina (INN-Spanish)","Ciclacillin","Ciclacilline (INN-French)","Ciclacillinum (INN-Latin)","Ciclacillum","Bastcillin","Calthor","Citosarin","Cyclapen","Cyclapen-W","Orfilina","Syngacillin","Ultracillin","Vastcillin","Vipicil"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:31444","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01000","Definition":"A cyclohexylamido analog of penicillanic acid. (PubChem) Pharmacology: Cyclacillin, a penicillin, is a cyclohexylamido analog of penicillanic acid. Cyclacillin is more resistant to beta-lactamase hydrolysis than ampicillin, is much better absorbed when given by mouth and, as a result, the levels reached in the blood and in the urine are considerably higher than those obtained with the same dose of ampicillin. Cyclacillin has been replaced by newer penicillin treatments. Mechanism of action: The bactericidal activity of cyclacillin results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cyclacillin is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Penicillins"}},{"Cyclic-nucleotide gated channel":{"RelatedTo":["Sodium(+)","Potassium(+)"],"Synonym":"CNG channel","Created":"2007-09-06","SuperCategory":"Tetrameric ion channel","Id":"nifext_2515"}},{"Cyclic-nucleotide gated channel - type A":{"RelatedTo":["Sodium(+)","Potassium(+)"],"Created":"2007-09-06","SuperCategory":"Cyclic-nucleotide gated channel","Id":"nifext_3034"}},{"Cyclic-nucleotide gated channel - type B":{"RelatedTo":["Sodium(+)","Potassium(+)"],"Created":"2007-09-06","SuperCategory":"Cyclic-nucleotide gated channel","Id":"nifext_3052"}},{"Cyclin-dependent kinase 5":{"Synonym":["Cell division protein kinase 5"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nlx_54066","Has role":"Kinase,","Abbrev":"CDK5","Definition":"serine/threonine kinase involved in synaptic regulation and neuronal development; phosphorylates synaptic protein Pctaire1; regulates acetylcholine receptor expression (from Rat Genome Database)"}},{"Cyclin-dependent kinase 5 regulatory subunit 1":{"Synonym":["Tau protein kinase II 23 kDa subunit,Cyclin-dependent kinase 5 activator 1,TPKII regulatory subunit"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nlx_65447","Abbrev":"CDK5R1","Definition":"A protein that serves as a neuron-specific activator of cyclin-dependent kinase 5 (CDK5)(from Entrez gene)"}},{"Cyclizine":{"RelatedTo":["Cholinergic system","Muscarinic acetylcholine receptor M3","Muscarinic acetylcholine receptor M1","Histamine H1 receptor"],"Synonym":["Ciclizina (INN-Spanish)","Cyclizine Chloride","Cyclizine Hydrochloride","Cyclizinum (INN-Latin)","Emoquil","Marazine","Marezine","Marezine Hydrochloride","Marzine","Nautazine","Ne-Devomit","Neo-Devomit","Reis-Fit","Valoid"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:3994","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01176","Definition":"A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) Pharmacology: Cyclizine is a piperazine-derivative antihistamine used as an antivertigo/antiemetic agent. Cyclizine is used in the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. Additionally, it has been used in the management of vertigo in diseases affecting the vestibular apparatus. Although the mechanism by which cyclizine exerts its antiemetic and antivertigo effects has not been fully elucidated, its central anticholinergic properties are partially responsible. The drug depresses labyrinth excitability and vestibular stimulation, and it may affect the medullary chemoreceptor trigger zone. It also possesses anticholinergic, antihistaminic, central nervous system depressant, and local anesthetic effects. Mechanism of action: Vomiting (emesis) is essentially a protective mechanism for removing irritant or otherwise harmful substances from the upper GI tract. Emesis or vomiting is controlled by the vomiting centre in the medulla region of the brain, an important part of which is the chemotrigger zone (CTZ). The vomiting centre possesses neurons which are rich in muscarinic cholinergic and histamine containing synapses. These types of neurons are especially involved in transmission from the vestibular apparatus to the vomiting centre. Motion sickness principally involves overstimulation of these pathways due to various sensory stimuli. Hence the action of cyclizine which acts to block the histamine receptors in the vomiting centre and thus reduce activity along these pathways. Furthermore since cyclizine possesses anti-cholinergic properties as well, the muscarinic receptors are similarly blocked. Drug type: Approved. Small Molecule. Drug category: Antiemetics. Histamine H1 Antagonists. Piperazine Derivatives"}},{"Cyclobenzaprine":{"RelatedTo":"5-hydroxytryptamine 2A receptor","Synonym":["Cyclobenzaprine HCL","Cyclobenz","Flexeril","Flexiban","Proeptatriene"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00924","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00924","Definition":"Cyclobenzaprine is a skeletal muscle relaxant and a central nervous system (CNS) depressant. Cyclobenzaprine acts on the locus coeruleus where it results in increased norepinephrine release, potentially through the gamma fibers which innervate and inhibit the alpha motor neurons in the ventral horn of the spinal cord. It is structurally similar to Amitriptyline, differing by only one double bond. Pharmacology: Cyclobenzaprine, closely related to the antidepressant amitriptyline, is used as a skeletal muscle relaxant to reduce pain and tenderness and improve mobility. Unlike dantrolene, cyclobenzaprine cannot be used to treat muscle spasm secondary to cerebral or spinal cord disease. Mechanism of action: Like other tricyclic antidepressants, cyclobenzaprine exhibits anticholinergic activity, potentiation of norepinephrine, and antagonism of reserpine. Cyclobenzaprine does not directly act on the neuromuscular junction or the muscle but relieves muscle spasms through a central action, possibly at the brain stem level. Cyclobenzaprine binds to the serotonin receptor and is considered a 5-HT2 receptor antagonist that reduces muscle tone by decreasing the activity of descending serotonergic neurons. Drug type: Approved. Small Molecule. Drug category: Antidepressive Agents, Tricyclic. Muscle Relaxants. Muscle Relaxants, Central. Skeletal Muscle Relaxants. Tranquilizing Agents"}},{"Cyclohexyl nitrite":{"CurationStatus":"uncurated","SuperCategory":"Alkyl nitrite","Id":"nlx_chem_100302","Has role":["Drug of abuse role","Inhalant","Drug"],"Definition":"An alkyl nitrite made from cyclohexanol. It acts as an antianginal. (Wikipedia)"}},{"Cyclopentolate":{"RelatedTo":["Cholinergic system"],"Synonym":["Ciclopentolato (INN-Spanish)","Cyclopentoiate","Cyclopentolate HCL","Cyclopentolatum (INN-Latin)","Cyclopentylate","Diopentolate","AK-Pentolate","Akpentolate","Cyclogyl","Cylate","Minims Cyclopentolate","Mydrilate","Ocu-Pentolate"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"DB00979","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00979","Definition":"A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia. (PubChem) Pharmacology: Cyclopentolate is an anti-muscarinic in the same class as atropine and scopolamine. Cyclopentolate blocks the receptors in the muscles of the eye (muscarinic receptors). These receptors are involved controlling the pupil size and the shape of the lens. Cyclopentolate thus induces relaxation of the sphincter of the iris and the ciliary muscles. When applied topically to the eyes, it causes a rapid, intense cycloplegic and mydriatic effect that is maximal in 15 to 60 minutes; recovery usually occurs within 24 hours. The cycloplegic and mydriatic effects are slower in onset and longer in duration in patients who have dark pigmented irises. Mechanism of action: By blocking muscarinic receptors, cyclopentolate produces dilatation of the pupil (mydriasis) and prevents the eye from accommodating for near vision (cycloplegia). Drug type: Approved. Small Molecule. Drug category: Antimuscarinic eye preparations. Muscarinic Antagonists. Mydriatics. Parasympatholytics"}},{"Cyclophosphamide":{"RelatedTo":"DNA","Synonym":["cyclophosphamide","ASTA","Asta B 518","CP","CPA","CTX","CY","Clafen","Claphene","Cyclophosphamid","Cyclophosphamide Monohydrate","Cyclophosphamide Sterile","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphoramide","Cyclostin","Cyklofosfamid","Cytophosphan","Cytoxan","Cytoxan Lyoph","Endoxan","Endoxan R","Endoxan-Asta","Endoxana","Endoxanal","Endoxane","Enduxan","Genoxal","Hexadrin","Lyophilized Cytoxan","Mitoxan","Neosar","Procytox","Rcra Waste Number U058","Revimmune","Semdoxan","Sendoxan","Senduxan"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:4027","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00531","Definition":"Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (PubChem) Pharmacology: Cyclophosphamide is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death. Mechanism of action: Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. Drug type: Approved. Investigational. Small Molecule. Drug category: Antineoplastic Agents. Antineoplastic Agents, Alkylating. Antirheumatic Agents. Immunosuppressive Agents. Mutagens. Myeloablative Agonists"}},{"Cycloserine":{"RelatedTo":["D-alanine--D-alanine ligase A"],"Synonym":["Cicloserina","D-CS","D-Cycloserine","D-Cycloserine synth","BP 88","D-Cycloserine","synthetic","D-Oxamicina","D-Oxamycin","DL-Cycloserine","L-Cycloserine","alpha-Cycloserine","Closerin","Closina","Cyclomycin","Cyclorin","Cycloserin","Farmiserina","Farmiserine","Micoserina","Miroserina","Miroseryn","Novoserin","Orientomycin","Oxamicina","Oxamycin","Oxymycin","Seromycin","Tebemicina","Tisomycin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:40009","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00260","Definition":"Antibiotic substance produced by Streptomyces garyphalus. (PubChem) Pharmacology: Cycloserine, a broad-spectrum antibiotic, may be bactericidal or bacteriostatic, depending on its concentration at the site of infection and the susceptibility of the organism. Cycloserine works by blocking the formation of these peptidoglycans. By doing this the walls of the bacteria become weak and it results in the death of the bacteria Mechanism of action: Cycloserine is an analog of the amino acid D-alanine. It interferes with an early step in bacterial cell wall synthesis in the cytoplasm by competitive inhibition of two enzymes, L-alanine racemase, which forms D-alanine from L-alanine, and D-alanylalanine synthetase, which incorporates D-alanine into the pentapeptide necessary for peptidoglycan formation and bacterial cell wall synthesis. Drug type: Approved. Small Molecule. Drug category: Anti-Infective Agents, Urinary. Antibiotics. Antibiotics, Antitubercular. Antimetabolites"}},{"Cyclosporine":{"RelatedTo":["Calcium signal-modulating cyclophilin ligand","Peptidyl-prolyl cis-trans isomerase A","Multidrug resistance protein 1","Photoreceptor"],"Synonym":["Ciclosporin","Cyclosporin","Cyclosporin A","cyclosporine","Gengraf (Abbott labs)","Neoral (Novartis)","Restasis","Restasis (Allergan Inc)","Sandimmune (Novartis)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00091","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00091","Definition":"A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Pharmacology: Used in immunosuppression for prophylactic treatment of organ transplants, cyclosporine exerts specific and reversible inhibition of immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited. The T1-helper cell is the main target, although the T1-suppressor cell may also be suppressed. Sandimmune (cyclosporine) also inhibits lymphokine production and release including interleukin-2. Mechanism of action: Cyclosporine binds to cyclophillin. The complex then inhibits calcineurin which is normally responsible for activating transcription of interleukin 2. Cyclosporine also inhibits lymphokine production and interleukin release. In ophthalmic applications, the precise mechanism of action is not known. Cyclosporine emulsion is thought to act as a partial immunomodulator in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Drug type: Approved. Biotech. Investigational. Drug category: Antifungal Agents. Antirheumatic Agents. Dermatologic Agents. Enzyme Inhibitors. Immunomodulatory Agents. Immunosuppressive Agents"}},{"Cyclothiazide":{"RelatedTo":["Sodium/potassium-transporting ATPase gamma chain","Carbonic anhydrase 1","Carbonic anhydrase 2","Carbonic anhydrase 4","Calcium-activated potassium channel subunit alpha 1"],"Synonym":["Ciclotiazida (INN-Spanish)","Ciclotiazide (DCIT)","Cyclothiazidum (INN-Latin)","Anhydron","Aquirel","Doburil","Fluidil","Renazide"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00606","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00606","Definition":"As a diuretic, cyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like cyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of cyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. Cyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Pharmacology: Like other thiazides, cyclothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Cyclothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Cyclothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. Mechanism of action: As a diuretic, cyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like cyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of cyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. Drug type: Approved. Small Molecule. Drug category: Antihypertensive Agents. Diuretics"}},{"Cyclothymic Disorder":{"Synonym":"Cyclothymic Personality","Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Bipolar Disorder","Id":"birnlex_12755","Definition":"An affective disorder characterized by periods of depression and hypomania. These may be separated by periods of normal mood (MeSH)."}},{"Cycrimine":{"RelatedTo":["Cholinergic system"],"Synonym":["Cycrimine hydrochloride"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"DB00942","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00942","Definition":"Cycrimine is a drug used to reduce levels of acetylcholine to return a balance with dopamine in the treatment and management of Parkinson's disease. Pharmacology: Cycrimine is a central anticholenergic used in the treatment of the symptoms of Parkinson's disease. It is a drug used to reduce levels of acetylcholine. Acetylcholine is usually in balance with dopamine neurotransmitters, however lower levels of dopamine are present in the brain of patients suffering from Parkinson's disease. By lowering levels of acetylcholine, it is thought that this balance may be restored. Mechanism of action: Cycrimine binds the muscarinic acetylcholine receptor M1, effectively inhibiting acetylcholine. This decrease in acetylcholine restores the normal dopamine-acetylcholine balance and relieves the symptoms of Parkinson's disease. Drug type: Approved. Small Molecule. Drug category: Antidyskinetics. Antiparkinson Agents"}},{"Cylinder Axis":{"ValueRepresentation":"FL","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0022_0009","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149810","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FL","Definition":"Axis value in degrees"}},{"Cylinder Lens Power":{"ValueRepresentation":"FL","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0022_0008","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149811","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FL","Definition":"Cylinder value in diopters"}},{"Cylindrical":{"Synonym":["tubular","rod-shaped"],"SuperCategory":"Convex 3-D shape","Id":"PATO_0001873","Definition":"A convex 3-D shape that has a consistently-sized round cross section."}},{"Cyprinidae":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C0010613","SuperCategory":"Cyprinoidea","Id":"birnlex_337"}},{"Cypriniformes":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C0010614","SuperCategory":"Cypriniphysi","Id":"birnlex_459"}},{"Cypriniphysi":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C1210431","SuperCategory":"Otophysi","Id":"birnlex_455"}},{"Cyprinoidea":{"Synonym":"Cyprinoidei","Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C1003344","SuperCategory":"Cypriniformes","Id":"birnlex_344"}},{"Cyproheptadine":{"RelatedTo":["Histamine H1 receptor"],"Synonym":[", Cypoheptadine","Cyproheptadiene","Cyproheptadine Hcl","Dibenzosuberonone/Cyproheptadine","Dronactin","Eiproheptadine","Periactin","Periactine","Periactinol"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00434","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00434","Definition":"A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. (PubChem) Pharmacology: Cyproheptadine is a piperidine antihistamine. Unlike other antihistamines, this drug also antagonizes serotonin receptors. This action makes Cyproheptadine useful in conditions such as vascular headache and anorexia. Cyproheptadine does not prevent the release of histamine but rather competes with free histamine for binding at HA-receptor sites. Cyproheptadine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. Most antihistamines possess significant anticholinergic properties, but Cyproheptadine exerts only weak anticholinergic actions. Blockade of central muscarinic receptors appears to account for Cyproheptadine's antiemetic effects, although the exact mechanism is unknown. Cyproheptadine also competes with serotonin at receptor sites in smooth muscle in the intestines and other locations. Antagonism of serotonin on the appetite center of the hypothalamus may account for Cyproheptadine's ability to stimulate appetite. Cyproheptadine also has been used to counter vascular headaches, which many believe are caused by changes in serotonin activity, however it is unclear how Cyproheptadine exerts a beneficial effect on this condition. Mechanism of action: Cyproheptadine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. Drug type: Approved. Small Molecule. Drug category: Anti-Allergic Agents. Antihistamine derivatives. Antipruritics. Gastrointestinal Agents. Histamine H1 Antagonists. Serotonin Antagonists"}},{"Cys-loop ligand-gated ion channel":{"Created":"2007-09-19","SuperCategory":"Pentameric ion channel","Id":"nifext_5237"}},{"CysLT1 receptor":{"Created":"2007-09-19","Synonym":"CysLT1; CysLTR1; Cysteinyl leukotriene D4 receptor; HG55; HMTMF81; LTD4 receptor; Cysteinyl leukotriene receptor 1","CurationStatus":"uncurated","SuperCategory":"Leukotriene and lipoxin receptor","Id":"nifext_7757"}},{"CysLT2 receptor":{"Created":"2007-09-19","Synonym":"CysLT2; CysLTR2; HG57; HPN321; hGPCR21; Cysteinyl leukotriene receptor 2","CurationStatus":"uncurated","SuperCategory":"Leukotriene and lipoxin receptor","Id":"nifext_6376"}},{"Cystatin C":{"SuperCategory":"Protein","Id":"nlx_174"}},{"Cysteamine":{"RelatedTo":"Somatostatin","Synonym":["(2-Mercaptoethyl)amine","2-Amino-1-ethanethiol","2-Aminoethanethiol","2-Aminoethyl mercaptan","2-Mercaptoethanamine","Aminoethyl mercaptan","Cisteamina","Cysteamide","Cysteamin","Cysteamine bitartate","Cysteamine hydrochloride","Cysteinamine","Decarboxycysteine","Ethanethiolamine","MEA","Mercamine","Mercaptamin","Thioethanolamine","beta-Aminoethanethiol","beta-MEA","beta-Mercaptoethylamine","Becaptan","Cystavision","Lambraten","Lambratene","Mecramine","Mercamin","Merkamin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:17141","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00847","Definition":"A radiation-protective agent that oxidizes in air to form cystamine. It can be given intravenously or orally to treat radiation sickness. The bitartrate has been used for the oral treatment of nephropathic cystinosis. (PubChem) Pharmacology: People born without the ability to metabolize the amino acid cystine suffer from cystinosis, a rare inherited disorder characterized by the deposition and accumulation of cystine crystals throughout the body. These crystals cause considerable damage, particularly in the kidney. Kidney failure can occur by the age of 10 in untreated patients. Cysteamine prevents the accumulation of cystine crystals and is prescribed to prevent further kidney damage. Cysteamine helps to convert cystine into less harmful chemical forms that can be removed from cells. Mechanism of action: The free thiol cysteamine depletes cystinotic leukocytes and other cells of cystine, whose accumulation is considered the cause of organ damage in cystinosis. Drug type: Approved. Investigational. Small Molecule. Drug category: Nephropathic cystinosis therapy. Radiation-Protective Agents"}},{"Cystic":{"Comment":"Cystic is an abnormal condition.","SuperCategory":["Structure"],"Id":"PATO_0001673"}},{"Cystoid macular retinal degeneration":{"Synonym":["Central cystoid Retinal Edema"],"Created":"2007-11-18","CurationStatus":"uncurated","Umlscui":["C0154850"],"SuperCategory":"Macular degeneration","Id":"birnlex_12814","Definition":"Fluid accumulation in the outer layer of the MACULA LUTEA at the center of the RETINA. Cystic spaces are formed and may lead to a macular depression or hole."}},{"Cytarabine":{"RelatedTo":["DNA polymerase beta"],"Synonym":["Ara-C","AraC","Arabinocytidine","Arabinofuranosylcytosine","Arabinosylcytosine","Aracytidine","Aracytin","Aracytine","Beta-cytosine arabinoside","Citarabina (INN-Spanish)","Cytarabin","Cytarabina","Cytarabinoside","Cytarabinum (INN-Latin)","Cytosine 1-beta-D-arabinofuranoside","Cytosine arabinofuranoside","Cytosine arabinose","Cytosine arabinoside","Cytosine beta-D-arabinoside","Cytosine","beta-D-arabinoside","Cytosine-1-beta-D-arabinofuranoside","Cytosine-beta-D-arabinofuranoside","Cytosine-beta-arabinoside","beta-Arabinosylcytosine","beta-D-Arabinosylcytosine","cytarabine liposome injection","AR3","Alexan","Arabitin","Arafcyt","Cytarbel","Cytosar","Cytosar-U","Depocyt","Depocyt (liposomal)","Erpalfa","Iretin","Spongocytidine","Tarabine"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:28680","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00987","Definition":"A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Pharmacology: Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the \"S\" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle. Mechanism of action: Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Although the mechanism of action is not completely understood, it appears that cytarabine acts through the inhibition of DNA polymerase. A limited, but significant, incorporation of cytarabine into both DNA and RNA has also been reported. Drug type: Approved. Investigational. Small Molecule. Drug category: Antimetabolites. Antimetabolites, Antineoplastic. Antineoplastic Agents. Antiviral Agents. Immunosuppressive Agents"}},{"Cytidine":{"Created":"2007-09-19","SuperCategory":"Pyrimidine Nucleoside","Id":"nifext_5191"}},{"Cytidine 5'-diphosphate":{"Created":"2007-09-19","SuperCategory":"Pyrimidine Nucleotide","Id":"nifext_5209"}},{"Cytidine 5'-monophosphate":{"Created":"2007-09-19","SuperCategory":"Pyrimidine Nucleotide","Id":"nifext_5208"}},{"Cytidine 5'-triphosphate":{"Created":"2007-09-19","SuperCategory":"Pyrimidine Nucleotide","Id":"nifext_5210"}},{"Cytoarchitectural fields of hippocampal formation":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1192"}},{"Cytoarchitectural part of dentate gyrus":{"Created":"2008-03-24","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_4126"}},{"Cytoarchitectural part of retina":{"CurationStatus":"uncurated","SuperCategory":"Regional part of retina","Id":"nlx_47000"}},{"Cytoarchitectural part of spinal cord gray matter":{"CurationStatus":"uncurated","SuperCategory":"Regional part of spinal cord","Id":"nlx_75658"}},{"Cytochrome c":{"SuperCategory":"Protein","Id":"nlx_subcell_20090205","Definition":"A small heme protein found loosely associated with the inner membrane of the mitochondrion."}},{"Cytokine":{"CurationStatus":"uncurated","SuperCategory":"Molecule role","Id":"sao1611333173","Definition":"Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner (MSH)."}},{"Cytoplasmic Surface":{"SuperCategory":"Membrane Surface","Id":"sao1514682949"}},{"Cytoskeletal Associated Protein":{"SuperCategory":"Molecule role","Id":"sao630204337"}},{"Cytoskeletal Element":{"CurationStatus":"uncurated","SuperCategory":"Cellular component","Id":"sao1635329413"}},{"Cytoskeletal Protein":{"SuperCategory":"Protein","Id":"sao1593305396","Definition":"Major constituent of the cytoskeleton found in the cytoplasm of eukaryotic cells. They form a flexible framework for the cell, provide attachment points for organelles and formed bodies, and make communication between parts of the cell possible (MSH)."}},{"Cytoskeletal system":{"Created":"2006-07-15","Synonym":"cytoskeleton","CurationStatus":"uncurated","SuperCategory":"Constitutional part of cell","Id":"birnlex_878"}},{"Cytosol":{"CurationStatus":"uncurated","SuperCategory":"Cellular component","Id":"sao101633890","Definition":"The part of the cytoplasm that does not contain membranous or particulate subcellular components (UMLS)."}},{"D Dopa":{"RelatedTo":["Dopamine"],"Synonym":"D-3-(3,4-dihydroxyphenyl)alanine; 3,4-dihydroxy-D-phenylalanine; D-3,4-dihydroxyphenylalanine; (+)-3,4-dihydroxyphenylalanine; dopa D-form; C9H11NO4; N[C@H](Cc1ccc(O)c(O)c1)C(O)","CurationStatus":"uncurated","SuperCategory":"DOPA","Id":"CHEBI:49169","Has role":"Drug,","Is part of":["Catecholamine system"],"DefiningCitation":"Chemical Entities of Biological Interest (CHEBI)","Definition":"A dopa that has formula C9H11NO4. It is a enantiomer of L-dopa. (Adapted from CHEBI)."}},{"D1 receptor":{"PMID":"215920","RelatedTo":["Dopamine","Schizophrenia"],"Created":"2007-09-19","Synonym":["D1; D(1A) dopamine receptor","DRD1","D1 dopamine receptor"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nifext_5845","Has role":["Dopamine receptor","Neurotransmitter Receptor"],"Is part of":["Catecholamine system"],"DefiningCitation":"Entrez Gene","Abbrev":"D1R","Definition":"Dopamine receptor that stimulates adenylyl cyclase activity, and has a high affinity for SKF 38393 and its homologs. It is a protien that is encoded, in humans, by the DRD1 gene. The D1 subtype is the most abundant dopamine receptor in the central nervous system. This G-protein coupled receptor stimulates adenylyl cyclase and activates cyclic AMP-dependent protein kinases. D1 receptors are enriched in Caudate-putamen, nucleus accumbens, and olfactory tubercles. These receptors regulate neuronal growth and development, mediate some behavioral responses, and modulate dopamine receptor D2-mediated events. Alternate transcription initiation sites result in two transcript variants of this gene. (adapted from Entrez Gene)"}},{"D2 receptor":{"PMID":"215920","RelatedTo":["Dopamine","Parkinsons disease","D3 receptor"],"Created":"2007-09-19","Synonym":"D2; D2S; D2L; D2S/D2L; Dopamine D2 receptor; D(2) dopamine receptor; DRD2","CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nifext_5833","Has role":["Dopamine receptor","Neurotransmitter Receptor"],"Is part of":["Catecholamine system"],"DefiningCitation":"Entrez Gene","Abbrev":"D2R","Definition":"Dopamine receptor is a G-protien coupled receptor that inhibits adenylyl cyclase activity, potentiate calcium evoked release of arachadonic acid, increase potassium channel opening and in some cells decrease intracellular calcium concentrations.  D2 receptors have a high affinity for antipsychotic drugs and have higher levels of expression in mammalian hippocampus and hypothalamus. It is encoded by the DRD2 gene in humans and a missense mutation in this gene causes myoclonus dystonia; other mutations have been associated with schizophrenia. Alternative splicing of this gene results in two transcript variants encoding different isoforms. A third variant has been described, but it has not been determined whether this form is normal or due to aberrant splicing. (adapted from Entrez Gene)."}},{"D3 receptor":{"PMID":"8071839","RelatedTo":["Dopamine","D2 receptor"],"Created":"2007-09-19","Synonym":["D3; D(3) dopamine receptor"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nifext_6751","Has role":["Dopamine receptor","Neurotransmitter Receptor"],"Is part of":["Catecholamine system"],"DefiningCitation":"Entrez Gene","Abbrev":"D3R","Definition":"D3 receptor is the transcription product of the DRD3 gene. This subtype of dopaminergic receptor decreases adenylyl cyclase activity through inhibitory G-proteins. This receptor is expressed in phylogenetically older regions of the brain, especially enriched in the Islands of Calleja, olfactory tubercles, and the nucleus accumbens. This suggests that this receptor plays a role in cognitive and emotional functions. It is a target for drugs which treat schizophrenia, drug addiction, and Parkinson's disease. Alternative splicing of this gene results in multiple transcript variants that would encode different isoforms, although some variants may be subject to nonsense-mediated decay. (Adapted from Entrez Gene)"}},{"D4 receptor":{"PMID":["1840645"],"RelatedTo":["Dopamine","D2 receptor"],"Created":"2007-09-19","Synonym":"D4; D(2C) dopamine receptor; Dopamine D4 receptor; D(4) dopamine receptor","CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nifext_7163","Has role":["Dopamine receptor","Neurotransmitter Receptor"],"Is part of":["Catecholamine system"],"DefiningCitation":"Wikipedia","Abbrev":"D4R","Definition":"This Dopaminergic receptor is a G protein-coupled receptor encoded by the DRD4 gene. As with other dopamine receptor subtypes, the D4  receptor is activated by the neurotransmitter dopamine, however this specific subtype is enriched in expression in the frontal cortex, diencephalon, and the brain stem. It is also a target for drugs which treat schizophrenia  and Parkinson disease. The D4 receptor is considered to be D2-like in which the activated receptor inhibits the enzyme adenylate cyclase, thereby reducing the intracellular concentration of the second messenger cyclic AMP. (Adapted from Wikipedia)"}},{"D5 receptor":{"PMID":["1774076"],"RelatedTo":["Dopamine"],"Created":"2007-09-19","Synonym":"D5; 1B; D(5) dopamine receptor; D1beta dopamine receptor; D(1B) dopamine receptor; DRD5;","CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nifext_7274","Has role":["Dopamine receptor","Neurotransmitter Receptor"],"Is part of":["Catecholamine system"],"DefiningCitation":"Entrez Gene","Abbrev":"D5R","Definition":"This dopaminergic receptor is a protein that in humans in encoded by the DRD5 gene. The D5 subtype is a G-protein coupled receptor which stimulates adenylyl cyclase.This receptor is expressed in neurons in the limbic regions of the brain, especially in the hippocampus and the hypothalamus. It has a 10-fold higher affinity for dopamine than the D1 subtype. Pseudogenes related to this gene reside on chromosome 1 and chromosome 2. (Adapted from Entrez Gene)."}},{"Dacarbazine":{"RelatedTo":"DNA polymerase subunit alpha B","Synonym":["Biocarbazine R","DIC","DTIC","DTIE","Dacarbazino (INN-Spanish)","Dacarbazinum (INN-Latin)","Dtic-Dome","ICDMT","ICDT","Imidazole Carboxamide"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:4305","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00851","Definition":"An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) Pharmacology: After intravenous administration of DTIC-Dome, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. 1 In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. 1 The average cumulative excretion of unchanged DTIC in the urine is 40% of the injected dose in 6 hours. 1 DTIC is subject to renal tubular secretion rather than glomerular filtration. At therapeutic concentrations DTIC is not appreciably bound to human plasma protein. Mechanism of action: Possibly blocking the formation of inosinic acid. Drug type: Approved. Small Molecule. Drug category: Antineoplastic Agents. Antineoplastic Agents, Alkylating"}},{"Daclizumab":{"RelatedTo":["Interleukin-2 receptor subunit beta","Interleukin-2 receptor alpha chain","High affinity immunoglobulin gamma Fc receptor I","Low affinity immunoglobulin gamma Fc region receptor III-B","Complement C1r subcomponent","Complement C1q subcomponent subunit A","Complement C1q subcomponent subunit B","Complement C1q subcomponent subunit C","Low affinity immunoglobulin gamma Fc region receptor III-A","Low affinity immunoglobulin gamma Fc region receptor II-a","Low affinity immunoglobulin gamma Fc region receptor II-b"],"Synonym":["Anti-IL-2","Humanized antiCD25","Ig gamma-1 chain C region"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00111","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00111","Definition":"Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. Pharmacology: Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection. Mechanism of action: Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. Drug type: Approved. Biotech. Investigational. Drug category: Immunomodulatory Agents. Immunosuppressive Agents"}},{"Dactinomycin":{"RelatedTo":"DNA","Synonym":["AD, Antibiotic From Streptomyces Parvullus","Dactinomicina (INN-Spanish)","Dactinomycine (INN-French)","Dactinomycinum (INN-Latin)","ACT","ACT D","ACTINOMYCIN D","ACTO-D","Actactinomycin a Iv","Actinomycin 11 Cosmegen","Actinomycin 7","Actinomycin Aiv","Actinomycin C1","Actinomycin I","Actinomycin I1","Actinomycin Iv","Actinomycin X 1","Actinomycindioic D Acid","Dilactone","Chounghwamycin B","Cosmegen","Dactinomycin D","Dilactone Actinomycin D Acid","Dilactone Actinomycindioic D Acid","HBF 386 Meractinomycin","Lyovac Cosmegen","Meractinomycin","Oncostatin K"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00970","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00970","Definition":"A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Pharmacology: Generally, the actinomycins exert an inhibitory effect on gram-positive and gram-negative bacteria and on some fungi. However, the toxic properties of the actinomycins (including dactinomycin) in relation to antibacterial activity are such as to preclude their use as antibiotics in the treatment of infectious diseases. Because the actinomycins are cytotoxic, they have an antineoplastic effect which has been demonstrated in experimental animals with various types of tumor implant. This cytotoxic action is the basis for their use in the treatment of certain types of cancer. Dactinomycin is believed to produce its cytotoxic effects by binding DNA and inhibiting RNA synthesis. Mechanism of action: Good evidence exists that this drug bind strongly, but reversibly, to DNA, interfering with synthesis of RNA and, consequently, with protein synthesis. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Antibiotics. Antibiotics, Antineoplastic. Antineoplastic Agents. Nucleic Acid Synthesis Inhibitors. Protein Synthesis Inhibitors"}},{"Damage":{"SuperCategory":"Structure","Id":"PATO_0001020"}},{"Damaged":{"SuperCategory":"Damage","Id":"PATO_0001167"}},{"Danazol":{"RelatedTo":["Estrogen receptor","Gonadotropin-releasing hormone receptor","Gonadotropin-releasing hormone II receptor","Sex hormone-binding globulin"],"Synonym":[", Anatrol","Chronogyn","Cyclomen"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:4315","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01406","Definition":"A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. (PubChem) Pharmacology: Danazol is a derivative of the synthetic steroid ethisterone, a modified testosterone. It was approved by the U.S. Food and Drug Administration (FDA) as the first drug to specifically treat endometriosis, but its role as a treatment for endometriosis has been largely replaced by the gonadotropin-releasing hormone (GnRH) agonists. Danazol has antigonadotropic and anti-estrogenic activities. Danazol acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Mechanism of action: As a gonadotropin inhibitor, danazol suppresses the pituitary-ovarian axis possibly by inhibiting the output of pituitary gonadotropins. Danazol also depresses the preovulatory surge in output of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) and therefore reduces ovarian estrogen production. Danazol also may directly inhibit ovarian steroidogenesis, bind to androgen, progesterone, and glucocorticoid receptors, bind to sex-hormone-binding globulin and corticosteroid-binding globulin, and increase the metabolic clearance rate of progesterone. Endometriosis - As a consequence of suppression of ovarian function, both normal and ectopic endometrial tissues become inactive and atrophic. As a result, anovulation and associated amenorrhea occur. Fibrocystic breast disease - The exact mechanism of action is unknown, but may be related to suppressed estrogenic stimulation as a result of decreased ovarian production of estrogen. A direct effect on steroid receptor sites in breast tissue also is possible. Disappearance of nodularity, relief of pain and tenderness, and possibly changes in the menstrual pattern result. Hereditary angioedema - Danazol corrects the underlying biochemical deficiency by increasing serum concentrations of the deficient C1 esterase inhibitor, resulting in increased serum concentrations of the C4 component of the complement system. (Source: PharmGKB) Drug type: Approved. Small Molecule. Drug category: Estrogen Antagonists"}},{"Danio":{"Synonym":"Brachydanio","Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C0998846","SuperCategory":"Rasborinae","Id":"birnlex_356"}},{"Dantrolene":{"RelatedTo":["Serum albumin"],"Synonym":["Dantrolene Sodium","Dantroleno (INN-Spanish)","Dantrolenum (INN-Latin)","Dantrium"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01219","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01219","Definition":"Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. Pharmacology: Dantrolene is classified as a direct-acting skeletal muscle relaxant. It is currently the only specific and effective treatment for malignant hyperthermia. In isolated nerve-muscle preparation, Dantrium has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. In skeletal muscle, Dantrium dissociates excitation-contraction coupling, probably by interfering with the release of Ca2+ from the sarcoplasmic reticulum. In the anesthetic-induced malignant hyperthermia syndrome, evidence points to an intrinsic abnormality of skeletal muscle tissue. In selected humans, it has been postulated that triggering agents (e.g.,general anesthetics and depolarizing neuromuscular blocking agents) produce a change within the cell which results in an elevated myoplasmic calcium. This elevated myoplasmic calcium activates acute cellular catabolic processes that cascade to the malignant hyperthermia crisis. It is hypothesized that addition of Dantrium to the triggered malignant hyperthermic muscle cell reestablishes a normal level of ionized calcium in the myoplasm. Mechanism of action: Dantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor 1, and decreasing intracellular calcium concentration. Ryanodine receptors mediate the release of calcium from the sarcoplasmic reticulum, an essential step in muscle contraction. Drug type: Approved. Small Molecule. Drug category: Muscle Relaxants, Central"}},{"Dapiprazole":{"RelatedTo":["Alpha-1A adrenergic receptor","Alpha-1B adrenergic receptor"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:51066","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00298","Definition":"Dapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination. (Wikipedia) Pharmacology: Dapiprazole is an alpha-adrenergic blocking agent. It produces miosis by blocking the alpha-adrenergic receptors on the dilator muscle of the iris. Dapiprazole produces no significant action on ciliary muscle contraction and thus, there are no changes in the depth of the anterior chamber of the thickness of the lens. It does not alter the IOP either in normal eyes or in eyes with elevated IOP. The rate of pupillary constriction may be slightly slower in clients with brown irises than in clients with blue or green irises. Mechanism of action: Dapiprazole acts through blocking the alpha1-adrenergic receptors in smooth muscle. It produces miosis through an effect on the dilator muscle of the iris and does not have any significant activity on ciliary muscle contraction and, therefore does not induce a significant change in the anterior chamber depth or the thickness of the lens. Drug type: Approved. Small Molecule. Drug category: Adrenergic alpha-Antagonists. Antimydriatics. Antipsychotic Agents. Ophthalmologicals"}},{"Dappled":{"Synonym":"blotched","SuperCategory":"Multi-colored","Id":"PATO_0001535","Definition":"A color pattern inhering to a bearer by virtue of being marked with small spots, patches, or specks of hue or degree of saturation differing from that of the background."}},{"Dapsone":{"RelatedTo":["Dihydrofolate reductase","Dihydropteroate synthase 1"],"Synonym":["Acedapsone","DADPS","DDS","DSS","Dapson","Dapsonum","Dds","Diaphenylsulfone","Dds","Pharmaceutical","Diamino-diphenyl sulphone","Diaminodifenilsulfona","Diaminodiphenyl Sulfone","Diaphenylsulfon","Diaphenylsulfone","Diaphenylsulphon","Diaphenylsulphone","Diphenasone","Metabolite C","N","N'-Diphenyl Sulfondiamide","P","P'-Sulfonyldianiline","P,P'-Diaminodiphenyl Sulfone","P,P-Diaminodiphenyl Sulphone","P,P-Sulfonylbisbenzamine","P,P-Sulfonylbisbenzenamine","P,P-Sulphonylbisbenzamine","P,P-Sulphonylbisbenzenamine","P,P-Sulphonyldianiline","P-Aminophenyl Sulfone","Sulfonyldianiline","Sulphadione","Sulphonyldianiline","dapsone","Araldite Ht","Avlosulfon","Avlosulfone","Avlosulphone","Croysulfone","Croysulphone","Dimitone","Diphone","Dubronax","Dumitone","Eporal","ICI","Normet","Novophone","Recolip","Sulfadione","Sulfanona-Mae","Sulfon-Mere","Sulfona","Sulfona-Mae","Sulfone Ucb","Sulphon-Mere","Sumicure S","Tarimyl"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00250","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00250","Definition":"A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) Pharmacology: Dapsone is a sulfone with anti-inflammatory immunosuppressive properties as well as antibacterial and antibiotic properties. Dapsone is the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. As an anti-infective agent, it is also used for treating malaria and, recently, for Pneumocystic carinii pneumonia in AIDS patients. Dapsone is absorbed rapidly and nearly completely from the gastrointestinal tract. Dapsone is distributed throughout total body water and is present in all tissues. However, it tends to be retained in skin and muscle and especially in the liver and kidney: traces of the drug are present in these organs up to 3 weeks after therapy cessation. Mechanism of action: Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-Infective Agents. Anti-Infectives. Anti-inflammatory Agents. Antimalarials. Antimycobacterials. Folic Acid Antagonists. Leprostatic Agents"}},{"Daptomycin":{"RelatedTo":["Gram positive bacteria cell membranes","Calcium ions","Phosphatidyl glycerol"],"Synonym":["LY 146032","daptomycin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00080","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00080","Definition":"Daptomycin is a lipopeptide antibiotic that kills susceptible gram positive bacteria by disrupting their membrane potential. It is a naturally-occurring compound found in the soil bacterium Streptomyces roseosporus. Antibiotics are used in the treatment of infections caused by bacteria. They work by killing bacteria or preventing their growth. Daptomycin will not work for colds, flu, or other virus infections. It was approved in September 2003 for the treatment of complicated skin and soft tissue infections. It has a safety profile similar to other agents commonly administered to treat gram-positive infections. Pharmacology: Daptomycin is a lipopeptide antibiotic active against Gram-positive bacteria only. It has proven in vitro activity against enterococci (including glycopeptide-resistant Enterococci (GRE)), staphylococci (including methicillin-resistant Staphylococcus aureus), streptococci and corynebacteria. Mechanism of action: Daptomycin appears to bind or insert into the outer membrane of gram positive bacteria. This binding casues rapid depolarisation, resulting in a loss of membrane potential leading to inhibition of protein, DNA and RNA synthesis, which results in bacterial cell death. The bactericidal activity of daptomycin is concentration-dependent. There is in vitro evidence of synergy with -lactam antibiotics. Drug type: Approved. Biotech. Investigational. Drug category: Anti-Bacterial Agents"}},{"Darbepoetin alfa":{"RelatedTo":"Erythropoietin receptor","Synonym":["Epoetin","Erythropoietin precursor"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00012","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00012","Definition":"Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW"}},{"Darifenacin":{"RelatedTo":["Cholinergic system"],"Synonym":["Darifenacin","Emselex"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"DB00496","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00496","Definition":"Darifenacin (Enablex, Novartis) is a medication used to treat urinary incontinence.Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It should not be used in people with urinary retention.It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome. Pharmacology: Darifenacin is a competitive muscarinic receptor antagonist. In vitro studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M3 receptor than for the other known muscarinic receptors (9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4). Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion. Adverse drug effects such as dry mouth, constipation and abnormal vision may be mediated through effects on M3 receptors in these organs. Mechanism of action: Darifenacin selectively antagonizes the muscarinic M3 receptor. M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function. Drug type: Approved. Investigational. Small Molecule. Drug category: Muscarinic Antagonists. Urinary antispasmodics"}},{"Dark blue":{"SuperCategory":"Blue","Id":"PATO_0001244","Definition":"A color consisting of blue hue and low brightness."}},{"Dark brown":{"SuperCategory":"Brown","Id":"PATO_0001245"}},{"Dark cyan":{"SuperCategory":"Cyan","Id":"PATO_0001248","Definition":"A color consisting of cyan hue and low brightness."}},{"Dark green":{"SuperCategory":"Green","Id":"PATO_0001249","Definition":"A color consisting of green hue and low brightness."}},{"Dark grey":{"SuperCategory":"Grey","Id":"PATO_0001251","Definition":"A color consisting of grey hue and low brightness."}},{"Dark magenta":{"SuperCategory":"Magenta","Id":"PATO_0001254","Definition":"A color consisting of magenta with low brightness."}},{"Dark Material":{"SuperCategory":"Protein Aggregate","Id":"sao1122901839","Definition":"Irregularly shaped clumps of denatured or misfolded proteins observed in some neurons after a period of ischemia that stain heavily with osmium in electon microscopic preparations."}},{"Dark orange":{"SuperCategory":"Orange","Id":"PATO_0001256","Definition":"A color consisting of orange color and low brightness."}},{"Dark pale pink":{"Synonym":"pale pink","SuperCategory":"Pink","Id":"PATO_0001280","Definition":"Pink color having medium brightness and low saturation."}},{"Dark phase":{"SuperCategory":"Phase","Id":"PATO_0000501","Definition":"The dark cycle phase."}},{"Dark purple":{"SuperCategory":"Purple","Id":"PATO_0001259","Definition":"A color consisting of purple color and low brightness."}},{"Dark rearing paradigm":{"CurationStatus":"uncurated","SuperCategory":"Experimental paradigm","Id":"nlx_152202"}},{"Dark red":{"SuperCategory":"Red","Id":"PATO_0001261","Definition":"A color consisting of red hue and low brightness."}},{"Dark red brown":{"SuperCategory":"Red brown","Id":"PATO_0001288"}},{"Dark violet":{"SuperCategory":"Violet","Id":"PATO_0001705","Definition":"A color consisting of violet hue and low brightness."}},{"Dark yellow":{"SuperCategory":"Yellow","Id":"PATO_0001263","Definition":"A color consisting of yellow hue and low brightness."}},{"Dark-field imaging protocol":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Light transmission optical imaging protocol","Id":"birnlex_2256"}},{"Darunavir":{"RelatedTo":["HIV-1 protease"],"Synonym":["AIDS073035","Darunavirum (INN-latin)","TMC-114","TMC114","UIC-94017"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01264","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01264","Definition":"Darunavir is a protease inhibitor used to treat HIV. It acts on the HIV aspartyl protease which the virus needs to cleave the HIV polyprotein into its functional fragments. Pharmacology: Darunavir is an inhibitor of the human immunodeficiency virus (HIV) protease.  In studies, the drug, co-administered with ritonavir in combination therapy, significantly reduced viral load and increased CD4 cell counts in this treatment-experienced patient population (Tibotec, 2006, Product Monograph, Prezista 2006). Darunavir is used as an adjunct therapy with low dose ritonavir, which inhibits cytochrome P450 3A (CYP3A) which increases the bioavailability and half life of darunavir. Mechanism of action: Darunavir is a HIV protease inhibitor which prevents HIV replication by cleaving HIV encoded Gag-Pol polyproteins in infected cells, reducing viral maturation, load and increasing CD4 T lymphocytes. HIV destroys CD4 T lymphocytes which are an integral part of the immune system. Drug type: Approved. Small Molecule. Drug category: Antiviral Agents. HIV Protease Inhibitors"}},{"Dasatinib":{"RelatedTo":["Proto-oncogene tyrosine-protein kinase ABL1","Beta platelet-derived growth factor receptor","Tyrosine-protein kinase ABL2","Mast/stem cell growth factor receptor","Proto-oncogene tyrosine-protein kinase Src","Proto-oncogene tyrosine-protein kinase Fyn","Proto-oncogene tyrosine-protein kinase Yes","Ephrin type-A receptor 2","Proto-oncogene tyrosine-protein kinase LCK"],"Synonym":["BMS-354825","dasatinib"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:49375","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01254","Definition":"Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinases inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR. Pharmacology: Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor Mechanism of action: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression. Drug type: Approved. Investigational. Small Molecule. Drug category: Protein Kinase Inhibitors"}}]}